activity_comment	activity_id	assay_chembl_id	assay_description	assay_type	canonical_smiles	data_validity_comment	molecule_chembl_id	relation	standard_type	standard_units	standard_value	target_chembl_id	target_organism	type	units	value
	1442934	CHEMBL830869	In vitro inhibitory concentration against human casein kinase 2 (CK2) by using [gamma-33P]-ATP] as radioligand	B	Nc1nc(C2=C3C(=Nc4ccccc43)C(=O)NCC2)c(O)[nH]1		CHEMBL332551	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
	1442934	CHEMBL830869	In vitro inhibitory concentration against human casein kinase 2 (CK2) by using [gamma-33P]-ATP] as radioligand	B	Nc1nc(C2=C3C(=Nc4ccccc43)C(=O)NCC2)c(O)[nH]1		CHEMBL332551	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
	1443233	CHEMBL830869	In vitro inhibitory concentration against human casein kinase 2 (CK2) by using [gamma-33P]-ATP] as radioligand	B	NC1=NC(=O)/C(=C2\CCNC(=O)c3[nH]c(Br)cc32)N1		CHEMBL361708	=	IC50	nM	7000.0	CHEMBL3629	Homo sapiens	IC50	nM	7000.0
Not Determined	1443240	CHEMBL832937	In vitro inhibitory concentration against human casein kinase 2 (CK2) by using [gamma-33P]-ATP] as radioligand; NA is value not available	B	NC1=N/C(=C2/CCNC(=O)c3[nH]ccc32)C(=O)N1		CHEMBL255465		IC50	nM		CHEMBL3629	Homo sapiens	IC50	nM	
	1902566	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(Nc3cccnc3)nc12		CHEMBL389604	=	Ki	nM	168.0	CHEMBL3629	Homo sapiens	Ki	uM	0.168
	1902567	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3cccc(OC(F)F)c3)n3ncc(C#N)c3n2)c1		CHEMBL398170	=	Ki	nM	190.0	CHEMBL3629	Homo sapiens	Ki	uM	0.19
	1902568	CHEMBL889430	Inhibition of human CK2 alpha	B	CCOc1cccc(Nc2nc(Nc3cccc(NC(C)=O)c3)nc3c(C#N)cnn23)c1		CHEMBL230987	=	Ki	nM	190.0	CHEMBL3629	Homo sapiens	Ki	uM	0.19
	1902569	CHEMBL889430	Inhibition of human CK2 alpha	B	CCN(CC)C(=O)c1cccc(Nc2nc(Nc3cccc(NC(C)=O)c3)nc3c(C#N)cnn23)c1		CHEMBL230886	=	Ki	nM	370.0	CHEMBL3629	Homo sapiens	Ki	uM	0.37
	1902570	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3cccc(C(=O)N4CCCC4)c3)n3ncc(C#N)c3n2)c1		CHEMBL397923	=	Ki	nM	700.0	CHEMBL3629	Homo sapiens	Ki	uM	0.7
	1902571	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3cccc(C(=O)NCCN(C)C)c3)n3ncc(C#N)c3n2)c1		CHEMBL230781	=	Ki	nM	190.0	CHEMBL3629	Homo sapiens	Ki	uM	0.19
	1902572	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3cccc(C(=O)O)c3)n3ncc(C#N)c3n2)c1		CHEMBL395969	=	Ki	nM	95.0	CHEMBL3629	Homo sapiens	Ki	uM	0.095
	1902573	CHEMBL889430	Inhibition of human CK2 alpha	B	CCN(CC)Cc1ccc(Nc2nc(Nc3cccc(NC(C)=O)c3)nc3c(C#N)cnn23)cc1		CHEMBL230779	=	Ki	nM	500.0	CHEMBL3629	Homo sapiens	Ki	uM	0.5
	1902574	CHEMBL889430	Inhibition of human CK2 alpha	B	CCN(CC)c1cccc(Nc2nc(Nc3cccc(NC(C)=O)c3)nc3c(C#N)cnn23)c1		CHEMBL230674	=	Ki	nM	550.0	CHEMBL3629	Homo sapiens	Ki	uM	0.55
	1902575	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccc(CN4CCNCC4)cc3)n3ncc(C#N)c3n2)c1		CHEMBL395968	=	Ki	nM	210.0	CHEMBL3629	Homo sapiens	Ki	uM	0.21
	1902576	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(NC3CC3)n3ncc(Br)c3n2)c1		CHEMBL230673	=	Ki	nM	17.0	CHEMBL3629	Homo sapiens	Ki	uM	0.017
	1902577	CHEMBL889430	Inhibition of human CK2 alpha	B	CCc1cnn2c(NC3CC3)nc(Nc3cccc(NC(C)=O)c3)nc12		CHEMBL230569	=	Ki	nM	2000.0	CHEMBL3629	Homo sapiens	Ki	uM	2.0
	1902578	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3)n3ncc(C)c3n2)c1		CHEMBL230568	=	Ki	nM	11.0	CHEMBL3629	Homo sapiens	Ki	uM	0.011
	1902579	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(NC3CC3)n3ncc(C)c3n2)c1		CHEMBL230463	=	Ki	nM	35.0	CHEMBL3629	Homo sapiens	Ki	uM	0.035
	1902580	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(NC3CCC3)n3ncc(C#N)c3n2)c1		CHEMBL230462	=	Ki	nM	1.9	CHEMBL3629	Homo sapiens	Ki	uM	0.0019
	1902581	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(NC3CC3)n3ncc(C#N)c3n2)c1		CHEMBL398149	=	Ki	nM	0.26	CHEMBL3629	Homo sapiens	Ki	uM	0.00026
	1902582	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(Nc3ccccc3)n3ncc(C#N)c3n2)c1		CHEMBL230354	=	Ki	nM	0.35	CHEMBL3629	Homo sapiens	Ki	uM	0.00035
	1902583	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(=O)Nc1cccc(Nc2nc(NCCc3ccccc3)n3ncc(C#N)c3n2)c1		CHEMBL230353	=	Ki	nM	8.0	CHEMBL3629	Homo sapiens	Ki	uM	0.008
	1902584	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(NCCc3ccccc3)nc(Nc3cccnc3)nc12		CHEMBL230352	=	Ki	nM	3400.0	CHEMBL3629	Homo sapiens	Ki	uM	3.4
	1902585	CHEMBL889430	Inhibition of human CK2 alpha	B	Cc1ccc(Nc2nc(NCCc3ccccc3)n3ncc(C#N)c3n2)cc1		CHEMBL230248	=	Ki	nM	137.0	CHEMBL3629	Homo sapiens	Ki	uM	0.137
	1902586	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(NCCc3cnc[nH]3)nc(Nc3ccccc3)nc12		CHEMBL389767	=	Ki	nM	137.0	CHEMBL3629	Homo sapiens	Ki	uM	0.137
	1902587	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(N3CCN(c4ccccn4)CC3)nc12		CHEMBL230246	=	Ki	nM	7.0	CHEMBL3629	Homo sapiens	Ki	uM	0.007
	1902588	CHEMBL889430	Inhibition of human CK2 alpha	B	CCN1CCN(c2nc(Nc3ccccc3)n3ncc(C#N)c3n2)CC1		CHEMBL230137	=	Ki	nM	24.0	CHEMBL3629	Homo sapiens	Ki	uM	0.024
	1902589	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(N3CCc4ccccc4C3)nc12		CHEMBL230136	=	Ki	nM	11.0	CHEMBL3629	Homo sapiens	Ki	uM	0.011
	1902590	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(-n3ccnc3)nc12		CHEMBL230135	=	Ki	nM	126.0	CHEMBL3629	Homo sapiens	Ki	uM	0.126
	1902591	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(N3CCCC3)nc12		CHEMBL388042	=	Ki	nM	14.0	CHEMBL3629	Homo sapiens	Ki	uM	0.014
	1902592	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(NC3Cc4ccccc4C3)nc12		CHEMBL230456	=	Ki	nM	12.0	CHEMBL3629	Homo sapiens	Ki	uM	0.012
	1902593	CHEMBL889430	Inhibition of human CK2 alpha	B	CC(C)CCNc1nc(Nc2ccccc2)n2ncc(C#N)c2n1		CHEMBL389765	=	Ki	nM	13.0	CHEMBL3629	Homo sapiens	Ki	uM	0.013
	1902594	CHEMBL889430	Inhibition of human CK2 alpha	B	CN(Cc1ccccc1)c1nc(Nc2ccccc2)n2ncc(C#N)c2n1		CHEMBL230455	=	Ki	nM	55.0	CHEMBL3629	Homo sapiens	Ki	uM	0.055
	1902595	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(NCc3ccc(Cl)cc3)nc12		CHEMBL230347	=	Ki	nM	5.0	CHEMBL3629	Homo sapiens	Ki	uM	0.005
	1902596	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(NCC3CCCCC3)nc12		CHEMBL438303	=	Ki	nM	8.0	CHEMBL3629	Homo sapiens	Ki	uM	0.008
	1902597	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(Nc3ncc[nH]3)nc12		CHEMBL389802	=	Ki	nM	45.0	CHEMBL3629	Homo sapiens	Ki	uM	0.045
	1902598	CHEMBL889430	Inhibition of human CK2 alpha	B	CCN(CC)c1ccc(Nc2nc(Nc3ccccc3)n3ncc(C#N)c3n2)cc1		CHEMBL231591	=	Ki	nM	23.0	CHEMBL3629	Homo sapiens	Ki	uM	0.023
	1902599	CHEMBL889430	Inhibition of human CK2 alpha	B	COc1ccc(Nc2nc(Nc3ccccc3)n3ncc(C#N)c3n2)cc1OC		CHEMBL231590	=	Ki	nM	9.0	CHEMBL3629	Homo sapiens	Ki	uM	0.009
	1902600	CHEMBL889430	Inhibition of human CK2 alpha	B	Cc1ccc(Nc2nc(Nc3ccccc3)n3ncc(C#N)c3n2)cc1		CHEMBL231492	=	Ki	nM	5.0	CHEMBL3629	Homo sapiens	Ki	uM	0.005
	1902628	CHEMBL889430	Inhibition of human CK2 alpha	B	N#Cc1cnn2c(Nc3ccccc3)nc(Nc3ccccc3)nc12		CHEMBL396230	=	Ki	nM	15.0	CHEMBL3629	Homo sapiens	Ki	uM	0.015
	1917473	CHEMBL895131	Inhibition of CK2 at 1 uM	B	O=c1ccc(=O)c2c1c1[nH]c3ccc(O)cc3c1c1c(=O)[nH]c(=O)c21		CHEMBL243931	=	Inhibition	%	92.0	CHEMBL3629	Homo sapiens	Inhibition	%	92.0
	1917495	CHEMBL895131	Inhibition of CK2 at 1 uM	B	Cc1ccc2[nH]c3c4c(O)ccc(O)c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL244141	=	Inhibition	%	108.0	CHEMBL3629	Homo sapiens	Inhibition	%	108.0
	2015688	CHEMBL885496	Inhibition of CK2 at 10 uM	B	NC[C@H]1CC[C@H](c2nc(-c3cccc(OCc4ccccc4)c3)c3c(N)nccn32)CC1		CHEMBL392284	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	Inhibition	%	50.0
	2051609	CHEMBL941747	Inhibition of CK2	B	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	>	Ki	nM	5833.0	CHEMBL3629	Homo sapiens	Ki	uM	5.833
	2081781	CHEMBL928804	Inhibition of CK2-alpha-1 at 10 uM	B	CC[C@@H](C)Nc1nc2ccc(-c3c(-c4ccccc4F)n[nH]c3N)cc2s1		CHEMBL404115	<=	Inhibition	%	20.0	CHEMBL3629	Homo sapiens	Inhibition	%	20.0
	2099529	CHEMBL948243	Inhibition of CK2 at 10 uM	B	CN(C)CCCOc1cc2c(cc1O)c1c3c(c(-c4ccccc4Cl)cc1n2C)C(=O)NC3=O		CHEMBL410261	=	Inhibition	%	106.0	CHEMBL3629	Homo sapiens	Inhibition	%	106.0
	2099641	CHEMBL948243	Inhibition of CK2 at 10 uM	B	Cn1c2cc(C(=O)NCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL272267	=	Inhibition	%	99.0	CHEMBL3629	Homo sapiens	Inhibition	%	99.0
	2099642	CHEMBL948243	Inhibition of CK2 at 10 uM	B	Cn1c2cc(SCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL404335	=	Inhibition	%	97.0	CHEMBL3629	Homo sapiens	Inhibition	%	97.0
	2099643	CHEMBL948243	Inhibition of CK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCOCC3)cc2n1CCO		CHEMBL271715	=	Inhibition	%	88.0	CHEMBL3629	Homo sapiens	Inhibition	%	88.0
	2099644	CHEMBL948243	Inhibition of CK2 at 10 uM	B	O=C1NC(=O)c2c1c(-c1ccccc1Cl)cc1c2c2cc(O)c(OCCCN3CCCC3)cc2n1CCO		CHEMBL270021	=	Inhibition	%	100.0	CHEMBL3629	Homo sapiens	Inhibition	%	100.0
	2099645	CHEMBL948243	Inhibition of CK2 at 10 uM	B	Cn1c2cc(OCCCN3CCCC3)c(O)cc2c2c3c(c(-c4ccccc4Cl)cc21)C(=O)NC3=O		CHEMBL255427	=	Inhibition	%	84.0	CHEMBL3629	Homo sapiens	Inhibition	%	84.0
	2132679	CHEMBL939035	Inhibition of CK2	B	Nc1nccn2c1c(-c1ccc3ccc(-c4ccccc4)nc3c1)nc2[C@H]1C[C@@H](CN2CCC2)C1		CHEMBL410659	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	uM	10.0
	2136824	CHEMBL939206	Inhibition of CK1 at 10000 nM	B	NC(=O)c1ccc2[nH]c(-c3ccc(Oc4ccc(Cl)cc4)cc3)nc2c1		CHEMBL179583	<	Inhibition	%	25.0	CHEMBL3629	Homo sapiens	Inhibition	%	25.0
	2136898	CHEMBL939371	Inhibition of CK1	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	>=	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	nM	100000.0
	2136899	CHEMBL936915	Inhibition of CK2	B	CCCCc1c(-c2ccc(O)cc2)[nH]c2nccnc12		CHEMBL75680	>=	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	nM	100000.0
	2137111	CHEMBL936915	Inhibition of CK2	B	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	IC50	nM	20000.0	CHEMBL3629	Homo sapiens	IC50	nM	20000.0
	2147096	CHEMBL927034	Inhibition of CK2 by radioactive flashplate assay	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	IC50	nM	20500.0	CHEMBL3629	Homo sapiens	IC50	uM	20.5
Not Active	2170346	CHEMBL927905	Activity at CK2 at 3 uM	B	COc1c(NC(=O)c2ccc(C)c(N3C=C(C(=O)NCC(C)(C)CN(C)C)NN3)c2)cc(C(C)(C)C)cc1NS(C)(=O)=O		CHEMBL254992		Activity			CHEMBL3629	Homo sapiens	Activity		
	2182807	CHEMBL941420	Inhibition of CSNK2A1 at 5 uM	B	O=c1cc(N2CCOCC2)nc2c3ccccc3ccn12		CHEMBL179242	=	Inhibition	%	3.0	CHEMBL3629	Homo sapiens	INH	%	3.0
	2197916	CHEMBL1004021	Inhibition of human CK2	B	CNc1nccc(-c2nc(C3CCNCC3)[nH]c2-c2cccc(C(F)(F)F)c2)n1		CHEMBL489344	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	uM	100.0
	2197924	CHEMBL1004021	Inhibition of human CK2	B	CC1CCC(c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)CC1		CHEMBL523938	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	uM	100.0
	2279751	CHEMBL958316	Inhibition of CK2alpha1	B	CN1CCCN(c2cncc(-c3cccc(/C=C/C(=O)O)c3)n2)CC1		CHEMBL493937	=	IC50	nM	663.0	CHEMBL3629	Homo sapiens	IC50	nM	663.0
	2279753	CHEMBL958318	Inhibition of CK2alpha1 at 10 uM	B	COC(=O)/C=C/c1cccc(-c2cncc(N3CCCN(C)CC3)n2)c1		CHEMBL521831	=	Inhibition	%	14.0	CHEMBL3629	Homo sapiens	INH	%	14.0
	2279755	CHEMBL958318	Inhibition of CK2alpha1 at 10 uM	B	CN1CCCN(c2cncc(-c3cccc(/C=C/C(N)=O)c3)n2)CC1		CHEMBL493536	=	Inhibition	%	42.0	CHEMBL3629	Homo sapiens	INH	%	42.0
Not Active	2301932	CHEMBL950811	Inhibition of CK2alpha1	B	COc1ncnc2ncn(CC(=O)c3ccccc3)c12		CHEMBL483271		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2301956	CHEMBL950811	Inhibition of CK2alpha1	B	COc1ncnc2c1ncn2CC(=O)c1ccccc1		CHEMBL519976		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2301980	CHEMBL950811	Inhibition of CK2alpha1	B	Nc1ncnc2c1ncn2CC(=O)c1cccnc1		CHEMBL501256		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2302004	CHEMBL950811	Inhibition of CK2alpha1	B	Nc1ncnc2c1ncn2CC(=O)c1ccccn1		CHEMBL504135		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2302028	CHEMBL950811	Inhibition of CK2alpha1	B	Nc1ncnc2ncn(CC(=O)c3ccccc3)c12		CHEMBL485444		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2302052	CHEMBL950811	Inhibition of CK2alpha1	B	Nc1ncnc2c1ncn2CC(=O)c1ccccc1		CHEMBL520515		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2302076	CHEMBL950811	Inhibition of CK2alpha1	B	Nc1ncnc2ncn(CC(=O)c3c[nH]c4ccccc34)c12		CHEMBL485246		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2302100	CHEMBL950811	Inhibition of CK2alpha1	B	Nc1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12		CHEMBL521155		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	2302140	CHEMBL950811	Inhibition of CK2alpha1	B	CN(C)c1ncnc2c1ncn2CC(=O)c1c[nH]c2ccccc12		CHEMBL519977		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	2461803	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	Cc1cc(O)cc2oc(=O)c3c(O)cc(O)cc3c12		CHEMBL519982	=	IC50	ug.mL-1	2.0	CHEMBL3629	Homo sapiens	IC50	10'-6g/ml	2.0
	2461884	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	O=C1C[C@H](O)[C@@H]2c3c(ccc(O)c31)-c1ccc(O)c3c1[C@@]2(O)CCC3=O		CHEMBL521470	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461885	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c(C(=O)O)c(C2=C(C)C[C@@H](O)C2=O)c1		CHEMBL519395	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461886	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(c1)C1(OC2=O)C(C)=CC(=O)C1O		CHEMBL408995	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461887	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(c1)-c1cc(O)c(O)cc1COC2=O		CHEMBL507058	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461888	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	Cc1cc(O)c(O)cc1-c1cc(O)cc(O)c1C(=O)O		CHEMBL483532	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461889	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c(C(=O)O)c(-c2cc(O)c(O)cc2C)c1		CHEMBL483531	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461890	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(=O)oc3c(O)c(O)cc(C)c3c2c1		CHEMBL520144	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461891	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(=O)oc3cc(O)cc(C)c3c2c1		CHEMBL483526	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	10'-5g/ml	1.0
	2461892	CHEMBL962879	Inhibition of recombinant CK2alpha1	B	Cc1cc(O)cc2oc(=O)c3c(O)cc(OS(=O)(=O)O)cc3c12		CHEMBL483525	=	IC50	ug.mL-1	2.0	CHEMBL3629	Homo sapiens	IC50	10'-6g/ml	2.0
	2465159	CHEMBL957990	Inhibition of human recombinant CK2A1	B	COc1cc(C2=C(c3cn(COCc4ccccc4)c4ccccc34)CNC2=O)cc(OC)c1OC		CHEMBL453336	=	IC50	nM	93000.0	CHEMBL3629	Homo sapiens	IC50	uM	93.0
	2470142	CHEMBL1034091	Inhibition of CSNK2A1 at 3 uM	B	CN(C)CCOc1cc(-c2cn[nH]c2)ccc1NC(=O)C1COc2ccccc2O1		CHEMBL521179	<	Inhibition	%	10.0	CHEMBL3629	Homo sapiens	INH	%	10.0
Not Evaluated	2476762	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	NC(=O)c1ccc(-c2cc(C(N)=O)c(N)c(-c3ccc(S(N)(=O)=O)cc3)c2)cc1		CHEMBL514582		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2478601	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	N#Cc1c(NC(=O)c2ccccc2)sc2c1CCCC2		CHEMBL233000		Activity			CHEMBL3629	Homo sapiens	Activity		
	2478804	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	O=C1Nc2ccccc2/C1=C/c1ccc[nH]1		CHEMBL86755	=	Activity	%	2.1	CHEMBL3629	Homo sapiens	Activity	%	2.1
	2479659	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	N#Cc1ccc(-c2cnc3[nH]cc(NC(=O)c4cccnc4)c3c2)cc1		CHEMBL516312	=	Activity	%	0.6	CHEMBL3629	Homo sapiens	Activity	%	0.6
Active	2479862	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	NC(=O)Nc1sc(-c2ccc(F)cc2)cc1C(N)=O		CHEMBL257167		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	2480659	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	CCS(=O)(=O)Nc1ccc2c(c1)/C(=C(/Nc1ccc(CN3CCCCC3)cc1)c1ccccc1)C(=O)N2		CHEMBL514409		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	2480861	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878		Activity			CHEMBL3629	Homo sapiens	Activity		
	2512012	CHEMBL970583	Inhibition of CK2alpha1 at 1 uM	B	CC(=O)N1CCN(C(=O)Cc2ccc(Nc3ncc(F)c(Nc4ccc(C(=O)Nc5ccccc5Cl)cc4)n3)cc2)CC1		CHEMBL508307	=	Inhibition	%	16.0	CHEMBL3629	Homo sapiens	INH	%	16.0
	2567230	CHEMBL973713	Inhibition of human CK2 kinase assessed as residual enzyme activity at 0.1 uM	B	CCN1C(=O)C(C)(C)c2cc3[nH]c4c(c3cc21)CCCc1c(C)n[nH]c1-4		CHEMBL223147	=	Activity	%	104.0	CHEMBL3629	Homo sapiens	Activity	%	104.0
Not Evaluated	2577280	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	CC(=O)c1c(-c2ccncc2)[nH]c(-c2ccncc2)c1C		CHEMBL526901		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2577483	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	NC(=O)c1ccc(Nc2cc(-c3ccc(F)cc3)[nH]n2)cc1		CHEMBL511337		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2593688	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	Cc1ccc(O)cc1Nc1ccnc(Nc2cccc(C(N)=O)c2)n1		CHEMBL249097		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2593954	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	Nc1ncnc2c1c(-c1cccc(O)c1)cn2C1CCNCC1		CHEMBL450519		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2594157	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	Cc1ccc(C(=O)Nc2cccc(C(C)(C)C)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL515466		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2594897	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL478649		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Evaluated	2595100	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	Cc1ccc(NC(=O)c2cccc(N3CCCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL1964275		Activity			CHEMBL3629	Homo sapiens	Activity		
	2595816	CHEMBL1017883	Inhibition of CSNK2A1 assessed as enzyme activity relative to control	B	C[C@@H]1CCN(C(=O)CC#N)C[C@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL459977	=	Activity	%	22.0	CHEMBL3629	Homo sapiens	Activity	%	22.0
	2596297	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	CN(C)c1ccc(-c2cc3ncccc3c(NCCCCN)n2)cc1		CHEMBL282342	=	Activity	%	2.4	CHEMBL3629	Homo sapiens	Activity	%	2.4
	2596500	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	O=C(Nc1n[nH]c2nc(-c3cccc(O)c3)ccc12)C1CC1		CHEMBL408019	=	Activity	%	12.9	CHEMBL3629	Homo sapiens	Activity	%	12.9
Not Evaluated	2597769	CHEMBL983560	Binding affinity to human CK2A1 at 10 uM relative to control	B	c1ccc(-c2n[nH]cc2-c2ccnc3ccccc23)nc1		CHEMBL261454		Activity			CHEMBL3629	Homo sapiens	Activity		
	2608608	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	BrCCn1nnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL505981	=	Inhibition	%	60.0	CHEMBL3629	Homo sapiens	INH	%	60.0
	2608609	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	BrCCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL456833	=	Inhibition	%	79.0	CHEMBL3629	Homo sapiens	INH	%	79.0
	2608610	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	CN(C)CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL454977	=	Inhibition	%	75.0	CHEMBL3629	Homo sapiens	INH	%	75.0
	2608611	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	ClCCCn1nnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL445500	=	Inhibition	%	87.0	CHEMBL3629	Homo sapiens	INH	%	87.0
	2608612	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	ClCCCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL459344	=	Inhibition	%	69.0	CHEMBL3629	Homo sapiens	INH	%	69.0
	2608613	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	CN(C)CCN1C(=O)c2c(Br)c(Br)c(Br)c(Br)c2C1=O		CHEMBL459576	=	Inhibition	%	88.0	CHEMBL3629	Homo sapiens	INH	%	88.0
	2608614	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	N#CCN1C(=O)c2c(Br)c(Br)c(Br)c(Br)c2C1=O		CHEMBL513786	=	Inhibition	%	80.0	CHEMBL3629	Homo sapiens	INH	%	80.0
	2608615	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	O=C1c2c(Br)c(Br)c(Br)c(Br)c2C(=O)N1CC(F)(F)F		CHEMBL500827	=	Inhibition	%	88.0	CHEMBL3629	Homo sapiens	INH	%	88.0
	2608616	CHEMBL1024748	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) at 5 uM assessed as [32P] incorporation by liquid scintillation counting	B	O=c1[nH][nH]c(=O)c2c(Br)c(Br)c(Br)c(Br)c12		CHEMBL459585	=	Inhibition	%	95.0	CHEMBL3629	Homo sapiens	INH	%	95.0
	2608617	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	uM	0.5
	2608618	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	OCCn1nnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL451155	=	IC50	nM	9250.0	CHEMBL3629	Homo sapiens	IC50	uM	9.25
	2608619	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	OCCCn1nnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL456634	=	IC50	nM	320.0	CHEMBL3629	Homo sapiens	IC50	uM	0.32
	2608620	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	OCCCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL459346	=	IC50	nM	340.0	CHEMBL3629	Homo sapiens	IC50	uM	0.34
	2608621	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	O=P(O)(O)OCCCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL459343	=	IC50	nM	2200.0	CHEMBL3629	Homo sapiens	IC50	uM	2.2
	2608622	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	CN1CCN(CCCn2nnc3c(Br)c(Br)c(Br)c(Br)c32)CC1		CHEMBL459345	=	IC50	nM	11200.0	CHEMBL3629	Homo sapiens	IC50	uM	11.2
	2608623	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	CN1CCN(CCCn2nc3c(Br)c(Br)c(Br)c(Br)c3n2)CC1		CHEMBL512747	=	IC50	nM	7300.0	CHEMBL3629	Homo sapiens	IC50	uM	7.3
	2608624	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	OCCCCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL459577	=	IC50	nM	1730.0	CHEMBL3629	Homo sapiens	IC50	uM	1.73
	2608625	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	IC50	nM	1300.0	CHEMBL3629	Homo sapiens	IC50	uM	1.3
	2608626	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	OCCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL453937	=	IC50	nM	540.0	CHEMBL3629	Homo sapiens	IC50	uM	0.54
	2608627	CHEMBL1024749	Inhibition of human recombinant casein kinase 2 subunit alpha expressed in Escherichia coli BL21 (DE3) assessed as [32P] incorporation by liquid scintillation counting	B	ClCCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL502728	=	IC50	nM	2900.0	CHEMBL3629	Homo sapiens	IC50	uM	2.9
	2639142	CHEMBL974405	Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)	B	O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23		CHEMBL6246	=	IC50	nM	40.0	CHEMBL3629	Homo sapiens	IC50	uM	0.04
	2639143	CHEMBL974405	Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)	B	OC[C@H]1O[C@@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O		CHEMBL375530	=	IC50	nM	13000.0	CHEMBL3629	Homo sapiens	IC50	uM	13.0
	2639144	CHEMBL974405	Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	IC50	nM	390.0	CHEMBL3629	Homo sapiens	IC50	uM	0.39
	2639145	CHEMBL974405	Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	IC50	nM	900.0	CHEMBL3629	Homo sapiens	IC50	uM	0.9
	2639146	CHEMBL974405	Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	IC50	nM	800.0	CHEMBL3629	Homo sapiens	IC50	uM	0.8
	2639147	CHEMBL974405	Inhibition of GST-fused human recombinant CK2alpha expressed in Escherichia coli HMS174 (DE3)	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	uM	2.0
	2671878	CHEMBL1026239	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)cc1C2=O		CHEMBL463054	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	ug ml-1	10.0
	2671880	CHEMBL1026239	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(c1)C(=O)c1cc(C)c(O)c(O)c1C2=O		CHEMBL556684	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	ug ml-1	10.0
	2672308	CHEMBL1026239	Inhibition of recombinant CK2alpha1	B	COc1cc(O)c2c(c1)C(=O)C1=C(C2=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O		CHEMBL512054	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	ug ml-1	10.0
	2672312	CHEMBL1026239	Inhibition of recombinant CK2alpha1	B	COc1cc2c(c(O)c1-c1c(OC)cc(O)c3c1C(=O)C1=C(C3=O)[C@H](O)[C@@H](O)[C@@](C)(O)[C@@H]1O)C(=O)c1cc(O)c(C)cc1C2=O		CHEMBL554993	>	IC50	ug.mL-1	10.0	CHEMBL3629	Homo sapiens	IC50	ug ml-1	10.0
	2893239	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893240	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893241	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893242	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893243	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893244	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893245	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	1400.0	CHEMBL3629	Homo sapiens	Kd	nM	1400.0
	2893246	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893247	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893248	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893249	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	COCC(=O)NC/C=C/c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1		CHEMBL483321	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893250	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893251	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL607707	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893252	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893253	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893254	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893255	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893256	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893257	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893258	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Nc1nc(Nc2ccc(S(N)(=O)=O)cc2)nn1C(=O)c1c(F)cccc1F		CHEMBL191003	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893259	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893260	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	=	Kd	nM	3600.0	CHEMBL3629	Homo sapiens	Kd	nM	3600.0
	2893261	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893262	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893263	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893264	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	250.0	CHEMBL3629	Homo sapiens	Kd	nM	250.0
	2893265	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893266	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL14762	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893267	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Oc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL278041	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893268	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893269	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL440084	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893270	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893271	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	36.0	CHEMBL3629	Homo sapiens	Kd	nM	36.0
	2893272	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	97.0	CHEMBL3629	Homo sapiens	Kd	nM	97.0
	2893273	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	81.0	CHEMBL3629	Homo sapiens	Kd	nM	81.0
	2893274	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	=	Kd	nM	400.0	CHEMBL3629	Homo sapiens	Kd	nM	400.0
	2893275	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2893276	CHEMBL1060241	Binding constant for full-length CSNK2A1	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	2897065	CHEMBL1063677	Inhibitory constant against maize casein kinase 2 	B	O=C1c2c(O)cccc2C(=O)c2c([N+](=O)[O-])ccc(O)c21		CHEMBL574060	=	Ki	nM	780.0	CHEMBL3629	Homo sapiens	Ki	uM	0.78
	2897066	CHEMBL1063677	Inhibitory constant against maize casein kinase 2 	B	O=c1c2c(O)cccc2oc2c([N+](=O)[O-])ccc(O)c12		CHEMBL270512	=	Ki	nM	800.0	CHEMBL3629	Homo sapiens	Ki	uM	0.8
	2897067	CHEMBL1063677	Inhibitory constant against maize casein kinase 2 	B	Nc1ccc(N)c2c1C(=O)c1c(O)ccc(O)c1C2=O		CHEMBL572879	=	Ki	nM	350.0	CHEMBL3629	Homo sapiens	Ki	uM	0.35
	2897068	CHEMBL1063677	Inhibitory constant against maize casein kinase 2 	B	O=C1c2cccc(O)c2C(=O)c2c(O)cccc21		CHEMBL53418	>	Ki	nM	40000.0	CHEMBL3629	Homo sapiens	Ki	uM	40.0
	2897069	CHEMBL1063677	Inhibitory constant against maize casein kinase 2 	B	O=c1c2c(O)cccc2oc2cccc(O)c12		CHEMBL494104	>	Ki	nM	40000.0	CHEMBL3629	Homo sapiens	Ki	uM	40.0
	2897070	CHEMBL1063677	Inhibitory constant against maize casein kinase 2 	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	>	Ki	nM	40000.0	CHEMBL3629	Homo sapiens	Ki	uM	40.0
	2897083	CHEMBL1063784	Inhibition of Zea mays CK2alpha	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	IC50	nM	390.0	CHEMBL3629	Homo sapiens	IC50	uM	0.39
	2897084	CHEMBL1063784	Inhibition of Zea mays CK2alpha	B	OCCCNc1cc(-c2ccnc(Nc3cccc(OC(F)(F)C(F)F)c3)n2)ccn1		CHEMBL574284	=	IC50	nM	3600.0	CHEMBL3629	Homo sapiens	IC50	uM	3.6
	2897085	CHEMBL1063784	Inhibition of Zea mays CK2alpha	B	NCCNc1cc(-c2ccnc(Nc3cccc(Cl)c3)n2)ccn1		CHEMBL584384	=	IC50	nM	9600.0	CHEMBL3629	Homo sapiens	IC50	uM	9.6
	2897086	CHEMBL1063784	Inhibition of Zea mays CK2alpha	B	Clc1cccc(Nc2nccc(-c3ccnc(NCCc4c[nH]cn4)c3)n2)c1		CHEMBL574285	=	IC50	nM	3200.0	CHEMBL3629	Homo sapiens	IC50	uM	3.2
	2897087	CHEMBL1063784	Inhibition of Zea mays CK2alpha	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	uM	0.5
	2897088	CHEMBL1063784	Inhibition of Zea mays CK2alpha	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	IC50	nM	890.0	CHEMBL3629	Homo sapiens	IC50	uM	0.89
	2897089	CHEMBL1061117	Inhibitory constant against Zea mays CK2alpha	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	Ki	nM	170.0	CHEMBL3629	Homo sapiens	Ki	uM	0.17
	2897090	CHEMBL1061117	Inhibitory constant against Zea mays CK2alpha	B	OC[C@H]1O[C@@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O		CHEMBL375530	=	Ki	nM	4500.0	CHEMBL3629	Homo sapiens	Ki	uM	4.5
	2897091	CHEMBL1061117	Inhibitory constant against Zea mays CK2alpha	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Ki	nM	400.0	CHEMBL3629	Homo sapiens	Ki	uM	0.4
	2897092	CHEMBL1061117	Inhibitory constant against Zea mays CK2alpha	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	Ki	nM	1850.0	CHEMBL3629	Homo sapiens	Ki	uM	1.85
	2897093	CHEMBL1061117	Inhibitory constant against Zea mays CK2alpha	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Ki	nM	740.0	CHEMBL3629	Homo sapiens	Ki	uM	0.74
	2897094	CHEMBL1061117	Inhibitory constant against Zea mays CK2alpha	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	Ki	nM	1180.0	CHEMBL3629	Homo sapiens	Ki	uM	1.18
	2897201	CHEMBL1062826	Percent residual CK2 activity in the presence of 10uM inhibitor	B	O=C(O)Cc1c2ccccc2n2c1[nH]c(=O)c1ccccc12		CHEMBL92361	=	Activity	%	10.0	CHEMBL3629	Homo sapiens	Activity	%	10.0
	2897202	CHEMBL1062826	Percent residual CK2 activity in the presence of 10uM inhibitor	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Activity	%	57.0	CHEMBL3629	Homo sapiens	Activity	%	57.0
	2897203	CHEMBL1062826	Percent residual CK2 activity in the presence of 10uM inhibitor	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	Activity	%	51.0	CHEMBL3629	Homo sapiens	Activity	%	51.0
	2921386	CHEMBL1055282	Inhibition of CSNK2A1 assessed as enzyme activity at 1 uM relative to untreated control	B	Cc1ccc2c(Nc3ccc(Cl)cc3)nccc2c1Nc1ncccc1-c1ncnc2[nH]cnc12.Cl.Cl.Cl		CHEMBL3215582	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	2992202	CHEMBL1044505	Inhibition of human CK2alpha1 at 20 uM by FRET assay	B	C#Cn1c(C#CCCO)nc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL576620	=	Inhibition	%	3.0	CHEMBL3629	Homo sapiens	INH	%	3.0
	3052570	CHEMBL1037111	Residual activity of CK2alpha1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	108.0	CHEMBL3629	Homo sapiens	Residual activity	%	108.0
	3053879	CHEMBL1044279	Residual activity of CK2alpha1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	264.0	CHEMBL3629	Homo sapiens	Residual activity	%	264.0
	3054131	CHEMBL1067252	Residual activity of CK2alpha1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	95.0	CHEMBL3629	Homo sapiens	Residual activity	%	95.0
	3055418	CHEMBL1037111	Residual activity of CK2alpha1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	90.0	CHEMBL3629	Homo sapiens	Residual activity	%	90.0
	3055670	CHEMBL1044279	Residual activity of CK2alpha1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL595143	=	Residual activity	%	229.0	CHEMBL3629	Homo sapiens	Residual activity	%	229.0
	3056975	CHEMBL1067252	Residual activity of CK2alpha1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	132.0	CHEMBL3629	Homo sapiens	Residual activity	%	132.0
	3058295	CHEMBL1037111	Residual activity of CK2alpha1 at 1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	94.0	CHEMBL3629	Homo sapiens	Residual activity	%	94.0
	3058547	CHEMBL1044279	Residual activity of CK2alpha1 at 10 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3)ncnc2cc1OCCCN1CCCC1		CHEMBL595373	=	Residual activity	%	188.0	CHEMBL3629	Homo sapiens	Residual activity	%	188.0
	3072893	CHEMBL1067252	Residual activity of CK2alpha1 at 0.1 uM by microplate scintillation counting	B	COc1cc2c(Oc3ccc(-c4nc5ccccc5s4)cc3F)ncnc2cc1OCCCN1CCN(C)CC1		CHEMBL604483	=	Residual activity	%	87.0	CHEMBL3629	Homo sapiens	Residual activity	%	87.0
	3124279	CHEMBL1068861	Inhibition of human recombinant CK2alpha1 expressed in Sf9 cells at 10 uM	B	CCc1cccc2c1ccc1c3occ(C)c3c(=O)oc21		CHEMBL215797	=	Inhibition	%	99.0	CHEMBL3629	Homo sapiens	INH	%	99.0
	3127291	CHEMBL1074369	Inhibition of CK2alpha1 at 1 uM	B	NC1(Cc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL263664	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	INH	%	2.0
	3127310	CHEMBL1074369	Inhibition of CK2alpha1 at 1 uM	B	CC(C)(C)c1ccc(CC2(N)CCN(c3ncnc4[nH]ccc34)CC2)cc1		CHEMBL597211	=	Inhibition	%	1.0	CHEMBL3629	Homo sapiens	INH	%	1.0
	3127329	CHEMBL1074369	Inhibition of CK2alpha1 at 1 uM	B	NC1(C(=O)NCc2ccc(Cl)cc2)CCN(c2ncnc3[nH]ccc23)CC1		CHEMBL598194	=	Inhibition	%	-2.0	CHEMBL3629	Homo sapiens	INH	%	-2.0
	3224792	CHEMBL1102786	Inhibition of CK2alpha1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1-c1cnc(CO)cn1		CHEMBL1081678	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3225042	CHEMBL1102786	Inhibition of CK2alpha1 at 10 uM	B	Cc1cc(OCc2ccc(F)cc2F)c(Br)c(=O)n1Cc1ccc(CN(C)C)cc1		CHEMBL1078665	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
Not Active	3293114	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Cc1ccccc1CC2=O		CHEMBL1096459		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293130	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(Nc3ccc(F)cc3F)ccc21		CHEMBL1096460		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293146	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Cc1ccccc1CC2=O		CHEMBL1096466		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293162	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(Nc3ccccc3)ccc21		CHEMBL1096672		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293178	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccc(Nc2ccc3c(c2)Cc2ccccc2CC3=O)cc1		CHEMBL1096769		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293194	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)C(=O)Cc1ccccc1C2		CHEMBL1096770		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293210	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Cc1ccccc1C(=O)C2		CHEMBL1096771		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293226	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Cc1ccccc1C(=O)C2		CHEMBL1097085		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293242	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	O=C1Cc2ccc(Nc3ccccc3)cc2Cc2ccccc21		CHEMBL1097086		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293258	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CC(=O)c1ccccc1C2		CHEMBL1097087		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293274	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)CC(=O)c1ccccc1C2		CHEMBL1097088		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293290	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	O=C1Cc2cc(Nc3ccccc3)ccc2Cc2ccccc21		CHEMBL1096988		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293306	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)Oc1ccccc1NC2=O		CHEMBL1098461		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293322	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	Nc1cc(F)ccc1Nc1ccc2c(c1)Oc1ccccc1NC2=O		CHEMBL1098462		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293338	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(-c3ccccc3)ccc21		CHEMBL1096442		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	3293354	CHEMBL1108237	Inhibition of CK2alpha1 at 10 uM	B	O=C1Cc2ccccc2Cc2cc(NCc3ccccc3)ccc21		CHEMBL1097171		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	3331885	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(F)ccc3F)CCN4)cn2)CC1		CHEMBL1165499	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3333300	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cn2)CC1		CHEMBL1164180	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3334705	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3Cl)CCN4)cn2)CC1		CHEMBL1164181	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3336125	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3337492	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	O=C(O)c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1		CHEMBL1163510	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3337740	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCCCC1		CHEMBL1163518	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3339072	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	COC1CCN(C(=O)c2ccc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)cc2)CC1		CHEMBL1163567	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3340374	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	O=C(c1ccc(-c2cnc3c(c2)N(Cc2cc(Cl)ccc2C(F)(F)F)CCN3)cc1)N1CCC(N2CCCC2)CC1		CHEMBL1163559	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3340653	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	FC(F)(F)c1ccc(Cl)cc1CN1CCNc2ncc(-c3ccnc(N4CCNCC4)c3)cc21		CHEMBL1163566	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3342069	CHEMBL1168844	Inhibition of CSNK2A1 at 1 uM	B	CC(=O)N1CCN(c2cc(-c3cnc4c(c3)N(Cc3cc(Cl)ccc3C(F)(F)F)CCN4)ccn2)CC1		CHEMBL1163565	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	3358518	CHEMBL1174190	Inhibition of CSNK2A1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cccnc4)c3)cc2C(F)(F)F)CC1		CHEMBL1171523	=	Inhibition	%	100.0	CHEMBL3629	Homo sapiens	INH	%	100.0
	3358960	CHEMBL1174190	Inhibition of CSNK2A1 at 10 uM	B	CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(C#Cc4cnc5[nH]ccc5c4)c3)cc2C(F)(F)F)CC1		CHEMBL1170139	=	Inhibition	%	100.0	CHEMBL3629	Homo sapiens	INH	%	100.0
	3370960	CHEMBL1211217	Inhibition of CK2alpha assessed as residual activity at 10 uM relative to control	B	O=C(Nc1ncnc2[nH]c(-c3ccc4ccccc4c3)nc12)C1CC1		CHEMBL1210406	=	Activity	%	59.45	CHEMBL3629	Homo sapiens	Activity	%	59.45
	3370974	CHEMBL1211279	Inhibition of CK2alpha	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	IC50	nM	3617.0	CHEMBL3629	Homo sapiens	IC50	nM	3617.0
	3375329	CHEMBL1211217	Inhibition of CK2alpha assessed as residual activity at 10 uM relative to control	B	c1ccc(Nc2ncnc3[nH]c(-c4ccccc4)nc23)cc1		CHEMBL1210175	=	Activity	%	77.02	CHEMBL3629	Homo sapiens	Activity	%	77.02
	3443371	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc(Br)c(O)c2)c2c(N)ncnc21		CHEMBL1241578	=	Inhibition	%	0.0	CHEMBL3629	Homo sapiens	INH	%	0.0
	3443588	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1		CHEMBL1081312	=	Inhibition	%	1.0	CHEMBL3629	Homo sapiens	INH	%	1.0
	3444743	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2ccc3ncccc3c2)c2c(N)ncnc21		CHEMBL1233882	=	Inhibition	%	9.0	CHEMBL3629	Homo sapiens	INH	%	9.0
	3445073	CHEMBL1244782	Binding affinity to CSNK2A1	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	69.0	CHEMBL3629	Homo sapiens	Kd	nM	69.0
	3445367	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	COc1ccc(-c2nn(C3CCC3)c3ncnc(N)c23)cc1OC		CHEMBL1233881	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	INH	%	2.0
	3445584	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Inhibition	%	12.0	CHEMBL3629	Homo sapiens	INH	%	12.0
	3445796	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	CC(C)n1nc(-c2cccc(O)c2)c2c(N)ncnc21		CHEMBL1230790	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	INH	%	2.0
	3445986	CHEMBL1244404	Inhibition of CK2alpha1 at 1 uM after 60 mins by FRET assay in presence of 10 uM ATP	B	Cn1nc(-c2ccc3ccccc3c2)c2c(N)ncnc21		CHEMBL1234815	=	Inhibition	%	1.0	CHEMBL3629	Homo sapiens	INH	%	1.0
	3448021	CHEMBL1249704	Inhibition of human CK2 activity at 10 uM by radiometric assay	B	NC(=O)c1cccc(-c2cc(Nc3ccc(OC(F)(F)F)cc3)ncn2)c1		CHEMBL483847	=	Inhibition	%	0.0	CHEMBL3629	Homo sapiens	INH	%	0.0
	3448097	CHEMBL1249704	Inhibition of human CK2 activity at 10 uM by radiometric assay	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	=	Inhibition	%	17.0	CHEMBL3629	Homo sapiens	INH	%	17.0
	3448390	CHEMBL1244782	Binding affinity to CSNK2A1	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	3448901	CHEMBL1244782	Binding affinity to CSNK2A1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	=	Kd	nM	250.0	CHEMBL3629	Homo sapiens	Kd	nM	250.0
	3449144	CHEMBL1244782	Binding affinity to CSNK2A1	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	81.0	CHEMBL3629	Homo sapiens	Kd	nM	81.0
	3449617	CHEMBL1244782	Binding affinity to CSNK2A1	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	3450039	CHEMBL1244782	Binding affinity to CSNK2A1	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	3450958	CHEMBL1244782	Binding affinity to CSNK2A1	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O		CHEMBL1240703	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	uM	10.0
	3463204	CHEMBL1252292	Inhibition of CSNK2A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL379300	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	INH	%	2.0
	3463423	CHEMBL1252292	Inhibition of CSNK2A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	COc1ccccc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1		CHEMBL1254209	=	Inhibition	%	18.0	CHEMBL3629	Homo sapiens	INH	%	18.0
	3463967	CHEMBL1252292	Inhibition of CSNK2A1 at 1 uM in presence of 10 uM ATP by Select Screen kinase assay relative to untreated control	B	O=C(NCCCNc1nc(Nc2cccc(NC(=O)N3CCCC3)c2)ncc1I)c1cccs1		CHEMBL577784	=	Inhibition	%	16.0	CHEMBL3629	Homo sapiens	INH	%	16.0
	3601430	CHEMBL1292404	Inhibition of CK2-alpha1	B	COc1ccc2cc(-c3n[nH]c4cccnc34)[nH]c2c1		CHEMBL1288582	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	5120839	CHEMBL1646924	Inhibition of CSNK2A1 at 10 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	5140507	CHEMBL1646780	Inhibition of CSNK2A1 at 1 uM	B	CC(C)(C)c1cc(C(=O)O)c(NC(=O)Nc2ccc3[nH]ncc3c2)s1		CHEMBL1641799	=	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	5190274	CHEMBL1663326	Inhibition of human recombinant CK2alpha by radiometric assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	1.0	CHEMBL3629	Homo sapiens	IC50	nM	1.0
	5190275	CHEMBL1663327	Inhibition of human recombinant CK2alpha at enzyme-substrate complex by radiometric assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	1.0	CHEMBL3629	Homo sapiens	IC50	nM	1.0
	6158182	CHEMBL1763019	Inhibition of CSNK2A1 at 1 uM relative to control	B	Cc1nc(N)nc(-n2c(Nc3cccc(O)c3)nc3ccccc32)n1		CHEMBL1762788	=	Inhibition	%	15.0	CHEMBL3629	Homo sapiens	INH	%	15.0
	6227701	CHEMBL1786244	Inhibition of CSNK2A1 at 100 nM relative to control	B	O=C(O)c1cc2cc(Br)cc(NCC3CCNCC3)c2o1		CHEMBL1782521	=	Inhibition	%	21.0	CHEMBL3629	Homo sapiens	INH	%	21.0
	6340966	CHEMBL1827290	Activity of CSNK2A1 kinase at 1 uM	B	CC(=O)Nc1cn2nc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(F)cc4)c3)ccc2n1		CHEMBL1822054	=	Activity	%	95.0	CHEMBL3629	Homo sapiens	Activity	%	95.0
	6352199	CHEMBL1825736	Inhibition of CK2alpha assessed as residual activity at 10 uM by radioactivity assay in presence of 20 uM ATP	B	Nc1n[nH]c(N)c1/N=N/c1ccc(O)cc1		CHEMBL215205	=	Activity	%	48.0	CHEMBL3629	Homo sapiens	Activity	%	48.0
	7567243	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7567702	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12		CHEMBL221959	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7568173	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7568631	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c(C)c1C(=O)NC[C@H](O)CN1CCOCC1		CHEMBL1721885	=	Kd	nM	1900.0	CHEMBL3629	Homo sapiens	Kd	nM	1900.0
	7569216	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21		CHEMBL1614701	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7569676	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL601719	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7570148	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1		CHEMBL1789941	=	Kd	nM	4200.0	CHEMBL3629	Homo sapiens	Kd	nM	4200.0
	7570169	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1		CHEMBL450786	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7570596	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C		CHEMBL535	=	Kd	nM	900.0	CHEMBL3629	Homo sapiens	Kd	nM	900.0
	7571192	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL513909	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7571649	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7572146	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Oc1cccc(-c2nc(N3CCOCC3)c3oc4ncccc4c3n2)c1		CHEMBL573339	=	Kd	nM	5400.0	CHEMBL3629	Homo sapiens	Kd	nM	5400.0
	7572562	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7573173	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1		CHEMBL502835	=	Kd	nM	7500.0	CHEMBL3629	Homo sapiens	Kd	nM	7500.0
	7573664	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1.Cl		CHEMBL1908395	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7574133	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL608533	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7574541	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Nc1nc(N)c2nc(-c3cccc(O)c3)c(-c3cccc(O)c3)nc2n1		CHEMBL230011	=	Kd	nM	2800.0	CHEMBL3629	Homo sapiens	Kd	nM	2800.0
	7575170	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7575641	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc(Oc2ccnc3cc(OC)c(OC)cc23)ccc1NC(=O)NC(C)c1nccs1		CHEMBL1908396	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7576106	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(Cl)cc23)c1F		CHEMBL1230020	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7576514	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1cnc(Nc2ccc(OCCN3CCCC3)cc2)nc1Nc1cccc(S(=O)(=O)NC(C)(C)C)c1		CHEMBL1287853	=	Kd	nM	920.0	CHEMBL3629	Homo sapiens	Kd	nM	920.0
	7576683	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1		CHEMBL1173655	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7577142	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3F)ccnc2cc1OCCCN1CCOCC1		CHEMBL1230609	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7577620	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1		CHEMBL1908397	=	Kd	nM	1200.0	CHEMBL3629	Homo sapiens	Kd	nM	1200.0
	7578090	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CC(C)n1nc(-c2cc3cc(O)ccc3[nH]2)c2c(N)ncnc21		CHEMBL1241674	=	Kd	nM	1200.0	CHEMBL3629	Homo sapiens	Kd	nM	1200.0
	7578495	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1		CHEMBL24828	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7578691	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1n[nH]c2ccc(-c3cncc(OC[C@@H](N)Cc4ccccc4)c3)cc12		CHEMBL379218	=	Kd	nM	5500.0	CHEMBL3629	Homo sapiens	Kd	nM	5500.0
	7579065	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7579515	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1		CHEMBL428690	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7579989	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7580458	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7580861	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7581049	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1		CHEMBL1908391	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7581434	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1ccc2nc(NCCN)c3ncc(C)n3c2c1		CHEMBL249697	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7581879	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	OCCn1cc(-c2ccc3c(c2)CC/C3=N\O)c(-c2ccncc2)n1		CHEMBL525191	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7582350	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cn1cc(C2=C(c3cn(C4CCN(Cc5ccccn5)CC4)c4ccccc34)C(=O)NC2=O)c2ccccc21		CHEMBL300138	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7582814	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Kd	nM	64.0	CHEMBL3629	Homo sapiens	Kd	nM	64.0
	7583395	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7583792	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCNCC3)s2)o1		CHEMBL296468	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7584237	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CS(=O)(=O)N1CCN(Cc2cc3nc(-c4cccc5[nH]ncc45)nc(N4CCOCC4)c3s2)CC1		CHEMBL521851	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7584708	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CN(C)C[C@@H]1CCn2cc(c3ccccc32)C2=C(C(=O)NC2=O)c2cn(c3ccccc23)CCO1		CHEMBL91829	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7585132	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7585725	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(-c3cn4c(n3)sc3cc(OCCN5CCOCC5)ccc34)cc2)no1		CHEMBL576982	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7586133	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1cc2c(F)c(Oc3ncnn4cc(OC[C@@H](C)O)c(C)c34)ccc2[nH]1		CHEMBL377300	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7586579	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7587062	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1ccc(F)c(F)c1C(=O)c1cnc(NC2CCN(S(C)(=O)=O)CC2)nc1N		CHEMBL384304	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7587686	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CNC(=O)c1ccccc1Sc1ccc2c(/C=C/c3ccccn3)n[nH]c2c1		CHEMBL1289926	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7588105	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C[C@]12O[C@H](C[C@]1(O)CO)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)CNC4=O		CHEMBL603469	=	Kd	nM	2600.0	CHEMBL3629	Homo sapiens	Kd	nM	2600.0
	7588587	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1c(Cl)cc2c([nH]c3cnccc32)c1NC(=O)c1cccnc1C		CHEMBL608154	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7589038	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7589651	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21		CHEMBL572881	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7590075	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	=	Kd	nM	2600.0	CHEMBL3629	Homo sapiens	Kd	nM	2600.0
	7590100	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CNC(=O)c1c(F)cccc1Nc1nc(Nc2cc3c(cc2OC)CCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL464552	=	Kd	nM	2800.0	CHEMBL3629	Homo sapiens	Kd	nM	2800.0
	7590574	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7591025	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cn1cc(-c2ccc3nnc(Sc4ccc5ncccc5c4)n3n2)cn1		CHEMBL1236107	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7591624	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CCN1CCN(Cc2ccc(NC(=O)Nc3ccc(Oc4cc(NC)ncn4)cc3)cc2C(F)(F)F)CC1		CHEMBL574738	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7592076	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C[C@@H](Oc1cc(-n2cnc3ccc(CN4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1908394	=	Kd	nM	7300.0	CHEMBL3629	Homo sapiens	Kd	nM	7300.0
	7592549	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7593002	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1cc(Nc2c(C#N)cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)c(Cl)cc1Cl		CHEMBL288441	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7593584	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cn1c(Nc2ccc(C(F)(F)F)cc2)nc2cc(Oc3ccnc(-c4ncc(C(F)(F)F)[nH]4)c3)ccc21		CHEMBL558752	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7594056	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@H]3CCCNC3)c21		CHEMBL494089	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7594529	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1		CHEMBL255863	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7594981	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7595117	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	O=C(NC1CCNCC1)c1n[nH]cc1NC(=O)c1c(Cl)cccc1Cl		CHEMBL445813	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7595561	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	C=CC(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1		CHEMBL31965	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7596035	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7596506	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O		CHEMBL477772	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7596953	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Kd	nM	940.0	CHEMBL3629	Homo sapiens	Kd	nM	940.0
	7597089	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7597542	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7598015	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/CN(C)C		CHEMBL180022	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7598485	CHEMBL1908545	Binding constant for CSNK2A1 kinase domain	B	CSc1cccc(Nc2ncc3cc(-c4c(Cl)cccc4Cl)c(=O)n(C)c3n2)c1		CHEMBL386051	>	Kd	nM	10000.0	CHEMBL3629	Homo sapiens	Kd	nM	10000.0
	7922684	CHEMBL1918462	Inhibition of human recombinant CK2alpha1 at 0.5 uM by radiometric filter-binding assay	B	Clc1ccccc1Nc1nc2c(-c3nnc[nH]3)cccc2c2cnccc12		CHEMBL1915438	=	Inhibition	%	42.0	CHEMBL3629	Homo sapiens	INH	%	42.0
	7959715	CHEMBL1932832	Inhibition of CK2alpha	B	CN(C)CCN1CCN(C(=O)c2cc(C(C)(C)C)sc2NC(=O)Nc2cccc(Cl)c2Cl)CCC1=O		CHEMBL1929238	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	7959716	CHEMBL1932832	Inhibition of CK2alpha	B	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	7978939	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	462.0	CHEMBL3629	Homo sapiens	Ki	nM	462.0
	7978940	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Ic1c(I)c(I)c2[nH]cnc2c1I		CHEMBL595730	=	Ki	nM	266.0	CHEMBL3629	Homo sapiens	Ki	nM	266.0
	7978941	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Ki	nM	97.0	CHEMBL3629	Homo sapiens	Ki	nM	97.0
	7978942	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1C		CHEMBL375230	=	Ki	nM	212.0	CHEMBL3629	Homo sapiens	Ki	nM	212.0
	7978943	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL223082	=	Ki	nM	106.0	CHEMBL3629	Homo sapiens	Ki	nM	106.0
	7978944	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928903	=	Ki	nM	116.0	CHEMBL3629	Homo sapiens	Ki	nM	116.0
	7978945	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CCCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928904	=	Ki	nM	77.0	CHEMBL3629	Homo sapiens	Ki	nM	77.0
	7978946	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Cn1c(SCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928905	=	Ki	nM	143.0	CHEMBL3629	Homo sapiens	Ki	nM	143.0
	7978947	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Cn1c(SCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928906	=	Ki	nM	112.0	CHEMBL3629	Homo sapiens	Ki	nM	112.0
	7978948	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	Cn1c(SCCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928907	=	Ki	nM	88.0	CHEMBL3629	Homo sapiens	Ki	nM	88.0
	7978949	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(I)c(I)c(I)c(I)c2[nH]1		CHEMBL610448	=	Ki	nM	110.0	CHEMBL3629	Homo sapiens	Ki	nM	110.0
	7978950	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL594575	=	Ki	nM	798.0	CHEMBL3629	Homo sapiens	Ki	nM	798.0
	7978951	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)CCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928908	=	Ki	nM	472.0	CHEMBL3629	Homo sapiens	Ki	nM	472.0
	7978952	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CC(=O)O		CHEMBL1233807	=	Ki	nM	88.0	CHEMBL3629	Homo sapiens	Ki	nM	88.0
	7978953	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCCC(=O)O		CHEMBL1928909	=	Ki	nM	860.0	CHEMBL3629	Homo sapiens	Ki	nM	860.0
	7978954	CHEMBL1930358	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BE21 (DE3) assessed as [33P]gamma-ATP incorporation into P2B substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(I)c(I)c(I)c(I)c21		CHEMBL593153	=	Ki	nM	378.0	CHEMBL3629	Homo sapiens	Ki	nM	378.0
	7978955	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	315.0	CHEMBL3629	Homo sapiens	Ki	nM	315.0
	7978956	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Ic1c(I)c(I)c2[nH]cnc2c1I		CHEMBL595730	=	Ki	nM	43.0	CHEMBL3629	Homo sapiens	Ki	nM	43.0
	7978957	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Ki	nM	139.0	CHEMBL3629	Homo sapiens	Ki	nM	139.0
	7978958	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1C		CHEMBL375230	=	Ki	nM	154.0	CHEMBL3629	Homo sapiens	Ki	nM	154.0
	7978959	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL223082	=	Ki	nM	170.0	CHEMBL3629	Homo sapiens	Ki	nM	170.0
	7978960	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928903	=	Ki	nM	172.0	CHEMBL3629	Homo sapiens	Ki	nM	172.0
	7978961	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CCCSc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL1928904	=	Ki	nM	210.0	CHEMBL3629	Homo sapiens	Ki	nM	210.0
	7978962	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Cn1c(SCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928905	=	Ki	nM	13.0	CHEMBL3629	Homo sapiens	Ki	nM	13.0
	7978963	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Cn1c(SCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928906	=	Ki	nM	137.0	CHEMBL3629	Homo sapiens	Ki	nM	137.0
	7978964	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	Cn1c(SCCCC(=O)O)nc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928907	=	Ki	nM	501.0	CHEMBL3629	Homo sapiens	Ki	nM	501.0
	7978965	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CSc1nc2c(I)c(I)c(I)c(I)c2[nH]1		CHEMBL610448	=	Ki	nM	80.0	CHEMBL3629	Homo sapiens	Ki	nM	80.0
	7978966	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL594575	=	Ki	nM	670.0	CHEMBL3629	Homo sapiens	Ki	nM	670.0
	7978967	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)CCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL1928908	=	Ki	nM	368.0	CHEMBL3629	Homo sapiens	Ki	nM	368.0
	7978968	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CC(=O)O		CHEMBL1233807	=	Ki	nM	83.0	CHEMBL3629	Homo sapiens	Ki	nM	83.0
	7978969	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCCC(=O)O		CHEMBL1928909	=	Ki	nM	456.0	CHEMBL3629	Homo sapiens	Ki	nM	456.0
	7978970	CHEMBL1930359	Inhibition of human CK2 alpha catalytic subunit expressed in Escherichia coli BL21 (DE3) assessed as [33P]gamma-ATP incorporation into RRRADDSDDDDD substrate after 15 mins by scintillation counting	B	O=C(O)Cn1cnc2c(I)c(I)c(I)c(I)c21		CHEMBL593153	=	Ki	nM	261.0	CHEMBL3629	Homo sapiens	Ki	nM	261.0
	7992180	CHEMBL1935898	Inhibition of CK2 alpha 1 at 1 uM	B	CN(c1ccccc1-c1cc(Cl)c2cnc(Nc3ccc(C4CCN(CC(N)=O)CC4)cc3)nn12)S(C)(=O)=O		CHEMBL1934353	=	Inhibition	%	5.0	CHEMBL3629	Homo sapiens	INH	%	5.0
	8047098	CHEMBL1958839	Inhibition of CSNK2A1 at 1 uM	B	CN1CCN(c2ccc(Nc3nc(N)c(C(=O)c4ccc5c(c4)OCCO5)s3)cc2)CC1		CHEMBL1956070	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	8061320	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	0.86	CHEMBL3629	Homo sapiens	Inhibition	%	0.86
	8061497	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	13.77	CHEMBL3629	Homo sapiens	Inhibition	%	13.77
	8061828	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	8.56	CHEMBL3629	Homo sapiens	Inhibition	%	8.56
	8062019	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	1.08	CHEMBL3629	Homo sapiens	Inhibition	%	1.08
	8062359	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	1.78	CHEMBL3629	Homo sapiens	Inhibition	%	1.78
	8062521	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	13.27	CHEMBL3629	Homo sapiens	Inhibition	%	13.27
	8062745	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	7.12	CHEMBL3629	Homo sapiens	Inhibition	%	7.12
	8062843	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-5.18	CHEMBL3629	Homo sapiens	Inhibition	%	-5.18
	8063199	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NCc1ccc(-c2nc(-c3ccc(Cl)c(O)c3)c(-c3ccncc3)[nH]2)cc1		CHEMBL1909412	=	Inhibition	%	1.53	CHEMBL3629	Homo sapiens	Inhibition	%	1.53
	8063366	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	2.8	CHEMBL3629	Homo sapiens	Inhibition	%	2.8
	8063698	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	2.1	CHEMBL3629	Homo sapiens	Inhibition	%	2.1
	8063880	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Inhibition	%	6.39	CHEMBL3629	Homo sapiens	Inhibition	%	6.39
	8064104	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	0.21	CHEMBL3629	Homo sapiens	Inhibition	%	0.21
	8064219	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cn1c(-c2nonc2N)nc2cnccc21		CHEMBL188048	=	Inhibition	%	-1.25	CHEMBL3629	Homo sapiens	Inhibition	%	-1.25
	8064429	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.08	CHEMBL3629	Homo sapiens	Inhibition	%	-1.08
	8064653	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@@H]1CN[C@@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL466412	=	Inhibition	%	-1.78	CHEMBL3629	Homo sapiens	Inhibition	%	-1.78
	8064791	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	1.03	CHEMBL3629	Homo sapiens	Inhibition	%	1.03
	8064957	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(Cl)c(C(F)(F)F)c3)n2)cc1		CHEMBL188794	=	Inhibition	%	8.2	CHEMBL3629	Homo sapiens	Inhibition	%	8.2
	8065181	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	3.46	CHEMBL3629	Homo sapiens	Inhibition	%	3.46
	8065297	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL1909378	=	Inhibition	%	4.61	CHEMBL3629	Homo sapiens	Inhibition	%	4.61
	8065696	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)c1		CHEMBL362155	=	Inhibition	%	-1.98	CHEMBL3629	Homo sapiens	Inhibition	%	-1.98
	8065811	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.64	CHEMBL3629	Homo sapiens	Inhibition	%	0.64
	8066245	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	0.7	CHEMBL3629	Homo sapiens	Inhibition	%	0.7
	8066381	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(Nc2ncc(-c3ccccc3)o2)cc1OC.Cl		CHEMBL1794060	=	Inhibition	%	6.83	CHEMBL3629	Homo sapiens	Inhibition	%	6.83
	8066771	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3n2)cc1		CHEMBL408732	=	Inhibition	%	8.9	CHEMBL3629	Homo sapiens	Inhibition	%	8.9
	8066895	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.56	CHEMBL3629	Homo sapiens	Inhibition	%	2.56
	8067119	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(Br)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909370	=	Inhibition	%	2.62	CHEMBL3629	Homo sapiens	Inhibition	%	2.62
	8067294	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	-0.42	CHEMBL3629	Homo sapiens	Inhibition	%	-0.42
	8067415	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(N(C)C)cc4)c3)cc21		CHEMBL220465	=	Inhibition	%	0.04	CHEMBL3629	Homo sapiens	Inhibition	%	0.04
	8067639	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	-0.45	CHEMBL3629	Homo sapiens	Inhibition	%	-0.45
	8067849	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL365072	=	Inhibition	%	-1.05	CHEMBL3629	Homo sapiens	Inhibition	%	-1.05
	8067984	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	8.84	CHEMBL3629	Homo sapiens	Inhibition	%	8.84
	8068208	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(-c3cnn4ncccc34)n2)cc(OC)c1		CHEMBL359999	=	Inhibition	%	42.73	CHEMBL3629	Homo sapiens	Inhibition	%	42.73
	8068372	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	2.39	CHEMBL3629	Homo sapiens	Inhibition	%	2.39
	8068721	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	0.61	CHEMBL3629	Homo sapiens	Inhibition	%	0.61
	8068895	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(S(=O)(=O)c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.Cl		CHEMBL1909367	=	Inhibition	%	-2.21	CHEMBL3629	Homo sapiens	Inhibition	%	-2.21
	8069244	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ccccc3c2-c2ccncc2)cc1		CHEMBL485745	=	Inhibition	%	0.13	CHEMBL3629	Homo sapiens	Inhibition	%	0.13
	8069539	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	8.53	CHEMBL3629	Homo sapiens	Inhibition	%	8.53
	8069700	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.N#Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL1794061	=	Inhibition	%	11.73	CHEMBL3629	Homo sapiens	Inhibition	%	11.73
	8070050	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)cc2)sc2c1CCCC2		CHEMBL397570	=	Inhibition	%	1.89	CHEMBL3629	Homo sapiens	Inhibition	%	1.89
	8070222	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	0.27	CHEMBL3629	Homo sapiens	Inhibition	%	0.27
	8070571	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.16	CHEMBL3629	Homo sapiens	Inhibition	%	0.16
	8070869	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(c2ccc(Nc3nccc(-c4cnn5ncccc45)n3)cc2C(F)(F)F)CC1		CHEMBL468963	=	Inhibition	%	47.13	CHEMBL3629	Homo sapiens	Inhibition	%	47.13
	8071026	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	3.02	CHEMBL3629	Homo sapiens	Inhibition	%	3.02
	8071250	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(Cl)cc2c1NC(=O)C2=NNc1ccc(S(N)(=O)=O)cc1		CHEMBL1909397	=	Inhibition	%	8.79	CHEMBL3629	Homo sapiens	Inhibition	%	8.79
	8071376	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	1.46	CHEMBL3629	Homo sapiens	Inhibition	%	1.46
	8071549	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4)n3C)ccc2c1		CHEMBL399410	=	Inhibition	%	-4.21	CHEMBL3629	Homo sapiens	Inhibition	%	-4.21
	8071773	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	-0.1	CHEMBL3629	Homo sapiens	Inhibition	%	-0.1
	8071898	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL206544	=	Inhibition	%	0.83	CHEMBL3629	Homo sapiens	Inhibition	%	0.83
	8072212	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.44	CHEMBL3629	Homo sapiens	Inhibition	%	-0.44
	8072593	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	1.57	CHEMBL3629	Homo sapiens	Inhibition	%	1.57
	8072718	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(-c2n[nH]cc2-c2ccc3ncccc3n2)n1		CHEMBL185238	=	Inhibition	%	4.82	CHEMBL3629	Homo sapiens	Inhibition	%	4.82
	8073109	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)c(Br)cc12)C1CC1		CHEMBL408564	=	Inhibition	%	-1.87	CHEMBL3629	Homo sapiens	Inhibition	%	-1.87
	8073234	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	-0.3	CHEMBL3629	Homo sapiens	Inhibition	%	-0.3
	8073458	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2s1.Cl		CHEMBL1909369	=	Inhibition	%	1.75	CHEMBL3629	Homo sapiens	Inhibition	%	1.75
	8073577	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-2.8	CHEMBL3629	Homo sapiens	Inhibition	%	-2.8
	8073810	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3cccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)c3)ccc2[nH]1.Cl		CHEMBL1909366	=	Inhibition	%	-0.84	CHEMBL3629	Homo sapiens	Inhibition	%	-0.84
	8074034	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	-0.41	CHEMBL3629	Homo sapiens	Inhibition	%	-0.41
	8074186	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4ccccc4)cc3)ccc2[nH]1.Cl		CHEMBL1909371	=	Inhibition	%	7.67	CHEMBL3629	Homo sapiens	Inhibition	%	7.67
	8074316	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	-0.24	CHEMBL3629	Homo sapiens	Inhibition	%	-0.24
	8074540	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)N(C)C)s3)c2cc1OC		CHEMBL482326	=	Inhibition	%	2.74	CHEMBL3629	Homo sapiens	Inhibition	%	2.74
	8074697	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	1.72	CHEMBL3629	Homo sapiens	Inhibition	%	1.72
	8075048	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.04	CHEMBL3629	Homo sapiens	Inhibition	%	1.04
	8075159	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL271843	=	Inhibition	%	-4.47	CHEMBL3629	Homo sapiens	Inhibition	%	-4.47
	8075383	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-2.49	CHEMBL3629	Homo sapiens	Inhibition	%	-2.49
	8075620	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(CN3CCCC3)cc21		CHEMBL1096290	=	Inhibition	%	0.78	CHEMBL3629	Homo sapiens	Inhibition	%	0.78
	8075761	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	2.24	CHEMBL3629	Homo sapiens	Inhibition	%	2.24
	8076127	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	-0.88	CHEMBL3629	Homo sapiens	Inhibition	%	-0.88
	8076275	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)Cc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785002	=	Inhibition	%	2.63	CHEMBL3629	Homo sapiens	Inhibition	%	2.63
	8076633	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc3ncccc23)c2cc[nH]c2n1		CHEMBL458438	=	Inhibition	%	1.8	CHEMBL3629	Homo sapiens	Inhibition	%	1.8
	8076959	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(CCCN3CCOCC3)c2-c2ccncc2)cc1		CHEMBL14112	=	Inhibition	%	-6.0	CHEMBL3629	Homo sapiens	Inhibition	%	-6.0
	8077206	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	-0.87	CHEMBL3629	Homo sapiens	Inhibition	%	-0.87
	8077334	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL156987	=	Inhibition	%	7.88	CHEMBL3629	Homo sapiens	Inhibition	%	7.88
	8077558	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	1.51	CHEMBL3629	Homo sapiens	Inhibition	%	1.51
	8077709	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4C(F)(F)F)c(C(N)=O)s3)c2c1		CHEMBL522709	=	Inhibition	%	5.02	CHEMBL3629	Homo sapiens	Inhibition	%	5.02
	8077852	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	1.36	CHEMBL3629	Homo sapiens	Inhibition	%	1.36
	8078076	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCCc4ccccc4)c(C(N)=O)s3)c2cc1OC		CHEMBL473629	=	Inhibition	%	-0.04	CHEMBL3629	Homo sapiens	Inhibition	%	-0.04
	8078215	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	5.31	CHEMBL3629	Homo sapiens	Inhibition	%	5.31
	8078541	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-3.67	CHEMBL3629	Homo sapiens	Inhibition	%	-3.67
	8078791	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(O[C@@H](CN)c3ccccc3)cc21.O=C(O)C(F)(F)F		CHEMBL1909349	=	Inhibition	%	3.9	CHEMBL3629	Homo sapiens	Inhibition	%	3.9
	8079131	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)Nc4cccc(C#N)c4)cc3)c2)o1		CHEMBL270164	=	Inhibition	%	6.5	CHEMBL3629	Homo sapiens	Inhibition	%	6.5
	8079289	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	1.09	CHEMBL3629	Homo sapiens	Inhibition	%	1.09
	8079655	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	-1.48	CHEMBL3629	Homo sapiens	Inhibition	%	-1.48
	8079794	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3ccc(O)c(F)c3)n[nH]2)cc1		CHEMBL103115	=	Inhibition	%	29.56	CHEMBL3629	Homo sapiens	Inhibition	%	29.56
	8080123	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.ON=C1CCc2cc(-c3nc(C4CCNCC4)[nH]c3-c3ccncc3)ccc21		CHEMBL1794071	=	Inhibition	%	-3.6	CHEMBL3629	Homo sapiens	Inhibition	%	-3.6
	8080375	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	7.86	CHEMBL3629	Homo sapiens	Inhibition	%	7.86
	8080714	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	3.44	CHEMBL3629	Homo sapiens	Inhibition	%	3.44
	8080878	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC[C@@H](O)CO)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794067	=	Inhibition	%	10.15	CHEMBL3629	Homo sapiens	Inhibition	%	10.15
	8081237	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(F)c5)c4c3)o2)CC1		CHEMBL1909391	=	Inhibition	%	1.56	CHEMBL3629	Homo sapiens	Inhibition	%	1.56
	8081381	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	32.4	CHEMBL3629	Homo sapiens	Inhibition	%	32.4
	8081605	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)CC1		CHEMBL476259	=	Inhibition	%	70.33	CHEMBL3629	Homo sapiens	Inhibition	%	70.33
	8081708	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-2.69	CHEMBL3629	Homo sapiens	Inhibition	%	-2.69
	8081960	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)COC(=O)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL269883	=	Inhibition	%	47.22	CHEMBL3629	Homo sapiens	Inhibition	%	47.22
	8082184	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	-0.44	CHEMBL3629	Homo sapiens	Inhibition	%	-0.44
	8082297	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909411	=	Inhibition	%	7.23	CHEMBL3629	Homo sapiens	Inhibition	%	7.23
	8082470	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	0.26	CHEMBL3629	Homo sapiens	Inhibition	%	0.26
	8082694	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	17.96	CHEMBL3629	Homo sapiens	Inhibition	%	17.96
	8082817	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	0.14	CHEMBL3629	Homo sapiens	Inhibition	%	0.14
	8083197	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	6.89	CHEMBL3629	Homo sapiens	Inhibition	%	6.89
	8083296	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc(Cl)c2)=C1Nc1ccc(O)c(Cl)c1		CHEMBL160333	=	Inhibition	%	-1.28	CHEMBL3629	Homo sapiens	Inhibition	%	-1.28
	8083520	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-2.9	CHEMBL3629	Homo sapiens	Inhibition	%	-2.9
	8083774	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CCCCC1		CHEMBL189231	=	Inhibition	%	4.16	CHEMBL3629	Homo sapiens	Inhibition	%	4.16
	8083884	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	8.38	CHEMBL3629	Homo sapiens	Inhibition	%	8.38
	8084293	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	5.01	CHEMBL3629	Homo sapiens	Inhibition	%	5.01
	8084411	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL517507	=	Inhibition	%	-0.02	CHEMBL3629	Homo sapiens	Inhibition	%	-0.02
	8084635	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	1.2	CHEMBL3629	Homo sapiens	Inhibition	%	1.2
	8084796	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCCn4ccnc4)cc32)cc1		CHEMBL272026	=	Inhibition	%	21.02	CHEMBL3629	Homo sapiens	Inhibition	%	21.02
	8085118	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL103080	=	Inhibition	%	-3.51	CHEMBL3629	Homo sapiens	Inhibition	%	-3.51
	8085374	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3Cc2ccccc2)ccc1O		CHEMBL1789962	=	Inhibition	%	-0.94	CHEMBL3629	Homo sapiens	Inhibition	%	-0.94
	8085482	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC1		CHEMBL95207	=	Inhibition	%	42.69	CHEMBL3629	Homo sapiens	Inhibition	%	42.69
	8085706	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(Nc3ccccc3)n2)CC1		CHEMBL318892	=	Inhibition	%	3.62	CHEMBL3629	Homo sapiens	Inhibition	%	3.62
	8085895	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc4ncccc4c32)cc1		CHEMBL409892	=	Inhibition	%	32.22	CHEMBL3629	Homo sapiens	Inhibition	%	32.22
	8086234	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4c(cnn4Cc4ccccc4)c3)ncnc2cn1		CHEMBL30432	=	Inhibition	%	-0.12	CHEMBL3629	Homo sapiens	Inhibition	%	-0.12
	8086396	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1		CHEMBL261129	=	Inhibition	%	6.41	CHEMBL3629	Homo sapiens	Inhibition	%	6.41
	8086719	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccncc21		CHEMBL185710	=	Inhibition	%	-4.19	CHEMBL3629	Homo sapiens	Inhibition	%	-4.19
	8086930	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	16.88	CHEMBL3629	Homo sapiens	Inhibition	%	16.88
	8087312	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1	Outside typical range	CHEMBL517666	=	Inhibition	%	-12.14	CHEMBL3629	Homo sapiens	Inhibition	%	-12.14
	8087426	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	7.45	CHEMBL3629	Homo sapiens	Inhibition	%	7.45
	8087650	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	6.18	CHEMBL3629	Homo sapiens	Inhibition	%	6.18
	8087788	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	3.7	CHEMBL3629	Homo sapiens	Inhibition	%	3.7
	8088154	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	2.82	CHEMBL3629	Homo sapiens	Inhibition	%	2.82
	8088302	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	0.89	CHEMBL3629	Homo sapiens	Inhibition	%	0.89
	8088654	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	6.99	CHEMBL3629	Homo sapiens	Inhibition	%	6.99
	8088971	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	-1.31	CHEMBL3629	Homo sapiens	Inhibition	%	-1.31
	8089099	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	0.96	CHEMBL3629	Homo sapiens	Inhibition	%	0.96
	8089471	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	1.84	CHEMBL3629	Homo sapiens	Inhibition	%	1.84
	8089591	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	4.79	CHEMBL3629	Homo sapiens	Inhibition	%	4.79
	8089815	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	3.8	CHEMBL3629	Homo sapiens	Inhibition	%	3.8
	8089995	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	2.55	CHEMBL3629	Homo sapiens	Inhibition	%	2.55
	8090160	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	6.72	CHEMBL3629	Homo sapiens	Inhibition	%	6.72
	8090384	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN1CCN(C(C)C)CC1)CC2		CHEMBL505915	=	Inhibition	%	10.06	CHEMBL3629	Homo sapiens	Inhibition	%	10.06
	8090551	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	13.34	CHEMBL3629	Homo sapiens	Inhibition	%	13.34
	8090690	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	7.82	CHEMBL3629	Homo sapiens	Inhibition	%	7.82
	8090914	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	2.7	CHEMBL3629	Homo sapiens	Inhibition	%	2.7
	8091119	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	9.29	CHEMBL3629	Homo sapiens	Inhibition	%	9.29
	8091256	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(Cl)cccc2Cl)c1		CHEMBL263796	=	Inhibition	%	14.9	CHEMBL3629	Homo sapiens	Inhibition	%	14.9
	8091480	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	33.71	CHEMBL3629	Homo sapiens	Inhibition	%	33.71
	8091635	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCC(=O)Nc1ccc(C)c(-c2ccc(C(=O)NCC3CC3)cc2)c1		CHEMBL517666	=	Inhibition	%	2.11	CHEMBL3629	Homo sapiens	Inhibition	%	2.11
	8091975	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Nc1ncc(-c2ccccc2)o1.Cl		CHEMBL1794062	=	Inhibition	%	8.04	CHEMBL3629	Homo sapiens	Inhibition	%	8.04
	8092112	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	6.73	CHEMBL3629	Homo sapiens	Inhibition	%	6.73
	8092487	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%		CHEMBL3629	Homo sapiens	Inhibition	%	
	8092635	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2cc(-c3ccccc3)cc(C(N)=O)c2N)cc1		CHEMBL230597	=	Inhibition	%	2.26	CHEMBL3629	Homo sapiens	Inhibition	%	2.26
	8092859	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	-0.4	CHEMBL3629	Homo sapiens	Inhibition	%	-0.4
	8092988	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL521806	=	Inhibition	%	3.34	CHEMBL3629	Homo sapiens	Inhibition	%	3.34
	8093300	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	1.23	CHEMBL3629	Homo sapiens	Inhibition	%	1.23
	8093440	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC(Oc2cc(Nc3nc(Nc4cccc(F)c4C(N)=O)c4cc[nH]c4n3)c(OC)cc2Cl)CC1		CHEMBL517171	=	Inhibition	%	7.7	CHEMBL3629	Homo sapiens	Inhibition	%	7.7
	8093664	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	0.95	CHEMBL3629	Homo sapiens	Inhibition	%	0.95
	8093803	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)=Cc1cccc2c1/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL270544	=	Inhibition	%	10.64	CHEMBL3629	Homo sapiens	Inhibition	%	10.64
	8094147	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3Cl)o2)c1		CHEMBL179453	=	Inhibition	%	23.3	CHEMBL3629	Homo sapiens	Inhibition	%	23.3
	8094327	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	1.49	CHEMBL3629	Homo sapiens	Inhibition	%	1.49
	8094726	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	15.72	CHEMBL3629	Homo sapiens	Inhibition	%	15.72
	8094882	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nc(-c2ccccc2)n2nc(NCCCN3CCOCC3)ncc12		CHEMBL486124	=	Inhibition	%	6.84	CHEMBL3629	Homo sapiens	Inhibition	%	6.84
	8095246	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2ccc(OC(F)(F)F)cc2)cc1)c1ccnc(Nc2cccc(S(N)(=O)=O)c2)n1		CHEMBL188381	=	Inhibition	%	1.68	CHEMBL3629	Homo sapiens	Inhibition	%	1.68
	8095449	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)o1.Cl		CHEMBL1909385	=	Inhibition	%	3.86	CHEMBL3629	Homo sapiens	Inhibition	%	3.86
	8095814	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCC=C(c2ccc(Nc3nc(Nc4ccccc4C(N)=O)c4cc[nH]c4n3)c(C)c2)C1		CHEMBL513897	=	Inhibition	%	72.01	CHEMBL3629	Homo sapiens	Inhibition	%	72.01
	8095962	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	-5.08	CHEMBL3629	Homo sapiens	Inhibition	%	-5.08
	8096303	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	12.04	CHEMBL3629	Homo sapiens	Inhibition	%	12.04
	8096442	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccccc3)n2)cc1		CHEMBL275798	=	Inhibition	%	1.68	CHEMBL3629	Homo sapiens	Inhibition	%	1.68
	8096666	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	3.5	CHEMBL3629	Homo sapiens	Inhibition	%	3.5
	8096822	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1cc(-c2cc3c(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)ncnc3s2)cs1		CHEMBL475599	=	Inhibition	%	2.87	CHEMBL3629	Homo sapiens	Inhibition	%	2.87
	8097193	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5cccs5)cc34)cc2Cl)c1		CHEMBL506414	=	Inhibition	%	1.52	CHEMBL3629	Homo sapiens	Inhibition	%	1.52
	8097280	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	3.41	CHEMBL3629	Homo sapiens	Inhibition	%	3.41
	8097500	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)/C=C/C(=O)O.OCCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909403	=	Inhibition	%	6.41	CHEMBL3629	Homo sapiens	Inhibition	%	6.41
	8097874	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@@H](N)c3ccccc3)cc21		CHEMBL1096626	=	Inhibition	%	1.36	CHEMBL3629	Homo sapiens	Inhibition	%	1.36
	8098007	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	1.52	CHEMBL3629	Homo sapiens	Inhibition	%	1.52
	8098351	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	11.62	CHEMBL3629	Homo sapiens	Inhibition	%	11.62
	8098531	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccco2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909353	=	Inhibition	%	3.8	CHEMBL3629	Homo sapiens	Inhibition	%	3.8
	8098755	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	1.23	CHEMBL3629	Homo sapiens	Inhibition	%	1.23
	8098940	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(N)=O)c2cc[nH]c2n1		CHEMBL458865	=	Inhibition	%	54.72	CHEMBL3629	Homo sapiens	Inhibition	%	54.72
	8099084	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	1.05	CHEMBL3629	Homo sapiens	Inhibition	%	1.05
	8099308	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1coc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)cc4)c3c2)c1.Cl		CHEMBL1909386	=	Inhibition	%	6.53	CHEMBL3629	Homo sapiens	Inhibition	%	6.53
	8099450	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	5.99	CHEMBL3629	Homo sapiens	Inhibition	%	5.99
	8099644	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	2.7	CHEMBL3629	Homo sapiens	Inhibition	%	2.7
	8100015	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	-0.43	CHEMBL3629	Homo sapiens	Inhibition	%	-0.43
	8100161	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc4c(cnn4Cc4ccccc4)c3)c2cc1OC.Cl		CHEMBL1909380	=	Inhibition	%	4.31	CHEMBL3629	Homo sapiens	Inhibition	%	4.31
	8100385	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	5.69	CHEMBL3629	Homo sapiens	Inhibition	%	5.69
	8100501	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL275666	=	Inhibition	%	6.22	CHEMBL3629	Homo sapiens	Inhibition	%	6.22
	8100865	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6ccccc6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909393	=	Inhibition	%	2.9	CHEMBL3629	Homo sapiens	Inhibition	%	2.9
	8101025	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%		CHEMBL3629	Homo sapiens	Inhibition	%	
	8101391	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	0.33	CHEMBL3629	Homo sapiens	Inhibition	%	0.33
	8101576	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2c1		CHEMBL493326	=	Inhibition	%	5.1	CHEMBL3629	Homo sapiens	Inhibition	%	5.1
	8101829	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	8.8	CHEMBL3629	Homo sapiens	Inhibition	%	8.8
	8102053	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-c2c[nH]c3c(N/N=C/c4ccncc4)ncnc23)c1		CHEMBL206010	=	Inhibition	%	43.74	CHEMBL3629	Homo sapiens	Inhibition	%	43.74
	8102208	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	-0.25	CHEMBL3629	Homo sapiens	Inhibition	%	-0.25
	8102339	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2cc(Oc3ccc(NC(=O)Nc4cccc(C(=O)O)c4)cc3)ccc2[nH]1.Cl		CHEMBL1909373	=	Inhibition	%	8.32	CHEMBL3629	Homo sapiens	Inhibition	%	8.32
	8102563	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	2.99	CHEMBL3629	Homo sapiens	Inhibition	%	2.99
	8102683	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(COc2cc(-n3cnc4ccccc43)sc2C(N)=O)c1		CHEMBL516248	=	Inhibition	%	-0.53	CHEMBL3629	Homo sapiens	Inhibition	%	-0.53
	8103085	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(COc2ccc(Nc3ncnc4ccc(-c5ccco5)cc34)cc2)cc1		CHEMBL215993	=	Inhibition	%	4.42	CHEMBL3629	Homo sapiens	Inhibition	%	4.42
	8103281	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	1.82	CHEMBL3629	Homo sapiens	Inhibition	%	1.82
	8103643	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	1.61	CHEMBL3629	Homo sapiens	Inhibition	%	1.61
	8103793	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(C)=O)s3)c2cc1OC		CHEMBL471789	=	Inhibition	%	2.45	CHEMBL3629	Homo sapiens	Inhibition	%	2.45
	8103978	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc2c(-c3ccnc(NC4CC4)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1885746	=	Inhibition	%	1.8	CHEMBL3629	Homo sapiens	Inhibition	%	1.8
	8104202	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	4.68	CHEMBL3629	Homo sapiens	Inhibition	%	4.68
	8104350	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C)cc4)ncnc32)c1		CHEMBL303687	=	Inhibition	%	23.14	CHEMBL3629	Homo sapiens	Inhibition	%	23.14
	8104720	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(-c4cnco4)cc32)cc1		CHEMBL269827	=	Inhibition	%	15.21	CHEMBL3629	Homo sapiens	Inhibition	%	15.21
	8104834	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%		CHEMBL3629	Homo sapiens	Inhibition	%	
	8105058	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL13972	=	Inhibition	%	4.89	CHEMBL3629	Homo sapiens	Inhibition	%	4.89
	8105198	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	2.72	CHEMBL3629	Homo sapiens	Inhibition	%	2.72
	8105364	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2ccncc2)cc1C(N)=O		CHEMBL231013	=	Inhibition	%	4.44	CHEMBL3629	Homo sapiens	Inhibition	%	4.44
	8105588	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	8.71	CHEMBL3629	Homo sapiens	Inhibition	%	8.71
	8105726	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1OC		CHEMBL443563	=	Inhibition	%	4.02	CHEMBL3629	Homo sapiens	Inhibition	%	4.02
	8106006	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-0.51	CHEMBL3629	Homo sapiens	Inhibition	%	-0.51
	8106395	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	1.85	CHEMBL3629	Homo sapiens	Inhibition	%	1.85
	8106551	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cccc(Nc2nccc(Nc3cccc4[nH]ncc34)n2)c1		CHEMBL251549	=	Inhibition	%	3.56	CHEMBL3629	Homo sapiens	Inhibition	%	3.56
	8106904	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)S(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL275473	=	Inhibition	%	15.09	CHEMBL3629	Homo sapiens	Inhibition	%	15.09
	8107025	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	9.36	CHEMBL3629	Homo sapiens	Inhibition	%	9.36
	8107249	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1cc(-c2ccnc3[nH]ccc23)c(-c2cccc(NC(=O)Nc3ccc(OCc4ccccc4)cc3)c2)n1		CHEMBL505187	=	Inhibition	%	-1.27	CHEMBL3629	Homo sapiens	Inhibition	%	-1.27
	8107421	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	-1.01	CHEMBL3629	Homo sapiens	Inhibition	%	-1.01
	8107622	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OC[C@H](N)c3ccccc3)cc21		CHEMBL1096634	=	Inhibition	%	4.54	CHEMBL3629	Homo sapiens	Inhibition	%	4.54
	8107981	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NC(=O)c1cccc(Nc2nccc(Nc3cccc(F)c3)n2)c1		CHEMBL1909382	=	Inhibition	%	3.67	CHEMBL3629	Homo sapiens	Inhibition	%	3.67
	8108139	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	5.33	CHEMBL3629	Homo sapiens	Inhibition	%	5.33
	8108538	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Oc3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)cc2[nH]1.Cl		CHEMBL1909364	=	Inhibition	%	1.84	CHEMBL3629	Homo sapiens	Inhibition	%	1.84
	8108685	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	6.48	CHEMBL3629	Homo sapiens	Inhibition	%	6.48
	8109051	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	1.35	CHEMBL3629	Homo sapiens	Inhibition	%	1.35
	8109389	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%		CHEMBL3629	Homo sapiens	Inhibition	%	
	8109519	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Cl)cc3)n2)cc1		CHEMBL275168	=	Inhibition	%	0.7	CHEMBL3629	Homo sapiens	Inhibition	%	0.7
	8109914	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794070	=	Inhibition	%	7.82	CHEMBL3629	Homo sapiens	Inhibition	%	7.82
	8110046	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.79	CHEMBL3629	Homo sapiens	Inhibition	%	3.79
	8110270	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc(-c3ccccc3)o2)cc(OC)c1		CHEMBL176553	=	Inhibition	%	3.91	CHEMBL3629	Homo sapiens	Inhibition	%	3.91
	8110325	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL205798	=	Inhibition	%	-4.66	CHEMBL3629	Homo sapiens	Inhibition	%	-4.66
	8110715	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCNc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1.CS(=O)(=O)O		CHEMBL1909405	=	Inhibition	%	6.47	CHEMBL3629	Homo sapiens	Inhibition	%	6.47
	8110873	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	-1.18	CHEMBL3629	Homo sapiens	Inhibition	%	-1.18
	8111220	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	1.32	CHEMBL3629	Homo sapiens	Inhibition	%	1.32
	8111571	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	13.91	CHEMBL3629	Homo sapiens	Inhibition	%	13.91
	8111737	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3cc(C(F)(F)F)ccc32)cc1OCc1ccccc1Br		CHEMBL480371	=	Inhibition	%	2.21	CHEMBL3629	Homo sapiens	Inhibition	%	2.21
	8111942	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	4.16	CHEMBL3629	Homo sapiens	Inhibition	%	4.16
	8112166	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Nc2ncc(-c3ccccc3)o2)c1		CHEMBL192417	=	Inhibition	%	3.49	CHEMBL3629	Homo sapiens	Inhibition	%	3.49
	8112303	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	2.16	CHEMBL3629	Homo sapiens	Inhibition	%	2.16
	8112471	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL518968	=	Inhibition	%	1.77	CHEMBL3629	Homo sapiens	Inhibition	%	1.77
	8112695	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	9.52	CHEMBL3629	Homo sapiens	Inhibition	%	9.52
	8112867	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	2.14	CHEMBL3629	Homo sapiens	Inhibition	%	2.14
	8113019	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1Cl		CHEMBL1794069	=	Inhibition	%	19.41	CHEMBL3629	Homo sapiens	Inhibition	%	19.41
	8113243	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.96	CHEMBL3629	Homo sapiens	Inhibition	%	3.96
	8113379	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=S(=O)(CCOCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL212250	=	Inhibition	%	4.52	CHEMBL3629	Homo sapiens	Inhibition	%	4.52
	8113727	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)c1C.O=C(O)C(F)(F)F		CHEMBL1909400	=	Inhibition	%	5.25	CHEMBL3629	Homo sapiens	Inhibition	%	5.25
	8113843	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	4.11	CHEMBL3629	Homo sapiens	Inhibition	%	4.11
	8114067	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)CCc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1785003	=	Inhibition	%	-0.73	CHEMBL3629	Homo sapiens	Inhibition	%	-0.73
	8114243	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	5.1	CHEMBL3629	Homo sapiens	Inhibition	%	5.1
	8114599	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	8.17	CHEMBL3629	Homo sapiens	Inhibition	%	8.17
	8114651	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	0.66	CHEMBL3629	Homo sapiens	Inhibition	%	0.66
	8114875	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CCCCC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477978	=	Inhibition	%	-5.06	CHEMBL3629	Homo sapiens	Inhibition	%	-5.06
	8115041	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	2.39	CHEMBL3629	Homo sapiens	Inhibition	%	2.39
	8115206	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CCN)ncc(OCCCN)c21.O=C(O)C(F)(F)F		CHEMBL1794064	=	Inhibition	%	10.08	CHEMBL3629	Homo sapiens	Inhibition	%	10.08
	8115430	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	2.14	CHEMBL3629	Homo sapiens	Inhibition	%	2.14
	8115550	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(NC(=O)Nc2ccc(Oc3ccc4nc(NC(=O)OC)[nH]c4c3)cc2)c1		CHEMBL243907	=	Inhibition	%	4.86	CHEMBL3629	Homo sapiens	Inhibition	%	4.86
	8115907	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC[C@@H]3CCCN3)c21.O=C(O)C(F)(F)F		CHEMBL1909375	=	Inhibition	%	-1.67	CHEMBL3629	Homo sapiens	Inhibition	%	-1.67
	8116066	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	2.49	CHEMBL3629	Homo sapiens	Inhibition	%	2.49
	8116290	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(CO)CNC(=O)c1ccc2c(c1)/C(=N/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL410072	=	Inhibition	%	23.51	CHEMBL3629	Homo sapiens	Inhibition	%	23.51
	8116493	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	5.58	CHEMBL3629	Homo sapiens	Inhibition	%	5.58
	8116627	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2nc(C)c3c(N/N=C(\C)c4ccncc4)ncnc32)c1		CHEMBL442363	=	Inhibition	%	6.88	CHEMBL3629	Homo sapiens	Inhibition	%	6.88
	8117023	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncc(-c2cccc(S(N)(=O)=O)c2)c2scc(-c3ccc(F)c(Cl)c3)c12		CHEMBL241517	=	Inhibition	%	3.4	CHEMBL3629	Homo sapiens	Inhibition	%	3.4
	8117194	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccoc1-c1ccc2ncnc(Nc3ccc(OCc4ccccc4)cc3)c2c1.Cl		CHEMBL1909388	=	Inhibition	%	1.94	CHEMBL3629	Homo sapiens	Inhibition	%	1.94
	8117576	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)nc(OCCNC)cc21.Cl		CHEMBL1909350	=	Inhibition	%	3.67	CHEMBL3629	Homo sapiens	Inhibition	%	3.67
	8117706	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	-1.12	CHEMBL3629	Homo sapiens	Inhibition	%	-1.12
	8117930	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Cl)c4)c3c2)o1.Cl		CHEMBL529066	=	Inhibition	%	1.71	CHEMBL3629	Homo sapiens	Inhibition	%	1.71
	8118068	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	1.69	CHEMBL3629	Homo sapiens	Inhibition	%	1.69
	8118408	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	1.48	CHEMBL3629	Homo sapiens	Inhibition	%	1.48
	8118580	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)o1.Cl		CHEMBL1909387	=	Inhibition	%	4.66	CHEMBL3629	Homo sapiens	Inhibition	%	4.66
	8118940	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncnc4sc(-c5ccco5)cc34)cc2Cl)c1		CHEMBL514938	=	Inhibition	%	3.13	CHEMBL3629	Homo sapiens	Inhibition	%	3.13
	8119211	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	7.08	CHEMBL3629	Homo sapiens	Inhibition	%	7.08
	8119370	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL588025	=	Inhibition	%	6.35	CHEMBL3629	Homo sapiens	Inhibition	%	6.35
	8119761	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)Nc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL205765	=	Inhibition	%	9.24	CHEMBL3629	Homo sapiens	Inhibition	%	9.24
	8119880	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	1.14	CHEMBL3629	Homo sapiens	Inhibition	%	1.14
	8120104	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(F)c(Cl)c4)c3c2)cs1.Cl		CHEMBL1909355	=	Inhibition	%	5.94	CHEMBL3629	Homo sapiens	Inhibition	%	5.94
	8120243	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	9.31	CHEMBL3629	Homo sapiens	Inhibition	%	9.31
	8120627	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	-2.6	CHEMBL3629	Homo sapiens	Inhibition	%	-2.6
	8120828	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794066	=	Inhibition	%	2.13	CHEMBL3629	Homo sapiens	Inhibition	%	2.13
	8120956	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	4.26	CHEMBL3629	Homo sapiens	Inhibition	%	4.26
	8121180	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc2c(c1)NC(=O)/C2=N/Nc1ccc(S(N)(=O)=O)cc1		CHEMBL271594	=	Inhibition	%	0.39	CHEMBL3629	Homo sapiens	Inhibition	%	0.39
	8121352	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	6.95	CHEMBL3629	Homo sapiens	Inhibition	%	6.95
	8121519	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	5.35	CHEMBL3629	Homo sapiens	Inhibition	%	5.35
	8121743	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3cccc(CCc4ccncc4)c32)cc1		CHEMBL1909399	=	Inhibition	%	2.3	CHEMBL3629	Homo sapiens	Inhibition	%	2.3
	8121906	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	5.03	CHEMBL3629	Homo sapiens	Inhibition	%	5.03
	8122251	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	-3.9	CHEMBL3629	Homo sapiens	Inhibition	%	-3.9
	8122389	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(F)c(F)c3)n2)cc1		CHEMBL1785004	=	Inhibition	%	3.12	CHEMBL3629	Homo sapiens	Inhibition	%	3.12
	8122733	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1c(C(N)=O)cc(-c2ccc(Cl)cc2)cc1-c1ccc(S(N)(=O)=O)cc1		CHEMBL268885	=	Inhibition	%	3.63	CHEMBL3629	Homo sapiens	Inhibition	%	3.63
	8122900	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	6.47	CHEMBL3629	Homo sapiens	Inhibition	%	6.47
	8123124	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3cccc(F)c3)n2)cc1		CHEMBL14014	=	Inhibition	%	8.56	CHEMBL3629	Homo sapiens	Inhibition	%	8.56
	8123266	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	7.47	CHEMBL3629	Homo sapiens	Inhibition	%	7.47
	8123544	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(NC(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL511765	=	Inhibition	%	35.45	CHEMBL3629	Homo sapiens	Inhibition	%	35.45
	8123694	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	9.38	CHEMBL3629	Homo sapiens	Inhibition	%	9.38
	8123918	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C=NNc2ncnc3c2cnn3-c2ccccc2)ccc1O		CHEMBL1789961	=	Inhibition	%	41.6	CHEMBL3629	Homo sapiens	Inhibition	%	41.6
	8124085	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	0.97	CHEMBL3629	Homo sapiens	Inhibition	%	0.97
	8124428	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	8.12	CHEMBL3629	Homo sapiens	Inhibition	%	8.12
	8124567	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c(-c3ccc(C(F)(F)F)cc3)nn2n1		CHEMBL188247	=	Inhibition	%	1.49	CHEMBL3629	Homo sapiens	Inhibition	%	1.49
	8124956	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(cnn5Cc5ccccc5)c4)c3s2)C1)N1CCOCC1		CHEMBL1909408	=	Inhibition	%	1.05	CHEMBL3629	Homo sapiens	Inhibition	%	1.05
	8125157	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	3.17	CHEMBL3629	Homo sapiens	Inhibition	%	3.17
	8125511	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	3.14	CHEMBL3629	Homo sapiens	Inhibition	%	3.14
	8125679	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(Cc5ccccc5)cc4)c3s2)C1)N1CCOCC1		CHEMBL1909409	=	Inhibition	%	1.52	CHEMBL3629	Homo sapiens	Inhibition	%	1.52
	8126067	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	5.2	CHEMBL3629	Homo sapiens	Inhibition	%	5.2
	8126231	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1Br		CHEMBL518953	=	Inhibition	%	5.76	CHEMBL3629	Homo sapiens	Inhibition	%	5.76
	8126570	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL247228	=	Inhibition	%	0.16	CHEMBL3629	Homo sapiens	Inhibition	%	0.16
	8126706	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	7.56	CHEMBL3629	Homo sapiens	Inhibition	%	7.56
	8126930	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/C=C2\C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL271595	=	Inhibition	%	27.99	CHEMBL3629	Homo sapiens	Inhibition	%	27.99
	8127052	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	4.31	CHEMBL3629	Homo sapiens	Inhibition	%	4.31
	8127443	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	15.43	CHEMBL3629	Homo sapiens	Inhibition	%	15.43
	8127585	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(N)=O)s3)c2cc1OC		CHEMBL514499	=	Inhibition	%	8.83	CHEMBL3629	Homo sapiens	Inhibition	%	8.83
	8127873	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	0.59	CHEMBL3629	Homo sapiens	Inhibition	%	0.59
	8128249	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	4.25	CHEMBL3629	Homo sapiens	Inhibition	%	4.25
	8128416	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2cnc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL204934	=	Inhibition	%	10.75	CHEMBL3629	Homo sapiens	Inhibition	%	10.75
	8128759	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL187081	=	Inhibition	%	40.91	CHEMBL3629	Homo sapiens	Inhibition	%	40.91
	8128896	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	9.34	CHEMBL3629	Homo sapiens	Inhibition	%	9.34
	8129120	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2cccc([N+](=O)[O-])c2)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL352222	=	Inhibition	%	-1.15	CHEMBL3629	Homo sapiens	Inhibition	%	-1.15
	8129291	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	-3.0	CHEMBL3629	Homo sapiens	Inhibition	%	-3.0
	8129480	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL428877	=	Inhibition	%	4.14	CHEMBL3629	Homo sapiens	Inhibition	%	4.14
	8129704	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	7.1	CHEMBL3629	Homo sapiens	Inhibition	%	7.1
	8129843	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nnc(-c3cccnc3)cc12)C1CC1.O=C(O)C(F)(F)F		CHEMBL1909343	=	Inhibition	%	5.42	CHEMBL3629	Homo sapiens	Inhibition	%	5.42
	8130004	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	9.47	CHEMBL3629	Homo sapiens	Inhibition	%	9.47
	8130228	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)CNc1nccc(-c2cnn3ncccc23)n1		CHEMBL446024	=	Inhibition	%	3.8	CHEMBL3629	Homo sapiens	Inhibition	%	3.8
	8130400	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(C(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.Cl		CHEMBL1909345	=	Inhibition	%	-0.24	CHEMBL3629	Homo sapiens	Inhibition	%	-0.24
	8130560	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	10.94	CHEMBL3629	Homo sapiens	Inhibition	%	10.94
	8130784	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCN(CC)Cc1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL1882194	=	Inhibition	%	31.11	CHEMBL3629	Homo sapiens	Inhibition	%	31.11
	8130900	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	3.58	CHEMBL3629	Homo sapiens	Inhibition	%	3.58
	8131263	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	3.37	CHEMBL3629	Homo sapiens	Inhibition	%	3.37
	8131383	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc(Oc4ccccc4)cc3)n2)cc1		CHEMBL13868	=	Inhibition	%	4.14	CHEMBL3629	Homo sapiens	Inhibition	%	4.14
	8131607	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	6.48	CHEMBL3629	Homo sapiens	Inhibition	%	6.48
	8131774	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(F)c3)o2)c1		CHEMBL179465	=	Inhibition	%	46.79	CHEMBL3629	Homo sapiens	Inhibition	%	46.79
	8131915	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	7.18	CHEMBL3629	Homo sapiens	Inhibition	%	7.18
	8132139	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL273564	=	Inhibition	%	4.76	CHEMBL3629	Homo sapiens	Inhibition	%	4.76
	8132201	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(Oc5ccccc5)c4)n3n2)cc(OC)c1OC		CHEMBL519881	=	Inhibition	%	12.73	CHEMBL3629	Homo sapiens	Inhibition	%	12.73
	8132425	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	0.17	CHEMBL3629	Homo sapiens	Inhibition	%	0.17
	8132572	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)N(C)C)c1		CHEMBL220244	=	Inhibition	%	5.95	CHEMBL3629	Homo sapiens	Inhibition	%	5.95
	8132740	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	0.75	CHEMBL3629	Homo sapiens	Inhibition	%	0.75
	8132964	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2Cl)c1		CHEMBL218970	=	Inhibition	%	8.72	CHEMBL3629	Homo sapiens	Inhibition	%	8.72
	8133085	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	2.95	CHEMBL3629	Homo sapiens	Inhibition	%	2.95
	8133447	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	5.23	CHEMBL3629	Homo sapiens	Inhibition	%	5.23
	8133619	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2cc(-c3ccc4c(c3)CCC4=NO)c(-c3ccncc3)o2)cc1.Cl		CHEMBL1794072	=	Inhibition	%	0.33	CHEMBL3629	Homo sapiens	Inhibition	%	0.33
	8134023	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(C(=O)c2ccc(NC(=O)Nc3ccc(N(C)c4ccnc(Nc5ccc(CS(C)(=O)=O)cc5)n4)cc3)cc2)CC1.Cl		CHEMBL1909360	=	Inhibition	%	2.55	CHEMBL3629	Homo sapiens	Inhibition	%	2.55
	8134171	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	4.9	CHEMBL3629	Homo sapiens	Inhibition	%	4.9
	8134555	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	2.64	CHEMBL3629	Homo sapiens	Inhibition	%	2.64
	8134739	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	2.93	CHEMBL3629	Homo sapiens	Inhibition	%	2.93
	8135123	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	7.89	CHEMBL3629	Homo sapiens	Inhibition	%	7.89
	8135238	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL418348	=	Inhibition	%	1.78	CHEMBL3629	Homo sapiens	Inhibition	%	1.78
	8135603	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1Oc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL417804	=	Inhibition	%	5.8	CHEMBL3629	Homo sapiens	Inhibition	%	5.8
	8135948	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL269450	=	Inhibition	%	2.41	CHEMBL3629	Homo sapiens	Inhibition	%	2.41
	8136116	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	5.99	CHEMBL3629	Homo sapiens	Inhibition	%	5.99
	8136484	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	11.32	CHEMBL3629	Homo sapiens	Inhibition	%	11.32
	8136774	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(C)c(N(C)C(=O)CN(C)C)cc1Nc1nc(Nc2cccc(F)c2C(N)=O)c2cc[nH]c2n1		CHEMBL467581	=	Inhibition	%	4.3	CHEMBL3629	Homo sapiens	Inhibition	%	4.3
	8136909	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	2.1	CHEMBL3629	Homo sapiens	Inhibition	%	2.1
	8137296	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	1.7	CHEMBL3629	Homo sapiens	Inhibition	%	1.7
	8137416	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(CNc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL513330	=	Inhibition	%	17.94	CHEMBL3629	Homo sapiens	Inhibition	%	17.94
	8137640	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	1.93	CHEMBL3629	Homo sapiens	Inhibition	%	1.93
	8137788	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062289	=	Inhibition	%	2.82	CHEMBL3629	Homo sapiens	Inhibition	%	2.82
	8137954	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	2.62	CHEMBL3629	Homo sapiens	Inhibition	%	2.62
	8138178	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2		CHEMBL234838	=	Inhibition	%	1.09	CHEMBL3629	Homo sapiens	Inhibition	%	1.09
	8138357	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	-0.05	CHEMBL3629	Homo sapiens	Inhibition	%	-0.05
	8138505	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc3c(N)ncnc3o2)cc1		CHEMBL373073	=	Inhibition	%	14.15	CHEMBL3629	Homo sapiens	Inhibition	%	14.15
	8138729	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	7.28	CHEMBL3629	Homo sapiens	Inhibition	%	7.28
	8138887	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccoc2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477583	=	Inhibition	%	1.38	CHEMBL3629	Homo sapiens	Inhibition	%	1.38
	8139072	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(N/C=C2\C(=O)Nc3ccccc32)cc1		CHEMBL1794058	=	Inhibition	%	0.34	CHEMBL3629	Homo sapiens	Inhibition	%	0.34
	8139455	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(-c2ccccn2)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909354	=	Inhibition	%	6.35	CHEMBL3629	Homo sapiens	Inhibition	%	6.35
	8139569	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	10.85	CHEMBL3629	Homo sapiens	Inhibition	%	10.85
	8139793	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(C(F)(F)F)c4)c3c2)o1.Cl		CHEMBL1909389	=	Inhibition	%	4.64	CHEMBL3629	Homo sapiens	Inhibition	%	4.64
	8139934	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	12.85	CHEMBL3629	Homo sapiens	Inhibition	%	12.85
	8140281	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	4.63	CHEMBL3629	Homo sapiens	Inhibition	%	4.63
	8140440	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(/C=N/Nc2ncnc3c2cnn3-c2cccc(OC)c2)c1		CHEMBL305477	=	Inhibition	%	3.05	CHEMBL3629	Homo sapiens	Inhibition	%	3.05
	8140807	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2ncn(C3CCNCC3)c2-c2ccnc(Oc3ccc4c(c3)OCO4)n2)cc1		CHEMBL273611	=	Inhibition	%	3.74	CHEMBL3629	Homo sapiens	Inhibition	%	3.74
	8141109	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	0.13	CHEMBL3629	Homo sapiens	Inhibition	%	0.13
	8141239	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(Cl)c(Cl)c2)CC(=O)N1		CHEMBL374453	=	Inhibition	%	3.35	CHEMBL3629	Homo sapiens	Inhibition	%	3.35
	8141463	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	0.99	CHEMBL3629	Homo sapiens	Inhibition	%	0.99
	8141623	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCCNc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL67241	=	Inhibition	%	14.12	CHEMBL3629	Homo sapiens	Inhibition	%	14.12
	8141966	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2c(C)cccc2C)c1		CHEMBL218859	=	Inhibition	%	5.37	CHEMBL3629	Homo sapiens	Inhibition	%	5.37
	8142127	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	7.89	CHEMBL3629	Homo sapiens	Inhibition	%	7.89
	8142519	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	6.68	CHEMBL3629	Homo sapiens	Inhibition	%	6.68
	8142695	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1nc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(C(F)(F)F)c5)cc4)c3c2)cs1.Cl		CHEMBL1909356	=	Inhibition	%	1.3	CHEMBL3629	Homo sapiens	Inhibition	%	1.3
	8143068	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC(C)C)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477979	=	Inhibition	%	0.22	CHEMBL3629	Homo sapiens	Inhibition	%	0.22
	8143223	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	4.6	CHEMBL3629	Homo sapiens	Inhibition	%	4.6
	8143410	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	4.28	CHEMBL3629	Homo sapiens	Inhibition	%	4.28
	8143634	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(I)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1880739	=	Inhibition	%	17.9	CHEMBL3629	Homo sapiens	Inhibition	%	17.9
	8143793	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	1.2	CHEMBL3629	Homo sapiens	Inhibition	%	1.2
	8144131	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	13.68	CHEMBL3629	Homo sapiens	Inhibition	%	13.68
	8144270	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.[O-][S+]1CCN(Cc2ccc(-c3ccc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4c3)o2)CC1		CHEMBL1909390	=	Inhibition	%	4.15	CHEMBL3629	Homo sapiens	Inhibition	%	4.15
	8144494	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	10.28	CHEMBL3629	Homo sapiens	Inhibition	%	10.28
	8144624	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C([O-])c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1.[Li+]		CHEMBL1909401	=	Inhibition	%	3.61	CHEMBL3629	Homo sapiens	Inhibition	%	3.61
	8144777	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	15.52	CHEMBL3629	Homo sapiens	Inhibition	%	15.52
	8145001	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccc(S(=O)(=O)N3CCCC3)cc2)c1N		CHEMBL230592	=	Inhibition	%	3.05	CHEMBL3629	Homo sapiens	Inhibition	%	3.05
	8145138	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	10.64	CHEMBL3629	Homo sapiens	Inhibition	%	10.64
	8145451	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(N3CCc4ccccc43)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL458415	=	Inhibition	%	-9.3	CHEMBL3629	Homo sapiens	Inhibition	%	-9.3
	8145799	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccco3)ccc12)C1CC1		CHEMBL101804	=	Inhibition	%	-0.44	CHEMBL3629	Homo sapiens	Inhibition	%	-0.44
	8145960	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	2.18	CHEMBL3629	Homo sapiens	Inhibition	%	2.18
	8146304	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	2.02	CHEMBL3629	Homo sapiens	Inhibition	%	2.02
	8146464	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL188257	=	Inhibition	%	3.92	CHEMBL3629	Homo sapiens	Inhibition	%	3.92
	8146688	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	8.25	CHEMBL3629	Homo sapiens	Inhibition	%	8.25
	8146855	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	C[C@@H](Oc1cc(-n2cnc3ccc(OCC4CCN(C)CC4)cc32)sc1C(N)=O)c1ccccc1C(F)(F)F		CHEMBL1794068	=	Inhibition	%	7.31	CHEMBL3629	Homo sapiens	Inhibition	%	7.31
	8147024	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	0.96	CHEMBL3629	Homo sapiens	Inhibition	%	0.96
	8147390	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	7.97	CHEMBL3629	Homo sapiens	Inhibition	%	7.97
	8147543	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)cc1		CHEMBL205966	=	Inhibition	%	2.02	CHEMBL3629	Homo sapiens	Inhibition	%	2.02
	8147767	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	6.68	CHEMBL3629	Homo sapiens	Inhibition	%	6.68
	8147954	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	14.71	CHEMBL3629	Homo sapiens	Inhibition	%	14.71
	8148112	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)c(-c3ccccc3)nn2n1		CHEMBL434729	=	Inhibition	%	3.98	CHEMBL3629	Homo sapiens	Inhibition	%	3.98
	8148450	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5ccccc5)c(Br)c4)c3c2)o1.Cl		CHEMBL1909392	=	Inhibition	%	5.24	CHEMBL3629	Homo sapiens	Inhibition	%	5.24
	8148813	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)(C)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275200	=	Inhibition	%	4.18	CHEMBL3629	Homo sapiens	Inhibition	%	4.18
	8148951	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	2.95	CHEMBL3629	Homo sapiens	Inhibition	%	2.95
	8149334	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	5.37	CHEMBL3629	Homo sapiens	Inhibition	%	5.37
	8149468	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=S(=O)(CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1)c1ccccc1		CHEMBL1909395	=	Inhibition	%	5.49	CHEMBL3629	Homo sapiens	Inhibition	%	5.49
	8149692	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	4.41	CHEMBL3629	Homo sapiens	Inhibition	%	4.41
	8149790	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	1.53	CHEMBL3629	Homo sapiens	Inhibition	%	1.53
	8150139	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	0.08	CHEMBL3629	Homo sapiens	Inhibition	%	0.08
	8150299	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)Nc2c(Cl)cccc2Cl)cc1)c1ccnc(Nc2cccc(CS(C)(=O)=O)c2)n1		CHEMBL189353	=	Inhibition	%	6.66	CHEMBL3629	Homo sapiens	Inhibition	%	6.66
	8150523	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	2.99	CHEMBL3629	Homo sapiens	Inhibition	%	2.99
	8150643	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)Nc1nc2ccc(Sc3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)cc2[nH]1.O=S(=O)(O)O		CHEMBL1909365	=	Inhibition	%	6.92	CHEMBL3629	Homo sapiens	Inhibition	%	6.92
	8151032	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2		CHEMBL456252	=	Inhibition	%	37.72	CHEMBL3629	Homo sapiens	Inhibition	%	37.72
	8151195	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-2.79	CHEMBL3629	Homo sapiens	Inhibition	%	-2.79
	8151372	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nc(-c4ccc(O)cc4)c(Br)cc23)CC1.O=C(O)/C=C\C(=O)O		CHEMBL1909347	=	Inhibition	%	1.03	CHEMBL3629	Homo sapiens	Inhibition	%	1.03
	8151596	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	1.46	CHEMBL3629	Homo sapiens	Inhibition	%	1.46
	8151734	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1cccc(Nc2nccc(-c3cnn4nc(-c5ccccc5)ccc34)n2)c1		CHEMBL189415	=	Inhibition	%	4.42	CHEMBL3629	Homo sapiens	Inhibition	%	4.42
	8152112	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3cccc(C(F)(F)F)c3)n2)cc1		CHEMBL186213	=	Inhibition	%	1.12	CHEMBL3629	Homo sapiens	Inhibition	%	1.12
	8152300	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1ccc2c(c1)C(=Cc1cc(Br)c(O)c(Br)c1)C(=O)N2		CHEMBL1794052	=	Inhibition	%	47.02	CHEMBL3629	Homo sapiens	Inhibition	%	47.02
	8152458	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	8.1	CHEMBL3629	Homo sapiens	Inhibition	%	8.1
	8152682	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL318728	=	Inhibition	%	4.81	CHEMBL3629	Homo sapiens	Inhibition	%	4.81
	8152796	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2nccc(N(C)c3ccc4c(C)n[nH]c4c3)n2)c1.Cl		CHEMBL1909358	=	Inhibition	%	13.8	CHEMBL3629	Homo sapiens	Inhibition	%	13.8
	8153159	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	12.69	CHEMBL3629	Homo sapiens	Inhibition	%	12.69
	8153296	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc(Oc2nccc(-c3c(-c4ccc(F)cc4)ncn3C3CCNCC3)n2)cc1		CHEMBL275724	=	Inhibition	%	2.91	CHEMBL3629	Homo sapiens	Inhibition	%	2.91
	8153520	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CCNCC3)c21.Cl		CHEMBL1909376	=	Inhibition	%	4.04	CHEMBL3629	Homo sapiens	Inhibition	%	4.04
	8153677	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCN(CC#N)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL384407	=	Inhibition	%	1.72	CHEMBL3629	Homo sapiens	Inhibition	%	1.72
	8154034	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)NCCNC)c21		CHEMBL506153	=	Inhibition	%	2.99	CHEMBL3629	Homo sapiens	Inhibition	%	2.99
	8154131	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)Oc1cc(C)c(/C=C/c2cncc(C(=O)NC)c2)c(C)c1		CHEMBL218932	=	Inhibition	%	0.66	CHEMBL3629	Homo sapiens	Inhibition	%	0.66
	8154355	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccccc21		CHEMBL365286	=	Inhibition	%	0.89	CHEMBL3629	Homo sapiens	Inhibition	%	0.89
	8154481	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccco4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909368	=	Inhibition	%	-0.44	CHEMBL3629	Homo sapiens	Inhibition	%	-0.44
	8154864	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207410	=	Inhibition	%	10.05	CHEMBL3629	Homo sapiens	Inhibition	%	10.05
	8154984	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCOCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL476351	=	Inhibition	%	0.81	CHEMBL3629	Homo sapiens	Inhibition	%	0.81
	8155384	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)nn3cc(C(F)(F)F)ccc23)n1		CHEMBL1909402	=	Inhibition	%	15.56	CHEMBL3629	Homo sapiens	Inhibition	%	15.56
	8155545	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(C(=O)NC2CC2)cc1-c1ccc2[nH]ncc2c1		CHEMBL495902	=	Inhibition	%	-1.68	CHEMBL3629	Homo sapiens	Inhibition	%	-1.68
	8155947	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1nn2ncccc2c1-c1ccnc(NC2CC2)n1		CHEMBL524057	=	Inhibition	%	4.59	CHEMBL3629	Homo sapiens	Inhibition	%	4.59
	8156085	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cccc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL183993	=	Inhibition	%	5.72	CHEMBL3629	Homo sapiens	Inhibition	%	5.72
	8156521	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	2.02	CHEMBL3629	Homo sapiens	Inhibition	%	2.02
	8156671	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	21.58	CHEMBL3629	Homo sapiens	Inhibition	%	21.58
	8157038	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	10.3	CHEMBL3629	Homo sapiens	Inhibition	%	10.3
	8157158	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	1.79	CHEMBL3629	Homo sapiens	Inhibition	%	1.79
	8157382	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]nc(C)c3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL218720	=	Inhibition	%	2.97	CHEMBL3629	Homo sapiens	Inhibition	%	2.97
	8157523	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	9.99	CHEMBL3629	Homo sapiens	Inhibition	%	9.99
	8157877	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	4.37	CHEMBL3629	Homo sapiens	Inhibition	%	4.37
	8158038	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-8.59	CHEMBL3629	Homo sapiens	Inhibition	%	-8.59
	8158288	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	4.57	CHEMBL3629	Homo sapiens	Inhibition	%	4.57
	8158670	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	4.49	CHEMBL3629	Homo sapiens	Inhibition	%	4.49
	8158839	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.27	CHEMBL3629	Homo sapiens	Inhibition	%	2.27
	8159198	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	4.85	CHEMBL3629	Homo sapiens	Inhibition	%	4.85
	8159542	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.23	CHEMBL3629	Homo sapiens	Inhibition	%	2.23
	8159673	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	3.26	CHEMBL3629	Homo sapiens	Inhibition	%	3.26
	8160038	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	1.12	CHEMBL3629	Homo sapiens	Inhibition	%	1.12
	8160175	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	6.02	CHEMBL3629	Homo sapiens	Inhibition	%	6.02
	8160399	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)CN2CCOCC2)sc2c1CCCC2.O=C(O)C(=O)O		CHEMBL1909342	=	Inhibition	%	10.89	CHEMBL3629	Homo sapiens	Inhibition	%	10.89
	8160549	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	-0.03	CHEMBL3629	Homo sapiens	Inhibition	%	-0.03
	8160843	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(-c2cc3c(NC(=O)C4CC4)ncnc3o2)cc1		CHEMBL182283	=	Inhibition	%	10.81	CHEMBL3629	Homo sapiens	Inhibition	%	10.81
	8160993	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	5.71	CHEMBL3629	Homo sapiens	Inhibition	%	5.71
	8161217	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(c1ccc(NC(=O)NCCN2CCOCC2)cc1)c1ccnc(Nc2ccc(CS(C)(=O)=O)cc2)n1.Cl		CHEMBL1909361	=	Inhibition	%	11.88	CHEMBL3629	Homo sapiens	Inhibition	%	11.88
	8161360	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	13.16	CHEMBL3629	Homo sapiens	Inhibition	%	13.16
	8161709	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	0.98	CHEMBL3629	Homo sapiens	Inhibition	%	0.98
	8161847	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2ncc3c(C)nc(-c4cccc(C(F)(F)F)c4)n3n2)cc(OC)c1OC		CHEMBL520037	=	Inhibition	%	43.14	CHEMBL3629	Homo sapiens	Inhibition	%	43.14
	8162201	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1C1=C(Nc2ccccc2)C(=O)NC1=O		CHEMBL156263	=	Inhibition	%	9.2	CHEMBL3629	Homo sapiens	Inhibition	%	9.2
	8162361	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-2.06	CHEMBL3629	Homo sapiens	Inhibition	%	-2.06
	8162585	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(CCCNc2nc3ccc(Oc4ccc(NC(=O)Nc5cc(C(F)(F)F)ccc5F)cc4)cc3[nH]2)CC1.Cl		CHEMBL1909372	=	Inhibition	%	-5.31	CHEMBL3629	Homo sapiens	Inhibition	%	-5.31
	8162614	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.78	CHEMBL3629	Homo sapiens	Inhibition	%	3.78
	8162838	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cncc(C(=O)N3CC[C@H](N)C3)c21.Cl		CHEMBL1909384	=	Inhibition	%	3.7	CHEMBL3629	Homo sapiens	Inhibition	%	3.7
	8162986	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	15.74	CHEMBL3629	Homo sapiens	Inhibition	%	15.74
	8163155	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3cc(F)ccc3F)ccc12)C1CC1		CHEMBL261440	=	Inhibition	%	2.39	CHEMBL3629	Homo sapiens	Inhibition	%	2.39
	8163379	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	1.53	CHEMBL3629	Homo sapiens	Inhibition	%	1.53
	8163513	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1)N1CCOCC1		CHEMBL507329	=	Inhibition	%	11.49	CHEMBL3629	Homo sapiens	Inhibition	%	11.49
	8163860	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2c(-c3ccncc3)nc3n2CCS3)cc1		CHEMBL266707	=	Inhibition	%	2.3	CHEMBL3629	Homo sapiens	Inhibition	%	2.3
	8163994	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	33.5	CHEMBL3629	Homo sapiens	Inhibition	%	33.5
	8164218	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN1CCCC(c2ccc(Nc3nc(Nc4cc(F)ccc4C(N)=O)c4cc[nH]c4n3)c(OC)c2)C1		CHEMBL477069	=	Inhibition	%	66.18	CHEMBL3629	Homo sapiens	Inhibition	%	66.18
	8164358	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	1.44	CHEMBL3629	Homo sapiens	Inhibition	%	1.44
	8164737	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	20.41	CHEMBL3629	Homo sapiens	Inhibition	%	20.41
	8164881	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL1888586	=	Inhibition	%	1.03	CHEMBL3629	Homo sapiens	Inhibition	%	1.03
	8165175	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	6.76	CHEMBL3629	Homo sapiens	Inhibition	%	6.76
	8165540	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	3.0	CHEMBL3629	Homo sapiens	Inhibition	%	3.0
	8165683	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(Nc4ccc5c(c4)OCCO5)n3)c2c1		CHEMBL361894	=	Inhibition	%	47.54	CHEMBL3629	Homo sapiens	Inhibition	%	47.54
	8166033	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cccc(O)c1		CHEMBL160937	=	Inhibition	%	0.1	CHEMBL3629	Homo sapiens	Inhibition	%	0.1
	8166171	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	5.22	CHEMBL3629	Homo sapiens	Inhibition	%	5.22
	8166395	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.NS(=O)(=O)c1cccc(Nc2cc(-c3ccc(F)cc3)n[nH]2)c1		CHEMBL1909351	=	Inhibition	%	13.55	CHEMBL3629	Homo sapiens	Inhibition	%	13.55
	8166525	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	3.96	CHEMBL3629	Homo sapiens	Inhibition	%	3.96
	8166850	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.29	CHEMBL3629	Homo sapiens	Inhibition	%	0.29
	8167162	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	2.94	CHEMBL3629	Homo sapiens	Inhibition	%	2.94
	8167303	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(NC=C2C(=O)Nc3ccc4ncsc4c32)cc1		CHEMBL1794055	=	Inhibition	%	46.4	CHEMBL3629	Homo sapiens	Inhibition	%	46.4
	8167691	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCC2		CHEMBL233001	=	Inhibition	%	-0.03	CHEMBL3629	Homo sapiens	Inhibition	%	-0.03
	8167824	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	4.71	CHEMBL3629	Homo sapiens	Inhibition	%	4.71
	8168048	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2ccc(F)cc21		CHEMBL426800	=	Inhibition	%	8.79	CHEMBL3629	Homo sapiens	Inhibition	%	8.79
	8168172	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	1.87	CHEMBL3629	Homo sapiens	Inhibition	%	1.87
	8168537	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.49	CHEMBL3629	Homo sapiens	Inhibition	%	3.49
	8168673	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1(C)CC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(N)n2)CC(C)(C)N1		CHEMBL95502	=	Inhibition	%	7.38	CHEMBL3629	Homo sapiens	Inhibition	%	7.38
	8169061	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1cccc(Nc2nccc(-c3cnn4ncccc34)n2)c1		CHEMBL495696	=	Inhibition	%	63.93	CHEMBL3629	Homo sapiens	Inhibition	%	63.93
	8169203	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	2.09	CHEMBL3629	Homo sapiens	Inhibition	%	2.09
	8169427	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)Nc1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL102936	=	Inhibition	%	0.41	CHEMBL3629	Homo sapiens	Inhibition	%	0.41
	8169507	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1ncccc1Nc1nc(Nc2cc3c(cc2OC)CCCN3C(=O)CN(C)C)nc2[nH]ccc12		CHEMBL1895450	=	Inhibition	%	22.83	CHEMBL3629	Homo sapiens	Inhibition	%	22.83
	8169865	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2Cl)=C1Nc1cc(Cl)c(O)c(Cl)c1		CHEMBL157258	=	Inhibition	%	10.79	CHEMBL3629	Homo sapiens	Inhibition	%	10.79
	8170010	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	0.36	CHEMBL3629	Homo sapiens	Inhibition	%	0.36
	8170234	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1ncnc2occ(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)cc(C(F)(F)F)c4)cc3)c12		CHEMBL396107	=	Inhibition	%	-5.3	CHEMBL3629	Homo sapiens	Inhibition	%	-5.3
	8170359	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	-0.53	CHEMBL3629	Homo sapiens	Inhibition	%	-0.53
	8170723	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	4.56	CHEMBL3629	Homo sapiens	Inhibition	%	4.56
	8170858	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Oc1cccc(-c2nc(-c3ccccc3)[nH]c2-c2ccncc2)c1		CHEMBL1909413	=	Inhibition	%	9.51	CHEMBL3629	Homo sapiens	Inhibition	%	9.51
	8171279	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(Nc2nccc(Nc3ccc4c(C)n[nH]c4c3)n2)cc(OC)c1OC		CHEMBL479079	=	Inhibition	%	0.37	CHEMBL3629	Homo sapiens	Inhibition	%	0.37
	8171496	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21.Cl		CHEMBL1909363	=	Inhibition	%	5.71	CHEMBL3629	Homo sapiens	Inhibition	%	5.71
	8171637	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	39.4	CHEMBL3629	Homo sapiens	Inhibition	%	39.4
	8171861	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2c(cc1Nc1nc(Nc3ccsc3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CCC2(C)C		CHEMBL463931	=	Inhibition	%	75.31	CHEMBL3629	Homo sapiens	Inhibition	%	75.31
	8172014	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	1.77	CHEMBL3629	Homo sapiens	Inhibition	%	1.77
	8172370	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	3.81	CHEMBL3629	Homo sapiens	Inhibition	%	3.81
	8172498	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)NC(=O)N1		CHEMBL384073	=	Inhibition	%	0.86	CHEMBL3629	Homo sapiens	Inhibition	%	0.86
	8172864	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1ccc2c(-c3ccnc(NCCCO)n3)c(-c3ccc(F)cc3)nn2c1		CHEMBL1909404	=	Inhibition	%	3.53	CHEMBL3629	Homo sapiens	Inhibition	%	3.53
	8173000	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	0.11	CHEMBL3629	Homo sapiens	Inhibition	%	0.11
	8173224	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)c1		CHEMBL407113	=	Inhibition	%	-0.44	CHEMBL3629	Homo sapiens	Inhibition	%	-0.44
	8173389	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	18.21	CHEMBL3629	Homo sapiens	Inhibition	%	18.21
	8173754	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	4.96	CHEMBL3629	Homo sapiens	Inhibition	%	4.96
	8173841	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	6.03	CHEMBL3629	Homo sapiens	Inhibition	%	6.03
	8174065	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCCc4c[nH]cn4)cc32)cc1		CHEMBL272028	=	Inhibition	%	18.61	CHEMBL3629	Homo sapiens	Inhibition	%	18.61
	8174197	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	3.51	CHEMBL3629	Homo sapiens	Inhibition	%	3.51
	8174569	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	0.31	CHEMBL3629	Homo sapiens	Inhibition	%	0.31
	8174691	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cccc2c1NC(=O)/C2=N\Nc1ccc(S(N)(=O)=O)cc1		CHEMBL1909398	=	Inhibition	%	0.34	CHEMBL3629	Homo sapiens	Inhibition	%	0.34
	8175058	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(C#CC(C)(C)O)ncc(OCC3CCNCC3)c21.O=C(O)C(F)(F)F		CHEMBL1794065	=	Inhibition	%	12.81	CHEMBL3629	Homo sapiens	Inhibition	%	12.81
	8175194	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	10.71	CHEMBL3629	Homo sapiens	Inhibition	%	10.71
	8175418	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1		CHEMBL359963	=	Inhibition	%	43.41	CHEMBL3629	Homo sapiens	Inhibition	%	43.41
	8175674	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc(-n2cncn2)cc1		CHEMBL1794056	=	Inhibition	%	12.81	CHEMBL3629	Homo sapiens	Inhibition	%	12.81
	8175837	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	2.59	CHEMBL3629	Homo sapiens	Inhibition	%	2.59
	8176214	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	9.32	CHEMBL3629	Homo sapiens	Inhibition	%	9.32
	8176363	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4cccc(F)c4)ncnc32)c1		CHEMBL69757	=	Inhibition	%	11.41	CHEMBL3629	Homo sapiens	Inhibition	%	11.41
	8176719	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C/Nc1ccc2[nH]c(=O)[nH]c2c1		CHEMBL1794057	=	Inhibition	%	13.86	CHEMBL3629	Homo sapiens	Inhibition	%	13.86
	8176849	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	1.26	CHEMBL3629	Homo sapiens	Inhibition	%	1.26
	8177073	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCn4ccnc4)cc3)c2)nc1		CHEMBL208437	=	Inhibition	%	2.53	CHEMBL3629	Homo sapiens	Inhibition	%	2.53
	8177215	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	2.01	CHEMBL3629	Homo sapiens	Inhibition	%	2.01
	8177577	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	6.4	CHEMBL3629	Homo sapiens	Inhibition	%	6.4
	8177741	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccncc4)ncnc32)c1		CHEMBL306865	=	Inhibition	%	59.73	CHEMBL3629	Homo sapiens	Inhibition	%	59.73
	8178105	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C1Nc2ccc(-c3cccnc3)cc2C1=Cc1cc(Br)c(O)c(Br)c1		CHEMBL1794050	=	Inhibition	%	14.51	CHEMBL3629	Homo sapiens	Inhibition	%	14.51
	8178417	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.63	CHEMBL3629	Homo sapiens	Inhibition	%	0.63
	8178544	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1cncc(/C=C/c2c(C)cc(O)cc2C)c1		CHEMBL220243	=	Inhibition	%	11.86	CHEMBL3629	Homo sapiens	Inhibition	%	11.86
	8178917	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(NCC1CC1)c1ccc(-c2cccc(C(=O)NC3CC3)c2)cc1		CHEMBL479038	=	Inhibition	%	-2.23	CHEMBL3629	Homo sapiens	Inhibition	%	-2.23
	8179040	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	0.94	CHEMBL3629	Homo sapiens	Inhibition	%	0.94
	8179264	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCNC(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL512076	=	Inhibition	%	-1.06	CHEMBL3629	Homo sapiens	Inhibition	%	-1.06
	8179408	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	4.7	CHEMBL3629	Homo sapiens	Inhibition	%	4.7
	8179769	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	4.77	CHEMBL3629	Homo sapiens	Inhibition	%	4.77
	8180026	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	6.73	CHEMBL3629	Homo sapiens	Inhibition	%	6.73
	8180180	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nn(C)c2cc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)ccc12.Cl		CHEMBL1794073	=	Inhibition	%	1.94	CHEMBL3629	Homo sapiens	Inhibition	%	1.94
	8180404	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	1.61	CHEMBL3629	Homo sapiens	Inhibition	%	1.61
	8180560	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NCc1ccc(-n2c(-c3nonc3N)nc3cnccc32)cc1		CHEMBL188268	=	Inhibition	%	9.93	CHEMBL3629	Homo sapiens	Inhibition	%	9.93
	8180708	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	2.93	CHEMBL3629	Homo sapiens	Inhibition	%	2.93
	8180932	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1ccc2c(c1)/C(=C/Nc1ccc(S(N)(=O)=O)cc1)C(=O)N2		CHEMBL272414	=	Inhibition	%	18.01	CHEMBL3629	Homo sapiens	Inhibition	%	18.01
	8181065	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	3.63	CHEMBL3629	Homo sapiens	Inhibition	%	3.63
	8181420	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	-0.1	CHEMBL3629	Homo sapiens	Inhibition	%	-0.1
	8181560	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(-c2nn[nH]n2)c1.Cl		CHEMBL1909352	=	Inhibition	%	6.14	CHEMBL3629	Homo sapiens	Inhibition	%	6.14
	8181784	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	1.99	CHEMBL3629	Homo sapiens	Inhibition	%	1.99
	8181923	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2[nH]c3c4[nH]c5ccc(OC)cc5c4c4c(c3c2c1)C(=O)NC4=O		CHEMBL1956068	=	Inhibition	%	15.94	CHEMBL3629	Homo sapiens	Inhibition	%	15.94
	8182086	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	6.47	CHEMBL3629	Homo sapiens	Inhibition	%	6.47
	8182310	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccc(F)cc2)c(-c2ccc3ncccc3n2)s1		CHEMBL361237	=	Inhibition	%	12.98	CHEMBL3629	Homo sapiens	Inhibition	%	12.98
	8182450	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	2.02	CHEMBL3629	Homo sapiens	Inhibition	%	2.02
	8182766	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)C(=O)O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3s2)C1		CHEMBL517123	=	Inhibition	%	0.63	CHEMBL3629	Homo sapiens	Inhibition	%	0.63
	8182888	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	4.77	CHEMBL3629	Homo sapiens	Inhibition	%	4.77
	8183112	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(F)cc4)ncnc32)c1		CHEMBL65884	=	Inhibition	%	15.91	CHEMBL3629	Homo sapiens	Inhibition	%	15.91
	8183261	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	5.03	CHEMBL3629	Homo sapiens	Inhibition	%	5.03
	8183614	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	8.02	CHEMBL3629	Homo sapiens	Inhibition	%	8.02
	8183756	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(C(=O)NCc4ccncc4)cc32)cc1		CHEMBL272165	=	Inhibition	%	13.07	CHEMBL3629	Homo sapiens	Inhibition	%	13.07
	8183980	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	4.94	CHEMBL3629	Homo sapiens	Inhibition	%	4.94
	8184116	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCCN(CCS(C)(=O)=O)Cc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1.Cl		CHEMBL1909394	=	Inhibition	%	9.35	CHEMBL3629	Homo sapiens	Inhibition	%	9.35
	8184382	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(C(=O)Nc2n[nH]c3nnc(-c4ccccc4)cc23)CC1.Cl		CHEMBL1909344	=	Inhibition	%	12.23	CHEMBL3629	Homo sapiens	Inhibition	%	12.23
	8184753	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1cccc(COc2ccc(Nc3ncnc4cc(-c5ccc[nH]5)sc34)cc2Cl)c1		CHEMBL1909415	=	Inhibition	%	2.66	CHEMBL3629	Homo sapiens	Inhibition	%	2.66
	8184910	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	2.03	CHEMBL3629	Homo sapiens	Inhibition	%	2.03
	8185283	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	-0.56	CHEMBL3629	Homo sapiens	Inhibition	%	-0.56
	8185414	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2ccc(S(C)(=O)=O)cc12		CHEMBL237347	=	Inhibition	%	8.35	CHEMBL3629	Homo sapiens	Inhibition	%	8.35
	8185769	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	C/C(Nc1ccc(S(N)(=O)=O)cc1)=C1/C(=O)Nc2ccccc21		CHEMBL405042	=	Inhibition	%	7.42	CHEMBL3629	Homo sapiens	Inhibition	%	7.42
	8186132	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccccc3)ccc12)C1CC1		CHEMBL405021	=	Inhibition	%	6.38	CHEMBL3629	Homo sapiens	Inhibition	%	6.38
	8186273	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	5.76	CHEMBL3629	Homo sapiens	Inhibition	%	5.76
	8186661	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	5.6	CHEMBL3629	Homo sapiens	Inhibition	%	5.6
	8186800	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(Nc2nccc(-c3c(-c4ccc(C(F)(F)F)cc4)nn4ncccc34)n2)cc1F		CHEMBL188784	=	Inhibition	%	1.28	CHEMBL3629	Homo sapiens	Inhibition	%	1.28
	8187122	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	Inhibition	%	2.0
	8187470	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	4.0	CHEMBL3629	Homo sapiens	Inhibition	%	4.0
	8187618	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(OC)c3)o2)c1		CHEMBL179311	=	Inhibition	%	29.27	CHEMBL3629	Homo sapiens	Inhibition	%	29.27
	8187842	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-0.28	CHEMBL3629	Homo sapiens	Inhibition	%	-0.28
	8187971	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	FC(F)(F)c1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL185939	=	Inhibition	%	19.81	CHEMBL3629	Homo sapiens	Inhibition	%	19.81
	8188338	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(N/N=C2\C(=O)Nc3ccc(Cl)cc32)cc1		CHEMBL270054	=	Inhibition	%	14.01	CHEMBL3629	Homo sapiens	Inhibition	%	14.01
	8188473	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	23.12	CHEMBL3629	Homo sapiens	Inhibition	%	23.12
	8188747	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	7.35	CHEMBL3629	Homo sapiens	Inhibition	%	7.35
	8189119	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	2.91	CHEMBL3629	Homo sapiens	Inhibition	%	2.91
	8189275	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc4c(c3)OCCO4)n2)cc1		CHEMBL365297	=	Inhibition	%	0.07	CHEMBL3629	Homo sapiens	Inhibition	%	0.07
	8189499	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	2.24	CHEMBL3629	Homo sapiens	Inhibition	%	2.24
	8189648	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC(=O)NCc1cccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)c1		CHEMBL207247	=	Inhibition	%	1.55	CHEMBL3629	Homo sapiens	Inhibition	%	1.55
	8189780	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	4.02	CHEMBL3629	Homo sapiens	Inhibition	%	4.02
	8190004	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	C#Cc1cccc(Nc2ncnc3ccc(OCCCCNCCS(C)(=O)=O)cc23)c1		CHEMBL517907	=	Inhibition	%	9.21	CHEMBL3629	Homo sapiens	Inhibition	%	9.21
	8190136	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	1.59	CHEMBL3629	Homo sapiens	Inhibition	%	1.59
	8190500	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	2.36	CHEMBL3629	Homo sapiens	Inhibition	%	2.36
	8190637	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccc(F)c(F)c3)n2)cc1		CHEMBL427159	=	Inhibition	%	10.46	CHEMBL3629	Homo sapiens	Inhibition	%	10.46
	8190861	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	4.78	CHEMBL3629	Homo sapiens	Inhibition	%	4.78
	8191025	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(C2=C(N3CCc4ccccc43)C(=O)NC2=O)cc1		CHEMBL347580	=	Inhibition	%	6.96	CHEMBL3629	Homo sapiens	Inhibition	%	6.96
	8191163	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	2.94	CHEMBL3629	Homo sapiens	Inhibition	%	2.94
	8191387	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCNC(=O)Nc1ccc(N(C)c2ccnc(Nc3ccc(CS(C)(=O)=O)cc3)n2)cc1.Cl		CHEMBL1909362	=	Inhibition	%	0.31	CHEMBL3629	Homo sapiens	Inhibition	%	0.31
	8191483	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(N)=O)c1		CHEMBL218088	=	Inhibition	%	1.41	CHEMBL3629	Homo sapiens	Inhibition	%	1.41
	8191829	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2c(-c3ccnc(Nc4cccc(OC(F)(F)F)c4)n3)cnn2n1		CHEMBL365248	=	Inhibition	%	20.02	CHEMBL3629	Homo sapiens	Inhibition	%	20.02
	8192202	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCc1cccc(CC)c1/C=C/c1cncc(C(=O)NC)c1		CHEMBL385426	=	Inhibition	%	-1.26	CHEMBL3629	Homo sapiens	Inhibition	%	-1.26
	8192331	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	6.07	CHEMBL3629	Homo sapiens	Inhibition	%	6.07
	8192699	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	4.87	CHEMBL3629	Homo sapiens	Inhibition	%	4.87
	8192835	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(S(C)(=O)=O)cc4)ncnc32)c1		CHEMBL66292	=	Inhibition	%	39.12	CHEMBL3629	Homo sapiens	Inhibition	%	39.12
	8193059	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	4.76	CHEMBL3629	Homo sapiens	Inhibition	%	4.76
	8193107	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCN(Cc2ccc(-c3cc4ncnc(Nc5ccc(OCc6cccc(F)c6)c(Cl)c5)c4s3)o2)CC1		CHEMBL475761	=	Inhibition	%	10.49	CHEMBL3629	Homo sapiens	Inhibition	%	10.49
	8193331	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	3.42	CHEMBL3629	Homo sapiens	Inhibition	%	3.42
	8193476	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3c2cnn3C(C)C)ccc1O		CHEMBL63728	=	Inhibition	%	11.83	CHEMBL3629	Homo sapiens	Inhibition	%	11.83
	8193857	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(N/C=C2\C(=O)Nc3ccccc32)c1		CHEMBL1794059	=	Inhibition	%	3.93	CHEMBL3629	Homo sapiens	Inhibition	%	3.93
	8194006	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.14	CHEMBL3629	Homo sapiens	Inhibition	%	-0.14
	8194361	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	2.65	CHEMBL3629	Homo sapiens	Inhibition	%	2.65
	8194492	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccccc1-c1cc(/C=C2\C(=O)Nc3ncc(Br)cc32)cc(Br)c1O		CHEMBL176857	=	Inhibition	%	3.83	CHEMBL3629	Homo sapiens	Inhibition	%	3.83
	8194716	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	1.59	CHEMBL3629	Homo sapiens	Inhibition	%	1.59
	8194859	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccncc2)cc(-c2ccccc2)c1N		CHEMBL230911	=	Inhibition	%	2.75	CHEMBL3629	Homo sapiens	Inhibition	%	2.75
	8195216	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN1CCC(n2cnc(-c3ccc(F)cc3)c2-c2ccnc(NCCO)n2)CC1		CHEMBL330422	=	Inhibition	%	13.23	CHEMBL3629	Homo sapiens	Inhibition	%	13.23
	8195380	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	18.01	CHEMBL3629	Homo sapiens	Inhibition	%	18.01
	8195743	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	2.74	CHEMBL3629	Homo sapiens	Inhibition	%	2.74
	8195841	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.45	CHEMBL3629	Homo sapiens	Inhibition	%	2.45
	8196065	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc(F)cc2)N=C(c2ccc(C(F)(F)F)nc2)N1		CHEMBL485598	=	Inhibition	%	2.14	CHEMBL3629	Homo sapiens	Inhibition	%	2.14
	8196182	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	3.02	CHEMBL3629	Homo sapiens	Inhibition	%	3.02
	8196556	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	1.08	CHEMBL3629	Homo sapiens	Inhibition	%	1.08
	8196684	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(CNC(=O)c2ccc(-c3cc(-c4nnc(C)o4)ccc3C)cc2)cc1		CHEMBL269985	=	Inhibition	%	16.43	CHEMBL3629	Homo sapiens	Inhibition	%	16.43
	8196908	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	5.63	CHEMBL3629	Homo sapiens	Inhibition	%	5.63
	8197049	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CNC(=O)c1cncc(/C=C/c2ccccc2C)c1		CHEMBL218969	=	Inhibition	%	7.63	CHEMBL3629	Homo sapiens	Inhibition	%	7.63
	8197410	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1ccc2c(-c3ccnc(Nc4cc(OC)cc(C(F)(F)F)c4)n3)cnn2n1		CHEMBL188426	=	Inhibition	%	15.35	CHEMBL3629	Homo sapiens	Inhibition	%	15.35
	8197685	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1cc(-c2ccc(F)cc2)cc(-c2ccncc2)c1N		CHEMBL231623	=	Inhibition	%	8.62	CHEMBL3629	Homo sapiens	Inhibition	%	8.62
	8197825	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	2.2	CHEMBL3629	Homo sapiens	Inhibition	%	2.2
	8198206	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	0.53	CHEMBL3629	Homo sapiens	Inhibition	%	0.53
	8198344	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCn1c(-c2nonc2N)nc2c(N3CCCC3)nccc21		CHEMBL187985	=	Inhibition	%	-0.49	CHEMBL3629	Homo sapiens	Inhibition	%	-0.49
	8198568	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	3.83	CHEMBL3629	Homo sapiens	Inhibition	%	3.83
	8198698	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncnc(Nc3ccc(C)c(O)c3)c2cc1OC.Cl		CHEMBL1909357	=	Inhibition	%	6.37	CHEMBL3629	Homo sapiens	Inhibition	%	6.37
	8199053	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(N2CCc3ccccc32)=C1c1ccc(Cl)cc1		CHEMBL156524	=	Inhibition	%	-1.39	CHEMBL3629	Homo sapiens	Inhibition	%	-1.39
	8199201	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	3.31	CHEMBL3629	Homo sapiens	Inhibition	%	3.31
	8199559	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	4.56	CHEMBL3629	Homo sapiens	Inhibition	%	4.56
	8199722	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccc(C(=O)c3ccco3)cc2C1=Cc1cc(Cl)c(O)c(Cl)c1		CHEMBL1789963	=	Inhibition	%	55.16	CHEMBL3629	Homo sapiens	Inhibition	%	55.16
	8199946	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	4.48	CHEMBL3629	Homo sapiens	Inhibition	%	4.48
	8200084	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	OCc1ccc(-c2nc(-c3ccccn3)c(-c3ccc4c(c3)OCO4)[nH]2)cc1		CHEMBL267228	=	Inhibition	%	-0.37	CHEMBL3629	Homo sapiens	Inhibition	%	-0.37
	8200412	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.72	CHEMBL3629	Homo sapiens	Inhibition	%	1.72
	8200527	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Cc2nc3ccc(Nc4ncnc5ccccc45)cc3[nH]2)cc1		CHEMBL1909379	=	Inhibition	%	9.95	CHEMBL3629	Homo sapiens	Inhibition	%	9.95
	8200751	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	8.38	CHEMBL3629	Homo sapiens	Inhibition	%	8.38
	8200901	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc2c(-c3ccnc(Nc4ccccc4)n3)c(-c3ccc(F)cc3)nn2n1		CHEMBL189459	=	Inhibition	%	-2.67	CHEMBL3629	Homo sapiens	Inhibition	%	-2.67
	8201255	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4cccs4)c(C(N)=O)s3)c2cc1OC		CHEMBL480382	=	Inhibition	%	20.8	CHEMBL3629	Homo sapiens	Inhibition	%	20.8
	8201390	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	5.15	CHEMBL3629	Homo sapiens	Inhibition	%	5.15
	8201747	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	2.77	CHEMBL3629	Homo sapiens	Inhibition	%	2.77
	8202026	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	3.22	CHEMBL3629	Homo sapiens	Inhibition	%	3.22
	8202166	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL514162	=	Inhibition	%	9.54	CHEMBL3629	Homo sapiens	Inhibition	%	9.54
	8202390	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	2.7	CHEMBL3629	Homo sapiens	Inhibition	%	2.7
	8202557	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Fc1ccc(-c2nc3n(c2-c2ccncc2)CCS3)cc1		CHEMBL1909406	=	Inhibition	%	-1.41	CHEMBL3629	Homo sapiens	Inhibition	%	-1.41
	8202906	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL381948	=	Inhibition	%	11.89	CHEMBL3629	Homo sapiens	Inhibition	%	11.89
	8203036	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	3.12	CHEMBL3629	Homo sapiens	Inhibition	%	3.12
	8203391	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	0.52	CHEMBL3629	Homo sapiens	Inhibition	%	0.52
	8203537	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)c1cc2c(Nc3ccc4nc(Cc5ccccc5)[nH]c4c3)ncnc2cn1		CHEMBL531804	=	Inhibition	%	1.45	CHEMBL3629	Homo sapiens	Inhibition	%	1.45
	8203761	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	1.83	CHEMBL3629	Homo sapiens	Inhibition	%	1.83
	8203895	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Fc1cccc(COc2ccc(Nc3ncncc3C#Cc3ccccc3)cc2Cl)c1		CHEMBL379093	=	Inhibition	%	11.26	CHEMBL3629	Homo sapiens	Inhibition	%	11.26
	8204285	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1cc(O)cc(C)c1/C=C/c1cncc(C(=O)OC(C)(C)C)c1		CHEMBL374060	=	Inhibition	%	7.86	CHEMBL3629	Homo sapiens	Inhibition	%	7.86
	8204422	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	1.53	CHEMBL3629	Homo sapiens	Inhibition	%	1.53
	8204751	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Clc1ccc(-c2nn3ncccc3c2-c2ccnc(Nc3ccccc3)n2)cc1		CHEMBL189148	=	Inhibition	%	1.08	CHEMBL3629	Homo sapiens	Inhibition	%	1.08
	8205090	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(/C=N/Nc2ncnc3[nH]ncc23)ccc1O		CHEMBL66004	=	Inhibition	%	34.8	CHEMBL3629	Homo sapiens	Inhibition	%	34.8
	8205239	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	1.46	CHEMBL3629	Homo sapiens	Inhibition	%	1.46
	8205599	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	5.33	CHEMBL3629	Homo sapiens	Inhibition	%	5.33
	8205738	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2cc3ccncc3cc2OCc2ccccc2)cc1		CHEMBL483748	=	Inhibition	%	12.58	CHEMBL3629	Homo sapiens	Inhibition	%	12.58
	8205962	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	4.55	CHEMBL3629	Homo sapiens	Inhibition	%	4.55
	8206094	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc([S+](C)[O-])cc4C)n3C)ccc2c1		CHEMBL237570	=	Inhibition	%	3.85	CHEMBL3629	Homo sapiens	Inhibition	%	3.85
	8206370	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(C(F)(F)F)c4)c3c2)o1		CHEMBL215814	=	Inhibition	%	5.65	CHEMBL3629	Homo sapiens	Inhibition	%	5.65
	8206737	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nc(-c2ccc3c(c2)C(=Cc2cc(Br)c(O)c(Br)c2)C(=O)N3)cs1		CHEMBL1794053	=	Inhibition	%	24.14	CHEMBL3629	Homo sapiens	Inhibition	%	24.14
	8206917	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	1.4	CHEMBL3629	Homo sapiens	Inhibition	%	1.4
	8207267	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	4.99	CHEMBL3629	Homo sapiens	Inhibition	%	4.99
	8207397	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccccc2)=C1Nc1ccccc1		CHEMBL346551	=	Inhibition	%	4.84	CHEMBL3629	Homo sapiens	Inhibition	%	4.84
	8207621	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	3.43	CHEMBL3629	Homo sapiens	Inhibition	%	3.43
	8207753	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1c2ccc(N(C)c3ccnc(Nc4cccc(S(N)(=O)=O)c4)n3)cc2nn1C.Cl		CHEMBL1909359	=	Inhibition	%	0.25	CHEMBL3629	Homo sapiens	Inhibition	%	0.25
	8208122	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1cnn2ncc(-c3ccnc(NCCCN4CCOCC4)n3)c2c1		CHEMBL524901	=	Inhibition	%	4.66	CHEMBL3629	Homo sapiens	Inhibition	%	4.66
	8208254	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	5.84	CHEMBL3629	Homo sapiens	Inhibition	%	5.84
	8208478	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2cc(-c3c[nH]nc3-c3ccccn3)ccn2)cc1		CHEMBL202891	=	Inhibition	%	8.65	CHEMBL3629	Homo sapiens	Inhibition	%	8.65
	8208644	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	3.48	CHEMBL3629	Homo sapiens	Inhibition	%	3.48
	8208777	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(O)cc1Nc1ccnc2cc(-c3ccccn3)ccc12.Cl		CHEMBL581096	=	Inhibition	%	-1.39	CHEMBL3629	Homo sapiens	Inhibition	%	-1.39
	8209001	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.54	CHEMBL3629	Homo sapiens	Inhibition	%	1.54
	8209106	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	1.79	CHEMBL3629	Homo sapiens	Inhibition	%	1.79
	8209446	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	2.62	CHEMBL3629	Homo sapiens	Inhibition	%	2.62
	8209596	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1cc(-c2cnn3nc(N4CCOCC4)ccc23)nc(NC2CC2)n1		CHEMBL495771	=	Inhibition	%	7.14	CHEMBL3629	Homo sapiens	Inhibition	%	7.14
	8209820	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.12	CHEMBL3629	Homo sapiens	Inhibition	%	1.12
	8209956	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCOc1nccc2c1nc(-c1nonc1N)n2CC		CHEMBL188240	=	Inhibition	%	14.62	CHEMBL3629	Homo sapiens	Inhibition	%	14.62
	8210321	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(NC(=O)CC2CC2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL516908	=	Inhibition	%	8.23	CHEMBL3629	Homo sapiens	Inhibition	%	8.23
	8210457	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	1.1	CHEMBL3629	Homo sapiens	Inhibition	%	1.1
	8210716	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	2.9	CHEMBL3629	Homo sapiens	Inhibition	%	2.9
	8210940	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2ccc(C)c(-c3ccc(C(=O)NCc4ccc(Cl)cc4)cc3)c2)o1		CHEMBL402108	=	Inhibition	%	5.39	CHEMBL3629	Homo sapiens	Inhibition	%	5.39
	8211084	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	0.66	CHEMBL3629	Homo sapiens	Inhibition	%	0.66
	8211254	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCCn1c(-c2nonc2N)nc2cnccc21		CHEMBL191105	=	Inhibition	%	-1.56	CHEMBL3629	Homo sapiens	Inhibition	%	-1.56
	8211478	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	7.47	CHEMBL3629	Homo sapiens	Inhibition	%	7.47
	8211601	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2cccc(Cl)c2)c(-c2ccc3ncccc3n2)s1		CHEMBL365663	=	Inhibition	%	15.26	CHEMBL3629	Homo sapiens	Inhibition	%	15.26
	8211954	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2nc(-c3ccc(O)cc3)c(Br)cc12)C1CC1		CHEMBL260417	=	Inhibition	%	5.84	CHEMBL3629	Homo sapiens	Inhibition	%	5.84
	8212086	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	1.61	CHEMBL3629	Homo sapiens	Inhibition	%	1.61
	8212451	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	2.04	CHEMBL3629	Homo sapiens	Inhibition	%	2.04
	8212808	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	5.98	CHEMBL3629	Homo sapiens	Inhibition	%	5.98
	8212978	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2ccc3[nH]ncc3c2)C(c2ccc3ccccc3c2)CC(=O)N1		CHEMBL441702	=	Inhibition	%	6.51	CHEMBL3629	Homo sapiens	Inhibition	%	6.51
	8213331	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.9	CHEMBL3629	Homo sapiens	Inhibition	%	1.9
	8213435	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(-c4ccccc4F)c3)o2)c1		CHEMBL372474	=	Inhibition	%	4.95	CHEMBL3629	Homo sapiens	Inhibition	%	4.95
	8213659	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-0.4	CHEMBL3629	Homo sapiens	Inhibition	%	-0.4
	8213772	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nc(-c2ccccn2)c(-c2ccc3ncccc3n2)s1		CHEMBL181361	=	Inhibition	%	10.05	CHEMBL3629	Homo sapiens	Inhibition	%	10.05
	8214143	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(-c2ccc3c(NC(=O)C4CC4)n[nH]c3c2)cc1		CHEMBL103098	=	Inhibition	%	1.51	CHEMBL3629	Homo sapiens	Inhibition	%	1.51
	8214280	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	5.76	CHEMBL3629	Homo sapiens	Inhibition	%	5.76
	8214638	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	4.12	CHEMBL3629	Homo sapiens	Inhibition	%	4.12
	8214790	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CCN1CCC(CC(=O)Nc2n[nH]c3nc(-c4cccs4)c(Br)cc23)CC1.O=C(O)C(O)C(O)C(=O)O		CHEMBL2062290	=	Inhibition	%	4.38	CHEMBL3629	Homo sapiens	Inhibition	%	4.38
	8215014	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-3.28	CHEMBL3629	Homo sapiens	Inhibition	%	-3.28
	8215265	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	2.78	CHEMBL3629	Homo sapiens	Inhibition	%	2.78
	8215418	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COC(=O)c1sc(-n2cnc3cc(OC)c(OC)cc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL473420	=	Inhibition	%	-0.18	CHEMBL3629	Homo sapiens	Inhibition	%	-0.18
	8215806	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(O)C(F)(F)F.O=C(O[C@H]1CN[C@H](C#Cc2cc3ncnc(Nc4ccc5c(ccn5Cc5cc(F)ccc5F)c4)c3s2)C1)N1CCOCC1		CHEMBL1909410	=	Inhibition	%	0.25	CHEMBL3629	Homo sapiens	Inhibition	%	0.25
	8215925	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	4.77	CHEMBL3629	Homo sapiens	Inhibition	%	4.77
	8216268	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	3.45	CHEMBL3629	Homo sapiens	Inhibition	%	3.45
	8216404	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NS(=O)(=O)c1cccc(-c2cc3ccncc3cc2OCc2ccccc2)c1		CHEMBL483747	=	Inhibition	%	-1.22	CHEMBL3629	Homo sapiens	Inhibition	%	-1.22
	8216628	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	3.18	CHEMBL3629	Homo sapiens	Inhibition	%	3.18
	8216766	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C(Nc1n[nH]c2cc(-c3ccc(F)cc3)ccc12)C1CC1		CHEMBL419903	=	Inhibition	%	0.79	CHEMBL3629	Homo sapiens	Inhibition	%	0.79
	8217124	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1nnc(-c2cccc(-c3ccc(C(=O)NCC4CC4)cc3)c2)o1		CHEMBL257113	=	Inhibition	%	8.99	CHEMBL3629	Homo sapiens	Inhibition	%	8.99
	8217298	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	3.77	CHEMBL3629	Homo sapiens	Inhibition	%	3.77
	8217653	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	2.39	CHEMBL3629	Homo sapiens	Inhibition	%	2.39
	8217978	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1NC(=O)C(c2ccc(Cl)cc2)=C1Nc1ccc(Cl)c(C(=O)O)c1		CHEMBL160876	=	Inhibition	%	-2.48	CHEMBL3629	Homo sapiens	Inhibition	%	-2.48
	8218093	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	3.04	CHEMBL3629	Homo sapiens	Inhibition	%	3.04
	8218444	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	30.98	CHEMBL3629	Homo sapiens	Inhibition	%	30.98
	8218587	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(O[C@H](C)c4ccccc4Cl)c(C(N)=O)s3)c2cc1OC		CHEMBL222419	=	Inhibition	%	19.52	CHEMBL3629	Homo sapiens	Inhibition	%	19.52
	8218811	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	6.63	CHEMBL3629	Homo sapiens	Inhibition	%	6.63
	8218942	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cc1ccc(Nc2ccnc(Nc3cccc(C(N)=O)c3)n2)cc1O.Cl		CHEMBL1909381	=	Inhibition	%	10.46	CHEMBL3629	Homo sapiens	Inhibition	%	10.46
	8219326	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	c1ccc(-c2n[nH]cc2-c2ccnc(-c3ccc(OCCN4CCOCC4)cc3)c2)nc1		CHEMBL205158	=	Inhibition	%	-4.72	CHEMBL3629	Homo sapiens	Inhibition	%	-4.72
	8219576	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2CCCN2CCOCC2)n1		CHEMBL274863	=	Inhibition	%	4.35	CHEMBL3629	Homo sapiens	Inhibition	%	4.35
	8219737	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	4.06	CHEMBL3629	Homo sapiens	Inhibition	%	4.06
	8219961	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL196022	=	Inhibition	%	-2.3	CHEMBL3629	Homo sapiens	Inhibition	%	-2.3
	8220130	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	2.99	CHEMBL3629	Homo sapiens	Inhibition	%	2.99
	8220259	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2ccc(F)cc2C(=O)NC[C@@H](O)CO)c2cc[nH]c2n1		CHEMBL450071	=	Inhibition	%	15.66	CHEMBL3629	Homo sapiens	Inhibition	%	15.66
	8220483	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	3.49	CHEMBL3629	Homo sapiens	Inhibition	%	3.49
	8220597	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	NC(=O)c1sc(-n2cnc3ccc(C(F)(F)F)cc32)cc1OCc1ccccc1Br		CHEMBL481510	=	Inhibition	%	5.66	CHEMBL3629	Homo sapiens	Inhibition	%	5.66
	8220959	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	O=C1Nc2ccccc2/C1=C1\CCc2cc(O)ccc21		CHEMBL175321	=	Inhibition	%	9.1	CHEMBL3629	Homo sapiens	Inhibition	%	9.1
	8221095	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.55	CHEMBL3629	Homo sapiens	Inhibition	%	1.55
	8221319	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nonc1-c1nc2cnccc2n1C1CC1		CHEMBL185962	=	Inhibition	%	1.11	CHEMBL3629	Homo sapiens	Inhibition	%	1.11
	8221452	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	6.3	CHEMBL3629	Homo sapiens	Inhibition	%	6.3
	8221617	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.c1ccc(Oc2ccc(Nc3ncc(-c4ccccc4)o3)cc2)cc1		CHEMBL1909341	=	Inhibition	%	5.82	CHEMBL3629	Homo sapiens	Inhibition	%	5.82
	8221841	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	2.91	CHEMBL3629	Homo sapiens	Inhibition	%	2.91
	8221972	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc2ncn(-c3cc(OCc4ccccc4S(C)(=O)=O)c(C#N)s3)c2cc1OC		CHEMBL373751	=	Inhibition	%	5.0	CHEMBL3629	Homo sapiens	Inhibition	%	5.0
	8222294	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CCS(=O)(=O)c1ccc(OC)c(Nc2ncc(-c3cccc(C(C)=O)c3)o2)c1		CHEMBL191705	=	Inhibition	%	6.61	CHEMBL3629	Homo sapiens	Inhibition	%	6.61
	8222428	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CN(C)CCOc1ccc(-c2nc(-c3ccncc3)c(-c3ccc4c(c3)CC/C4=N\O)[nH]2)cc1.Cl.O		CHEMBL1909414	=	Inhibition	%	7.33	CHEMBL3629	Homo sapiens	Inhibition	%	7.33
	8222652	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2ncc(-c3ccccc3)o2)cc1		CHEMBL194062	=	Inhibition	%	3.56	CHEMBL3629	Homo sapiens	Inhibition	%	3.56
	8222770	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cccc(-n2ncc3c(N/N=C/c4ccc(C(=O)NCCN(C)C)cc4)ncnc32)c1.Cl		CHEMBL1909383	=	Inhibition	%	62.21	CHEMBL3629	Homo sapiens	Inhibition	%	62.21
	8223138	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1ccc(-c2oc3ncnc(N)c3c2-c2ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc2)cc1.Cl		CHEMBL1909396	=	Inhibition	%	16.66	CHEMBL3629	Homo sapiens	Inhibition	%	16.66
	8223267	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	2.74	CHEMBL3629	Homo sapiens	Inhibition	%	2.74
	8223491	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.O=C(Nc1ccc(Oc2ccc3[nH]c(NC(=O)c4ccccc4)nc3c2)cc1)Nc1cc(C(F)(F)F)ccc1F		CHEMBL1909374	=	Inhibition	%	4.99	CHEMBL3629	Homo sapiens	Inhibition	%	4.99
	8223652	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc(COc2ccc(Cc3cnc(N)nc3N)cc2OC)cc1		CHEMBL261849	=	Inhibition	%	-2.39	CHEMBL3629	Homo sapiens	Inhibition	%	-2.39
	8223902	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	COc1ccc2cc(-c3c(-c4ccncc4)nc(-c4ccc(S(C)(=O)=O)cc4C)n3C)ccc2c1		CHEMBL237571	=	Inhibition	%	3.63	CHEMBL3629	Homo sapiens	Inhibition	%	3.63
	8224288	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cc1ccc(NC(=O)c2ccnc(N3CCCC3)c2)cc1-c1ccc(C(=O)NCC2CC2)cc1		CHEMBL477182	=	Inhibition	%	7.04	CHEMBL3629	Homo sapiens	Inhibition	%	7.04
	8224458	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2ccc(F)c3ccccc23)sc2c1CCCC2		CHEMBL233002	=	Inhibition	%	-1.66	CHEMBL3629	Homo sapiens	Inhibition	%	-1.66
	8224817	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	N#Cc1c(NC(=O)c2cccc3ccccc23)sc2c1CCCN2C(=O)C1CC1		CHEMBL232601	=	Inhibition	%	8.12	CHEMBL3629	Homo sapiens	Inhibition	%	8.12
	8224931	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	3.06	CHEMBL3629	Homo sapiens	Inhibition	%	3.06
	8225155	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	CC1=C(C(=O)Nc2cc(Cl)c3[nH]ncc3c2)C(c2ccc(C(F)(F)F)cc2)CC(=O)N1		CHEMBL427058	=	Inhibition	%	1.13	CHEMBL3629	Homo sapiens	Inhibition	%	1.13
	8225289	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	NS(=O)(=O)c1ccc(Nc2cc(-c3cccc(O)c3)n[nH]2)cc1		CHEMBL103104	=	Inhibition	%	2.68	CHEMBL3629	Homo sapiens	Inhibition	%	2.68
	8225651	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Cl.c1ccc(-c2nc3n(c2-c2ccc4c(c2)OCO4)CCC3)nc1		CHEMBL1909377	=	Inhibition	%	0.8	CHEMBL3629	Homo sapiens	Inhibition	%	0.8
	8225786	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	COc1cc(N2CCN(C(C)C)CC2)ccc1Nc1nc(Nc2cccc(F)c2C(=O)O)c2cc[nH]c2n1		CHEMBL514261	=	Inhibition	%	22.4	CHEMBL3629	Homo sapiens	Inhibition	%	22.4
	8226168	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Cl.Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL1909407	=	Inhibition	%	2.93	CHEMBL3629	Homo sapiens	Inhibition	%	2.93
	8226293	CHEMBL1962078	GSK_PKIS: CK2 mean inhibition at 0.1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	1.6	CHEMBL3629	Homo sapiens	Inhibition	%	1.6
	8226517	CHEMBL1962079	GSK_PKIS: CK2 mean inhibition at 1 uM [Nanosyn]	B	Nc1nccc(C#Cc2cncnc2Nc2ccc(OCc3cccc(F)c3)c(Cl)c2)n1		CHEMBL381604	=	Inhibition	%	2.69	CHEMBL3629	Homo sapiens	Inhibition	%	2.69
active	9582640	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(-c2[nH]c(-c3ccnc(N)n3)cc2C(N)=O)c1C		CHEMBL1964290	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9582641	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)c(OC)c1		CHEMBL2003768	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582642	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2onc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL213505	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582643	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)c1		CHEMBL1982880	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9582644	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1ncn2nc(Sc3ccc(F)cc3F)ccc2c1-c1c(Cl)cccc1Cl		CHEMBL119385	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582645	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#CCOc1ccc(Nc2nc(Nc3cccc(S(N)(=O)=O)c3)ncc2Br)cc1		CHEMBL1987034	=	Ki	nM	3.981	CHEMBL3629	Homo sapiens	pKi		8.4
inactive	9582646	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1993941	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582647	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1Cl		CHEMBL377383	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582648	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(Nc2ccnc(Nc3ccccc3)n2)cc1		CHEMBL578061	=	Ki	nM	15848.93	CHEMBL3629	Homo sapiens	pKi		4.8
inactive	9582649	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(N2CCOCC2)cc2[nH]c(-c3c(NCC(O)c4cccc(Cl)c4)cc[nH]c3=O)nc12		CHEMBL2005886	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582650	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1sc(-n2cnc3ccccc32)cc1OCc1ccccc1C(F)(F)F		CHEMBL481491	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582651	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682345	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
active	9582652	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)Nc1c(C(N)=O)sc2ccc(Cl)c(Cl)c12		CHEMBL1973142	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9582653	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4nc(N)nc(N)c34)cc2)c1		CHEMBL1973145	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582654	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982924	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
active	9582655	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL2005936	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
active	9582656	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC1CCC(Nc2nccc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1966628	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9582657	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc(C(N)=O)c3)cc2)c1		CHEMBL1971141	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582658	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC1CCCCC1Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL1995813	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582659	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(C)n(Cc2ccccc2)c2ccc(C(=O)Nc3nc[nH]n3)cc12		CHEMBL1979718	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582660	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COCc1ccccc1)COc1cncc(C=Cc2ccncc2)c1		CHEMBL1993781	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582661	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCn1c2cc(Cl)c(O)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL523823	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
active	9582662	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1(C)CC2=Nc3cc(Cl)ccc3SC2=C(O)C1		CHEMBL1562756	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
active	9582663	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3cn[nH]c3c2)n1		CHEMBL244378	=	Ki	nM	10.0	CHEMBL3629	Homo sapiens	pKi		8.0
inactive	9582664	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cc(F)cc13)CN(C(=O)N1CCCCC1)CC2		CHEMBL362558	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582665	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(OCC(F)(F)F)nccn23)n1		CHEMBL2001957	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582666	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCCNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1969372	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582667	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnn2ccc(C(=O)Nc3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1990583	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582668	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	158.49	CHEMBL3629	Homo sapiens	pKi		6.8
active	9582669	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nc2ccc(NS(=O)(=O)c3ccc(N)cc3)cc2nc1C		CHEMBL2006263	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9582670	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1993584	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582671	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCn1c(C)c(-c2ccnc(Nc3cccc(OC)c3)n2)sc1=O		CHEMBL1986263	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9582672	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CSc1c[nH]c2ncnc(NCCCO)c12		CHEMBL2000114	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582673	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(NC(=O)Cc2cc(OC)ccc2OC)cc(N)c1C#N		CHEMBL210618	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582674	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1csc(Nc2ccccc2)n1		CHEMBL1998975	=	Ki	nM	10000.0	CHEMBL3629	Homo sapiens	pKi		5.0
active	9582675	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnccn1)Nc1ccnc2c(F)cccc12		CHEMBL1975647	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9582676	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1968380	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582677	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCc1ccccc1)Nc1ncc([N+](=O)[O-])s1		CHEMBL1964644	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582678	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCc1ccc(Cl)c(Cl)c1)Nc1ccc2[nH]ncc2c1		CHEMBL1981782	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
active	9582679	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1cc2c(-c3ccccc3F)n[nH]c2s1		CHEMBL1977681	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9582680	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)C(C)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(C)cc5)cc4)csc23)cn1		CHEMBL1970142	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582681	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2c(N3CCN(C(=O)Nc4ccc(OC(C)C)cc4)CC3)ncnc2cc1OCCCN1CCCCC1		CHEMBL124660	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582682	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCNc1cc2cc(-c3cccnc3)ccc2cn1		CHEMBL1990912	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582683	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL223360	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9582684	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(-c4ccccc4)c3n2)c1		CHEMBL1988163	=	Ki	nM	39.81	CHEMBL3629	Homo sapiens	pKi		7.4
inactive	9582685	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(O)ccc1-n1c2cc(Cl)ccc2c(=O)c2c(N)nc(N)nc21		CHEMBL1995592	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582686	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1CCCc2oc3cc(C(F)(F)F)ccc3c(=O)c21		CHEMBL2006493	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582687	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(OC)c(CNC(=O)c2cc(N)c(C#N)c(OC(C)C)n2)c1		CHEMBL1982541	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582688	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1cc2nn[nH]c2cc1Cl		CHEMBL1996923	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582689	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1C		CHEMBL1983449	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582690	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]cnc2c1oc1ccc(Cl)cc12		CHEMBL1992323	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9582691	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(Cl)nccn23)n1		CHEMBL1969735	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582692	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCc1nc2c(c3cc(OC)c(OC)cc13)C(=O)NC2=O		CHEMBL2003524	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582693	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc2c(c1)C(=Cc1c[nH]cn1)C(=O)N2		CHEMBL2002649	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582694	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCn1c(C2CCNCC2)nc(-c2ccc(Cl)c(Cl)c2)c1-c1ccnc(NC2CCCCC2)n1		CHEMBL437747	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582695	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Brc1ccc2c(c1)-c1[nH]ncc1C2		CHEMBL1995172	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582696	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL507936	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9582697	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=S(=O)(NCCNCC=Cc1ccc(Br)cc1)c1cccc2cnccc12		CHEMBL1987756	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582698	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCNS(C)(=O)=O)cnc(N)c34)cc2)c1		CHEMBL1994321	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582699	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NCCc2[nH]c(-c3ccnc(C=Cc4ccccc4)c3)cc21		CHEMBL1997129	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
inactive	9582700	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc(Cl)cc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1984788	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582701	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	FC(F)(F)c1ccc(-c2nnc3ccc(NC4CC4)nn23)cc1		CHEMBL451964	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582702	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL1964307	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9582703	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1ccc(-c2nc3sccn3c2-c2ccncc2)cc1		CHEMBL2000508	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582704	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCCNc1n[s+]([O-])nc1Nc1ccc(F)cc1		CHEMBL1971694	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582705	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2001547	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582706	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1Cl		CHEMBL210928	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582707	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1F		CHEMBL1994361	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582708	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(NC(=O)CCNC(=O)Nc2nc(C)c(-c3ccc(-n4cccn4)cc3)s2)no1		CHEMBL1986603	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582709	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1		CHEMBL553	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582710	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(-c2cc3cnccc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1972840	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9582711	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CCO)c5)cnc(N)c34)cc2)cc1		CHEMBL1977148	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9582712	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(C=C2SC(=O)NC2=O)ccc1O		CHEMBL2003286	=	Ki	nM	3.981	CHEMBL3629	Homo sapiens	pKi		8.4
inactive	9586276	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccn1		CHEMBL1992306	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586277	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(O)Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL2002165	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586278	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]cc(I)c2nc(-c3ccccc3)cn12		CHEMBL2001668	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586279	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2c1C(c1ccccc1I)C(C#N)=C(N)O2		CHEMBL1979318	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586280	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1989518	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586281	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1998585	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586282	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cncc1C(OCc1c(-c2ccc(OC(F)(F)F)cc2)cc(C#N)c(=O)n1C)c1ccc(C#N)cc1		CHEMBL127898	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586283	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2C		CHEMBL519697	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586284	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(F)c2)c1		CHEMBL2004934	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586285	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3I)cc12		CHEMBL1975128	=	Ki	nM	251.19	CHEMBL3629	Homo sapiens	pKi		6.6
inactive	9586286	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(-c2cc3c(NCCN)ccc(C(N)=O)c3[nH]2)cc1		CHEMBL1996048	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586287	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)C1CCCN(C(=O)c2cc(-c3ccc4[nH]ncc4c3)on2)C1		CHEMBL1970369	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586288	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2c(cc1Nc1nc(Nc3cccc(F)c3C(N)=O)c3cc[nH]c3n1)N(C(=O)CN(C)C)CC2		CHEMBL461876	=	Ki	nM	630.96	CHEMBL3629	Homo sapiens	pKi		6.2
inactive	9586289	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C(C)C(=O)N(C)C)c5)cnc(N)c34)cc2)cc1		CHEMBL2001485	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586290	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1		CHEMBL491473	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586291	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)c2c(n1)sc1c(N)ncnc12		CHEMBL504950	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586292	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1966425	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586293	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(NC(=O)Cc2ccc(-c3cccc4[nH]nc(N)c34)cc2)ccc1F		CHEMBL1984363	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586294	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)COc1ccc(Nc2nc(Nc3ccc(C)c(S(N)(=O)=O)c3)ncc2F)cc1		CHEMBL1978099	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9586295	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COC(=O)c1c(-c2ccc(NC(=O)Nc3ccccc3)cc2)c2c(N)ncnn2c1C		CHEMBL1977041	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586296	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cccc2c1Nc1nnc(Cl)cc1C(=O)N2		CHEMBL1968070	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
active	9586297	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)Nc1cccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)c1		CHEMBL1988608	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9586298	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)cc1C		CHEMBL184847	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586299	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)c1ccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)cc1		CHEMBL1984367	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586300	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NC(=O)C(c2cnc3ccccn23)=C1c1cn2c3c(cccc13)CN(C(=O)N1CCOCC1)CC2		CHEMBL178737	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586301	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2cnc(-c3cncc(OCC(N)Cc4cccc(C(F)(F)F)c4)c3)cc12		CHEMBL1998159	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9586302	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(C)nccn23)n1		CHEMBL1982563	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586303	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1CCCN1Cc1ccc2c(c1)[nH]c(=O)c1cccn12		CHEMBL539474	=	Ki	nM	79.43	CHEMBL3629	Homo sapiens	pKi		7.1
inactive	9586304	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(-c2ccc3[nH]c(=O)oc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1987679	<	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9586305	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5ccc(OC(F)F)cc5)cc4)csc23)cn1		CHEMBL1988387	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586306	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1997759	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586307	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586308	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586309	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2cc(Cl)cc(Cl)c2c(-c2cc(Cl)ccc2O)c1O		CHEMBL1974803	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9586310	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12		CHEMBL1970074	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586311	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ccc2[nH]c(=O)cnc2c1		CHEMBL2002635	=	Ki	nM	12589.25	CHEMBL3629	Homo sapiens	pKi		4.9
inactive	9586312	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586313	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCCN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1986970	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586314	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1=NN(c2cccc(Br)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2005112	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
active	9586315	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1cc(-c2ccncc2)nc(NC2CCCCC2)[nH]1		CHEMBL1958401	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9586316	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)CCOc1ccc(-c2nc3c(C(N)=O)cccc3[nH]2)cc1		CHEMBL1984044	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586317	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2cc(-c3ccccc3)cnc2[nH]1		CHEMBL2003456	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586318	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(F)cccc12		CHEMBL1966816	=	Ki	nM	79.43	CHEMBL3629	Homo sapiens	pKi		7.1
inactive	9586319	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586320	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(N)C1CCC(C(=O)Nc2ccnc3[nH]ccc23)CC1		CHEMBL2002992	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586321	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1cnc(NC(=O)Nc2ccc3cc(C(=O)O)ccc3c2)cn1		CHEMBL560813	=	Ki	nM	125.89	CHEMBL3629	Homo sapiens	pKi		6.9
inactive	9586322	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CC(CN2CCCC2)C1		CHEMBL1968791	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586323	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1CC(c2ccc(Cl)cc2Cl)Cc2nc3cc(Cl)ccc3c(O)c21		CHEMBL326282	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586324	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(Cl)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)NCCOCCOCCN)[nH]c12		CHEMBL2002682	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586325	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1ccccc1C=NNC(=O)c1nnn(-c2nonc2N)c1N1CCCC1		CHEMBL1992732	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586326	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1ccc(-c2nc3occn3c2-c2ccnc(NC3CCNCC3)n2)cc1		CHEMBL1971186	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586327	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Cc1ccc(Cl)cc1)Nc1[nH]nc2c1CCC2		CHEMBL2003482	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586328	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCCC5)cnc(N)c34)cc2)c1		CHEMBL1973211	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586329	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1984700	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586330	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1ccc(Nc2nnc(Cc3ccncc3)c3ccccc23)cc1		CHEMBL101253	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586331	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(-c2cccc(OCc3ccccc3)c2)c2c(N)ncnc2n1C1CCC(N2CCCC2)CC1		CHEMBL2007151	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586332	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1ccccc1		CHEMBL1972125	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586333	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1ccc2[nH]ncc2c1)c1cccc(F)c1		CHEMBL1461728	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9586334	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL941	<	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
active	9586335	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1cc2cc(-c3ccc4cn[nH]c4c3)cnc2[nH]1		CHEMBL1976134	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9586336	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(C(=O)Nc2c(C(N)=O)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL1965131	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9586337	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCOc1cccc(Nc2ccnc(N)n2)c1		CHEMBL1995448	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586338	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccccc3)cc12		CHEMBL1972158	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
active	9586339	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1974457	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9586340	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(Cl)c1)Nc1ncc(CCN=c2[nH]cnc3ccsc23)s1		CHEMBL482767	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586341	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Oc1ccc(Nc2ncnc3scc(Cl)c23)cc1		CHEMBL2006580	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9586342	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1Cl		CHEMBL2006581	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586343	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCCC1		CHEMBL2006481	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586344	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)c1cc(NC(=O)Nc2cccc3ccccc23)n(-c2cccc(C(=O)NCC#N)c2)n1		CHEMBL1979855	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586345	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1noc2cccc(-c3cccc(O)c3)c12		CHEMBL1970340	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586346	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)NC(=O)COc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3ccccc3n2)c1		CHEMBL2005186	=	Ki	nM	100.0	CHEMBL3629	Homo sapiens	pKi		7.0
inactive	9586347	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCNc1nc2cc(Cl)c(OC)cc2nc1NCC		CHEMBL1995927	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586348	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCC(O)C(O)Cn1cc(I)c2c(N)ncnc21		CHEMBL1975534	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586349	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NS(=O)(=O)c1cccc(Nc2ncc3ccn(Cc4ccccc4)c3n2)c1		CHEMBL1993424	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9586350	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2c1C(c1ccccc1F)C1=C(CC(C)(C)CC1=O)N2		CHEMBL1966703	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586351	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)N(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1969561	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586352	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586353	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)c1cc2sncc2cc1NC(=O)C(=O)O		CHEMBL1997023	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9586354	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1964687	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586355	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586356	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(-c3ccc(Br)c(F)c3F)cncc2s1		CHEMBL1999918	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586357	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1974254	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586358	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C(=O)N2c3ccccc3Sc3c(Cl)cncc32)cc1		CHEMBL1988537	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9586359	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)c(C)c2)c1		CHEMBL1969049	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586360	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)cc1		CHEMBL2005828	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586361	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccc3ccccc3c2)n1		CHEMBL2002240	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586362	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCc1nc(-c2cccc(C)c2)c(-c2ccnc(NC(=O)c3ccccc3)c2)s1		CHEMBL363648	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586363	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(-n2nc(C)c3c(=O)c4cc(Cl)ccc4n(O)c32)cc1		CHEMBL1991143	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586364	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1		CHEMBL1336	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586365	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1sc2c(Br)ccc(Cl)c2c1N		CHEMBL1998611	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9586366	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C(=O)C1CCCCC1)c1ccc2c(c1)nc(NC(=O)c1ccc(C#N)cc1)n2CCC(N)=O		CHEMBL485556	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586367	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1c(NCc2ccc(Cl)c(Cl)c2)c(Nc2ccncc2)c1=O		CHEMBL1975900	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586368	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(=O)CC)c3c2)cc1		CHEMBL1972221	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586369	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3cc(F)c4[nH]c(C)cc4c3)csc12		CHEMBL2006778	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9586370	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(S(C)(=O)=O)c(OC)cc1CC(=O)Nc1cc(N)c(C#N)c(OC(C)C)n1		CHEMBL378627	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586371	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1c(F)cccc1F		CHEMBL1996979	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9586372	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cccc2[nH]c(-c3ccc(C4CCCNC4)cc3F)nc12		CHEMBL1997025	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586373	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1968406	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586374	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)csc12		CHEMBL1982476	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586375	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1C(=NNc2cccc3c(=O)[nH][nH]c(=O)c23)C(c2ccccc2)=NN1c1ccccc1		CHEMBL1984274	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586376	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1998545	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586377	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1csc(NC(=O)c2sc3nc(-c4ccncc4)ccc3c2N)n1		CHEMBL1986869	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586378	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)c(Cl)ccc12		CHEMBL2006010	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586379	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1ccc(-c2ncn(CCN3CCOCC3)c2-c2ccc3[nH]ncc3c2)cc1		CHEMBL1682558	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586380	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1c(NCC(N)Cc2ccccc2)nc(-c2ccncc2)c(-c2ccc3ccccc3c2)c1=O		CHEMBL1990496	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586381	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2cc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)ccc12		CHEMBL1997623	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9586382	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccc(Cl)cc5o4)cc3)c1)CNC2=O		CHEMBL2002479	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586383	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCN(C)CCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1993166	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586384	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCc1ccc(Cl)cc1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL1967094	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586385	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)c1ccccc1		CHEMBL1966035	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586386	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NC(CO)c1cc(Cl)cc(Cl)c1)c1ccc(-c2ccncc2)cc1		CHEMBL2003341	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586387	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(-c2n[nH]cc2-c2ccncc2)cc1		CHEMBL1992644	<	Ki	nM	15848.93	CHEMBL3629	Homo sapiens	pKi		4.8
inactive	9586388	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NS(=O)(=O)c1ccc(NCCSc2ccc(O)cc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1		CHEMBL1992645	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586389	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Oc1cccc(Nc2ncnc3scc(Cl)c23)c1		CHEMBL1982992	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9586390	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(-c2ccccc2)n(-c2cc(NN=Cc3ccco3)ncn2)n1		CHEMBL1999590	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586391	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1F		CHEMBL1981079	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
inactive	9586392	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)CCCNc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)n1		CHEMBL1972276	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586393	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1c(NCc2ccc(Cl)cc2)c(Nc2ccncc2)c1=O		CHEMBL1980489	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586394	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCc4cccc(F)c4)cc2NC3=O)ccc1O		CHEMBL2000832	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586395	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)c1		CHEMBL1967116	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586396	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nn(C)c2c1c(=O)c1cc(Cl)ccc1n2OCC(C)C		CHEMBL1977814	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586397	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nc2ccccn2c1-c1csc(Nc2ccc(O)cc2)n1		CHEMBL513846	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
inactive	9586398	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCc1ccc(Br)cc1)Nc1ccc2[nH]ncc2c1		CHEMBL1970709	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586399	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	199.53	CHEMBL3629	Homo sapiens	pKi		6.7
inactive	9586400	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(-c2cc3nccn3c(Nc3ccccc3C(N)=O)n2)cc1OC		CHEMBL1998112	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586401	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)n1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)cc21		CHEMBL1969126	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586402	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Cc4cccc(Cl)c4)cc3)c12		CHEMBL1980896	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586403	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)NC1CCN(c2nc3[nH]cc(C(=O)O)c(=O)c3c(C)c2F)C1		CHEMBL1975208	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586404	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9586405	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1		CHEMBL1991429	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586406	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(Oc3cccc(F)c3)cncc2s1		CHEMBL1964777	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9586407	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)C(=O)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1971149	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586408	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc2c(c1)NC(=O)c1ccccc1N2		CHEMBL1999714	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586409	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Cc1ccccc1Cl)Nc1ccc2cn[nH]c2c1		CHEMBL1987533	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586410	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(O)CNc1nccc(-c2c(-c3ccc(F)cc3F)nc3c(CC4CC4)nccn23)n1		CHEMBL1994040	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586411	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC1CC2OC(C)(C1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL1980995	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9586412	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(-c2ccc3c(c2)CC(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL1967302	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586413	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCCCN4CCOCC4)cc2-3)cn1		CHEMBL398951	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586414	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2cnc3c(c2cc1OC)C(=O)NC3=O		CHEMBL1982506	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586415	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)CCNC(=O)C=Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2004716	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586416	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1		CHEMBL1968127	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586417	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(C)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1975233	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586418	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cccc(F)c3F)cc12		CHEMBL1985406	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586419	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1nc(C(F)(F)F)c2c(=O)c3cc(Cl)ccc3n(O)c21		CHEMBL207400	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586420	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(O)ccc1-n1cc(C(=O)NN)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL2000894	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586421	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nsc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL2002553	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9586422	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccccc1NC(=O)Nc1ccc2c(c1)CCc1sc3ncnc(N)c3c1-2		CHEMBL1982135	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586423	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1sc1ncnc(N)c12		CHEMBL1976090	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9586424	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4c(c3)OCO4)csc12		CHEMBL1993243	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586425	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCC(CO)Nc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1992922	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586426	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3o2)cc1		CHEMBL2004771	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586427	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CC(CN2CCCC2)C1		CHEMBL1988370	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586428	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1997597	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586429	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	S=c1[nH]nc2c3c4c(sc3n3c(=S)[nH]nc3n12)CCC4		CHEMBL1969537	=	Ki	nM	79.43	CHEMBL3629	Homo sapiens	pKi		7.1
inactive	9586430	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586431	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CC(C)(C)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1976093	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586432	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccccc2)n1		CHEMBL210032	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586433	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(-c2ccc(F)cc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1996543	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586434	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1cccs1		CHEMBL1975256	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586435	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cnc4c(-c5cnn(C)c5)cnn4c3N)cc2)c1		CHEMBL508928	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586436	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(-c2cc3c(=O)[nH]c4ccccc4n3c2)c1		CHEMBL1991356	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586437	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C(=O)Nc2nc3ccc(Cl)cc3s2)c(OC)c1		CHEMBL1983309	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586438	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL2004892	=	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586439	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1=NN(c2ccccc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1999126	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9586440	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Oc1ccc(-c2noc(-c3ccc(NC4CCC(C(=O)O)C4)cc3)n2)cc1Cl		CHEMBL1997503	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586441	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(Oc3ccc(Br)cc3)cncc2s1		CHEMBL116070	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586442	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)c(C)c(OCCCc2c(C(=O)O)[nH]c3c(-c4ccccc4C)cccc23)c1		CHEMBL1990821	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586443	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc(-c2cccc(N)c2)cc2cccnc12		CHEMBL1970314	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586444	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCCn1cnc(-c2ccc(F)cc2)c1-c1ccncc1		CHEMBL2004871	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586445	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncn3)cc2)c1		CHEMBL2004872	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586446	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Nc2ccccc2Nc2ccccc21		CHEMBL1727312	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586447	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1CCN(C(=O)CO)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL1969879	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586448	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1		CHEMBL1971463	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
active	9586449	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnccn1)Nc1ccnc2ccccc12		CHEMBL1981720	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9586450	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(N)COc1cnc(Cl)c(C=Cc2ccncc2)c1		CHEMBL1993548	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586451	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3nsc4ncnc(N)c34)cc2)c1		CHEMBL262433	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586452	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(-c2nn(C(C)(C)C)c3ncnc(N)c23)cc1		CHEMBL306380	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586453	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NNC(=S)Nc1ccc(Cl)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1966722	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9586454	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(C(=O)NCCNC(C)=O)cc2NC3=O)ccc1O		CHEMBL1975500	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9586455	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4snc(N)c34)cc2)c1		CHEMBL1976328	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586456	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ccnc(N)c34)cc2)c1		CHEMBL394619	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586457	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)cc1OC		CHEMBL1964399	=	Ki	nM	316.23	CHEMBL3629	Homo sapiens	pKi		6.5
active	9586458	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1c2c(nc3ccccc13)C(=C1CCCC1)CC2		CHEMBL1996831	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9586459	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cc(C(F)(F)F)ccc3F)cc1)CCN2		CHEMBL411903	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586460	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN)cnc(N)c34)cc2)c1		CHEMBL1965988	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586461	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCC(c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)C(O)C1		CHEMBL422897	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586462	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(-c2ccc3[nH]nc(N)c3c2)nnn1Cc1ccccc1		CHEMBL1989646	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9586463	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(Cc2cc(-c3ccc4[nH]ncc4c3)on2)cc1		CHEMBL1682357	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586464	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NCCc2[nH]c(-c3ccncc3)cc21		CHEMBL225519	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9586465	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2cccnc2)cc(N)c1C#N		CHEMBL209534	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586466	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nccn2c(-c3ccnc(NCCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1978200	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586467	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1		CHEMBL522892	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586468	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(C=C2SC(=Nc3ccccc3)NC2=O)ccc1O		CHEMBL1970522	=	Ki	nM	31.62	CHEMBL3629	Homo sapiens	pKi		7.5
inactive	9586469	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586470	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1n[nH]c2nc3ccccc3cc12)c1ccncc1		CHEMBL1990415	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9586471	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	C(=Cc1cncc(OC2CCNC2)c1)c1ccncc1		CHEMBL1966087	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586472	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1nc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)cncc21		CHEMBL1964692	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586473	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NC(CO)Cc1ccc(Cl)cc1)c1ccc(-c2ccncc2)cc1		CHEMBL1996931	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586474	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	FC(F)(F)c1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C(F)(F)F)c1		CHEMBL1964413	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586475	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL1973483	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586476	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(Cn2cc(-c3ccc4[nH]ncc4c3)nn2)c(C)c1		CHEMBL1984432	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586477	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL1970735	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586478	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL219722	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586479	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(c1cc(-c2ccc3[nH]ncc3c2)on1)N1CCCC(O)C1		CHEMBL1997340	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586480	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOC(=O)C1=C(N)n2c(sc(=Cc3cccs3)c2=O)=C(C(N)=O)C1c1cccs1		CHEMBL2004365	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9586481	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(Nc2ncnc3ccccc23)c1		CHEMBL117697	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586482	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nc(N)sc1-c1ccnc(Nc2ccc(N3CCOCC3)cc2)n1		CHEMBL482967	=	Ki	nM	125.89	CHEMBL3629	Homo sapiens	pKi		6.9
inactive	9586483	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cc(-c2ccncn2)c(-c2ccc(F)cc2)n1		CHEMBL1989474	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586484	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCOCC4)c3)n2)c1		CHEMBL1090360	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586485	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1nc2ccccc2n1CCCO)c1cccc([N+](=O)[O-])c1		CHEMBL210887	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586486	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1ccccc1Nc1nc(Nc2ccc(N3CCOCC3)cc2OC)ncc1Cl		CHEMBL458997	=	Ki	nM	100.0	CHEMBL3629	Homo sapiens	pKi		7.0
inactive	9586487	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C(F)(F)F)c2)c1		CHEMBL1971021	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586488	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(OC(F)(F)F)c4)c3)cc12		CHEMBL1965836	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9586489	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]cnc2c1sc1c(Cl)ccc(Cl)c12		CHEMBL583144	=	Ki	nM	125.89	CHEMBL3629	Homo sapiens	pKi		6.9
active	9586490	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(-c3ccc(F)cc3)cncc2s1		CHEMBL1974310	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9586491	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc2c(NC(=O)Nc3cccc(C(F)(F)F)n3)ccnc2c1		CHEMBL1982660	<	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9586492	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2sc3c(c12)-c1ccc(NC(=O)Nc2ccccc2)cc1CC3		CHEMBL1994693	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586493	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cccc(-c2cnc3[nH]cc(-c4ccccc4)c3c2)c1		CHEMBL1982957	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
active	9586494	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Oc1c2ccccc2c2c3c(cccc13)N=N2		CHEMBL1725279	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9586495	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NNC(=S)Nc1ccc(F)cc1)C(O)(c1ccccc1)c1ccccc1		CHEMBL1975138	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586496	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2ccc(S(C)(=O)=O)cc2)cc(N)c1C#N		CHEMBL424872	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586497	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1=NN(c2ccc(C(=O)O)cc2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL2006836	=	Ki	nM	316.23	CHEMBL3629	Homo sapiens	pKi		6.5
inactive	9586498	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#Cc5cccnc5)cnc(N)c34)cc2)c1		CHEMBL1971947	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586499	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c[nH]c(-c2cnc(NCCNc3ccc(C#N)cn3)nc2-c2ccc(Cl)cc2Cl)n1		CHEMBL412142	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586500	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(-n2nc(C(C)(C)C)cc2NC(=O)Nc2ccc(OCCN3CCOCC3)c3ccccc23)cc1		CHEMBL103667	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586501	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc2nnc(SCc3cn4ccccc4n3)n2c2ccccc12		CHEMBL1980704	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
active	9586502	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1sc2ccc(Cl)c(Cl)c2c1NC(=O)c1ccc(Cl)cc1		CHEMBL2003271	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
active	9586503	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccncc4)nn12)CCCC3		CHEMBL1966808	=	Ki	nM	100.0	CHEMBL3629	Homo sapiens	pKi		7.0
inactive	9586504	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)c1n[nH]c2c1C(c1ccccc1F)C(C#N)=C(N)O2		CHEMBL2004447	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586505	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)NCC(=O)N1C2CCC1c1cc(Nc3ncc(C(F)(F)F)c(NC4CCC4)n3)ccc12		CHEMBL1983111	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9586506	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCNc1cc2cc(-c3ccsc3)ccc2cn1		CHEMBL1973860	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586507	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2nnc(-c3ccccc3)c(-c3ccccc3)c12		CHEMBL260135	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9586508	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCn1c(-c2nonc2N)nc2cnc(Oc3cccc(NC(=O)c4ccc(OCCN5CCOCC5)cc4)c3)cc21		CHEMBL220241	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9586509	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=S(=O)(O)c1ccc(NCc2ccc3c(c2)OCO3)c2c(O)cccc12		CHEMBL2004544	=	Ki	nM	630.96	CHEMBL3629	Homo sapiens	pKi		6.2
active	9590076	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]cc(I)c2nc(-c3cccc(Cl)c3)cn12		CHEMBL1982610	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9590077	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CCOc1cccc(-c2nc3c(C(N)=O)cccc3[nH]2)c1		CHEMBL1989569	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9590078	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(C2(c3cccc(C)c3)CC2C(=O)Nc2ccncc2)c1		CHEMBL1999496	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590079	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CSc1cnc2c(ccc3cnccc32)c1O		CHEMBL2006933	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9590080	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ccc(-c2csc3c(C=Cc4nc5ccccc5[nH]4)cnc(N)c23)cc1		CHEMBL1988300	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590081	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C(=O)Nc2n[nH]c3ccc(-c4cn(Cc5ccccc5)nn4)cc23)cc1OC		CHEMBL1991078	=	Ki	nM	15.85	CHEMBL3629	Homo sapiens	pKi		7.8
active	9590082	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1		CHEMBL259084	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
active	9590083	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCCNc1ccc2c3c(cccc13)C(=O)N(CCNCCO)C2=O		CHEMBL1987359	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9590084	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=NNC(=N)N)c1cc(NC(=O)c2cccc(C(=O)Nc3cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c3)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL2000685	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590085	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1		CHEMBL565612	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590086	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(CO)ccc4F)cc3)c12		CHEMBL1985311	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9590087	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)cc3n21		CHEMBL1989265	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590088	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc(-c2ccnc(N)n2)[nH]c1-c1ccc(Cl)cc1Cl		CHEMBL1965660	=	Ki	nM	199.53	CHEMBL3629	Homo sapiens	pKi		6.7
active	9590089	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NN=Cc2c[nH]c3cc(NC(=O)C4CC4c4ccccc4)cc1c23		CHEMBL1969502	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9590090	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1c(-c1cccc(OCc3ccccc3)c1)cn2C1CCC(N2CCCC2)CC1		CHEMBL1965910	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590091	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Nc1c(-c2ccc3[nH]ncc3c2)nc2ncccn12		CHEMBL1682553	=	Ki	nM	158.49	CHEMBL3629	Homo sapiens	pKi		6.8
inactive	9590092	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(-c2c(-c3ccncc3)nc(NCC(N)Cc3ccccc3)n(C)c2=O)c1		CHEMBL1971430	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590093	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C(=O)Nc2cnc3[nH]cc(-c4ccccc4)c3c2)cc1		CHEMBL1997764	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9590094	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3coc4ncnc(N)c34)cc2)c1		CHEMBL1983963	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590095	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(CN)Cc4ccccc4)c3)cc12		CHEMBL2000271	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590096	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Oc1ccc(-c2n[nH]c(Nc3cccc(Cl)c3)c2-c2ccc(O)cc2)cc1		CHEMBL1985092	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590097	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2cccs2)c1-c1ccccc1		CHEMBL2004692	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590098	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL1981410	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590099	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1(O)CC(c2nc(-c3ccc4ccc(-c5ccccc5)nc4c3)c3c(N)nccn23)C1		CHEMBL1996234	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590100	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C=C2C(=O)ON=C2c2ccc(Br)cc2)cc1OC		CHEMBL1991434	=	Ki	nM	158.49	CHEMBL3629	Homo sapiens	pKi		6.8
inactive	9590101	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)c1cccc2c(S(=O)(=O)N(CCN)c3cncc(-c4ccc5cnccc5c4)c3)cccc12		CHEMBL1967544	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590102	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ncc2nc1OCCCCCOc1cc(CCCO)c(Cl)cc1NC(=O)N2		CHEMBL223367	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590103	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(c2ccc(C(=O)Nc3n[nH]c4ccc(Cc5cc(F)cc(F)c5)cc34)c(NC3CCOCC3)c2)CC1		CHEMBL1983268	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590104	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cn(-c2ccc(O)cc2Cl)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL340384	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590105	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1996587	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590106	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CS(=O)(=O)NCCOc1cncc(-c2ccc3cnccc3c2)c1		CHEMBL1964804	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590107	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(-c2cnc3c(Br)cnn3c2)cc1		CHEMBL443962	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
active	9590108	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	C(=Cc1cncc(OCCc2c[nH]c3ccccc23)c1)c1ccncc1		CHEMBL1996282	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
active	9590109	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C=C2SC(=Nc3ccccc3)NC2=O)cc1O		CHEMBL2000354	=	Ki	nM	19.95	CHEMBL3629	Homo sapiens	pKi		7.7
inactive	9590110	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1965507	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590111	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1ncc2c1CCCC2=O		CHEMBL1981107	=	Ki	nM	15848.93	CHEMBL3629	Homo sapiens	pKi		4.8
active	9590112	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL274064	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9590113	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1n[nH]c2nc3ccccc3cc12		CHEMBL1967564	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590114	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL592030	=	Ki	nM	100.0	CHEMBL3629	Homo sapiens	pKi		7.0
inactive	9590115	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCCNc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL2000071	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590116	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc2c(NC(=O)Nc3cc(C(F)(F)F)ccn3)ccnc2c1		CHEMBL1979176	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590117	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1970317	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590118	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc2c(C)n1		CHEMBL2000408	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590119	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ncc2nc1OCCCCOc1cc(NCc3cncs3)c(Cl)cc1NC(=O)N2		CHEMBL248757	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590120	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCC(C(=O)n2nc(N)c3cc(-c4cn(Cc5ccccc5)nn4)ccc32)CC1		CHEMBL1978014	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590121	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnccn1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1994538	=	Ki	nM	39.81	CHEMBL3629	Homo sapiens	pKi		7.4
active	9590122	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1983195	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590123	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCCOc1cc2c(c(-c3ccc(Nc4nc5ccccc5o4)cc3)c1)CNC2=O		CHEMBL1975490	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590124	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc2nccc(NC(=O)Nc3cccc(C(F)(F)F)n3)c2c1		CHEMBL1964444	=	Ki	nM	251.19	CHEMBL3629	Homo sapiens	pKi		6.6
active	9590125	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)Nc1cc(N)c(C#N)c(-c2ccsc2)n1		CHEMBL2006567	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
active	9590126	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1csc2ncnc(Nc3ccccc3)c12		CHEMBL1986139	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9590127	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(Cc1cccc2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1985580	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590128	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(Cl)cccc12		CHEMBL1980540	=	Ki	nM	50.12	CHEMBL3629	Homo sapiens	pKi		7.3
inactive	9590129	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN(C)C)cnc(N)c34)cc2)c1		CHEMBL1979883	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590130	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(C)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1984162	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590131	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1cnc(Nc2ccccc2)nc1Nc1ccccc1		CHEMBL491758	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590132	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C(C)(C)C		CHEMBL1986186	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590133	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1cc2[nH]ncc2cc1-c1cc(CN2CCCCC2)no1		CHEMBL1682360	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590134	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2c1C(c1ccccc1Cl)C(C#N)=C(N)O2		CHEMBL1970189	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590135	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1c(I)nn2C1CCC(O)CC1		CHEMBL1996791	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590136	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3c(C)sc4ncnc(N)c34)cc2)c1		CHEMBL371206	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590137	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(C=NNc2ncnc3c2[nH]c2ccccc23)cc1OC		CHEMBL1974664	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590138	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)c1ccc2nc(-c3n[nH]c4ccccc34)[nH]c2c1		CHEMBL1970104	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9590139	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NC(CO)c1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1974288	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590140	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)c1		CHEMBL196363	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590141	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(-c2cc3nccn3c(Nc3ncccc3C(N)=O)n2)cc1OC		CHEMBL1190711	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590142	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2cccc(-c3ccc(Br)cc3)c12		CHEMBL1990346	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9590143	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1cccc(-c2nc(Nc3ccc4[nH]ncc4c3)c3cc(OCCN4CCCC4)ccc3n2)c1		CHEMBL1968705	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9590144	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL404367	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590145	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Cc1cc(-c2ccc3[nH]nc(N)c3c2)on1		CHEMBL1966343	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590146	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCCN)c3)cc12		CHEMBL1967887	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590147	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL2000568	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9590148	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4ncnc(N)c34)cc2)cc1C		CHEMBL2000335	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590149	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1CSc2c(C(=O)O)c(=O)c3cc(F)c(N4CCC(N)C4)c(F)c3n21		CHEMBL1977604	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590150	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O		CHEMBL1084546	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9590151	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cc(-c2cnn3c(N)c(-c4ccc(NC(=O)Nc5cccc(C(F)(F)F)c5)cc4)cnc23)cn1		CHEMBL1988717	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590152	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(Nc2nc(NC3CCCCC3N)cnc2C(N)=O)c1		CHEMBL1974328	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9590153	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1		CHEMBL509032	<	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9590154	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1ccc2[nH]ncc2c1)c1ccc(Cl)cc1		CHEMBL1973808	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590155	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Oc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL2000429	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590156	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)cc1		CHEMBL1972576	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590157	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NN=Cc1ccc(Sc2nc3ccccc3[nH]2)o1)c1cccc([N+](=O)[O-])c1		CHEMBL1992555	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590158	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590159	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1ccc2c(c1)-c1n[nH]cc1CS2		CHEMBL1989069	=	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590160	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(N)c3c2)cc1		CHEMBL1992342	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590161	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(Cl)ccc1NC(=S)NNC(=O)C(O)(c1ccccc1)c1ccccc1		CHEMBL1988173	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9590162	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(c2ccc(-c3cnc4c(c3)N(Cc3c(F)ccc(F)c3Cl)CCN4)cn2)CC1		CHEMBL1164265	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590163	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	C(=NNc1nc2ccccc2[nH]1)c1c[nH]c2ccccc12		CHEMBL535331	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590164	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#CC1=C(N)n2c(sc(=Cc3ccco3)c2=O)=C(C(N)=O)C1c1ccco1		CHEMBL1989805	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590165	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=S(=O)(c1cccc2cnccc12)N1CCCNCC1		CHEMBL38380	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590166	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Cn1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL1965423	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590167	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)=C(C)c1cccc2c(CCCOc3cccc(Cl)c3Cl)c(C(=O)O)[nH]c12		CHEMBL1982980	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590168	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCC(N)(C#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12)CC		CHEMBL1983025	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590169	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(Cc1c[nH]c2ccccc12)C(=O)Nc1cncc(C=Cc2ccncc2)c1		CHEMBL1983945	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590170	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCc1ccccc1)c1ccc(-c2ccncc2)cc1		CHEMBL1977135	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590171	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NC(=S)SC1=C1C(=O)Nc2ccc(Br)cc21		CHEMBL2001920	=	Ki	nM	630.96	CHEMBL3629	Homo sapiens	pKi		6.2
inactive	9590172	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(-c3cc(C(F)(F)F)cc(C(F)(F)F)c3)cncc2s1		CHEMBL2002322	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590173	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(F)c(-c2ccc3nnc(N)n3c2)c1		CHEMBL2002323	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590174	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(Nc2ncc([N+](=O)[O-])c(Nc3ccccc3C(N)=O)n2)cc(OC)c1OC		CHEMBL1241473	=	Ki	nM	3.981	CHEMBL3629	Homo sapiens	pKi		8.4
active	9590175	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CS(=O)(=O)N(Cc1ccc2[nH]c(=O)c3cccn3c2c1)C1CC1		CHEMBL1978448	=	Ki	nM	15.85	CHEMBL3629	Homo sapiens	pKi		7.8
inactive	9590176	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCCOc1cncc(C=Cc2ccncc2)c1		CHEMBL1972258	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590177	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)CC#Cc1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(C)c4)cc3)csc12		CHEMBL2001257	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590178	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(Cl)cc4Cl)c(=O)c3=O)ccc21		CHEMBL2005548	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590179	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(CNc2c(Nc3ccc4[nH]ncc4c3)c(=O)c2=O)cc1		CHEMBL1992536	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590180	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccccc1-c1c(C(=O)O)n(CCCOc2cccc3ccccc23)c2ccccc12		CHEMBL1987793	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590181	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN1CCN(CCCC(=O)Nc2n[nH]c3nnc(-c4cccc(F)c4F)cc23)CC1		CHEMBL1992740	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590182	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCCn1cnc(-c2ccccc2)c1-c1ccncc1		CHEMBL2002373	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590183	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ccc(-c2cncc(OCC(N)Cc3c[nH]c4ccccc34)c2)cc1C(=O)c1cccc(Cl)c1		CHEMBL1973348	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590184	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2NCCCN)c1		CHEMBL2006188	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590185	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2scc(-c3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1967531	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590186	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1nn(C(=O)CC)c2nc3ccccc3cc12		CHEMBL1970913	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590187	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCS(=O)(=O)Nc1ccc(-c2ccc3[nH]nc(NC(C)=O)c3c2)cc1		CHEMBL1973893	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590188	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOC(=O)c1cccc2[nH]c(-c3ccc(N4CCC(N)C4)cc3)nc12		CHEMBL1995736	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590189	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590190	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2cc(C)c(-c3ccc4[nH]nc(C)c4c3)s2)c1		CHEMBL1997534	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590191	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)O)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1996500	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590192	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)Cn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL1985095	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590193	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(O)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1998551	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590194	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4n3CCC4)nn12		CHEMBL1977374	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590195	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCc1nnn(-c2nonc2N)c1C(=O)NN=C(C)c1ccc(O)cc1O		CHEMBL1991180	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590196	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)O)c5)cnc(N)c34)cc2)c1		CHEMBL1989708	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590197	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)cn2c1		CHEMBL1682540	=	Ki	nM	630.96	CHEMBL3629	Homo sapiens	pKi		6.2
inactive	9590198	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(O)cccc1NC(=O)c1cnn2c(-c3ccccc3)ccnc12		CHEMBL1978656	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590199	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCc1c(-c2ccc(C(C)(C)O)cc2)[nH]c2nccnc12		CHEMBL1976420	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590200	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(CNc2c(Nc3ccncc3)c(=O)c2=O)cc1		CHEMBL1994864	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590201	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCO)c(Cl)cc1NC(=O)N2		CHEMBL413779	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590202	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(Cc2ccc3c(c2)Cc2c(-c4csc(C#CCOCC5CC5)c4)n[nH]c2-3)CC1		CHEMBL2002446	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590203	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1nc(-c2cc3c(Oc4ccc(I)cc4)cncc3s2)[nH]o1		CHEMBL497151	=	Ki	nM	100.0	CHEMBL3629	Homo sapiens	pKi		7.0
inactive	9590204	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(N2CCN(C)CC2)ccc1C(=O)Nc1n[nH]c2ccc(Cc3cc(F)cc(F)c3)cc12		CHEMBL1973961	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590205	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCC1CCC(CNc2nc(NCc3ccccc3Cl)ncc2[N+](=O)[O-])CC1		CHEMBL246970	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590206	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(O)ccc1-n1cc(C(N)=O)c(=O)c2ccc(-c3ccncc3)cc21		CHEMBL340921	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590207	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCCCO)c(Cl)cc1NC(=O)N2		CHEMBL373598	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590208	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ccc(NC(=O)Nc2ccnc3cc(C(F)(F)F)ccc23)nc1		CHEMBL1999718	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590209	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Nc2ccc3ncsc3c2C1=CNc1ccc(S(=O)(=O)Nc2ccccn2)cc1		CHEMBL1973540	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9590210	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Nc2ccccc2Nc2nnc(I)cc21		CHEMBL1977346	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590211	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3ccc4nccnc4c3N)cc2)c1		CHEMBL1971649	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590212	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)S(=O)(=O)n1c(N)nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2003657	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590213	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(Sc3ccc(NC(=O)C4CC4)cc3)n2)n[nH]1		CHEMBL572878	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590214	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCNc1cc2cc(-c3ccncc3)ccc2cn1		CHEMBL1998435	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590215	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1cc(-c2c[nH]c3ncccc23)nc(NC2CCCCC2)n1		CHEMBL2006439	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
active	9590216	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)N(C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1)C(C)C		CHEMBL2006156	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9590217	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(-c2ccc(NC(=O)Nc3cc(F)cc(F)c3)cc2)c2c(N)noc12		CHEMBL1969190	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590218	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)n[nH]c12		CHEMBL1973937	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590219	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)NC(=O)C(C)(C)O4)n2)cc(OC)c1OC		CHEMBL475251	=	Ki	nM	39.81	CHEMBL3629	Homo sapiens	pKi		7.4
active	9590220	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OC1CCC(Nc2cc(Cl)nc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1991674	=	Ki	nM	100.0	CHEMBL3629	Homo sapiens	pKi		7.0
active	9590221	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1ccc(-c2c[nH]c3nccc(Cl)c23)cc1		CHEMBL1982711	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590222	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1984842	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590223	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5cn[nH]c5)cnc(N)c34)cc2)c1		CHEMBL1969102	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590224	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1682346	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590225	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)CC#Cc1ccc2c(c1)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL2007044	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590226	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)N1CCN(CCCOc2ccc3c(c2)-c2[nH]nc(-c4ccc(C#N)nc4)c2C3)CC1		CHEMBL2001998	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590227	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CS(=O)(=O)Nc1cc2c(cc1Cl)NC(=O)Nc1cnc(C#N)c(n1)OCCCCCO2		CHEMBL223460	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590228	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1ccc(Cl)cc1		CHEMBL1998829	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590229	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Cc2c([nH]c3ccc([N+](=O)[O-])cc23)-c2ccccc2N1		CHEMBL50894	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
active	9590230	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cnc(Nc2cccc(S(N)(=O)=O)c2)nc1Nc1ccc(OCC(N)=O)cc1		CHEMBL1988838	=	Ki	nM	630.96	CHEMBL3629	Homo sapiens	pKi		6.2
inactive	9590231	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN1CCN(c2ccc(Nc3nccc(-c4c(-c5cccc(C(=O)Nc6ccccc6F)c5)nc5ccccn45)n3)cc2)CC1		CHEMBL1981725	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590232	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]ncc34)cc2)c1		CHEMBL375284	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590233	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCCn1cc(-c2ccncn2)c(-c2ccc(Cl)cc2)n1		CHEMBL1982866	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590234	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2005792	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590235	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(CSc2nc(-c3ccncc3)n[nH]2)cc1		CHEMBL1968926	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590236	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2ccncc2)cc(N)c1C#N		CHEMBL1984206	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9590237	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1c(-c2ccccc2)c2cc(Cl)ccc2[nH]c1=O		CHEMBL462120	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590238	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Nc1c(Nc2ccncc2)c(=O)c1=O)C1CCCCC1		CHEMBL1991577	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590239	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4ccccc4F)cc3)c12		CHEMBL1965570	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590240	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2sc3c(c2c2nc(-c4ccccc4)nn12)CCCC3		CHEMBL2007592	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9590241	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(NC(=O)Cc2cc(OC)c(S(C)(=O)=O)cc2OC)cc(N)c1C#N		CHEMBL210963	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590242	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cncc2cccc(S(=O)(=O)N3CCCNCC3C)c12		CHEMBL1082440	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590243	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(CO)N1CCC(c2[nH]nc(-c3ccc(Cl)cc3F)c2-c2ccncn2)CC1		CHEMBL1614705	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590244	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL1972362	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9590245	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2cnc(-c3ccncc3)s2)c1		CHEMBL1984633	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590246	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590247	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL2007372	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590248	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)N2CC=C(c3c[nH]c4ncccc34)CC2)c1		CHEMBL1965845	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590249	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(OC)c(NC(=O)c2cnn3c(-c4ccccc4)ccnc23)c1		CHEMBL1982167	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590250	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3cccc(N4CCCC4=O)c3)n2)c1)c1c(F)cccc1F		CHEMBL2006715	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590251	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cccc2[nH]c(-c3ccc(NC(=O)c4cccc(S(=O)(=O)N5CCOCC5)c4)cc3)nc12		CHEMBL1986597	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9590252	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(-c3cccc(F)c3)cncc2s1		CHEMBL1971017	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9590253	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cccc2[nH]c(-c3ccncc3)nc12		CHEMBL1990482	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590254	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1ccc(-c2nc3cnccn3c2-c2ccnc(NCC3CC3)n2)cc1		CHEMBL1990904	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590255	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1975121	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590256	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCC1CCCCC1)c1cc2c(-c3ccccc3)n[nH]c2s1		CHEMBL2005475	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590257	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCS(=O)(=O)c1ccc(-c2cncc3sc(C(N)=O)cc23)cc1		CHEMBL2000104	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9590258	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(F)c(NC(=O)Nc2ccc(-c3cncc4c3c(N)nn4C)cc2)c1		CHEMBL402846	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590259	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1=NN(c2ccc(Cl)c(Cl)c2)C(=O)C1=Cc1c(C)c(C#N)c2nc3ccccc3n2c1O		CHEMBL1997349	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
inactive	9590260	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2C)c1		CHEMBL183844	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590261	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4[nH]nc(N)c34)cc2)c1		CHEMBL220057	<	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
active	9590262	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(Nc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682545	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9590263	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1c[nH]c2ccccc12		CHEMBL1974935	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590264	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(OC2CCCC2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL2001224	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590265	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	C[S+]([O-])c1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL10	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590266	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(O)Cc1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1976732	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590267	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)OC(=O)n1ncc2cc(Nc3c(NCc4ccc(S(N)(=O)=O)cc4)c(=O)c3=O)ccc21		CHEMBL1969506	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590268	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NC(CO)c1ccccc1)N1CC=C(c2c[nH]c3ncccc23)CC1		CHEMBL1964937	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590269	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(COc2ccc(Nc3ncnc4ccccc34)cc2)cc1		CHEMBL1980163	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590270	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCn1cc(-c2cc(-c3cc4ccccc4s3)c3[nH]ncc3c2)c2nc(N)ncc21		CHEMBL590109	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590271	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2nn(C3CCC(N4CCN(C(C)=O)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C		CHEMBL1970879	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590272	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(C=O)c(O)n2c(nc3ccccc32)c1C#N		CHEMBL1989856	=	Ki	nM	63.1	CHEMBL3629	Homo sapiens	pKi		7.2
inactive	9590273	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)N(c1ccncc1)c1c(NC(C)C(C)(C)C)c(=O)c1=O		CHEMBL2005899	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590274	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1cnc2nc(-c3ccc4[nH]ncc4c3)c(NC3CCCCC3)n2c1		CHEMBL1682552	=	Ki	nM	316.23	CHEMBL3629	Homo sapiens	pKi		6.5
inactive	9590275	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(CNC(=O)Nc2ncc([N+](=O)[O-])s2)cc1		CHEMBL259850	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590276	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cncc(C=Cc2ccncc2)c1		CHEMBL1972568	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590277	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCC1COc1cncc(CCc2ccncc2)c1		CHEMBL1996155	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590278	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4cccc(Cl)c4)c3)cc12		CHEMBL1974870	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9590279	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCc1cc(-c2ccc3[nH]ncc3c2)on1		CHEMBL1682359	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590280	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)c(C=C2C(=O)Nc3ccccc32)[nH]1		CHEMBL2002702	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590281	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4c[nH]c5ccccc45)c3)cc12		CHEMBL1970903	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590282	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(C=Cc2ccncc2)c1)Cc1ccccc1		CHEMBL1991846	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590283	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(Nc2nccc(Nc3c(NC(C)C(C)(C)C)c(=O)c3=O)n2)c1		CHEMBL1969523	=	Ki	nM	316.23	CHEMBL3629	Homo sapiens	pKi		6.5
inactive	9590284	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(C=O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL207995	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590285	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1988995	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590286	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Nc2cc(CCOc3ccc(N4CCOCC4)cc3)ccc2Nc2cc(-c3cn(Cc4cc(F)c(F)c(F)c4)c4cnccc34)ccc21		CHEMBL2001923	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590287	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)N1CCC(Nc2nccc(-c3c(-c4ccc(F)cc4)nc4occn34)n2)CC1		CHEMBL1986781	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590288	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccccc2)[nH]1		CHEMBL526133	=	Ki	nM	25.12	CHEMBL3629	Homo sapiens	pKi		7.6
inactive	9590289	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1c(=O)c(Oc2ccc(F)cc2F)cc2cnc(NC3CCOCC3)nc21		CHEMBL1230122	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590290	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NCc2c1cccc2-c1ccc(Nc2nc3ccccc3[nH]2)cc1		CHEMBL1979057	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590291	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1OCC(O)CO		CHEMBL1981045	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590292	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCCOCC#Cc1cc(-c2n[nH]c3c2C(=O)c2cc(CN4CCN(C)CC4)ccc2-3)cs1		CHEMBL387971	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590293	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(Cn2nnc(-c3ccc4[nH]ncc4c3)c2C2CC2)cc1		CHEMBL1975418	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9590294	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2ccc(Cl)cc2c(-c2ccccc2)c1C1=NNC(c2ccccc2)C1		CHEMBL1992796	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590295	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1999428	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590296	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ncc2nc1OCCCCCOc1cc(OCC(O)CO)c(Cl)cc1NC(=O)N2		CHEMBL223257	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590297	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCN(C)CC4)cc3OC)nc2N1C1CCCC1		CHEMBL1967560	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590298	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cc(C=C2C(=O)Nc3cccnc32)c2ccccc21		CHEMBL1516890	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
active	9590299	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3noc4ncnc(N)c34)cc2)c1		CHEMBL211378	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9590300	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CCN5CCOCC5)cnc(N)c34)cc2)c1		CHEMBL1982465	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590301	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(-c2ccc3c(c2)C(=Cc2ccco2)C(=O)N3)c1)Cc1c[nH]c2ccccc12		CHEMBL2001751	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590302	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCCCCCCNC(=O)NCc1cccnc1)NCc1cccnc1		CHEMBL2003420	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590303	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccccc1NC(=O)Nc1ccc(-c2coc3ncnc(N)c23)cc1		CHEMBL1984586	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9590304	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(Cl)c(N2CCC(CN)C2)nc2[nH]cc(C(=O)O)c(=O)c12		CHEMBL1999774	=	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590305	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1c(O)ccc2c1CCCC2=NNC(=O)Cc1cccc2ccccc12		CHEMBL1972659	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590306	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OC1CCN(c2ncnc3[nH]cc(-c4ccccc4)c23)CC1		CHEMBL1973395	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590307	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(NC(=O)Nc2ccc(-c3cccc4onc(N)c34)cc2)cc1Cl		CHEMBL272453	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590308	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3C)cc2)c1		CHEMBL1970217	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9590309	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Nc2ccccc2Nc2nnccc21		CHEMBL1971801	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593878	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Nc2ccccc2Nc2nnc(Cl)cc21		CHEMBL1968850	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593879	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOC(=O)c1ccc2[nH]c3c(c2c1)CCNC3=O		CHEMBL2005528	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593880	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)cc2)c1		CHEMBL185569	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9593881	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1cc2[nH]ncc2cc1-c1cn(CC2CCOCC2)nn1		CHEMBL1969843	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
active	9593882	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3[nH]nc(C(=O)Nc4ccccc4)c3c2)ccc1O		CHEMBL2007002	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9593883	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Nc1nccc(-c2c(-c3ccc(F)cc3)nc3occn23)n1)c1ccccc1		CHEMBL1990288	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593884	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCC(NC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)CC1		CHEMBL1987007	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593885	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1cc(-c2c[nH]c3ncccc23)cc(NCc2ccccc2)n1		CHEMBL1969588	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9593886	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(Nc2nccc(Nc3cc(C4CCCCC4)no3)n2)cc(OC)c1OC		CHEMBL1984711	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9593887	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(Nc2ncc(F)c(NC3C4C=CC(C4)C3C(N)=O)n2)ccc1N1CCN(C)CC1		CHEMBL1967878	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593888	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(OC)c(Nc2ccc3nnc(-c4ccccc4)n3n2)cc1Cl		CHEMBL1990212	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9593889	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCC(NC(=O)c1ccc(-c2ccncc2)cc1)c1ccccc1		CHEMBL1990254	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593890	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCCn1c(NC(=O)c2ccc(C#N)cc2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL484390	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593891	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1c(NCc2cccc(C(F)(F)F)c2)c(Nc2ccncc2)c1=O		CHEMBL1979252	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593892	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(Cc2cn(-c3ccc4[nH]ncc4c3)nn2)cc1		CHEMBL1682341	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593893	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(CC(C)(C)O)c5)cnc(N)c34)cc2)cc1		CHEMBL2004290	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593894	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2ccc(-c3nnn(Cc4ccccc4)c3-c3ccc(F)cc3)cc12		CHEMBL1986499	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
active	9593895	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C=C2SC(=Nc3ccccc3)NC2=O)c1		CHEMBL1972937	=	Ki	nM	63.1	CHEMBL3629	Homo sapiens	pKi		7.2
inactive	9593896	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	C#Cc1cc2c(cc1OC)-c1[nH]nc(-c3ccc(C#N)nc3)c1C2		CHEMBL1972250	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593897	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1C1CCOc2c(F)cccc21		CHEMBL2000393	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593898	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4c3CNC4=O)c(C)c2)c1		CHEMBL2004311	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593899	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Brc1cnc2[nH]cc(-c3ccccc3)c2c1		CHEMBL1992634	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9593900	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc3c(c2)CCc2sc4ncnc(N)c4c2-3)c1		CHEMBL1242373	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593901	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCNNc1cc(C)c(C#N)c2nc3ccccc3n12		CHEMBL2000433	=	Ki	nM	794.33	CHEMBL3629	Homo sapiens	pKi		6.1
inactive	9593902	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#CC(=Cc1ccc(O)c(O)c1)C(=O)NCc1ccccc1		CHEMBL1974157	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593903	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Fc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL316264	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593904	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1988075	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593905	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1991678	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593906	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc(Nc2cc(CNC(=O)C(F)(F)F)c(O)c(-c3ccc(Cl)cc3)c2)n1		CHEMBL2001239	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593907	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2scc(C(=O)Nc3ccc(NC(=O)Nc4ccccc4)cc3)c12		CHEMBL1988594	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593908	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1c(I)nn2C1OC(CO)C(O)C1O		CHEMBL2001288	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593909	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncnc2c1N=C(c1ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc1)CCN2		CHEMBL260092	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593910	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1c(OCc2c(F)cc(Br)cc2F)nsc1NC(=O)NCCCCN1CCCC1		CHEMBL253969	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593911	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NN=Cc1ccc(O)cc1O)Nc1cccc2nsnc12		CHEMBL1999811	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9593912	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ncc(C#N)c(-c3ccccc3)c12		CHEMBL1965495	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593913	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CSc1ccc2nc3c(c(Cl)c2c1)CCNC3=O		CHEMBL1985074	=	Ki	nM	501.19	CHEMBL3629	Homo sapiens	pKi		6.3
inactive	9593914	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nc2ccc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc2n1CC1CC1		CHEMBL1982874	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593915	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL2000481	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593916	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1		CHEMBL1173055	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593917	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CC(=O)NC(COc1cncc(-c2ccc3cnccc3c2)c1)Cc1c[nH]c2ccccc12		CHEMBL1991725	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593918	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(-c3cccc4sncc34)cc2)c1		CHEMBL1992242	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593919	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCOc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL2007296	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593920	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(NC(C)=O)cc(N)c1C#N		CHEMBL208637	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593921	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2ccc3[nH]ncc3c2)n1		CHEMBL396523	=	Ki	nM	25.12	CHEMBL3629	Homo sapiens	pKi		7.6
inactive	9593922	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NC(=O)C(Nc2ccccc2)=C1Cl		CHEMBL2007138	<	Ki	nM	15848.93	CHEMBL3629	Homo sapiens	pKi		4.8
inactive	9593923	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)cc(NC(=O)Nc2ccc(NC(=O)c3csc4ncnc(N)c34)cc2)c1		CHEMBL1970203	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593924	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(c1cc(Cc2n[nH]c(=O)c3c2CCCC3)ccc1F)N1CCN(c2ncccn2)CC1		CHEMBL1986530	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593925	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1c(NCCc2ccc(Oc3ccccc3)cc2)c(Nc2ccncc2)c1=O		CHEMBL1999321	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593926	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)C=Cc1cnc(N)c2c(-c3ccc4sc(C)nc4c3)csc12		CHEMBL1968590	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593927	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(Nc2ncnc3ccc(-c4ccc(CN5CC6C(CO)C6C5)cc4)cc23)ccc1Oc1ccccc1		CHEMBL1999749	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593928	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCC1C(=O)N(C)c2cnc(Nc3ccc(C(=O)NC4CCCCC4)cc3OC)nc2N1C1CCCC1		CHEMBL2005375	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593929	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1ccc(-c2n[nH]cc2-c2ccncn2)cc1Cl		CHEMBL1984191	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593930	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(C(=O)O)c(Cl)cc1NC(=O)Nc1cnc(C#N)cn1		CHEMBL1983006	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593931	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCCC1COc1cncc(CCc2ccccc2)c1		CHEMBL1972183	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593932	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(N3CCN(C(C)=O)CC3)ccc2OC)ncc1Br		CHEMBL1971029	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9593933	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Nc1n[nH]c2ccc(N)cc12		CHEMBL1995391	<	Ki	nM	15848.93	CHEMBL3629	Homo sapiens	pKi		4.8
inactive	9593934	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Cl)c4)cc3)c12		CHEMBL394790	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593935	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NCCc2[nH]c(-c3ccnc(-c4ccccc4F)c3)cc21		CHEMBL226471	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
active	9593936	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nc2c(sc3c(Br)ccc(Cl)c32)c(=O)o1		CHEMBL1974702	=	Ki	nM	50.12	CHEMBL3629	Homo sapiens	pKi		7.3
inactive	9593937	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)C(=O)c1c(-c2ccc3[nH]ncc3c2)nnn1Cc1ccccc1		CHEMBL1996111	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593938	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nccn2c(-c3ccnc(NCC4(O)CC4)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1965589	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593939	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCCCCCCNC(=O)Nc1cccnc1)Nc1cccnc1		CHEMBL1998193	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593940	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2ncn(-c3cc(OCc4ccccc4C(F)(F)F)c(C(=O)O)s3)c2cc1OC		CHEMBL474432	=	Ki	nM	158.49	CHEMBL3629	Homo sapiens	pKi		6.8
active	9593941	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nnc(-c2cc3c(Oc4ccc(C(F)(F)F)cc4)cncc3s2)o1		CHEMBL1988153	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9593942	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=O)N1CCN(C2CCC(n3nc(-c4ccc(NC(=O)c5cc6ccccc6n5C)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1972584	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593943	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ccc2[nH]c(O)c(-c3ccc(CN4CCOCC4)cn3)c2c1		CHEMBL1969664	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593944	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1999556	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9593945	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1ccccc1Sc1ccc2c(C=Cc3ccccn3)n[nH]c2c1		CHEMBL1988437	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9593946	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cc(C=Cc2ccncc2)cnc1Cl)Cc1c[nH]c2ccccc12		CHEMBL1968245	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593947	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1oc2ccccc2c2[nH]c(-c3ccccc3)nc12		CHEMBL1968646	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9593948	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCC(C(=O)Nc1ccc2[nH]ncc2c1)c1ccc(Cl)c(Cl)c1		CHEMBL1998121	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593949	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(C#CC(C)(C)N)cnc(N)c34)cc2)c1		CHEMBL1979577	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593950	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CC4CC4)nccn23)n1		CHEMBL1991800	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593951	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCC(CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1		CHEMBL52387	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593952	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nn(-c2ccccc2)c2c1c(=O)c1cc(Cl)ccc1n2O		CHEMBL379835	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593953	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1cc(C(CN)c2cncc(C=Cc3ccncc3)c2)c2ccccc21		CHEMBL1979357	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593954	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ncc2nc1OCC(O)C(O)COc1ccc(Cl)cc1NC(=O)N2		CHEMBL1980802	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593955	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1c(NCc2ccc(Cl)cc2Cl)c(Nc2ccc3[nH]ncc3c2)c1=O		CHEMBL1979554	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593956	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCCOc1ncnc2[nH]cc(-c3ccccc3)c12		CHEMBL1996817	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9593957	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nonc1-n1nnc(C(=O)NN=Cc2ccncc2)c1-c1ccccc1		CHEMBL1419458	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593958	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2ccc(S(N)(=O)=O)cc2)cc(N)c1C#N		CHEMBL2004355	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593959	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O		CHEMBL483158	=	Ki	nM	1995.26	CHEMBL3629	Homo sapiens	pKi		5.7
inactive	9593960	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCn1c2cc(Cl)c(F)cc2c(=O)c2c(=O)o[nH]c21		CHEMBL468280	<	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9593961	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(C)c2oc(Nc3ccc(-c4cccc(C(N)=O)c4N)cc3F)nc2c1		CHEMBL1990884	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593962	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CC)CCNC(=O)c1c(C)[nH]c(C=C2C(=O)Nc3ccc(F)cc32)c1C		CHEMBL1990885	<	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9593963	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCC(O)CC2)n1		CHEMBL256835	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593964	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(C(F)(F)F)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1980142	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593965	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL41783	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593966	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1c(-c2ccc(NC(=O)Nc3cccc(C(F)(F)F)c3)cc2)ccc2nccnc12		CHEMBL2004438	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593967	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc2c1Nc1cc(Nc3ccncc3)ccc1C(=O)N2		CHEMBL2006276	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593968	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(-c2ccc(NC(=O)Nc3cccc(Br)c3)cc2)c2c(N)noc12		CHEMBL271381	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593969	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(C(=O)Nc2c(C#N)sc3ccc(Cl)c(Cl)c23)cc1		CHEMBL2006785	=	Ki	nM	1000.0	CHEMBL3629	Homo sapiens	pKi		6.0
inactive	9593970	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(NC(=O)Nc2ccc(-c3csc4c(-c5cnn(C)c5)cnc(N)c34)cc2)cc1		CHEMBL1982466	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593971	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3c(c2)Nc2ccc([N+](=O)[O-])cc2NC3=O)ccc1O		CHEMBL1995740	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593972	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1cc2c(-c3ccccc3)cncc2s1		CHEMBL1996390	=	Ki	nM	1258.93	CHEMBL3629	Homo sapiens	pKi		5.9
active	9593973	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OC1CCC(Nc2nc(Cl)cc(-c3c[nH]c4ncccc34)n2)CC1		CHEMBL1986943	=	Ki	nM	158.49	CHEMBL3629	Homo sapiens	pKi		6.8
inactive	9593974	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC1CCN(C(=O)CC#N)CC1N(C)c1ncnc2[nH]ccc12		CHEMBL234085	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593975	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3F)nc12		CHEMBL1995832	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593976	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2sc(C(=O)NCCc3ccc(Cl)cc3)cc12		CHEMBL1998414	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593977	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Oc1ccc(Nc2[nH]nc(-c3ccc(O)cc3)c2-c2ccc(O)cc2)cc1		CHEMBL1969042	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593978	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1ccccc1		CHEMBL1999931	=	Ki	nM	3.162	CHEMBL3629	Homo sapiens	pKi		8.5
inactive	9593979	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]sc2c1c(=O)c1cc(F)c(NCc3ccccc3)c(F)c1n2C1CC1		CHEMBL1991640	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593980	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1375418	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593981	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cn1c2ccccc2c2c3c(c4c5ccccc5n(CCC#N)c4c21)CNC3=O		CHEMBL302449	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593982	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1[nH]c(C=C2C(=O)Nc3ccccc32)c(C)c1CCC(=O)O		CHEMBL2007064	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
inactive	9593983	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COC(C(=O)N1Cc2[nH]nc(NC(=O)c3ccc(N4CCN(C)CC4)cc3)c2C1)c1ccccc1		CHEMBL1981047	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593984	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccc(Cl)c(Cl)c4)c3)cc12		CHEMBL1991063	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593985	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(CN)NC(=O)c2ccc(-c3ccncc3)cc2)c1		CHEMBL1976240	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593986	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc(-c2ccc(NC(=O)Nc3ccc(F)c(C)c3)cc2)c2c(N)noc12		CHEMBL1979093	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593987	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2sccc2c2nc(-c3ccncc3)nn12		CHEMBL1968151	=	Ki	nM	125.89	CHEMBL3629	Homo sapiens	pKi		6.9
inactive	9593988	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1ccc(CNc2ccc3nnc(-c4ccccc4)n3n2)cc1		CHEMBL1381197	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593989	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(CNC(=O)c2cc3c(-c4ccccc4)n[nH]c3s2)c1		CHEMBL1987009	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593990	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1n[nH]c2ccc(-c3cncc(OCC(N)Cc4ccccc4)c3)cc12		CHEMBL2002726	=	Ki	nM	316.23	CHEMBL3629	Homo sapiens	pKi		6.5
inactive	9593991	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnccn1)Nc1ccnc2cc(C(F)(F)F)ccc12		CHEMBL2003817	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593992	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ncccc2N1		CHEMBL336961	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
active	9593993	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nnc(-c2cc3c(Oc4ccc(Cl)cc4)cncc3s2)o1		CHEMBL1994830	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9593994	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COCCOC1CCC(n2nc(-c3ccc(Nc4nc5cc(C)cc(Cl)c5o4)cc3)c3c(N)ncnc32)CC1		CHEMBL1987054	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593995	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncc(-c2ccncc2)c2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12		CHEMBL1970083	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9593996	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1NCCc2[nH]c(-c3ccnc(-c4cnc5ccccc5c4)c3)cc21		CHEMBL226403	=	Ki	nM	630.96	CHEMBL3629	Homo sapiens	pKi		6.2
inactive	9593997	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cc(C)ccc4F)cc3)csc12		CHEMBL2005631	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593998	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncc(C=CC(=O)NCCCn2ccnc2)c2scc(-c3ccc(Br)cc3)c12		CHEMBL1994938	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9593999	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl		CHEMBL1825138	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594000	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1977223	=	Ki	nM	316.23	CHEMBL3629	Homo sapiens	pKi		6.5
inactive	9594001	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)C(=O)Oc1ccc2c(c1)nc(NC(=O)c1cccc([N+](=O)[O-])c1)n2CCCO		CHEMBL1236126	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594002	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NCCCNS(=O)(=O)c1cccc(C(=O)Nc2ccc(-c3n[nH]c(=O)c4ccccc34)cc2)c1		CHEMBL1966279	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594003	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Clc1cc(NC2CCCCC2)nc(-c2c[nH]c3ncccc23)n1		CHEMBL1997846	=	Ki	nM	251.19	CHEMBL3629	Homo sapiens	pKi		6.6
inactive	9594004	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)Cn1c(N)nc2c(F)cc(-c3c(-c4ccc(F)cc4)nc4sccn34)cc21		CHEMBL2004419	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594005	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(=NNC(=N)N)c1cc(NC(=O)NCCCCCCNC(=O)Nc2cc(C(C)=NNC(=N)N)cc(C(C)=NNC(=N)N)c2)cc(C(C)=NNC(=N)N)c1		CHEMBL1991728	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594006	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(=O)c1cc2c(-c3ccc(F)cc3F)cncc2s1		CHEMBL1975787	<	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9594007	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(C=C(C#N)c2n[nH]c(N)c2C#N)ccc1O		CHEMBL2002407	=	Ki	nM	5.012	CHEMBL3629	Homo sapiens	pKi		8.3
inactive	9594008	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1ccc2cn[nH]c2c1)c1ccc(Cl)cc1		CHEMBL1972489	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594009	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Brc1ccc2[nH]nc(-c3ccccc3)c2c1		CHEMBL1994074	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9594010	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(Nc2nc3ccc([N+](=O)[O-])cc3[nH]2)nc1		CHEMBL1992937	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9594011	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3c(c2)Nc2ccc(CCOc4ccc(N5CCOCC5)cc4)cc2NC3=O)ccc1CC#N		CHEMBL1985566	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594012	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cccc(N2CCOCC2)n1)Nc1ccnc2c(C(F)(F)F)cccc12		CHEMBL1972119	=	Ki	nM	50.12	CHEMBL3629	Homo sapiens	pKi		7.3
active	9594013	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)C(=O)Nc1ccc2nc(-c3ccco3)c(-c3ccco3)nc2c1		CHEMBL1986328	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9594014	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCNCC2)n1		CHEMBL95692	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594015	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Cc1ccccc1)Nc1cccc(-c2nc3sccn3c2-c2ccnc(Nc3ccc(N4CCOCC4)cc3)n2)c1		CHEMBL1090356	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594016	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnccn1)Nc1ccnc2ccc(C(F)(F)F)cc12		CHEMBL1976455	=	Ki	nM	158.49	CHEMBL3629	Homo sapiens	pKi		6.8
inactive	9594017	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(Nc2cc(N3CCN(C)CC3)nc(C=Cc3ccccc3)n2)n[nH]1		CHEMBL1983923	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594018	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1		CHEMBL939	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594019	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(CNc2nc3ccc(-c4ccncc4)cc3s2)cc1		CHEMBL1983534	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594020	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1c(NCc2ccccc2F)c(Nc2ccncc2)c1=O		CHEMBL1982361	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594021	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOC(=O)C1=c2sc(=Cc3ccco3)c(=O)n2C(N)=C(C#N)C1c1ccco1		CHEMBL1999112	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594022	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	OCCC(Nc1nc2ccc(-c3ccncc3)cc2s1)c1ccccc1		CHEMBL1982122	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594023	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1ccc(-c2cccc3sncc23)cc1)Nc1ccc(F)c(C(F)(F)F)c1		CHEMBL2000801	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594024	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc(CNc2nc(-c3ccc4[nH]ncc4c3)cs2)cc1		CHEMBL1682546	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594025	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3cnccn23)n1		CHEMBL1991395	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594026	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(c2cccc(Nc3nccc(-c4c(C(N)=O)nc5ccccn45)n3)c2)CC1		CHEMBL1971245	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594027	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nccn2c(-c3ccnc(NCC(C)(C)CO)n3)c(-c3ccc(F)cc3)nc12		CHEMBL1987648	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594028	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOC(=O)c1cn(-c2ccc(O)cc2C)c2cc(-c3ccncc3)ccc2c1=O		CHEMBL1996780	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594029	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NCc1ccccc1)c1cccc(-c2cnc3[nH]ccc3c2)c1		CHEMBL1972142	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594030	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncc(-c2ccoc2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1966514	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594031	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCCCCCCCCCCOc1ccc(NC(=N)N)cc1NC(=N)N		CHEMBL1980715	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594032	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12)c1cccc(F)c1		CHEMBL2003638	=	Ki	nM	6.31	CHEMBL3629	Homo sapiens	pKi		8.2
active	9594033	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1Cc2c([nH]c3ccc(Br)cc23)-c2ccccc2N1		CHEMBL296586	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
active	9594034	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ccc2nc(N)n(-c3nc(-c4ccccc4)cs3)c2c1		CHEMBL1996066	=	Ki	nM	63.1	CHEMBL3629	Homo sapiens	pKi		7.2
active	9594035	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC(COc1cncc(-c2cc3ccncc3s2)c1)Cc1c[nH]c2ccccc12		CHEMBL1966524	=	Ki	nM	398.11	CHEMBL3629	Homo sapiens	pKi		6.4
active	9594036	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1n[nH]c2cccc(-c3ccc(NC(=O)Nc4cc(C(=O)O)ccc4F)cc3)c12		CHEMBL1993722	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9594037	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=c1[nH]c2sc3c(c2c2nc(-c4cccnc4)nn12)CCCC3		CHEMBL1970806	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594038	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nc(COc2ccccc2Cl)sc1-c1ccnc(N)n1		CHEMBL1375640	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594039	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCC(=O)Nc1n[nH]c2nnc(-c3cccc(F)c3F)cc12		CHEMBL1979970	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
inactive	9594040	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1ccc(-c2n[nH]c3c2Cc2ccc(OCCN4CCOCC4)cc2-3)cn1		CHEMBL249282	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594041	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C)NC(=O)c1ccc2nc3[nH]c4ccccc4c3nc2c1		CHEMBL1969264	=	Ki	nM	6.31	CHEMBL3629	Homo sapiens	pKi		8.2
active	9594042	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	N#Cc1c(O)[nH]c(=O)c2c(=N)oc3ccc(Cl)cc3c12		CHEMBL1973711	=	Ki	nM	251.19	CHEMBL3629	Homo sapiens	pKi		6.6
inactive	9594043	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(CCCNc2cccc(-c3nc4c(C(N)=O)cccc4[nH]3)n2)CC1		CHEMBL2006237	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594044	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(C(N)=O)n1cc(-c2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(F)c5)cc4)csc23)cn1		CHEMBL1967720	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594045	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NC1C2CN(c3nc4c(cc3F)c(=O)c(C(=O)O)cn4-c3ccc(F)cc3F)CC12		CHEMBL1624529	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594046	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nccn2c(C3CC(CN4CCCC4)C3)nc(-c3cccc(OCc4ccccc4)c3)c12		CHEMBL1991138	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594047	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(NC(CO)Cc1ccccc1)c1ccc(-c2ccncc2)cc1F		CHEMBL1969755	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594048	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCNC(=O)c1cnc(N)c2c(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)csc12		CHEMBL1979516	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594049	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(N)C1CCC(C(=O)Nc2ccncc2)CC1		CHEMBL1994526	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594050	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1ccc(N2C(=O)c3ccccc3C2=O)cc1O		CHEMBL1972820	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594051	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	NNc1cc(N2CCOCC2)nc(OCCc2ccccn2)n1		CHEMBL1996208	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594052	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)OC1=NNC(=O)C1=Cc1c[nH]c2ccccc12		CHEMBL1989029	=	Ki	nM	3981.07	CHEMBL3629	Homo sapiens	pKi		5.4
active	9594053	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CSc1ccccc1CNc1ncc([N+](=O)[O-])c(NCC2CCC(CN)CC2)n1		CHEMBL392642	=	Ki	nM	5011.87	CHEMBL3629	Homo sapiens	pKi		5.3
active	9594054	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN(C)CC(=O)Nc1n[nH]c2ccc(-c3cn(Cc4ccccc4)nn3)cc12		CHEMBL1965631	=	Ki	nM	3162.28	CHEMBL3629	Homo sapiens	pKi		5.5
inactive	9594055	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccccc1NC(=O)Nc1ccc(NC(=O)c2csc3ncnc(N)c23)cc1		CHEMBL1980144	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594056	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cccc(C(C)NC(=O)c2ccc(-c3ccncc3F)cc2OC)c1		CHEMBL1991188	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594057	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)c1nnc2ccc(-c3c(-c4ccc(F)cc4F)nc4occn34)nn12		CHEMBL1972849	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594058	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCOc1nc(C(=O)NCc2ccccc2S(N)(=O)=O)cc(N)c1C#N		CHEMBL377408	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594059	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCN(CCO)CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1		CHEMBL215152	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594060	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL231209	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594061	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4cccc(Br)c4)cc3)c12		CHEMBL1976220	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594062	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1ccc(C(=O)Nc2ccon2)cc1Nc1ncnc2c1cnn2-c1ccccc1		CHEMBL259922	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594063	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CN1CCN(C2CCC(n3cc(-c4ccc(Oc5ccccc5)cc4)c4c(N)ncnc43)CC2)CC1		CHEMBL1997617	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594064	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CC(C)(CO)CNc1nccc(-c2c(-c3ccc(F)cc3)nc3c(CCN)nccn23)n1		CHEMBL1982383	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594065	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CCCCn1c(NC(=O)c2cccc(C#N)c2)nc2cc(N(C)C(=O)C3CCCCC3)ccc21		CHEMBL1969301	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594066	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CSc1ccc(-c2nc(-c3ccc(F)cc3)c(-c3ccncc3)[nH]2)cc1		CHEMBL17370	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594067	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C1ON=C(c2ccc(Br)cc2)C1=Cc1ccc2c(c1)OCO2		CHEMBL1966068	=	Ki	nM	1584.89	CHEMBL3629	Homo sapiens	pKi		5.8
inactive	9594068	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1nccc2scc(-c3ccc(NC(=O)Nc4ccccc4C(F)(F)F)cc3)c12		CHEMBL1987910	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594069	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1ccc2c(NC(=O)Nc3cccc(Br)n3)ccnc2c1		CHEMBL1983932	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594070	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Nc1ncc(-c2cnn(CCO)c2)c2scc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)c12		CHEMBL1980297	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594071	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	c1ccc2c(c1)nnn2Cc1cn(-c2ccc3[nH]ncc3c2)nn1		CHEMBL1966069	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594072	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1		CHEMBL554	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594073	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc2cc(-c3csc4c(-c5cccc(S(C)(=O)=O)c5)cnc(N)c34)ccc2[nH]1		CHEMBL1997822	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594074	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1cc(OCC2CCC(C(=O)O)C2)c(NC(=O)Nc2cnc(C#N)cn2)cc1Cl		CHEMBL1991285	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594075	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(O)c1ccccc1Nc1ccnc(Nc2cccc(O)c2)n1		CHEMBL243088	=	Ki	nM	79.43	CHEMBL3629	Homo sapiens	pKi		7.1
inactive	9594076	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc(-c2ccc3c(c2)NC(=O)c2ccc(-c4ccccc4NS(C)(=O)=O)cc2N3)cc(OC)c1OC		CHEMBL1984038	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594077	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CNS(=O)(=O)c1ccccc1Nc1nc(Nc2cc(OC)c(OC)c(OC)c2)ncc1Cl		CHEMBL1993661	=	Ki	nM	125.89	CHEMBL3629	Homo sapiens	pKi		6.9
inactive	9594078	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(Nc1cnc2[nH]cc(-c3ccccc3)c2c1)c1cccc(F)c1F		CHEMBL1974416	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594079	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	CSc1nn(-c2ccccn2)c(N)c1C(N)=O		CHEMBL2004615	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
inactive	9594080	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	Cc1nn(C)c(C)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)[nH]c12		CHEMBL1984039	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
active	9594081	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	COc1cc2c(cc1F)C(c1ccccc1Cl)=Nc1c(n[nH]c1C)N2		CHEMBL1980391	=	Ki	nM	2511.89	CHEMBL3629	Homo sapiens	pKi		5.6
inactive	9594082	CHEMBL1963735	PUBCHEM_BIOASSAY: Navigating the Kinome. (Class of assay: other) Panel member name: CSNK2A1	F	O=C(c1cccc(-c2cnc3[nH]ccc3c2)c1)N1CCOCC1		CHEMBL1997872	<	Ki	nM	6309.57	CHEMBL3629	Homo sapiens	pKi		5.2
Active	10964267	CHEMBL2065184	Binding affinity to CK2alpha at 150 uM followed by UV irradiation for 30 mins with Wood's glass filtered medium pressure mercury arc light by SDS-PAGE based pull down assay	B	O=C(CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12)NCCOCCOCCNC(=O)COc1cc(O)c2c(=O)c(O)c(-c3ccc(O)c(O)c3)oc2c1		CHEMBL2063416		Activity			CHEMBL3629	Homo sapiens	Activity		
	10975113	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	N#Cc1cnn2c(N)cc(-c3cccs3)nc12		CHEMBL2062555	=	IC50	nM	100.0	CHEMBL3629	Homo sapiens	IC50	uM	0.1
	10975114	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	N#Cc1cnn2c(N)cc(-c3ccccc3)nc12		CHEMBL2062556	=	IC50	nM	180.0	CHEMBL3629	Homo sapiens	IC50	uM	0.18
	10975115	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	COc1ccc(-c2cc(N)n3ncc(C#N)c3n2)cc1		CHEMBL2062557	=	IC50	nM	58.0	CHEMBL3629	Homo sapiens	IC50	uM	0.058
	10975116	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	N#Cc1cnn2c(N)cc(-c3ccc(F)cc3)nc12		CHEMBL2062558	=	IC50	nM	430.0	CHEMBL3629	Homo sapiens	IC50	uM	0.43
	10975117	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	N#Cc1cnn2c(NC3CC3)cc(-c3cccs3)nc12		CHEMBL2062559	=	IC50	nM	460.0	CHEMBL3629	Homo sapiens	IC50	uM	0.46
	10975118	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	COc1ccc(-c2cc(NC3CC3)n3ncc(C#N)c3n2)cc1		CHEMBL2062560	=	IC50	nM	78.0	CHEMBL3629	Homo sapiens	IC50	uM	0.078
	10975119	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	COc1ccc(-c2cc(Nc3ccn(C)n3)n3ncc(C#N)c3n2)cc1		CHEMBL2062561	=	IC50	nM	52.0	CHEMBL3629	Homo sapiens	IC50	uM	0.052
	10975120	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	COc1ccncc1-c1cc(NC2CC2)n2ncc(C#N)c2n1		CHEMBL2062562	=	IC50	nM	250.0	CHEMBL3629	Homo sapiens	IC50	uM	0.25
	10975121	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062563	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	uM	0.01
	10975122	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2cnn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062564	=	IC50	nM	26.0	CHEMBL3629	Homo sapiens	IC50	uM	0.026
	10975123	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1cnc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062565	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	10975124	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)N(c1cc(NC3CC3)n3ncc(C#N)c3n1)CC2		CHEMBL2062566	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	uM	0.004
	10975125	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)N(c1cc(NC3CC3)n3ncc(C#N)c3n1)CCO2		CHEMBL2062567	=	IC50	nM	270.0	CHEMBL3629	Homo sapiens	IC50	uM	0.27
	10975126	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)N(c1cc(NC3CC3)n3ncc(C#N)c3n1)CCC2		CHEMBL2062568	=	IC50	nM	240.0	CHEMBL3629	Homo sapiens	IC50	uM	0.24
	10975127	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1cc2c(ccn2-c2cc(NC3CC3)n3ncc(C#N)c3n2)cc1C		CHEMBL2062569	=	IC50	nM	79.0	CHEMBL3629	Homo sapiens	IC50	uM	0.079
	10975128	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(Nc4ccn(C)n4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062570	=	IC50	nM	24.0	CHEMBL3629	Homo sapiens	IC50	uM	0.024
	10975154	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NC4COC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062571	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	uM	0.004
	10975155	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCCCO)n4ncc(C#N)c4n3)c2c1		CHEMBL2062572	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	uM	0.03
	10975156	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCN4CCOCC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062573	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	uM	0.03
	10975157	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCN4CCCC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062574	=	IC50	nM	40.0	CHEMBL3629	Homo sapiens	IC50	uM	0.04
	10975158	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCCN(C)C)n4ncc(C#N)c4n3)c2c1		CHEMBL2062575	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	uM	0.03
	10975159	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCCN4CCCC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062576	=	IC50	nM	18.0	CHEMBL3629	Homo sapiens	IC50	uM	0.018
	10975160	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)N(C)c1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062577	=	IC50	nM	11.0	CHEMBL3629	Homo sapiens	IC50	uM	0.011
	10975161	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	N#Cc1cnn2c(NC3CC3)cc(-n3ccc4ccc(CO)cc43)nc12		CHEMBL2062578	=	IC50	nM	120.0	CHEMBL3629	Homo sapiens	IC50	uM	0.12
	10975162	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CS(=O)(=O)Cc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062579	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	uM	0.007
	10975169	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2ccn(-c3cc(NC4COC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062571	=	IC50	nM	57.0	CHEMBL3629	Homo sapiens	IC50	uM	0.057
	10975170	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCCCO)n4ncc(C#N)c4n3)c2c1		CHEMBL2062572	=	IC50	nM	190.0	CHEMBL3629	Homo sapiens	IC50	uM	0.19
	10975171	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCN4CCOCC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062573	=	IC50	nM	460.0	CHEMBL3629	Homo sapiens	IC50	uM	0.46
	10975172	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCN4CCCC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062574	=	IC50	nM	780.0	CHEMBL3629	Homo sapiens	IC50	uM	0.78
	10975173	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCCN(C)C)n4ncc(C#N)c4n3)c2c1		CHEMBL2062575	=	IC50	nM	1200.0	CHEMBL3629	Homo sapiens	IC50	uM	1.2
	10975174	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2ccn(-c3cc(NCCCN4CCCC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062576	=	IC50	nM	860.0	CHEMBL3629	Homo sapiens	IC50	uM	0.86
	10975175	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)N(C)c1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062577	=	IC50	nM	34.0	CHEMBL3629	Homo sapiens	IC50	uM	0.034
	10975176	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	N#Cc1cnn2c(NC3CC3)cc(-n3ccc4ccc(CO)cc43)nc12		CHEMBL2062578	=	IC50	nM	830.0	CHEMBL3629	Homo sapiens	IC50	uM	0.83
	10975177	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CS(=O)(=O)Cc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062579	=	IC50	nM	83.0	CHEMBL3629	Homo sapiens	IC50	uM	0.083
	10975206	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2C		CHEMBL2062580	=	IC50	nM	6000.0	CHEMBL3629	Homo sapiens	IC50	uM	6.0
	10975207	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2[nH]cc(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062581	=	IC50	nM	5000.0	CHEMBL3629	Homo sapiens	IC50	uM	5.0
	10975208	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCO		CHEMBL2062582	<	IC50	nM	3000.0	CHEMBL3629	Homo sapiens	IC50	uM	3.0
	10975209	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCCO		CHEMBL2062583	<	IC50	nM	3000.0	CHEMBL3629	Homo sapiens	IC50	uM	3.0
	10975210	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	COC(=O)CCn1cc(-c2cc(NC3CC3)n3ncc(C#N)c3n2)c2cc(NC(C)=O)ccc21		CHEMBL2062584	=	IC50	nM	15000.0	CHEMBL3629	Homo sapiens	IC50	uM	15.0
	10975211	CHEMBL2065439	Inhibition of full length N-terminus His-tagged human CK2alpha expressed in insect Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 20 mins	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCC(=O)O	Potential transcription error	CHEMBL2062585	<	IC50	nM	3000.0	CHEMBL3629	Homo sapiens	IC50	uM	3.0
	10975217	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2C		CHEMBL2062580	=	IC50	nM	27.0	CHEMBL3629	Homo sapiens	IC50	uM	0.027
	10975218	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2[nH]cc(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062581	=	IC50	nM	77.0	CHEMBL3629	Homo sapiens	IC50	uM	0.077
	10975219	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCO		CHEMBL2062582	=	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	uM	0.5
	10975220	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCCO		CHEMBL2062583	=	IC50	nM	210.0	CHEMBL3629	Homo sapiens	IC50	uM	0.21
Not Determined	10975221	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	COC(=O)CCn1cc(-c2cc(NC3CC3)n3ncc(C#N)c3n2)c2cc(NC(C)=O)ccc21		CHEMBL2062584		IC50			CHEMBL3629	Homo sapiens	IC50		
	10975222	CHEMBL2065441	Inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCC(=O)O		CHEMBL2062585	=	IC50	nM	3100.0	CHEMBL3629	Homo sapiens	IC50	uM	3.1
	10975255	CHEMBL2065442	Inhibition of CK2alpha in human DLD-1 cells assessed as decrease in AKT phosphorylation at S129 residue after 24 hrs by ELISA	B	CC(=O)Nc1ccc2ccn(-c3cc(Nc4ccn(C)n4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062570	=	IC50	nM	16.0	CHEMBL3629	Homo sapiens	IC50	uM	0.016
Active	10975257	CHEMBL2065444	Inhibition of CK2alpha in human SW480 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot analysis	B	CC(=O)Nc1cnc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062565		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	11013389	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(=O)Nc1nnc(-c2ccc([N+](=O)[O-])cc2)s1		CHEMBL2087004	=	IC50	nM	26800.0	CHEMBL3629	Homo sapiens	IC50	uM	26.8
	11013391	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087005	=	IC50	nM	29900.0	CHEMBL3629	Homo sapiens	IC50	uM	29.9
	11013393	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3ccccc3)s2)cc1		CHEMBL2087006	=	IC50	nM	4400.0	CHEMBL3629	Homo sapiens	IC50	uM	4.4
	11013395	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3ccc(F)cc3)s2)cc1		CHEMBL2087007	=	IC50	nM	6600.0	CHEMBL3629	Homo sapiens	IC50	uM	6.6
	11013397	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2nnc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087008	=	IC50	nM	3400.0	CHEMBL3629	Homo sapiens	IC50	uM	3.4
	11013399	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3cccs3)s2)cc1		CHEMBL2087009	=	IC50	nM	6400.0	CHEMBL3629	Homo sapiens	IC50	uM	6.4
	11013401	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)c3ccco3)s2)cc1		CHEMBL2087010	=	IC50	nM	5100.0	CHEMBL3629	Homo sapiens	IC50	uM	5.1
	11013403	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(CO)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087011	=	IC50	nM	5100.0	CHEMBL3629	Homo sapiens	IC50	uM	5.1
	11013405	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COCC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087012	=	IC50	nM	6000.0	CHEMBL3629	Homo sapiens	IC50	uM	6.0
	11013407	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)c1ccc(-c2nnc(NC(=O)C3CC3)s2)cc1		CHEMBL2087013	=	IC50	nM	3900.0	CHEMBL3629	Homo sapiens	IC50	uM	3.9
	11013409	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	C/C=C(\C)C(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087014	=	IC50	nM	3600.0	CHEMBL3629	Homo sapiens	IC50	uM	3.6
	11013411	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087015	=	IC50	nM	6800.0	CHEMBL3629	Homo sapiens	IC50	uM	6.8
	11013413	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	C=CCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087016	=	IC50	nM	8100.0	CHEMBL3629	Homo sapiens	IC50	uM	8.1
	11013415	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087017	=	IC50	nM	5700.0	CHEMBL3629	Homo sapiens	IC50	uM	5.7
	11013417	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(C)OC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087018	=	IC50	nM	14100.0	CHEMBL3629	Homo sapiens	IC50	uM	14.1
	11013419	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087019	=	IC50	nM	7700.0	CHEMBL3629	Homo sapiens	IC50	uM	7.7
	11013421	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CC(C)COC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087020	=	IC50	nM	5100.0	CHEMBL3629	Homo sapiens	IC50	uM	5.1
	11013423	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087021	=	IC50	nM	4500.0	CHEMBL3629	Homo sapiens	IC50	uM	4.5
	11013425	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	CCCCCCOC(=O)Nc1nnc(-c2ccc(C(=O)O)cc2)s1		CHEMBL2087022	=	IC50	nM	6100.0	CHEMBL3629	Homo sapiens	IC50	uM	6.1
	11013427	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	O=C(O)Cc1ccn(-c2cncc(-n3ncc4ccc(NC5CCCC5)cc43)n2)c1		CHEMBL2048144	=	IC50	nM	110.0	CHEMBL3629	Homo sapiens	IC50	uM	0.11
	11013428	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	IC50	nM	32.0	CHEMBL3629	Homo sapiens	IC50	uM	0.032
	11013429	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2nnc(-c3ccc(C(=O)O)cc3)o2)cc1		CHEMBL2087024	=	IC50	nM	74000.0	CHEMBL3629	Homo sapiens	IC50	uM	74.0
	11013430	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2cc(-c3ccc(C(=O)O)cc3)[nH]n2)cc1		CHEMBL2087025	=	IC50	nM	140.0	CHEMBL3629	Homo sapiens	IC50	uM	0.14
	11013431	CHEMBL2092253	Competitive inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 after 10 mins in presence of ATP	B	COc1ccc(C(=O)Nc2cnc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087026	=	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	11013453	CHEMBL2092256	Inhibition of GST fused human CK2alpha expressed in Escherichia coli BL21 at 0.3 uM	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	Inhibition	%	84.0	CHEMBL3629	Homo sapiens	INH	%	84.0
Active	12039930	CHEMBL2149577	Inhibition of CK2alpha in human LNCAP cells assessed as reduction of p21 phosphorylation at threonine145 at 10 uM after 12 to 24 hrs by Western blot analysis	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	12039931	CHEMBL2149578	Inhibition of CK2alpha in human LNCAP cells assessed as reduction of Akt phosphorylation at Ser473 at 10 uM after 12 to 24 hrs by Western blot analysis	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	12039932	CHEMBL2149109	Inhibition of CK2alpha in human LNCAP cells assessed as reduction of survivin expression at 10 uM after 12 to 24 hrs by Western blot analysis	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	12039933	CHEMBL2149579	Inhibition of CK2alpha in human LNCAP cells assessed as reduction of XIAP expression at 10 uM after 12 to 24 hrs by Western blot analysis	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	12039936	CHEMBL2149581	Inhibition of CK2alpha in human LNCAP cells assessed as induction of CHOP expression at 10 uM after 12 to 24 hrs by Western blot analysis	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12040520	CHEMBL2149582	Inhibition of CK2alpha in human LNCAP cells assessed as effect on DR5 expression at 10 uM after 12 to 24 hrs by Western blot analysis	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	12046271	CHEMBL2156508	Inhibition of CK2alpha1 at 1 uM	B	CC(C)(O)C1CCN(Cc2ccc3nc(-c4c(F)ccc5[nH]ccc45)nc(N4CCOCC4)c3n2)CC1		CHEMBL2152768	=	Inhibition	%	9.6	CHEMBL3629	Homo sapiens	INH	%	9.6
Not Active	12047556	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccccc3Cl)cc1CC2		CHEMBL2152781		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048347	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccccc3C(F)(F)F)cc1CC2		CHEMBL2152782		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048362	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)cc3Cl)cc1CC2		CHEMBL2152785		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048377	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)cc3C)cc1CC2		CHEMBL2152786		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048392	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(C(F)(F)F)cc3N)cc1CC2		CHEMBL2152787		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048407	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3ccc(F)c(C)c3)cc1CC2		CHEMBL2152788		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048422	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(Nc3cc(F)cc(F)c3F)cc1CC2		CHEMBL2152789		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048437	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2c(c1)C(=O)c1ccc(-c3ccccc3)cc1CC2		CHEMBL2152791		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048452	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1ccc2ccc3cc(Nc4ccc(F)cc4F)ccc3c(=O)c2c1		CHEMBL2152792		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048467	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)C(=O)c2ccc(Nc4ccccc4N)cc2CC3)O1		CHEMBL2152798		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048482	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CCc1ccc(OC[C@H](O)CO)cc1C2=O		CHEMBL2152936		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048497	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(=O)c3cc(OCCN4CCOCC4)ccc3ccc2c1		CHEMBL2152939		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048512	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCO)cc21		CHEMBL2152940		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048527	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCCO)cc21		CHEMBL2152941		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048542	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC3CCOCC3)cc21		CHEMBL2152942		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048557	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)C(=O)c2ccc(Nc4ccc(F)cc4F)cc2CC3)O1		CHEMBL2152943		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048572	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@@H](O)CO)cc21		CHEMBL2152946		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048587	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@@H](CCOc2ccc3c(c2)C(=O)c2ccc(Nc4ccc(F)cc4F)cc2CC3)O1		CHEMBL2152947		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048602	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OCCCN3CCOCC3)cc21		CHEMBL2152950		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048617	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@H](COc2ccc3c(c2)CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152957		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048632	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2cc(OC[C@H](O)CO)ccc21		CHEMBL2152958		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048647	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@@H](COc2ccc3c(c2)CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152959		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12048662	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2cc(OC[C@@H](O)CO)ccc21		CHEMBL2152960		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049606	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1cccc2c1CCc1cc(Nc3ccc(F)cc3F)ccc1C2=O		CHEMBL2152965		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049621	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(O)cccc21		CHEMBL2152966		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049636	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c1cccc2C1CCOCC1		CHEMBL2152967		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049651	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@H](COc2cccc3c2CCc2cc(Nc4ccc(F)cc4F)ccc2C3=O)O1		CHEMBL2152968		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049666	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(OC[C@H](O)CO)cccc21		CHEMBL2152969		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049681	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2c(OCCN3CCOCC3)cccc21		CHEMBL2152970		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049696	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	COc1cccc2c1CCc1cc(Nc3ccccc3N)ccc1C2=O		CHEMBL2152971		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049711	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	CC1(C)OC[C@H](COc2cccc3c2CCc2cc(Nc4ccccc4N)ccc2C3=O)O1		CHEMBL2152972		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	12049726	CHEMBL2155710	Inhibition of CK2alpha1 at 10 uM	B	Nc1ccccc1Nc1ccc2c(c1)CCc1c(OC[C@H](O)CO)cccc1C2=O		CHEMBL2152973		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	12074624	CHEMBL2161021	Inhibition of CK2-alpha1 at 1 uM	B	CN(C)CC(=O)N1CCC(c2ccc(NC(=O)c3nc(C#N)c[nH]3)c(C3=CCCCC3)c2)CC1		CHEMBL1908842	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	12139738	CHEMBL2184781	Competitive inhibition of CK2alpha using RRREDEESDDEE as substrate after 5 mins by scintillation counter in presence of [gamma-32P]ATP	B	O=C(O)c1cc2c(ccc3cc4c(ccc5oc(C(=O)O)cc54)cc32)o1		CHEMBL2177299	=	IC50	nM	63.0	CHEMBL3629	Homo sapiens	IC50	uM	0.063
	12173672	CHEMBL2209308	Inhibition of CSNK2A1 assessed as residual activity at 10 uM relative to control	B	O=C(Nc1cccnc1)c1cc(-c2ccnc(F)c2)ccc1OCc1ccccc1		CHEMBL2204495	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	12183899	CHEMBL2211487	Inhibition of CSNK2A1	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	pIC50		5.0
	12183907	CHEMBL2211477	Inhibition of CK2a1	B	CC(C)(C)NS(=O)(=O)c1cncc(-c2ccn3nc(N)nc3c2)c1		CHEMBL2205766	<	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	pIC50		5.0
	12626684	CHEMBL2317133	Inhibition of CK2alpha (unknown origin) at 1 uM	B	COc1cc(Nc2ncc(Cl)c(-c3cccc(CC#N)c3)n2)ccc1N1CCN(C)CC1		CHEMBL2312140	>=	Inhibition	%	80.0	CHEMBL3629	Homo sapiens	INH	%	80.0
	12674057	CHEMBL2344164	Inhibition of CK2-alpha1 (unknown origin)	B	O=C(NCCc1ccc(O)c(Br)c1)/C(Cc1cc(Br)c(O)c(-c2cc(C/C(=N/O)C(=O)NCCc3ccc(O)c(Br)c3)cc(Br)c2O)c1)=N\O		CHEMBL505637	=	IC50	nM	4100.0	CHEMBL3629	Homo sapiens	IC50	uM	4.1
	12700120	CHEMBL2344133	Inhibition of recombinant CSNK2A1 (unknown origin) at 5 uM by FRET-based Z'-LYTE assay	B	O=C1/C(=C/c2ccccn2)CNC/C1=C\c1ccccn1		CHEMBL574646	=	Inhibition	%	5.0	CHEMBL3629	Homo sapiens	INH	%	5.0
	12730893	CHEMBL2349821	Inhibition of CK2a (unknown origin) using [gamma-33P]ATP assessed as residual activity at 3 uM	B	CCc1ccc(-c2ccc3c(c2)-c2[nH]ncc2S(=O)(=O)N3C)cc1		CHEMBL2333445	=	Activity	%	89.0	CHEMBL3629	Homo sapiens	Activity	%	89.0
Not Active	13328776	CHEMBL2388500	Inhibition of CSNK1A1 (unknown origin)	B	Cc1cccc2nc(Cn3cnc4ccccc43)cc(=O)n12		CHEMBL2386917		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	13375900	CHEMBL2405310	Inhibition of CK2alpha1 (unknown origin) at 10 uM relative to control	B	CC[C@@H]1C(=O)N(C)c2cnc(-n3ccnc3-c3ccc(F)cc3)nc2N1c1ccn(C)n1		CHEMBL2402081	=	Inhibition	%	4.0	CHEMBL3629	Homo sapiens	INH	%	4.0
	13380357	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3COC3)n3ncc(C#N)c3n2)c(F)cc1C1CC1		CHEMBL2409198	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380358	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3COC3)n3ncc(C#N)c3n2)ccc1C1CC1		CHEMBL2409197	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380359	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3COC3)n3ncc(C#N)c3n2)c(F)cc1C		CHEMBL2409196	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380360	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3COC3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409195	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380361	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3COC3)n3ncc(C#N)c3n2)ccc1Cl		CHEMBL2409194	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380362	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3cn(CCN4CCOCC4)cn3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409193	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380363	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3cn(CCN4CCCC4)cn3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409192	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380364	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3cn(CCN(C)C)cn3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409191	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380365	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3ccn(CCN4CCOCC4)n3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409190	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380366	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3ccn(CCN4CCCC4)n3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409189	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380367	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3ccn(CCN(C)C)n3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409188	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380368	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3cn(CCO)cn3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409187	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380369	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3ccn(CCO)n3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409186	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380370	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3cn(C)cn3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409184	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380371	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(Nc3ccn(C)n3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409183	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380372	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CCC3)n3ncc(C#N)c3n2)c(F)cc1C		CHEMBL2409182	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380373	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CCC3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409181	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380374	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ncc1C		CHEMBL2409180	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380375	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)cnc1C		CHEMBL2407112	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380376	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)c(F)cc1C1CC1		CHEMBL2409179	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380377	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C1CC1		CHEMBL2409177	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380378	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)c(F)cc1C		CHEMBL2409178	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380379	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C(C)C		CHEMBL2409176	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380380	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062563	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
	13380381	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)N(C)c1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062577	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
	13380382	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)N1CCc2ccc(Nc3cc(NC4CC4)n4ncc(C#N)c4n3)cc21		CHEMBL2409173	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
	13380383	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1Cl		CHEMBL2409174	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13380384	CHEMBL2411106	Inhibition of N-terminal His6X-tagged recombinant human full length casein kinase-2alpha expressed in SF21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate preincubated for 20 mins measured after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409175	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	13414890	CHEMBL2424249	Inhibition of CK2alpha2 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O[C@H]1CC[C@H](Nc2nc3ccccc3n3ccnc23)CC1		CHEMBL2420582	=	Inhibition	%	49.6	CHEMBL3629	Homo sapiens	INH	%	49.6
	13414891	CHEMBL2424249	Inhibition of CK2alpha2 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	c1ccc(CNc2nc3ccccc3n3ccnc23)cc1		CHEMBL2420578	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13414892	CHEMBL2424249	Inhibition of CK2alpha2 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	c1ccc(CCNc2nc3ccccc3n3ccnc23)cc1		CHEMBL2420577	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13414893	CHEMBL2424249	Inhibition of CK2alpha2 in human PC3 cell lysates at 30 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	c1ccc2c(c1)nc(NC1CCCCC1)c1nccn12		CHEMBL2420576	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438308	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(Cc2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420551	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438309	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccc(F)cc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420555	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438310	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CCC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420573	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438311	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(NC1(c2ccccc2)CC1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420572	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438312	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC(C)(NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420570	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438313	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CCC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420565	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438314	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(N[C@H](CO)c1ccccc1)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420564	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438315	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	CC[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420562	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438316	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420560	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438317	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	C[C@@H](NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1)c1ccccc1		CHEMBL2420556	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438318	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	NC(=O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420587	<	Inhibition	%	35.0	CHEMBL3629	Homo sapiens	INH	%	35.0
	13438319	CHEMBL2422675	Inhibition of CK2alpha2 in human PC3 cell lysates at 10 uM using desthiobiotin-tagged ATP probe AX9989 followed by trypsinization by LC/MS analysis	B	O=C(O)c1ccc2nc(N[C@H]3CC[C@H](O)CC3)c3nccn3c2c1		CHEMBL2420585	=	Inhibition	%	40.6	CHEMBL3629	Homo sapiens	INH	%	40.6
	13442378	CHEMBL2428000	Competitive binding affinity to CSNK2A1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ccc4ccccc43)n2)CC1		CHEMBL2425646	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	13445513	CHEMBL2428000	Competitive binding affinity to CSNK2A1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-c3n[nH]c4ccccc34)n2)CC1		CHEMBL2425644	=	Inhibition	%	98.0	CHEMBL3629	Homo sapiens	INH	%	98.0
	13448568	CHEMBL2428000	Competitive binding affinity to CSNK2A1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3ncc4ccccc43)n2)CC1		CHEMBL2425645	=	Inhibition	%	87.0	CHEMBL3629	Homo sapiens	INH	%	87.0
	13448704	CHEMBL2428000	Competitive binding affinity to CSNK2A1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O=C([C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1)N1CCOCC1		CHEMBL2425649	=	Inhibition	%	71.0	CHEMBL3629	Homo sapiens	INH	%	71.0
	13451499	CHEMBL2428000	Competitive binding affinity to CSNK2A1 (unknown origin) at 10 uM in presence of ATP relative to control	B	N[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425652	=	Inhibition	%	99.0	CHEMBL3629	Homo sapiens	INH	%	99.0
	13454684	CHEMBL2428000	Competitive binding affinity to CSNK2A1 (unknown origin) at 10 uM in presence of ATP relative to control	B	O[C@H]1CC[C@H](Nc2nccc(-n3nnc4ccccc43)n2)CC1		CHEMBL2425654	=	Inhibition	%	80.0	CHEMBL3629	Homo sapiens	INH	%	80.0
	13918676	CHEMBL3117016	Inhibition of human recombinant 6 X His-tagged full length CK2alpha expressed in insect sf21 cells using CK2tide as substrate after 20 mins by fluorescence assay	B	C[C@H](Nc1nc(Nc2cn(C)cn2)c2cc[nH]c2n1)c1ncc(F)cn1		CHEMBL3116050	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	14585689	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)N4CCN(C)CC4)cc3)nc12		CHEMBL3237848	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585690	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)N4CCOCC4)cc3)nc12		CHEMBL3237849	>	IC50	nM	25000.0	CHEMBL3629	Homo sapiens	IC50	uM	25.0
	14585691	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)N4CCNCC4)cc3)nc12		CHEMBL3237850	>	IC50	nM	25000.0	CHEMBL3629	Homo sapiens	IC50	uM	25.0
	14585692	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)NCCO)cc3)nc12		CHEMBL3237851	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585693	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)N4CCCNCC4)cc3)nc12		CHEMBL3237852	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585694	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)N4CCCC4)cc3)nc12		CHEMBL3233061	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585695	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)N4CCCCC4)cc3)nc12		CHEMBL3237853	>	IC50	nM	25000.0	CHEMBL3629	Homo sapiens	IC50	uM	25.0
	14585696	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)NCCN)cc3)nc12		CHEMBL3237854	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585697	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(N)(=O)=O)cc3)nc12		CHEMBL3237855	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585698	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)NC(CO)C(C)C)cc3)nc12		CHEMBL3237856	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585699	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)NCCN4CCOCC4)cc3)nc12		CHEMBL3237857	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585700	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	Cc1nn(C)c2nnc(Nc3ccc(S(=O)(=O)NCC(O)CO)cc3)nc12		CHEMBL3237858	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	14585701	CHEMBL3239584	Inhibition of CK2alpha1 (unknown origin) using casein as substrate in presence of [gamma33P]ATP	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	100.0	CHEMBL3629	Homo sapiens	IC50	uM	0.1
	14663256	CHEMBL3270860	Inhibition of CSNK2A1 (unknown origin) at 1 uM relative to control	B	CCOC(=O)c1sc(-c2ccncc2)nc1O		CHEMBL3261228	=	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	14663257	CHEMBL3270860	Inhibition of CSNK2A1 (unknown origin) at 1 uM relative to control	B	NC(=O)c1sc(-c2ccnc(N)n2)nc1-c1ccc(Cl)cc1Cl		CHEMBL3261514	=	Inhibition	%	66.0	CHEMBL3629	Homo sapiens	INH	%	66.0
	14663258	CHEMBL3270860	Inhibition of CSNK2A1 (unknown origin) at 1 uM relative to control	B	COc1ccc(-c2nc(-c3ccnc(N)n3)sc2C(N)=O)c(Cl)c1		CHEMBL3261517	=	Inhibition	%	95.0	CHEMBL3629	Homo sapiens	INH	%	95.0
	14981079	CHEMBL3375428	Inhibition of CK2a (unknown origin) at 1 uM	B	CC(C)(O)[C@H]1CC[C@H](Nc2ccn3ncc(-c4cccc(Cl)c4)c3n2)CC1		CHEMBL3355987	>	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	14984383	CHEMBL3384992	Inhibition of CSNK2A1 (unknown origin) at 1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	3.0	CHEMBL3629	Homo sapiens	INH	%	3.0
	14984449	CHEMBL3382478	Inhibition of CSNK2A1 (unknown origin) at 0.1 uM	B	CN1CCN(c2ccc(-c3cnc4[nH]c5cnc(C#N)cc5c4c3)cc2)CC1		CHEMBL3359895	=	Inhibition	%	7.0	CHEMBL3629	Homo sapiens	INH	%	7.0
	15018566	CHEMBL3361880	Inhibition of CK2 alpha-1 (unknown origin) at 100 nM	B	O=C(N[C@H](CO)c1ccc(Cl)c(F)c1)N1CCc2cnc(NC3CCOCC3)nc2C1		CHEMBL3298678	=	Inhibition	%	-1.5	CHEMBL3629	Homo sapiens	INH	%	-1.5
	15033181	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1cccc(Br)c1		CHEMBL3322692	=	Activity	%	43.36	CHEMBL3629	Homo sapiens	Activity	%	43.36
	15033182	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1cccc(Cl)c1		CHEMBL3322693	=	Activity	%	23.77	CHEMBL3629	Homo sapiens	Activity	%	23.77
	15033183	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	COc1cccc(C(O)CCn2nc3c(Br)c(Br)c(Br)c(Br)c3n2)c1		CHEMBL3322694	=	Activity	%	87.51	CHEMBL3629	Homo sapiens	Activity	%	87.51
	15033199	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(F)cc1		CHEMBL3322691	=	Activity	%	35.35	CHEMBL3629	Homo sapiens	Activity	%	35.35
	15033200	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(Cl)cc1		CHEMBL3322690	=	Activity	%	45.38	CHEMBL3629	Homo sapiens	Activity	%	45.38
	15033201	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(Br)cc1		CHEMBL3322689	=	Activity	%	33.45	CHEMBL3629	Homo sapiens	Activity	%	33.45
	15033202	CHEMBL3363838	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 200 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccccc1		CHEMBL3322688	=	Activity	%	31.09	CHEMBL3629	Homo sapiens	Activity	%	31.09
	15033203	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	COc1cccc(C(O)CCn2nc3c(Br)c(Br)c(Br)c(Br)c3n2)c1		CHEMBL3322694	=	Activity	%	95.12	CHEMBL3629	Homo sapiens	Activity	%	95.12
	15033204	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1cccc(Cl)c1		CHEMBL3322693	=	Activity	%	74.9	CHEMBL3629	Homo sapiens	Activity	%	74.9
	15033205	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1cccc(Br)c1		CHEMBL3322692	=	Activity	%	96.61	CHEMBL3629	Homo sapiens	Activity	%	96.61
	15033206	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(F)cc1		CHEMBL3322691	=	Activity	%	91.42	CHEMBL3629	Homo sapiens	Activity	%	91.42
	15033207	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(Cl)cc1		CHEMBL3322690	=	Activity	%	95.6	CHEMBL3629	Homo sapiens	Activity	%	95.6
	15033208	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(Br)cc1		CHEMBL3322689	=	Activity	%	97.42	CHEMBL3629	Homo sapiens	Activity	%	97.42
	15033209	CHEMBL3363837	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate at 20 uM by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccccc1		CHEMBL3322688	=	Activity	%	93.0	CHEMBL3629	Homo sapiens	Activity	%	93.0
	15033210	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OCC(O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322704	=	IC50	nM	2170.0	CHEMBL3629	Homo sapiens	IC50	uM	2.17
Not Determined	15033211	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	CC[C@@H](O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322703		IC50			CHEMBL3629	Homo sapiens	IC50		
	15033212	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	CC[C@H](O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322702	=	IC50	nM	3600.0	CHEMBL3629	Homo sapiens	IC50	uM	3.6
	15033213	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	CCC(O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322701	=	IC50	nM	2500.0	CHEMBL3629	Homo sapiens	IC50	uM	2.5
	15033214	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	C[C@@H](O)CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322700	=	IC50	nM	800.0	CHEMBL3629	Homo sapiens	IC50	uM	0.8
	15033215	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	C[C@H](O)CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322699	=	IC50	nM	2500.0	CHEMBL3629	Homo sapiens	IC50	uM	2.5
	15033216	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	CC(O)CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322698	=	IC50	nM	4160.0	CHEMBL3629	Homo sapiens	IC50	uM	4.16
	15033217	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	C[C@@H](O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322697	=	IC50	nM	7350.0	CHEMBL3629	Homo sapiens	IC50	uM	7.35
	15033218	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	C[C@H](O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322696	=	IC50	nM	5600.0	CHEMBL3629	Homo sapiens	IC50	uM	5.6
	15033219	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	CC(O)Cn1nc2c(Br)c(Br)c(Br)c(Br)c2n1		CHEMBL3322695	=	IC50	nM	5400.0	CHEMBL3629	Homo sapiens	IC50	uM	5.4
Not Determined	15033220	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	COc1cccc(C(O)CCn2nc3c(Br)c(Br)c(Br)c(Br)c3n2)c1		CHEMBL3322694		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	15033221	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1cccc(Cl)c1		CHEMBL3322693		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	15033222	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1cccc(Br)c1		CHEMBL3322692		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	15033223	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(F)cc1		CHEMBL3322691		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	15033224	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(Cl)cc1		CHEMBL3322690		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	15033225	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccc(Br)cc1		CHEMBL3322689		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	15033226	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	OC(CCn1nc2c(Br)c(Br)c(Br)c(Br)c2n1)c1ccccc1		CHEMBL3322688		IC50			CHEMBL3629	Homo sapiens	IC50		
	15033227	CHEMBL3363836	Inhibition of human CK2alpha using RRRDDDSDDD peptide substrate by P81 filter-binding assay	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	IC50	nM	320.0	CHEMBL3629	Homo sapiens	IC50	uM	0.32
	15037753	CHEMBL3365678	Binding affinity to CK2alpha (unknown origin)	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Ki	nM	400.0	CHEMBL3629	Homo sapiens	Ki	uM	0.4
	15037754	CHEMBL3365678	Binding affinity to CK2alpha (unknown origin)	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Ki	nM	40.0	CHEMBL3629	Homo sapiens	Ki	uM	0.04
	15055341	CHEMBL3380479	Inhibition of human recombinant CK2A1 using Casein substrate	B	COc1cc(-c2nc(-c3c[nH]c4ccccc34)c[nH]c2=O)cc(OC)c1OC		CHEMBL3358966	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	uM	100.0
	15095686	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1cccc(O)c1)c1cc2cc(O)ccc2s1		CHEMBL3335350	=	Inhibition	%	12.0	CHEMBL3629	Homo sapiens	INH	%	12.0
	15095687	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1cccc(O)c1)c1cc2cc(O)ccc2o1		CHEMBL3335351	=	Inhibition	%	21.0	CHEMBL3629	Homo sapiens	INH	%	21.0
	15095688	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1cccc(O)c1)c1cc2cc(O)ccc2[nH]1		CHEMBL3335352	=	Inhibition	%	22.0	CHEMBL3629	Homo sapiens	INH	%	22.0
	15095689	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	Cn1c(C(=O)c2cccc(O)c2)cc2cc(O)ccc21		CHEMBL3335353	=	Inhibition	%	31.0	CHEMBL3629	Homo sapiens	INH	%	31.0
	15095690	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1ccc(O)cc1)c1cc2cc(O)ccc2s1		CHEMBL3335354	=	Inhibition	%	33.0	CHEMBL3629	Homo sapiens	INH	%	33.0
	15095691	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1ccc(O)cc1)c1cc2cc(O)ccc2o1		CHEMBL3335355	=	Inhibition	%	17.0	CHEMBL3629	Homo sapiens	INH	%	17.0
	15095692	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	Cc1ccc(C(=O)c2cc3cc(O)ccc3s2)cc1O		CHEMBL3335356	=	Inhibition	%	10.0	CHEMBL3629	Homo sapiens	INH	%	10.0
	15095693	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1cc2cc(O)ccc2s1)c1cc(O)ccc1F		CHEMBL3335358	=	Inhibition	%	20.0	CHEMBL3629	Homo sapiens	INH	%	20.0
	15095694	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1ccc(F)c(O)c1)c1cc2cc(O)ccc2s1		CHEMBL3335359	=	Inhibition	%	15.0	CHEMBL3629	Homo sapiens	INH	%	15.0
	15095695	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	N#Cc1cccc(C(=O)c2cc3cc(O)ccc3s2)c1		CHEMBL3335360	=	Inhibition	%	10.0	CHEMBL3629	Homo sapiens	INH	%	10.0
	15095696	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1ccccc1)c1cc2cc(O)ccc2s1		CHEMBL3335361	=	Inhibition	%	13.0	CHEMBL3629	Homo sapiens	INH	%	13.0
	15095697	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	O=C(c1cccc(O)c1)c1cc2ccccc2s1		CHEMBL3335362	=	Inhibition	%	24.0	CHEMBL3629	Homo sapiens	INH	%	24.0
	15095698	CHEMBL3382861	Inhibition of CK2alpha (unknown origin) at 5 uM	B	CC(=O)c1cc2cc(O)ccc2s1		CHEMBL3335363	=	Inhibition	%	9.0	CHEMBL3629	Homo sapiens	INH	%	9.0
	15236107	CHEMBL3424700	Inhibition of human Casein kinase 2 alpha 1 polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCCCCCCCC[C@@H](O)[C@H](C)N		CHEMBL1835439	=	Activity	%	87.0	CHEMBL3629	Homo sapiens	Activity	%	87.0
	15236131	CHEMBL3424700	Inhibition of human Casein kinase 2 alpha 1 polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)[C@@H](C)O		CHEMBL3422705	=	Activity	%	71.0	CHEMBL3629	Homo sapiens	Activity	%	71.0
	15236165	CHEMBL3424700	Inhibition of human Casein kinase 2 alpha 1 polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CC(C)C		CHEMBL3422697	=	Activity	%	84.0	CHEMBL3629	Homo sapiens	Activity	%	84.0
	15236189	CHEMBL3424700	Inhibition of human Casein kinase 2 alpha 1 polypeptide assessed as residual activity at 10 uM relative to control	B	CCCCCCCCC[C@@H](O)[C@@H](N)Cc1ccccc1		CHEMBL3422700	=	Activity	%	70.0	CHEMBL3629	Homo sapiens	Activity	%	70.0
	15754926	CHEMBL3631709	Inhibition of CK2alpha1 (unknown origin) at 1 uM by FRET method	B	N#Cc1ccnc(Nc2cc(C3CCN(C4COC4)CC3)n(C3CCCC3)n2)c1		CHEMBL3629013	=	Inhibition	%	1.3	CHEMBL3629	Homo sapiens	INH	%	1.3
	15756053	CHEMBL3632318	Inhibition of CK2alpha (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CS(=O)(=O)c1cccc(Nc2nccc(-c3sc(N4CCOCC4)nc3-c3cccc(NS(=O)(=O)c4c(F)cccc4F)c3)n2)c1		CHEMBL3628627	=	Inhibition	%	19.71	CHEMBL3629	Homo sapiens	INH	%	19.71
	15757007	CHEMBL3632318	Inhibition of CK2alpha (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Oc3ccncc3)cc2)no1		CHEMBL166031	=	Inhibition	%	19.97	CHEMBL3629	Homo sapiens	INH	%	19.97
	15758669	CHEMBL3632318	Inhibition of CK2alpha (unknown origin) at 10 uM after 120 mins P33 radiolabeled kinase activity assay	B	COCCNC(=O)c1ccc2c(c1)nc(-c1cnc(-c3ccc(Cl)cc3)[nH]1)n2CCOC		CHEMBL3628628	=	Inhibition	%	8.6	CHEMBL3629	Homo sapiens	INH	%	8.6
257600	16258971	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CNCCCNC(=O)c1cc(-c2ccncc2)n2ncnc(N)c12		CHEMBL3681196	=	IC50	nM	4400.0	CHEMBL3629	Homo sapiens	IC50	nM	4400.0
279006	16261581	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(N4CCC(NC[C@@H](C)O)CC4)c3Cl)nn12		CHEMBL3699285	=	IC50	nM	1.33	CHEMBL3629	Homo sapiens	IC50	nM	1.33
279014	16262173	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2ccc3c(c2)c(C#N)nn3C2CCN(C3COC3)CC2)nn2c(C#N)cnc12		CHEMBL3699293	=	IC50	nM	1.44	CHEMBL3629	Homo sapiens	IC50	nM	1.44
279007	16263212	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2cc(C#N)cc(N3CC[C@@H]4[C@@H](C3)OCCN4C3COC3)c2Cl)nn2c(C#N)cnc12		CHEMBL3699286	=	IC50	nM	1.37	CHEMBL3629	Homo sapiens	IC50	nM	1.37
278995	16263599	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC1(N2CCN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)COC1		CHEMBL3699274	=	IC50	nM	1.42	CHEMBL3629	Homo sapiens	IC50	nM	1.42
279019	16263632	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1C(C)(C)CC(Oc2cc(F)c(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)cc2C#N)CC1(C)C		CHEMBL3699298	=	IC50	nM	25.51	CHEMBL3629	Homo sapiens	IC50	nM	25.51
279021	16266475	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1C(C)(C)CC(Oc2cc(F)c(C#N)cc2Nc2nc(NC3CC3)c3ncc(C#N)n3n2)CC1(C)C		CHEMBL3699300	=	IC50	nM	8.62	CHEMBL3629	Homo sapiens	IC50	nM	8.62
257618	16266768	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC1CCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1		CHEMBL3681210	=	IC50	nM	440.0	CHEMBL3629	Homo sapiens	IC50	nM	440.0
278996	16267432	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cnc2c(NC3CC3)nc(Nc3cc(C(F)F)cc(N4CCC(C5COC5)CC4)c3Cl)nn12		CHEMBL3699275	=	IC50	nM	6.04	CHEMBL3629	Homo sapiens	IC50	nM	6.04
278983	16267516	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC=C(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699262	=	IC50	nM	0.31	CHEMBL3629	Homo sapiens	IC50	nM	0.31
278979	16268766	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COCCOC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1O		CHEMBL3699258	=	IC50	nM	1.53	CHEMBL3629	Homo sapiens	IC50	nM	1.53
278962	16268833	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CS(=O)(=O)CCN1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699241	=	IC50	nM	1.44	CHEMBL3629	Homo sapiens	IC50	nM	1.44
257625	16270342	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	NC(=O)c1cccc(-c2cc(C(=O)N[C@H]3CC[C@H](O)CC3)c3c(N)ncnn23)c1		CHEMBL3681217	=	IC50	nM	4300.0	CHEMBL3629	Homo sapiens	IC50	nM	4300.0
257601	16271110	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)(C)OC(=O)NCCCCCNC(=O)c1cc(-c2ccncc2)n2ncnc(N)c12		CHEMBL3681221	=	IC50	nM	340.0	CHEMBL3629	Homo sapiens	IC50	nM	340.0
279017	16271714	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2cc(C#N)cc(N3CCN(C4COC4)CC3)c2Cl)nn2c(C#N)cnc12		CHEMBL3699296	=	IC50	nM	1.39	CHEMBL3629	Homo sapiens	IC50	nM	1.39
278957	16272018	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC2(C1)CN(c1cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c1Cl)C2		CHEMBL3699236	=	IC50	nM	1.4	CHEMBL3629	Homo sapiens	IC50	nM	1.4
257622	16272333	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)(C)N(CC1CCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1)C(=O)O		CHEMBL3681214	=	IC50	nM	2800.0	CHEMBL3629	Homo sapiens	IC50	nM	2800.0
278977	16272762	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1O		CHEMBL3699256	=	IC50	nM	0.41	CHEMBL3629	Homo sapiens	IC50	nM	0.41
278976	16274146	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CC(N3CC(O)C3)C2)c1		CHEMBL3699255	=	IC50	nM	0.3	CHEMBL3629	Homo sapiens	IC50	nM	0.3
278968	16274571	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NCC(F)F)CC2)c1		CHEMBL3699247	=	IC50	nM	178.4	CHEMBL3629	Homo sapiens	IC50	nM	178.4
257614	16276744	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CCOC3)c3c(N)ncnn23)ccn1		CHEMBL3681206	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	nM	30.0
279012	16277878	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2ccc3c(c2)c(C#N)nn3C2CCN(C[C@H](C)O)CC2)nn2c(C#N)cnc12		CHEMBL3699291	=	IC50	nM	0.27	CHEMBL3629	Homo sapiens	IC50	nM	0.27
278994	16278077	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cnc2c(NC3CC3)nc(Nc3cc(C(F)F)cc(N4CCN(C5(CS(=O)(=O)c6ccccc6)COC5)CC4)c3Cl)nn12		CHEMBL3699273	=	IC50	nM	13.86	CHEMBL3629	Homo sapiens	IC50	nM	13.86
257598	16278342	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccnc(F)c3)cc(C(=O)N[C@H]3CC[C@H](O)CC3)c12		CHEMBL3681193	=	IC50	nM	110.0	CHEMBL3629	Homo sapiens	IC50	nM	110.0
278972	16279007	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CN(C2CCN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C[C@@H]1C		CHEMBL3699251	=	IC50	nM	1.31	CHEMBL3629	Homo sapiens	IC50	nM	1.31
278992	16282872	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC(CN2CCN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C1		CHEMBL3699271	=	IC50	nM	6.16	CHEMBL3629	Homo sapiens	IC50	nM	6.16
278978	16283042	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@@H]1O		CHEMBL3699257	=	IC50	nM	0.72	CHEMBL3629	Homo sapiens	IC50	nM	0.72
278984	16284333	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(C)(C)[Si](C)(C)O[C@@H]1CC(N2CCC(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)CC[C@H]1N		CHEMBL3699263	=	IC50	nM	8.54	CHEMBL3629	Homo sapiens	IC50	nM	8.54
257612	16287604	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)NC[C@H]3CC[C@H](O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681204	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
279020	16288878	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC1(C)CC(Oc2cc(F)c(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)cc2C#N)CC(C)(C)N1		CHEMBL3699299	=	IC50	nM	13.06	CHEMBL3629	Homo sapiens	IC50	nM	13.06
279013	16289189	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2ccc3c(c2)c(C#N)nn3C2CCN(C[C@@H](C)O)CC2)nn2c(C#N)cnc12		CHEMBL3699292	=	IC50	nM	0.22	CHEMBL3629	Homo sapiens	IC50	nM	0.22
279001	16292036	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(=O)N1CC(N2CCC(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C1		CHEMBL3699280	=	IC50	nM	0.28	CHEMBL3629	Homo sapiens	IC50	nM	0.28
257607	16292449	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)CC(C)(C)O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681199	=	IC50	nM	60.0	CHEMBL3629	Homo sapiens	IC50	nM	60.0
278971	16293110	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(N[C@H]3C[C@@H](O)C3)CC2)c1		CHEMBL3699250	=	IC50	nM	0.3	CHEMBL3629	Homo sapiens	IC50	nM	0.3
279011	16293670	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(Nc3nc(C)n(C)n3)nc(Nc3ccc4c(c3)c(C#N)nn4C[C@@H](C)O)nn12		CHEMBL3699290	=	IC50	nM	7.54	CHEMBL3629	Homo sapiens	IC50	nM	7.54
278988	16294598	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(C2CCN(C(=O)OC3COC3)CC2)c1		CHEMBL3699267	=	IC50	nM	1.35	CHEMBL3629	Homo sapiens	IC50	nM	1.35
257616	16295763	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)C(C)(C)CN4CCCC4)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681208	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
278964	16296454	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(C)NC1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699243	=	IC50	nM	31.02	CHEMBL3629	Homo sapiens	IC50	nM	31.02
257621	16297517	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	NCC1CCCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)C1		CHEMBL3681213	=	IC50	nM	12000.0	CHEMBL3629	Homo sapiens	IC50	nM	12000.0
279018	16298154	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(NC2CCN(C3COC3)CC2)c1		CHEMBL3699297	=	IC50	nM	1.32	CHEMBL3629	Homo sapiens	IC50	nM	1.32
279023	16298331	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(OC2CCNCC2)cc1F		CHEMBL3699302	=	IC50	nM	9.8	CHEMBL3629	Homo sapiens	IC50	nM	9.8
279005	16300547	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(C4CCNCC4)c3Cl)nn12		CHEMBL3699284	=	IC50	nM	1.42	CHEMBL3629	Homo sapiens	IC50	nM	1.42
278975	16300778	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CN(C2CN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C[C@H]1C		CHEMBL3699254	=	IC50	nM	0.27	CHEMBL3629	Homo sapiens	IC50	nM	0.27
279004	16301321	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cccc(C#N)n3)nn12		CHEMBL3699283	=	IC50	nM	173.5	CHEMBL3629	Homo sapiens	IC50	nM	173.5
257623	16302998	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CN(CCCN)C(=O)c1cc(-c2ccncc2)n2ncnc(N)c12		CHEMBL3681215	=	IC50	nM	5900.0	CHEMBL3629	Homo sapiens	IC50	nM	5900.0
279024	16303197	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CCNc1nc(Nc2cc(C#N)cc(N3CCN(CC(F)F)CC3)c2Cl)nn2c(C#N)cnc12		CHEMBL3699303	=	IC50	nM	1.39	CHEMBL3629	Homo sapiens	IC50	nM	1.39
278974	16303482	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC1CCN(C2CN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C1		CHEMBL3699253	=	IC50	nM	0.21	CHEMBL3629	Homo sapiens	IC50	nM	0.21
278969	16303601	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(N(CC3CC3)CC3CC3)CC2)c1		CHEMBL3699248	=	IC50	nM	91.56	CHEMBL3629	Homo sapiens	IC50	nM	91.56
278986	16304447	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(C2CCN(CCC(F)(F)F)CC2)c1		CHEMBL3699265	=	IC50	nM	5.87	CHEMBL3629	Homo sapiens	IC50	nM	5.87
278959	16305516	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCN(C3CCOC3)CC2)c1		CHEMBL3699238	=	IC50	nM	0.29	CHEMBL3629	Homo sapiens	IC50	nM	0.29
279003	16307528	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(N4CC[C@H](NC(=O)OC)[C@@H](O)C4)c3Cl)nn12		CHEMBL3699282	=	IC50	nM	0.52	CHEMBL3629	Homo sapiens	IC50	nM	0.52
257617	16308096	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](OCC(C)(C)C)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681209	=	IC50	nM	150.0	CHEMBL3629	Homo sapiens	IC50	nM	150.0
257610	16308955	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)C(C)(C)O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681202	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
278961	16309619	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N1CCC(N2CCN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)CC1		CHEMBL3699240	=	IC50	nM	1.35	CHEMBL3629	Homo sapiens	IC50	nM	1.35
279000	16309710	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CCN(C5COC5)C(C(=O)N5CCOCC5)C4)c3Cl)nn12		CHEMBL3699279	=	IC50	nM	1.4	CHEMBL3629	Homo sapiens	IC50	nM	1.4
257608	16309834	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](NC(=O)C4(CN)CC4)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681200	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
257626	16312514	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)Oc1cc(-c2cc(C(=O)NC3CCC(N)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681218	=	IC50	nM	5800.0	CHEMBL3629	Homo sapiens	IC50	nM	5800.0
257627	16312834	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccnc(CCO)c3)cc(C(=O)NC3CCC(N)CC3)c12		CHEMBL3681219	=	IC50	nM	2100.0	CHEMBL3629	Homo sapiens	IC50	nM	2100.0
279002	16313008	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C#N)cc(N4CC[C@@H](NC(=O)OC)[C@H](O)C4)c3Cl)nn12		CHEMBL3699281	=	IC50	nM	4.71	CHEMBL3629	Homo sapiens	IC50	nM	4.71
278973	16313106	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CS(=O)(=O)C1CCN(C2CN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C1		CHEMBL3699252	=	IC50	nM	0.24	CHEMBL3629	Homo sapiens	IC50	nM	0.24
278970	16314813	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COCCNC1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699249	=	IC50	nM	20.88	CHEMBL3629	Homo sapiens	IC50	nM	20.88
278955	16315846	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	Cn1nc(C#N)c2cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)ccc21		CHEMBL3699234	=	IC50	nM	0.15	CHEMBL3629	Homo sapiens	IC50	nM	0.15
278965	16315850	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NC3CCS(=O)(=O)C3)CC2)c1		CHEMBL3699244	=	IC50	nM	0.22	CHEMBL3629	Homo sapiens	IC50	nM	0.22
279025	16317052	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3nc(C#N)ncc3Cl)nn12		CHEMBL3699304	=	IC50	nM	23.09	CHEMBL3629	Homo sapiens	IC50	nM	23.09
279022	16318874	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1C(C)(C)CC(Oc2cc(OC3CC(C)(C)N(C)C(C)(C)C3)c(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)cc2C#N)CC1(C)C		CHEMBL3699301	=	IC50	nM	60.08	CHEMBL3629	Homo sapiens	IC50	nM	60.08
278998	16319030	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@@H]1F		CHEMBL3699277	=	IC50	nM	0.14	CHEMBL3629	Homo sapiens	IC50	nM	0.14
257619	16319839	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(C)(C)C(OC(N)=O)C1CCN(C(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)C1		CHEMBL3681211	=	IC50	nM	2200.0	CHEMBL3629	Homo sapiens	IC50	nM	2200.0
278960	16320538	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	C[C@@H](O)CN1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699239	=	IC50	nM	0.3	CHEMBL3629	Homo sapiens	IC50	nM	0.3
278980	16321235	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CC[C@@H](NC(=O)OC3COC3)[C@H](O)C2)c1		CHEMBL3699259	=	IC50	nM	1.36	CHEMBL3629	Homo sapiens	IC50	nM	1.36
257602	16321873	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CC(=O)NC1CCC(NC(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1		CHEMBL3681197	=	IC50	nM	170.0	CHEMBL3629	Homo sapiens	IC50	nM	170.0
278956	16324418	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(O)C2)c1		CHEMBL3699235	=	IC50	nM	0.17	CHEMBL3629	Homo sapiens	IC50	nM	0.17
278966	16324564	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NC3CC(C#N)C3)CC2)c1		CHEMBL3699245	=	IC50	nM	1.56	CHEMBL3629	Homo sapiens	IC50	nM	1.56
279015	16324679	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	C=Cc1cc(C#N)cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c1Cl		CHEMBL3699294	=	IC50	nM	0.23	CHEMBL3629	Homo sapiens	IC50	nM	0.23
278987	16326215	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CC(=O)N1CCC(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)CC1		CHEMBL3699266	=	IC50	nM	0.21	CHEMBL3629	Homo sapiens	IC50	nM	0.21
257606	16326359	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccncc3)cc(C(=O)NC3CCOCC3)c12		CHEMBL3681198	=	IC50	nM	170.0	CHEMBL3629	Homo sapiens	IC50	nM	170.0
257605	16326407	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccncc3)cc(C(=O)NCCc3ccccn3)c12		CHEMBL3681222	=	IC50	nM	150.0	CHEMBL3629	Homo sapiens	IC50	nM	150.0
279008	16326944	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CC(N5CCN(C)CC5)C4)c3F)nn12		CHEMBL3699287	=	IC50	nM	0.39	CHEMBL3629	Homo sapiens	IC50	nM	0.39
257609	16327631	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@@H]3CCCN(C(=O)C4(N)CC4)C3)c3c(N)ncnn23)ccn1		CHEMBL3681201	=	IC50	nM	40.0	CHEMBL3629	Homo sapiens	IC50	nM	40.0
278963	16327762	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CCC(NC5CC(F)(F)C5)CC4)c3Cl)nn12		CHEMBL3699242	=	IC50	nM	1.37	CHEMBL3629	Homo sapiens	IC50	nM	1.37
257603	16333622	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CCOC(=O)N[C@H]1CC[C@H](NC(=O)c2cc(-c3ccncc3)n3ncnc(N)c23)CC1		CHEMBL3681195	=	IC50	nM	190.0	CHEMBL3629	Homo sapiens	IC50	nM	190.0
257620	16335892	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N3CCC(O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681212	=	IC50	nM	1700.0	CHEMBL3629	Homo sapiens	IC50	nM	1700.0
279016	16336019	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(CO)c(Cl)c(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c1		CHEMBL3699295	=	IC50	nM	0.16	CHEMBL3629	Homo sapiens	IC50	nM	0.16
278982	16338290	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1OC		CHEMBL3699261	=	IC50	nM	220.1	CHEMBL3629	Homo sapiens	IC50	nM	220.1
278997	16339326	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@@H]1CCN(c2cc(C#N)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1OP(=O)(O)O		CHEMBL3699276	=	IC50	nM	0.27	CHEMBL3629	Homo sapiens	IC50	nM	0.27
278991	16339503	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC1CN(C2CN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C2)C1		CHEMBL3699270	=	IC50	nM	9.61	CHEMBL3629	Homo sapiens	IC50	nM	9.61
278999	16339775	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NC3CC3)nc(Nc3cc(C#N)cc(N4CCN(C5COC5)CC(F)C4)c3Cl)nn12		CHEMBL3699278	=	IC50	nM	0.29	CHEMBL3629	Homo sapiens	IC50	nM	0.29
278967	16340468	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(N2CCC(NCC(F)(F)F)CC2)c1		CHEMBL3699246	=	IC50	nM	29.89	CHEMBL3629	Homo sapiens	IC50	nM	29.89
279010	16341045	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(Nc3nc(C)n(C)n3)nc(Nc3ccc4c(c3)c(C#N)nn4C)nn12		CHEMBL3699289	=	IC50	nM	0.13	CHEMBL3629	Homo sapiens	IC50	nM	0.13
257599	16341504	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CCOC(=O)NC1CCC(NC(=O)c2cc(-c3ccnc(OC)c3)n3ncnc(N)c23)CC1		CHEMBL3681194	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
278989	16341884	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	COC(=O)N[C@H]1CN(c2cc(C(F)F)cc(Nc3nc(NC4CC4)c4ncc(C#N)n4n3)c2Cl)C[C@H]1OC		CHEMBL3699268	=	IC50	nM	3.83	CHEMBL3629	Homo sapiens	IC50	nM	3.83
257604	16343346	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	Nc1ncnn2c(-c3ccncc3)cc(C(=O)N[C@H]3CC[C@@H](O)CC3)c12		CHEMBL3681220	=	IC50	nM	290.0	CHEMBL3629	Homo sapiens	IC50	nM	290.0
278990	16343457	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CC(N2CCN(c3cc(C(F)F)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)CC2)C1		CHEMBL3699269	=	IC50	nM	1.5	CHEMBL3629	Homo sapiens	IC50	nM	1.5
279009	16346502	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	[C-]#[N+]c1cnc2c(NCC)nc(Nc3cc(C(F)F)cc(N4CCN(C5COC5)CC4)c3Cl)nn12		CHEMBL3699288	=	IC50	nM	8.0	CHEMBL3629	Homo sapiens	IC50	nM	8.0
257611	16347690	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@@H](CO)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681203	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
257624	16350538	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](O)CC3)c3c(N)ncnn23)ccc1C(N)=O		CHEMBL3681216	=	IC50	nM	2300.0	CHEMBL3629	Homo sapiens	IC50	nM	2300.0
257615	16350992	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	CCN1CCCC1CNC(=O)[C@H]1CC[C@H](NC(=O)c2cc(-c3ccnc(OC)c3)n3ncnc(N)c23)CC1		CHEMBL3681207	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
278981	16352812	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	CN1CCN(CC(=O)N[C@@H]2CCN(c3cc(C#N)cc(Nc4nc(NC5CC5)c5ncc(C#N)n5n4)c3Cl)C[C@H]2O)CC1		CHEMBL3699260	=	IC50	nM	1.37	CHEMBL3629	Homo sapiens	IC50	nM	1.37
278985	16353731	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(C2CCN(C3CC(CO)(CO)C3)CC2)c1		CHEMBL3699264	=	IC50	nM	1.34	CHEMBL3629	Homo sapiens	IC50	nM	1.34
278958	16354685	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cc(Nc2nc(NC3CC3)c3ncc(C#N)n3n2)c(Cl)c(NN2CCOCC2)c1		CHEMBL3699237	=	IC50	nM	0.23	CHEMBL3629	Homo sapiens	IC50	nM	0.23
257613	16355329	CHEMBL3705455	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates. Incorporation of radioactive phosphate into the peptide substrate was determined.	B	COc1cc(-c2cc(C(=O)N[C@H]3CC[C@H](C(=O)O)CC3)c3c(N)ncnn23)ccn1		CHEMBL3681205	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
278993	16355447	CHEMBL3706079	Kinase Assay: The effectiveness of compounds of the present invention as inhibitors of protein kinases can be readily tested by assays known to those skilled in the art. For example, in vitro protein kinase assays may be conducted with a relevant purified protein kinase and an appropriate synthetic substrate to determine the inhibitory activity of the compounds. Assays for inhibition of CK2 by the instant compounds were performed in 384-well plates with reaction mixtures containing 10 uM of peptide substrate (RRRADDSDDDDD-NH2), [gamma-33P]ATP (10 uCi) at 25 uM (CK2A1) or 5 uM (CK2A2), 20 mM Hepes (pH 7.4), 100 mM NaCl, 10 mM MgCl2, 0.25 mM dithiothreitol, Brij-35 at 0.015%, and recombinant CK2A1 (10 nM, Invitrogen) or CK2A2 (5 nM, Upstate Biotechnology). Reaction mixtures were incubated at 30 C. for 1 hour, and reaction products were captured by binding to phosphocellulose (P81) filter plates.	B	N#Cc1cnc2c(NC3CC3)nc(Nc3cc(C(F)F)cc(N4CCN(C5(C#N)COC5)CC4)c3Cl)nn12		CHEMBL3699272	=	IC50	nM	15.25	CHEMBL3629	Homo sapiens	IC50	nM	15.25
	16425292	CHEMBL3751092	Inhibition of CK2 alpha1 (unknown origin) at 1 uM	B	Cc1c(-c2cc(Nc3cc4n(n3)CCN(C)C4)c(=O)[nH]n2)ccc(F)c1NC(=O)c1cc2ccccc2s1		CHEMBL3746293	=	Inhibition	%	0.8	CHEMBL3629	Homo sapiens	INH	%	0.8
	16428146	CHEMBL3748818	Inhibition of CSNK2A1 (unknown origin)	B	CCc1cc2c(cc1-c1cnn(CCCN(C)C)c1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL3746678	<	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	uM	10.0
	16428147	CHEMBL3748818	Inhibition of CSNK2A1 (unknown origin)	B	CCc1cc2c(cc1-c1cnn(CC(=O)N(C)C)c1)C(C)(C)c1[nH]c3cc(C#N)ccc3c1C2=O		CHEMBL3735401	<	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	uM	10.0
	16431786	CHEMBL3748990	Inhibition of human CK2alpha using as [RRRDDDSDDD] substrate	B	Cn1c(=O)c(S(=O)(=O)c2ccc(F)cc2F)cc2cnc(Nc3ccc4[nH]ccc4c3)nc21		CHEMBL3745885	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	uM	10.0
	16445217	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	1030.0	CHEMBL3629	Homo sapiens	Ki	uM	1.03
	16445218	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	Cc1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL3754770	=	Ki	nM	1110.0	CHEMBL3629	Homo sapiens	Ki	uM	1.11
	16445219	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	N#CCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL3752778	=	Ki	nM	1270.0	CHEMBL3629	Homo sapiens	Ki	uM	1.27
	16445220	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	Cc1nc2c(Br)c(Br)c(Br)c(Br)c2n1CC#N		CHEMBL3753027	=	Ki	nM	1630.0	CHEMBL3629	Homo sapiens	Ki	uM	1.63
	16445221	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	N#CCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL3753482	=	Ki	nM	2770.0	CHEMBL3629	Homo sapiens	Ki	uM	2.77
	16445222	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	Cc1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCC#N		CHEMBL3754483	=	Ki	nM	5030.0	CHEMBL3629	Homo sapiens	Ki	uM	5.03
	16445223	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	N#CCCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL3751963	=	Ki	nM	2490.0	CHEMBL3629	Homo sapiens	Ki	uM	2.49
	16445224	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	Cc1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCCC#N		CHEMBL3753165	=	Ki	nM	1420.0	CHEMBL3629	Homo sapiens	Ki	uM	1.42
	16445225	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	N#CCCCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21		CHEMBL3753068	=	Ki	nM	2510.0	CHEMBL3629	Homo sapiens	Ki	uM	2.51
	16445226	CHEMBL3755571	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate peptide by scintillation counter in presence of [32P]ATP	B	Cc1nc2c(Br)c(Br)c(Br)c(Br)c2n1CCCCC#N		CHEMBL3751908	=	Ki	nM	2420.0	CHEMBL3629	Homo sapiens	Ki	uM	2.42
	16450793	CHEMBL3762311	Inhibition of CK2alpha1 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	1.4	CHEMBL3629	Homo sapiens	INH	%	1.4
	16450794	CHEMBL3762312	Inhibition of CK2alpha2 (unknown origin) at 100 nM	B	CC1(C)OCc2c(Nc3n[nH]c4ccccc34)nc(-c3cn[nH]c3)nc21		CHEMBL3758502	=	Inhibition	%	4.2	CHEMBL3629	Homo sapiens	INH	%	4.2
	16463676	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccn3)s2)cc1		CHEMBL3758606	=	IC50	nM	15.0	CHEMBL3629	Homo sapiens	IC50	uM	0.015
	16463677	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3C#N)s2)cc1		CHEMBL3759349	=	IC50	nM	16.0	CHEMBL3629	Homo sapiens	IC50	uM	0.016
	16463678	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3OC)s2)cc1		CHEMBL3758895	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	uM	0.014
	16463679	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3Br)s2)cc1		CHEMBL3758777	=	IC50	nM	17.0	CHEMBL3629	Homo sapiens	IC50	uM	0.017
	16463680	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3F)s2)cc1		CHEMBL3759871	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	uM	0.014
	16463681	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccc(Cl)cc3)s2)cc1		CHEMBL3759193	=	IC50	nM	26.0	CHEMBL3629	Homo sapiens	IC50	uM	0.026
	16463682	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3cccc(Cl)c3)s2)cc1		CHEMBL3759388	=	IC50	nM	330.0	CHEMBL3629	Homo sapiens	IC50	uM	0.33
	16463683	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3Cl)s2)cc1		CHEMBL3759512	=	IC50	nM	16.0	CHEMBL3629	Homo sapiens	IC50	uM	0.016
	16463684	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCCc3ccccc3)s2)cc1		CHEMBL3760009	=	IC50	nM	15.0	CHEMBL3629	Homo sapiens	IC50	uM	0.015
	16463685	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3COc3ccccc3)s2)cc1		CHEMBL3760064	=	IC50	nM	28.0	CHEMBL3629	Homo sapiens	IC50	uM	0.028
	16463686	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3OCc3ccccc3)s2)cc1		CHEMBL3758270	=	IC50	nM	19.0	CHEMBL3629	Homo sapiens	IC50	uM	0.019
	16463687	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3Oc3ccccc3)s2)cc1		CHEMBL3758519	=	IC50	nM	15.0	CHEMBL3629	Homo sapiens	IC50	uM	0.015
	16463688	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)c4ccccc34)s2)cc1		CHEMBL3758475	=	IC50	nM	1300.0	CHEMBL3629	Homo sapiens	IC50	uM	1.3
	16463689	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)nn3)s2)cc1		CHEMBL3758317	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	uM	0.014
	16463690	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cn3)s2)cc1		CHEMBL3759755	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	uM	0.014
	16463691	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)nc3)s2)cc1		CHEMBL3760043	=	IC50	nM	17.0	CHEMBL3629	Homo sapiens	IC50	uM	0.017
	16463692	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	uM	0.02
	16463693	CHEMBL3760460	Inhibition of GST-tagged human CK2alpha (1 to 391 residues) using CK2tide as substrate incubated for 1 hr by off-chip mobility shift assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	19.0	CHEMBL3629	Homo sapiens	IC50	uM	0.019
	16474684	CHEMBL3767170	Inhibition of CK2alpha (unknown origin) at 10 uM	B	CN1CCN(CCCOc2ccc(N3C(=O)/C(=C/c4ccc(Oc5ccc(F)cc5)cc4)SC3=S)cc2)CC1		CHEMBL3765499	=	Inhibition	%	0.0	CHEMBL3629	Homo sapiens	INH	%	0.0
	16495370	CHEMBL3778350	Inhibition of N-terminal His6-tagged recombinant human CK2alpha2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CCOCC5)cc34)cc2)cn1		CHEMBL3774885	=	Activity	%	7.0	CHEMBL3629	Homo sapiens	Activity	%	7.0
	16508139	CHEMBL3778350	Inhibition of N-terminal His6-tagged recombinant human CK2alpha2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	CNC(=O)c1ccc2[nH]nc(Cc3ccc4c(cnn4C)c3)c2c1		CHEMBL3775576	=	Activity	%	6.0	CHEMBL3629	Homo sapiens	Activity	%	6.0
	16509116	CHEMBL3778350	Inhibition of N-terminal His6-tagged recombinant human CK2alpha2 expressed in baculovirus infected insect Sf9 cells assessed as remaining activity at 1 uM relative to control	B	Cn1cc(-c2ccc(Cc3n[nH]c4ccc(C(=O)N5CC[C@@H](O)C5)cc34)cc2)cn1		CHEMBL3775317	=	Activity	%	4.0	CHEMBL3629	Homo sapiens	Activity	%	4.0
	16548621	CHEMBL3796659	Competitive inhibition of human wild type CK2alpha by Dixon plot analysis	B	CS(=O)(=O)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL3793598	=	Ki	nM	150.0	CHEMBL3629	Homo sapiens	Ki	uM	0.15
	16548622	CHEMBL3796658	Inhibition of human wild type CK2alpha	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	45.0	CHEMBL3629	Homo sapiens	Ki	uM	0.045
	16548623	CHEMBL3796658	Inhibition of human wild type CK2alpha	B	S=c1[nH]c2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL608394	=	Ki	nM	70.0	CHEMBL3629	Homo sapiens	Ki	uM	0.07
	16548630	CHEMBL3796660	Inhibition of CK2alpha (unknown origin)	B	FC(F)(F)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL227370	=	Ki	nM	400.0	CHEMBL3629	Homo sapiens	Ki	uM	0.4
	16548631	CHEMBL3796659	Competitive inhibition of human wild type CK2alpha by Dixon plot analysis	B	Clc1c(Cl)c(I)c2[nH]cnc2c1I		CHEMBL595953	=	Ki	nM	300.0	CHEMBL3629	Homo sapiens	Ki	uM	0.3
	16548632	CHEMBL3796659	Competitive inhibition of human wild type CK2alpha by Dixon plot analysis	B	Cc1nc2c(I)c(Cl)c(Cl)c(I)c2[nH]1		CHEMBL592970	=	Ki	nM	200.0	CHEMBL3629	Homo sapiens	Ki	uM	0.2
	16578335	CHEMBL3804389	Inhibition of full length wild type human CSNK2A1 expressed in mammalian system assessed as enzyme activity at 1 uM relative to control	B	CN(C)S(=O)(=O)Nc1ccc(F)c(Nc2ncccc2-c2ncnc3[nH]cnc23)c1F		CHEMBL3798256	=	Activity	%	64.0	CHEMBL3629	Homo sapiens	Activity	%	64.0
	16596831	CHEMBL3812036	Inhibition of full-length human CSNK2A2 expressed in mammalian system assessed as remaining enzyme activity at 1 uM by KINOMEscan assay	B	Cc1nc2cccc3c2nc1N[C@H](C)/C=C\C[C@H]1CNC(=O)c2cc-3[nH]c21		CHEMBL3809691	<	Activity	%	10.0	CHEMBL3629	Homo sapiens	Activity	%	10.0
	16596834	CHEMBL3812477	Inhibition of full-length human CSNK2A1 expressed in mammalian system assessed as remaining enzyme activity at 1 uM by KINOMEscan assay	B	Cc1nc2cccc3c2nc1N[C@H](C)/C=C\C[C@H]1CNC(=O)c2cc-3[nH]c21		CHEMBL3809691	<	Activity	%	10.0	CHEMBL3629	Homo sapiens	Activity	%	10.0
	16604885	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)C[C@H](C)N		CHEMBL3809915	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604886	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)C[C@@H](C)N		CHEMBL3809024	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604887	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CCC[C@@H](N)C1		CHEMBL3808817	=	IC50	nM	5.0	CHEMBL3629	Homo sapiens	IC50	uM	0.005
	16604888	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CCC[C@H](N)C1		CHEMBL3809526	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604889	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CC[C@@H](N)C1		CHEMBL3809288	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604890	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CC[C@H](N)C1		CHEMBL3810252	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604891	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CCC[C@@H](N(C)C)C1		CHEMBL3808583	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	uM	0.004
	16604892	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CC[C@H](N(C)C)C1		CHEMBL3808911	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	uM	0.006
	16604893	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CCN(CCN)c1ccc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)cc1NC(C)=O		CHEMBL3808860	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604894	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN		CHEMBL3103192	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604895	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCCN(C)C		CHEMBL3810318	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	uM	0.006
	16604896	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1NCCCO		CHEMBL3809011	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16604897	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN1CC(F)(F)C1		CHEMBL3809094	=	IC50	nM	13.0	CHEMBL3629	Homo sapiens	IC50	uM	0.013
	16606673	CHEMBL3810721	Binding affinity to His-tagged recombinant human CK2alpha assessed as dissociation rate	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN	Non standard unit for type	CHEMBL3103192	=	Kd	/s	0.00025	CHEMBL3629	Homo sapiens	Kd	/s	0.00025
	16606712	CHEMBL3810691	Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN	Outside typical range	CHEMBL3103192	=	Kd	nM	0.00633	CHEMBL3629	Homo sapiens	Kd	pM	6.33
	16606713	CHEMBL3810691	Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN(C)C		CHEMBL3103191	=	Kd	nM	0.0482	CHEMBL3629	Homo sapiens	Kd	pM	48.2
	16606714	CHEMBL3810691	Binding affinity to His-tagged recombinant human CK2alpha (6 to 335 residues) after 50 to 116.7 mins by surface plasmon resonance assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C	Outside typical range	CHEMBL2409175	=	Kd	nM	0.00491	CHEMBL3629	Homo sapiens	Kd	pM	4.91
	16606752	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN1CCOCC1		CHEMBL3810020	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16606753	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CCN(CC)CCN(C)c1ccc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)cc1NC(C)=O		CHEMBL3809620	=	IC50	nM	9.0	CHEMBL3629	Homo sapiens	IC50	uM	0.009
	16606754	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N(C)CCN(C)C		CHEMBL3103191	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16606755	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1N1CCN(C)CC1		CHEMBL3809764	=	IC50	nM	41.0	CHEMBL3629	Homo sapiens	IC50	uM	0.041
	16606756	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409175	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	16606757	CHEMBL3811873	Inhibition of full length N-terminal 6xHis-tagged recombinant human CK2alpha expressed in fall armyworm Sf21 cells using BODIPY-FL-RRRDDDSDDD-CONH2 as substrate after 90 mins by mobility shift assay	B	CC(=O)Nc1cccc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)c1		CHEMBL3808764	=	IC50	nM	9.0	CHEMBL3629	Homo sapiens	IC50	uM	0.009
	16611883	CHEMBL3816738	Inhibition of human CK2alpha (2 to 391 residues) assessed as enzyme activity at 1 uM using 33P ATP by radioactive filter binding assay	B	Nc1nccc(-c2c[nH]c3ncccc23)n1		CHEMBL405665	=	Activity	%	-3.0	CHEMBL3629	Homo sapiens	Activity	%	-3.0
	16614432	CHEMBL3817298	Inhibition of human CK2alpha at 1 uM using as [RRRDDDSDDD] substrate	B	CNS(=O)(=O)c1ccc(N(C)C)c(Nc2ncnc3cc(OC)c(OC)cc23)c1		CHEMBL3815093	=	Inhibition	%	6.0	CHEMBL3629	Homo sapiens	INH	%	6.0
	16618256	CHEMBL3817068	Inhibition of full length recombinant human GST-tagged CK2alpha2 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	16618257	CHEMBL3817067	Inhibition of full length recombinant human His-tagged CK2alpha1 expressed in baculovirus expression system at 1 uM relative to control	B	CC1(C)OCCn2c1nc1c(N3CCOCC3)nc(-c3cnc(N)nc3)nc12		CHEMBL3813842	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	16632828	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	COc1ccc(C(=O)Nc2ncc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087023	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	uM	0.02
	16632829	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	O=C(Nc1n[nH]c2cccc(F)c12)c1ccc2c(c1)CCO2		CHEMBL3823658	>	IC50	nM	200000.0	CHEMBL3629	Homo sapiens	IC50	uM	200.0
	16632830	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	NC(=O)Cc1csc(NC(=O)c2n[nH]c3ccccc23)n1		CHEMBL3823403	=	IC50	nM	520.0	CHEMBL3629	Homo sapiens	IC50	uM	0.52
	16632831	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	Cc1cc2cc(NC(=O)c3n[nH]c4ccccc34)ccc2[nH]1		CHEMBL3823750	>	IC50	nM	200000.0	CHEMBL3629	Homo sapiens	IC50	uM	200.0
	16632832	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	O=C(Nc1ccc2c(c1)OCCO2)c1n[nH]c2ccccc12		CHEMBL3823241	=	IC50	nM	15200.0	CHEMBL3629	Homo sapiens	IC50	uM	15.2
	16632833	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	CCc1nnc(-c2cccc(NC(=O)c3n[nH]c4ccccc34)c2)o1		CHEMBL3823560	>	IC50	nM	200000.0	CHEMBL3629	Homo sapiens	IC50	uM	200.0
	16632834	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	CS(=O)(=O)Cc1cc(NC(=O)c2n[nH]c3ccccc23)ccc1Cl		CHEMBL3823802	=	IC50	nM	20000.0	CHEMBL3629	Homo sapiens	IC50	uM	20.0
	16632835	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	Cc1ccc(NC(=O)c2n[nH]c3ccccc23)cc1NS(C)(=O)=O		CHEMBL3823253	=	IC50	nM	11500.0	CHEMBL3629	Homo sapiens	IC50	uM	11.5
	16632836	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	CS(=O)(=O)c1cccc(NC(=O)c2n[nH]c3ccccc23)c1		CHEMBL3824310	=	IC50	nM	10900.0	CHEMBL3629	Homo sapiens	IC50	uM	10.9
	16632837	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	CS(=O)(=O)Nc1ccc(NC(=O)c2n[nH]c3ccccc23)cc1		CHEMBL3824125	=	IC50	nM	16100.0	CHEMBL3629	Homo sapiens	IC50	uM	16.1
	16632838	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	O=C(Nc1cccc(NC(=O)C2CC2)c1)c1n[nH]c2ccccc12		CHEMBL3823185	=	IC50	nM	102600.0	CHEMBL3629	Homo sapiens	IC50	uM	102.6
	16632839	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	NC(=O)Cc1cccc(NC(=O)c2n[nH]c3ccccc23)c1		CHEMBL3823073	=	IC50	nM	16900.0	CHEMBL3629	Homo sapiens	IC50	uM	16.9
	16632840	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	Cc1ccc(NC(=O)c2n[nH]c3ccc([N+](=O)[O-])cc23)cc1S(N)(=O)=O		CHEMBL3823680	=	IC50	nM	79300.0	CHEMBL3629	Homo sapiens	IC50	uM	79.3
	16632841	CHEMBL3824787	Inhibition of human CK2alpha (2 to 391 residues) using [33P]-ATP by scintillation counting based radioactive filter binding assay	B	O=C(Nc1ccccc1)c1n[nH]c2ccc([N+](=O)[O-])cc12		CHEMBL3822582	>	IC50	nM	200000.0	CHEMBL3629	Homo sapiens	IC50	uM	200.0
	16777161	CHEMBL3864823	Competitive binding affinity to full length wild type human CSNK2A1 expressed in mammalian expression system at 10 uM by kinomescan method relative to control	B	C[C@@H]1C[C@H](N)CN(c2ccncc2Nc2ncc3ccc(-c4c(F)cccc4F)nn23)C1		CHEMBL3942186	=	Activity	%	4.2	CHEMBL3629	Homo sapiens	Activity	%	4.2
	16837430	CHEMBL3876074	Inhibition of human recombinant full length His-tagged CSNK2A1 expressed in baculovirus expression system	B	CC1(C)C(=O)N([C@H]2CCc3c(O)cccc32)c2nc(Nc3ccccc3)ncc21		CHEMBL3884319	=	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
	16896860	CHEMBL3882347	Inhibition of human CK2alpha assessed as residual activity using RRRDDDSDDD as substrate in presence of [gamma-33P]-ATP	B	Cc1ccc(N/C=C2\C(=O)CCc3c2oc2c(Cl)c(Cl)c(O)cc32)cc1		CHEMBL3920024	=	Activity	%	24.0	CHEMBL3629	Homo sapiens	Activity	%	24.0
213405	17602784	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	N#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700520	=	IC50	nM	10660.0	CHEMBL3629	Homo sapiens	IC50	nM	10660.0
308857	17689493	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=c1[nH]c2cc(-c3nnn[nH]3)ccc2c2ccccc12		CHEMBL3696943	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	nM	2000.0
308858	17689494	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)[nH]c(=O)c1ccncc12		CHEMBL3696944	=	IC50	nM	180.0	CHEMBL3629	Homo sapiens	IC50	nM	180.0
308859	17689495	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)[nH]c(=O)c1ccncc12		CHEMBL3696945	=	IC50	nM	2500.0	CHEMBL3629	Homo sapiens	IC50	nM	2500.0
308860	17689496	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2ccccc12		CHEMBL3696946	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
308861	17689497	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccccc12		CHEMBL1652693	=	IC50	nM	1600.0	CHEMBL3629	Homo sapiens	IC50	nM	1600.0
308862	17689498	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL1652697	=	IC50	nM	13.0	CHEMBL3629	Homo sapiens	IC50	nM	13.0
308863	17689499	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(OCCCO)c1ccsc12		CHEMBL1652715	=	IC50	nM	1200.0	CHEMBL3629	Homo sapiens	IC50	nM	1200.0
308864	17689500	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Cl)c1ccsc12		CHEMBL3696947	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
308865	17689501	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(NCCCO)c1ccc2c(c1)nc(NCCCO)c1ccsc12		CHEMBL3696948	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
308866	17689502	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCCO)c1ccsc12		CHEMBL1652716	=	IC50	nM	670.0	CHEMBL3629	Homo sapiens	IC50	nM	670.0
308867	17689503	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCO)c1ccsc12		CHEMBL3700381	=	IC50	nM	1100.0	CHEMBL3629	Homo sapiens	IC50	nM	1100.0
308868	17689504	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700382	=	IC50	nM	270.0	CHEMBL3629	Homo sapiens	IC50	nM	270.0
308869	17689505	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccccn1)c1ccsc12		CHEMBL3700383	=	IC50	nM	950.0	CHEMBL3629	Homo sapiens	IC50	nM	950.0
308870	17689506	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccsc12		CHEMBL3700384	=	IC50	nM	320.0	CHEMBL3629	Homo sapiens	IC50	nM	320.0
308871	17689507	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1cccnc1)c1ccsc12		CHEMBL3700385	=	IC50	nM	900.0	CHEMBL3629	Homo sapiens	IC50	nM	900.0
308872	17689508	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCN1CCOCC1)c1ccsc12		CHEMBL3700386	=	IC50	nM	1220.0	CHEMBL3629	Homo sapiens	IC50	nM	1220.0
308873	17689509	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccncc1)c1ccsc12		CHEMBL3700387	=	IC50	nM	430.0	CHEMBL3629	Homo sapiens	IC50	nM	430.0
308874	17689510	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccccc1Nc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700388	=	IC50	nM	550.0	CHEMBL3629	Homo sapiens	IC50	nM	550.0
308875	17689511	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(O)c1)c1ccsc12		CHEMBL3700389	=	IC50	nM	350.0	CHEMBL3629	Homo sapiens	IC50	nM	350.0
308876	17689512	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c(OC)c1		CHEMBL3700390	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	nM	2000.0
308877	17689513	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Clc1nc2ccccc2c2sccc12		CHEMBL3700391	>	IC50	nM	5000.0	CHEMBL3629	Homo sapiens	IC50	nM	5000.0
308878	17689514	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700392	=	IC50	nM	190.0	CHEMBL3629	Homo sapiens	IC50	nM	190.0
308879	17689515	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(c1ccccc1)c1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700393	=	IC50	nM	1500.0	CHEMBL3629	Homo sapiens	IC50	nM	1500.0
308880	17689516	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)cc1)c1ccsc12		CHEMBL3700394	=	IC50	nM	310.0	CHEMBL3629	Homo sapiens	IC50	nM	310.0
308881	17689517	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccsc12		CHEMBL3700395	=	IC50	nM	150.0	CHEMBL3629	Homo sapiens	IC50	nM	150.0
308882	17689518	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1ccccc1Nc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700396	=	IC50	nM	1100.0	CHEMBL3629	Homo sapiens	IC50	nM	1100.0
308883	17689519	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3639992	=	IC50	nM	120.0	CHEMBL3629	Homo sapiens	IC50	nM	120.0
308884	17689520	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(Cl)cc1)c1ccsc12		CHEMBL3700397	=	IC50	nM	210.0	CHEMBL3629	Homo sapiens	IC50	nM	210.0
308885	17689521	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)cc1F)c1ccsc12		CHEMBL3700398	=	IC50	nM	670.0	CHEMBL3629	Homo sapiens	IC50	nM	670.0
308886	17689522	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1ccsc12		CHEMBL3700399	=	IC50	nM	970.0	CHEMBL3629	Homo sapiens	IC50	nM	970.0
308887	17689523	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(N1CCc3ccccc31)c1ccsc12		CHEMBL3700400	=	IC50	nM	580.0	CHEMBL3629	Homo sapiens	IC50	nM	580.0
308888	17689524	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)cc1Cl		CHEMBL3700401	=	IC50	nM	430.0	CHEMBL3629	Homo sapiens	IC50	nM	430.0
308889	17689525	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1O)c1ccsc12		CHEMBL3700402	=	IC50	nM	820.0	CHEMBL3629	Homo sapiens	IC50	nM	820.0
308890	17689526	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(N3CCOCC3)cc1)c1ccsc12		CHEMBL3700403	=	IC50	nM	1170.0	CHEMBL3629	Homo sapiens	IC50	nM	1170.0
308891	17689527	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(OC)c(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700404	=	IC50	nM	430.0	CHEMBL3629	Homo sapiens	IC50	nM	430.0
308892	17689528	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)[nH]c(=O)c1ccsc12		CHEMBL1652711	=	IC50	nM	4000.0	CHEMBL3629	Homo sapiens	IC50	nM	4000.0
308893	17689529	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c3sccc3c(=O)n(CCCO)c2c1		CHEMBL1652714	=	IC50	nM	2800.0	CHEMBL3629	Homo sapiens	IC50	nM	2800.0
308894	17689530	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=c1[nH]c2cc(-c3nn[nH]n3)ccc2c2sccc12		CHEMBL3700405	=	IC50	nM	900.0	CHEMBL3629	Homo sapiens	IC50	nM	900.0
308895	17689531	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCn1c(=O)c2ccsc2c2ccc(C(=O)O)cc21		CHEMBL3700406	=	IC50	nM	12500.0	CHEMBL3629	Homo sapiens	IC50	nM	12500.0
308902	17689538	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL1652697	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
308903	17689539	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2cnccc12		CHEMBL1652698	=	IC50	nM	25.0	CHEMBL3629	Homo sapiens	IC50	nM	25.0
308904	17689540	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)cc1		CHEMBL3700407	=	IC50	nM	70.0	CHEMBL3629	Homo sapiens	IC50	nM	70.0
308905	17689541	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(-c3nnn[nH]3)ccc2c2cnccc12		CHEMBL3700408	=	IC50	nM	311.0	CHEMBL3629	Homo sapiens	IC50	nM	311.0
308906	17689542	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL3700409	=	IC50	nM	113.0	CHEMBL3629	Homo sapiens	IC50	nM	113.0
308907	17689543	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL1652706	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	nM	4.0
308908	17689544	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccncc12		CHEMBL1652707	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	nM	4.0
308909	17689545	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccncc12		CHEMBL3700410	=	IC50	nM	1469.0	CHEMBL3629	Homo sapiens	IC50	nM	1469.0
308910	17689546	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1cccc(OC)c1)c1ccncc12		CHEMBL3700411	=	IC50	nM	25000.0	CHEMBL3629	Homo sapiens	IC50	nM	25000.0
308911	17689547	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ncncc12		CHEMBL1682280	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
308912	17689548	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ccncc12		CHEMBL1652708	=	IC50	nM	5.0	CHEMBL3629	Homo sapiens	IC50	nM	5.0
308913	17689549	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCc1ccccc1)c1ccncc12		CHEMBL1652704	=	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
308914	17689550	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12	Potential transcription error	CHEMBL1230165	=	IC50	nM	2.0	CHEMBL3629	Homo sapiens	IC50	nM	2.0
308915	17689551	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Cl)c1ncncc12		CHEMBL3700412	=	IC50	nM	651.0	CHEMBL3629	Homo sapiens	IC50	nM	651.0
308916	17689552	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1ncncc12		CHEMBL1682281	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
308917	17689553	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ncncc12		CHEMBL1682282	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
308918	17689554	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ncncc12		CHEMBL1649770	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	nM	7.0
308919	17689555	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cncnc23)c1		CHEMBL1682283	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
308920	17689556	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)c1		CHEMBL3700413	=	IC50	nM	47.0	CHEMBL3629	Homo sapiens	IC50	nM	47.0
308921	17689557	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)ccc1Cl		CHEMBL3700414	=	IC50	nM	52.0	CHEMBL3629	Homo sapiens	IC50	nM	52.0
308922	17689558	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNc1ncc2c(n1)c(Nc1ccccc1)nc1cc(C(=O)O)ccc12		CHEMBL3700415	=	IC50	nM	19.0	CHEMBL3629	Homo sapiens	IC50	nM	19.0
308923	17689559	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(Cl)cc1)c1ccncc12		CHEMBL1652710	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	nM	7.0
308924	17689560	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL1652737	=	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
308925	17689561	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Clc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)c1		CHEMBL1652742	=	IC50	nM	45.0	CHEMBL3629	Homo sapiens	IC50	nM	45.0
308926	17689562	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccccc1)c1ccncc12		CHEMBL1652703	=	IC50	nM	9.0	CHEMBL3629	Homo sapiens	IC50	nM	9.0
308927	17689563	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCc1cccc(Cl)c1)c1ccncc12		CHEMBL3700416	=	IC50	nM	5.0	CHEMBL3629	Homo sapiens	IC50	nM	5.0
308928	17689564	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCc1cccc(F)c1)c1ccncc12		CHEMBL3700417	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	nM	7.0
308929	17689565	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCCc1ccccc1)c1ccncc12		CHEMBL1652705	=	IC50	nM	16.0	CHEMBL3629	Homo sapiens	IC50	nM	16.0
308930	17689566	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1ccncc12		CHEMBL3700418	=	IC50	nM	5.0	CHEMBL3629	Homo sapiens	IC50	nM	5.0
308931	17689567	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	N#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL1652738	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	nM	4.0
308932	17689568	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1649759	>	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	nM	500.0
308933	17689569	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(SC)ncc12		CHEMBL3700419	>	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	nM	500.0
308934	17689570	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(S(C)(=O)=O)ncc12		CHEMBL3700420	>	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	nM	500.0
308935	17689571	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNc1ncc2c(n1)c(Nc1ccccc1)nc1cc(C(=O)OC)ccc12		CHEMBL3700421	>	IC50	nM	500.0	CHEMBL3629	Homo sapiens	IC50	nM	500.0
308936	17689572	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	OCc1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1649760	=	IC50	nM	711.0	CHEMBL3629	Homo sapiens	IC50	nM	711.0
308937	17689573	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNc1ncc2c(n1)c(Nc1ccccc1)nc1cc(C(=O)O)ccc12		CHEMBL3700415	=	IC50	nM	18.0	CHEMBL3629	Homo sapiens	IC50	nM	18.0
308938	17689574	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(NC3CC3)ncc12		CHEMBL1682293	=	IC50	nM	27.0	CHEMBL3629	Homo sapiens	IC50	nM	27.0
308939	17689575	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCCNc1ncc2c(n1)c(Nc1ccccc1)nc1cc(C(=O)O)ccc12		CHEMBL3700422	=	IC50	nM	51.0	CHEMBL3629	Homo sapiens	IC50	nM	51.0
308940	17689576	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COCCNc1ncc2c(n1)c(Nc1ccccc1)nc1cc(C(=O)O)ccc12		CHEMBL3700423	=	IC50	nM	69.0	CHEMBL3629	Homo sapiens	IC50	nM	69.0
308941	17689577	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(NCCO)ncc12		CHEMBL3700424	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
308942	17689578	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(NCCCO)ncc12		CHEMBL3700425	=	IC50	nM	26.0	CHEMBL3629	Homo sapiens	IC50	nM	26.0
308943	17689579	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(NC3CCNCC3)ncc12		CHEMBL3700426	=	IC50	nM	56.0	CHEMBL3629	Homo sapiens	IC50	nM	56.0
308944	17689580	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCN(CC)CCNc1ncc2c(n1)c(Nc1ccccc1)nc1cc(C(=O)O)ccc12		CHEMBL3700427	=	IC50	nM	163.0	CHEMBL3629	Homo sapiens	IC50	nM	163.0
308945	17689581	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(NCCN3CCOCC3)ncc12		CHEMBL3700428	=	IC50	nM	107.0	CHEMBL3629	Homo sapiens	IC50	nM	107.0
308946	17689582	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(NCCCN3CCOCC3)ncc12		CHEMBL3700429	=	IC50	nM	89.0	CHEMBL3629	Homo sapiens	IC50	nM	89.0
308947	17689583	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NC4CC4)nc23)c1		CHEMBL1682296	=	IC50	nM	46.0	CHEMBL3629	Homo sapiens	IC50	nM	46.0
308948	17689584	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCC)nc23)c1		CHEMBL3700430	=	IC50	nM	60.0	CHEMBL3629	Homo sapiens	IC50	nM	60.0
308949	17689585	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCOC)nc23)c1		CHEMBL3700431	=	IC50	nM	40.0	CHEMBL3629	Homo sapiens	IC50	nM	40.0
308950	17689586	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NC4CCNCC4)nc23)c1		CHEMBL3700432	=	IC50	nM	144.0	CHEMBL3629	Homo sapiens	IC50	nM	144.0
308951	17689587	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCCN4CCOCC4)nc23)c1		CHEMBL3700433	=	IC50	nM	250.0	CHEMBL3629	Homo sapiens	IC50	nM	250.0
308952	17689588	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NC)nc23)c1		CHEMBL3700434	=	IC50	nM	9.0	CHEMBL3629	Homo sapiens	IC50	nM	9.0
308953	17689589	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(Cl)c(C(F)(F)F)c1)c1ccncc12		CHEMBL3700435	=	IC50	nM	18.0	CHEMBL3629	Homo sapiens	IC50	nM	18.0
308954	17689590	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1nc(NC3CC3)ncc12		CHEMBL1682292	=	IC50	nM	13.0	CHEMBL3629	Homo sapiens	IC50	nM	13.0
308955	17689591	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1ncncc12		CHEMBL1682285	=	IC50	nM	11.0	CHEMBL3629	Homo sapiens	IC50	nM	11.0
308956	17689592	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCOc1ncc2c(n1)c(Nc1cccc(C(F)(F)F)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682298	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308957	17689593	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682288	=	IC50	nM	18.0	CHEMBL3629	Homo sapiens	IC50	nM	18.0
308958	17689594	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)c1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682289	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308959	17689595	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Nc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682287	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	nM	4.0
308960	17689596	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(C)Nc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682291	=	IC50	nM	134.0	CHEMBL3629	Homo sapiens	IC50	nM	134.0
308961	17689597	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL1682297	=	IC50	nM	9.0	CHEMBL3629	Homo sapiens	IC50	nM	9.0
308962	17689598	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCNc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682290	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	nM	30.0
308963	17689599	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700436	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
308964	17689600	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Nc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700437	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	nM	7.0
308965	17689601	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1nc(NC3CC3)ncc12		CHEMBL3700438	=	IC50	nM	83.0	CHEMBL3629	Homo sapiens	IC50	nM	83.0
308966	17689602	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COCCNc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700439	=	IC50	nM	52.0	CHEMBL3629	Homo sapiens	IC50	nM	52.0
308967	17689603	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCOCC)nc23)c1		CHEMBL3700440	=	IC50	nM	171.0	CHEMBL3629	Homo sapiens	IC50	nM	171.0
308968	17689604	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCCOCC)nc23)c1		CHEMBL3700441	=	IC50	nM	107.0	CHEMBL3629	Homo sapiens	IC50	nM	107.0
308969	17689605	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCCOC(C)C)nc23)c1		CHEMBL3700442	=	IC50	nM	349.0	CHEMBL3629	Homo sapiens	IC50	nM	349.0
308970	17689606	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCC4CCCO4)nc23)c1		CHEMBL3700443	=	IC50	nM	114.0	CHEMBL3629	Homo sapiens	IC50	nM	114.0
308971	17689607	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCC4CC4)nc23)c1		CHEMBL3700444	=	IC50	nM	50.0	CHEMBL3629	Homo sapiens	IC50	nM	50.0
308972	17689608	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1nc(O)ncc12		CHEMBL3700445	=	IC50	nM	214.0	CHEMBL3629	Homo sapiens	IC50	nM	214.0
308973	17689609	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682286	=	IC50	nM	172.0	CHEMBL3629	Homo sapiens	IC50	nM	172.0
308974	17689610	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)OC)ccc3c3cnc(NOC)nc23)c1		CHEMBL3700446	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308975	17689611	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1nc(NCCC(N)=O)ncc12		CHEMBL3700447	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308976	17689612	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(NC1CC1)c1nc(SCc3ccccc3Cl)ncc12		CHEMBL3700448	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308977	17689613	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	NC(=O)CCNc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700449	=	IC50	nM	28.0	CHEMBL3629	Homo sapiens	IC50	nM	28.0
308978	17689614	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)CCNc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700450	=	IC50	nM	21.0	CHEMBL3629	Homo sapiens	IC50	nM	21.0
308979	17689615	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(SCc3ccccc3Cl)ncc12		CHEMBL3700451	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308980	17689616	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCOc1ncc2c(n1)c(NC1CC1)nc1cc(C(=O)O)ccc12		CHEMBL3700452	=	IC50	nM	493.0	CHEMBL3629	Homo sapiens	IC50	nM	493.0
308981	17689617	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(NC3CC3)ncc12		CHEMBL3700453	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
308982	17689618	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(NCc3ccccc3)ncc12		CHEMBL3700454	=	IC50	nM	59.0	CHEMBL3629	Homo sapiens	IC50	nM	59.0
308983	17689619	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(Nc3ccccc3)ncc12		CHEMBL3700455	=	IC50	nM	26.0	CHEMBL3629	Homo sapiens	IC50	nM	26.0
308984	17689620	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cncc(C3CC3)c1)c1ccncc12		CHEMBL3700456	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308985	17689621	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL3700457	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
308986	17689622	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1ccncc12		CHEMBL3700458	=	IC50	nM	11.0	CHEMBL3629	Homo sapiens	IC50	nM	11.0
308987	17689623	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1nc(NC3CC3)ncc12		CHEMBL3700459	=	IC50	nM	102.0	CHEMBL3629	Homo sapiens	IC50	nM	102.0
308988	17689624	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1nc(NC3CC3)ncc12		CHEMBL1682295	=	IC50	nM	86.0	CHEMBL3629	Homo sapiens	IC50	nM	86.0
308989	17689625	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NC4CC4)nc23)c1		CHEMBL3700460	=	IC50	nM	134.0	CHEMBL3629	Homo sapiens	IC50	nM	134.0
308990	17689626	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1cccnc1)c1nc(NC3CC3)ncc12		CHEMBL3700461	=	IC50	nM	18.0	CHEMBL3629	Homo sapiens	IC50	nM	18.0
308991	17689627	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccccc1)c1nc(NC3CC3)ncc12		CHEMBL3700462	=	IC50	nM	35.0	CHEMBL3629	Homo sapiens	IC50	nM	35.0
308992	17689628	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(N1CCOCC1)c1nc(NC3CC3)ncc12		CHEMBL3700463	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308993	17689629	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700464	=	IC50	nM	168.0	CHEMBL3629	Homo sapiens	IC50	nM	168.0
308994	17689630	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC1CCCCN1CCCNc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700465	=	IC50	nM	686.0	CHEMBL3629	Homo sapiens	IC50	nM	686.0
308995	17689631	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1nc(NCc3ccccn3)ncc12		CHEMBL3700466	=	IC50	nM	356.0	CHEMBL3629	Homo sapiens	IC50	nM	356.0
308996	17689632	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(CNc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12)OC		CHEMBL3700467	=	IC50	nM	103.0	CHEMBL3629	Homo sapiens	IC50	nM	103.0
308997	17689633	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL1682297	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308998	17689634	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(NC1CC1)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL3700468	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
308999	17689635	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNC(=O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL3700469	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
309000	17689636	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1cc(Nc2ncc3c(n2)c(Nc2ccc(F)c(Cl)c2)nc2cc(C(=O)O)ccc23)[nH]n1		CHEMBL3700470	=	IC50	nM	513.0	CHEMBL3629	Homo sapiens	IC50	nM	513.0
309001	17689637	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1nc(NCc3cccnc3)ncc12		CHEMBL3700471	=	IC50	nM	27.0	CHEMBL3629	Homo sapiens	IC50	nM	27.0
309002	17689638	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1nc(Nc3ccccc3)ncc12		CHEMBL1682301	=	IC50	nM	185.0	CHEMBL3629	Homo sapiens	IC50	nM	185.0
309003	17689639	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1ccncc12		CHEMBL1652701	=	IC50	nM	16.0	CHEMBL3629	Homo sapiens	IC50	nM	16.0
309004	17689640	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(C)OC(=O)Nc1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL3700472	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
309005	17689641	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(NC1CC1)c1nc(SC)ncc12		CHEMBL3700473	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
309006	17689642	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2cnc(NC3CC3)nc12		CHEMBL3700474	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
309007	17689643	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Nc1ncc2c(n1)c(NC1CC1)nc1cc(C(=O)O)ccc12		CHEMBL3700475	=	IC50	nM	23.0	CHEMBL3629	Homo sapiens	IC50	nM	23.0
309008	17689644	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCCNc1ncc2c(n1)c(NC1CC1)nc1cc(C(=O)O)ccc12		CHEMBL3700476	=	IC50	nM	15.0	CHEMBL3629	Homo sapiens	IC50	nM	15.0
309009	17689645	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNc1ncc2c(n1)c(NC1CC1)nc1cc(C(=O)O)ccc12		CHEMBL3700477	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	nM	14.0
309010	17689646	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)c1ncc2c(n1)c(NC1CC1)nc1cc(C(=O)O)ccc12		CHEMBL3700478	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
309011	17689647	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(N)=O)ccc3c3cncnc23)c1		CHEMBL1682284	=	IC50	nM	87.0	CHEMBL3629	Homo sapiens	IC50	nM	87.0
309012	17689648	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(=O)Nc1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL3700479	>	IC50	nM	750.0	CHEMBL3629	Homo sapiens	IC50	nM	750.0
309013	17689649	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Nc1ncc2c(n1)c(Nc1cccc(C(F)(F)F)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700480	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	nM	14.0
309014	17689650	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(NCc3ccncc3)ncc12		CHEMBL3700481	=	IC50	nM	93.0	CHEMBL3629	Homo sapiens	IC50	nM	93.0
309015	17689651	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(NCCO)ncc12		CHEMBL3700482	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
309016	17689652	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(NCc3ccccn3)ncc12		CHEMBL3700483	=	IC50	nM	35.0	CHEMBL3629	Homo sapiens	IC50	nM	35.0
309017	17689653	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(NCCc3ccccc3)ncc12		CHEMBL3700484	=	IC50	nM	33.0	CHEMBL3629	Homo sapiens	IC50	nM	33.0
309018	17689654	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(C)Nc1ncc2c(n1)c(NC1CC1)nc1cc(C(=O)O)ccc12		CHEMBL3700485	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
309019	17689655	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1nc(Nc3cccc(C(F)(F)F)c3)ncc12		CHEMBL3700486	=	IC50	nM	198.0	CHEMBL3629	Homo sapiens	IC50	nM	198.0
309020	17689656	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(OCCCO)c1ccsc12		CHEMBL1652715	=	IC50	nM	995.0	CHEMBL3629	Homo sapiens	IC50	nM	995.0
309021	17689657	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCCO)c1ccsc12		CHEMBL1652716	=	IC50	nM	748.0	CHEMBL3629	Homo sapiens	IC50	nM	748.0
309022	17689658	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCO)c1ccsc12		CHEMBL3700381	=	IC50	nM	1258.0	CHEMBL3629	Homo sapiens	IC50	nM	1258.0
309023	17689659	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700382	=	IC50	nM	102.0	CHEMBL3629	Homo sapiens	IC50	nM	102.0
309024	17689660	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccccn1)c1ccsc12		CHEMBL3700383	=	IC50	nM	622.0	CHEMBL3629	Homo sapiens	IC50	nM	622.0
309025	17689661	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccsc12		CHEMBL3700384	=	IC50	nM	92.0	CHEMBL3629	Homo sapiens	IC50	nM	92.0
309026	17689662	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1cccnc1)c1ccsc12		CHEMBL3700385	=	IC50	nM	367.0	CHEMBL3629	Homo sapiens	IC50	nM	367.0
309027	17689663	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCN1CCOCC1)c1ccsc12		CHEMBL3700386	=	IC50	nM	922.0	CHEMBL3629	Homo sapiens	IC50	nM	922.0
309028	17689664	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccncc1)c1ccsc12		CHEMBL3700387	=	IC50	nM	168.0	CHEMBL3629	Homo sapiens	IC50	nM	168.0
309029	17689665	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccccc1Nc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700388	=	IC50	nM	171.0	CHEMBL3629	Homo sapiens	IC50	nM	171.0
309030	17689666	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(O)c1)c1ccsc12		CHEMBL3700389	=	IC50	nM	507.0	CHEMBL3629	Homo sapiens	IC50	nM	507.0
309031	17689667	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c(OC)c1		CHEMBL3700390	=	IC50	nM	771.0	CHEMBL3629	Homo sapiens	IC50	nM	771.0
309032	17689668	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCN1CCCC1)c1ccsc12		CHEMBL3700487	=	IC50	nM	231.0	CHEMBL3629	Homo sapiens	IC50	nM	231.0
309033	17689669	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCc1ccccc1)c1ccsc12		CHEMBL3700488	=	IC50	nM	516.0	CHEMBL3629	Homo sapiens	IC50	nM	516.0
309034	17689670	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700392	=	IC50	nM	96.0	CHEMBL3629	Homo sapiens	IC50	nM	96.0
309035	17689671	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)cc1)c1ccsc12		CHEMBL3700394	=	IC50	nM	219.0	CHEMBL3629	Homo sapiens	IC50	nM	219.0
309036	17689672	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(N1CCc3ccccc31)c1ccsc12		CHEMBL3700400	=	IC50	nM	320.0	CHEMBL3629	Homo sapiens	IC50	nM	320.0
309037	17689673	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)cc1Cl		CHEMBL3700401	=	IC50	nM	131.0	CHEMBL3629	Homo sapiens	IC50	nM	131.0
309038	17689674	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1O)c1ccsc12		CHEMBL3700402	=	IC50	nM	257.0	CHEMBL3629	Homo sapiens	IC50	nM	257.0
309039	17689675	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(N3CCOCC3)cc1)c1ccsc12		CHEMBL3700403	=	IC50	nM	666.0	CHEMBL3629	Homo sapiens	IC50	nM	666.0
309040	17689676	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(OC)c(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700404	=	IC50	nM	238.0	CHEMBL3629	Homo sapiens	IC50	nM	238.0
309041	17689677	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(-c3nnn[nH]3)ccc2c2sccc12		CHEMBL3700489	=	IC50	nM	252.0	CHEMBL3629	Homo sapiens	IC50	nM	252.0
309042	17689678	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700490	=	IC50	nM	371.0	CHEMBL3629	Homo sapiens	IC50	nM	371.0
309043	17689679	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1Cl		CHEMBL3700491	=	IC50	nM	194.0	CHEMBL3629	Homo sapiens	IC50	nM	194.0
309044	17689680	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700492	=	IC50	nM	172.0	CHEMBL3629	Homo sapiens	IC50	nM	172.0
309045	17689681	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Clc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700493	=	IC50	nM	233.0	CHEMBL3629	Homo sapiens	IC50	nM	233.0
309046	17689682	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1Cl		CHEMBL3700494	=	IC50	nM	256.0	CHEMBL3629	Homo sapiens	IC50	nM	256.0
309047	17689683	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(OC)c(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700495	=	IC50	nM	358.0	CHEMBL3629	Homo sapiens	IC50	nM	358.0
309048	17689684	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	FC(F)(F)Oc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3639993	=	IC50	nM	611.0	CHEMBL3629	Homo sapiens	IC50	nM	611.0
309049	17689685	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(C)Oc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700496	=	IC50	nM	420.0	CHEMBL3629	Homo sapiens	IC50	nM	420.0
309050	17689686	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc(OC)c1		CHEMBL3700497	=	IC50	nM	348.0	CHEMBL3629	Homo sapiens	IC50	nM	348.0
309051	17689687	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)ccc1F		CHEMBL3700498	=	IC50	nM	812.0	CHEMBL3629	Homo sapiens	IC50	nM	812.0
309052	17689688	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	FC(F)(F)c1cccc(Nc2nc3cc(C4=NNNN4)ccc3c3sccc23)c1		CHEMBL3700499	=	IC50	nM	458.0	CHEMBL3629	Homo sapiens	IC50	nM	458.0
309053	17689689	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	OCc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700500	=	IC50	nM	154.0	CHEMBL3629	Homo sapiens	IC50	nM	154.0
309054	17689690	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Clc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700501	=	IC50	nM	129.0	CHEMBL3629	Homo sapiens	IC50	nM	129.0
309055	17689691	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700502	=	IC50	nM	171.0	CHEMBL3629	Homo sapiens	IC50	nM	171.0
309056	17689692	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	NS(=O)(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700503	=	IC50	nM	198.0	CHEMBL3629	Homo sapiens	IC50	nM	198.0
309057	17689693	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(=O)Nc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700504	=	IC50	nM	485.0	CHEMBL3629	Homo sapiens	IC50	nM	485.0
309058	17689694	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Brc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700505	=	IC50	nM	122.0	CHEMBL3629	Homo sapiens	IC50	nM	122.0
309059	17689695	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700506	=	IC50	nM	75.0	CHEMBL3629	Homo sapiens	IC50	nM	75.0
309060	17689696	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700507	=	IC50	nM	235.0	CHEMBL3629	Homo sapiens	IC50	nM	235.0
309061	17689697	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCOc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700508	=	IC50	nM	346.0	CHEMBL3629	Homo sapiens	IC50	nM	346.0
309062	17689698	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700509	=	IC50	nM	358.0	CHEMBL3629	Homo sapiens	IC50	nM	358.0
309063	17689699	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1cc2c(Nc3ccc4c(c3)OCCO4)nc3cc(-c4nnn[nH]4)ccc3c2s1		CHEMBL3700510	=	IC50	nM	290.0	CHEMBL3629	Homo sapiens	IC50	nM	290.0
309064	17689700	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700511	=	IC50	nM	135.0	CHEMBL3629	Homo sapiens	IC50	nM	135.0
309065	17689701	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1ccsc12		CHEMBL3700512	=	IC50	nM	70.0	CHEMBL3629	Homo sapiens	IC50	nM	70.0
309066	17689702	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ccsc12		CHEMBL3700513	=	IC50	nM	68.0	CHEMBL3629	Homo sapiens	IC50	nM	68.0
309067	17689703	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccsc12		CHEMBL3700514	=	IC50	nM	32.0	CHEMBL3629	Homo sapiens	IC50	nM	32.0
309068	17689704	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(Cl)ccc1F)c1ccsc12		CHEMBL3700515	=	IC50	nM	70.0	CHEMBL3629	Homo sapiens	IC50	nM	70.0
309069	17689705	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCOc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700516	=	IC50	nM	126.0	CHEMBL3629	Homo sapiens	IC50	nM	126.0
309070	17689706	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Oc3ccccc3)c1)c1ccsc12		CHEMBL3700517	=	IC50	nM	395.0	CHEMBL3629	Homo sapiens	IC50	nM	395.0
309071	17689707	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNC(=O)c1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700518	=	IC50	nM	129.0	CHEMBL3629	Homo sapiens	IC50	nM	129.0
309072	17689708	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	NS(=O)(=O)c1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700519	=	IC50	nM	103.0	CHEMBL3629	Homo sapiens	IC50	nM	103.0
309073	17689709	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	N#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700520	=	IC50	nM	81.0	CHEMBL3629	Homo sapiens	IC50	nM	81.0
309074	17689710	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700521	=	IC50	nM	28.0	CHEMBL3629	Homo sapiens	IC50	nM	28.0
309075	17689711	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCCNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700522	=	IC50	nM	380.0	CHEMBL3629	Homo sapiens	IC50	nM	380.0
309076	17689712	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1)N1CCOCC1		CHEMBL3700523	=	IC50	nM	502.0	CHEMBL3629	Homo sapiens	IC50	nM	502.0
309077	17689713	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700524	=	IC50	nM	549.0	CHEMBL3629	Homo sapiens	IC50	nM	549.0
309078	17689714	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)CNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700525	=	IC50	nM	240.0	CHEMBL3629	Homo sapiens	IC50	nM	240.0
309079	17689715	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(NCc1cccnc1)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700526	=	IC50	nM	363.0	CHEMBL3629	Homo sapiens	IC50	nM	363.0
309080	17689716	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)C(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700527	=	IC50	nM	318.0	CHEMBL3629	Homo sapiens	IC50	nM	318.0
309081	17689717	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(NC1CC1)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700528	=	IC50	nM	237.0	CHEMBL3629	Homo sapiens	IC50	nM	237.0
309082	17689718	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1cc(CNC(=O)c2cccc(Nc3nc4cc(-c5nnn[nH]5)ccc4c4sccc34)c2)no1		CHEMBL3700529	=	IC50	nM	288.0	CHEMBL3629	Homo sapiens	IC50	nM	288.0
309083	17689719	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COCCNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700530	=	IC50	nM	251.0	CHEMBL3629	Homo sapiens	IC50	nM	251.0
309084	17689720	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(=O)N1CCN(C(=O)c2cccc(Nc3nc4cc(-c5nnn[nH]5)ccc4c4sccc34)c2)CC1		CHEMBL3700531	=	IC50	nM	303.0	CHEMBL3629	Homo sapiens	IC50	nM	303.0
309085	17689721	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCCNC(=O)c1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700532	=	IC50	nM	224.0	CHEMBL3629	Homo sapiens	IC50	nM	224.0
309086	17689722	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(=O)N3CCOCC3)c1)c1ccsc12		CHEMBL3700533	=	IC50	nM	307.0	CHEMBL3629	Homo sapiens	IC50	nM	307.0
309087	17689723	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)CNC(=O)c1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700534	=	IC50	nM	192.0	CHEMBL3629	Homo sapiens	IC50	nM	192.0
309088	17689724	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNC(=O)c1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700535	=	IC50	nM	366.0	CHEMBL3629	Homo sapiens	IC50	nM	366.0
309089	17689725	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(=O)NC3CC3)c1)c1ccsc12		CHEMBL3700536	=	IC50	nM	221.0	CHEMBL3629	Homo sapiens	IC50	nM	221.0
309090	17689726	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNC(=O)Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700537	=	IC50	nM	137.0	CHEMBL3629	Homo sapiens	IC50	nM	137.0
309091	17689727	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Br)c1)c1ccsc12		CHEMBL3700538	=	IC50	nM	187.0	CHEMBL3629	Homo sapiens	IC50	nM	187.0
309092	17689728	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1F)c1ccsc12		CHEMBL3700539	=	IC50	nM	335.0	CHEMBL3629	Homo sapiens	IC50	nM	335.0
309093	17689729	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc3[nH]ccc3c1)c1ccsc12		CHEMBL3700540	=	IC50	nM	156.0	CHEMBL3629	Homo sapiens	IC50	nM	156.0
309094	17689730	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700541	=	IC50	nM	90.0	CHEMBL3629	Homo sapiens	IC50	nM	90.0
309095	17689731	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc3cc[nH]c3c1)c1ccsc12		CHEMBL3700542	=	IC50	nM	121.0	CHEMBL3629	Homo sapiens	IC50	nM	121.0
309096	17689732	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNS(=O)(=O)c1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700543	=	IC50	nM	281.0	CHEMBL3629	Homo sapiens	IC50	nM	281.0
309097	17689733	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1ccsc12		CHEMBL3700544	=	IC50	nM	61.0	CHEMBL3629	Homo sapiens	IC50	nM	61.0
309098	17689734	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700545	=	IC50	nM	242.0	CHEMBL3629	Homo sapiens	IC50	nM	242.0
309099	17689735	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(I)c1)c1ccsc12		CHEMBL3700546	=	IC50	nM	91.0	CHEMBL3629	Homo sapiens	IC50	nM	91.0
309100	17689736	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1F)c1ccsc12		CHEMBL3700547	=	IC50	nM	256.0	CHEMBL3629	Homo sapiens	IC50	nM	256.0
309101	17689737	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(C(F)(F)F)c1)c1ccsc12		CHEMBL3700548	=	IC50	nM	156.0	CHEMBL3629	Homo sapiens	IC50	nM	156.0
309102	17689738	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1cc(F)cc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700549	=	IC50	nM	127.0	CHEMBL3629	Homo sapiens	IC50	nM	127.0
309103	17689739	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)ccc1F)c1ccsc12		CHEMBL3700550	=	IC50	nM	138.0	CHEMBL3629	Homo sapiens	IC50	nM	138.0
309104	17689740	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(S(=O)(=O)NC3CC3)c1)c1ccsc12		CHEMBL3700551	=	IC50	nM	116.0	CHEMBL3629	Homo sapiens	IC50	nM	116.0
309105	17689741	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(Cl)cc(Cl)c1)c1ccsc12		CHEMBL3700552	=	IC50	nM	35.0	CHEMBL3629	Homo sapiens	IC50	nM	35.0
309106	17689742	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(F)c1)c1ccsc12		CHEMBL3700553	=	IC50	nM	127.0	CHEMBL3629	Homo sapiens	IC50	nM	127.0
309107	17689743	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(Cl)c1)c1ccsc12		CHEMBL3700554	=	IC50	nM	76.0	CHEMBL3629	Homo sapiens	IC50	nM	76.0
309108	17689744	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	N#Cc1cc(F)cc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700555	=	IC50	nM	131.0	CHEMBL3629	Homo sapiens	IC50	nM	131.0
309109	17689745	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1cc(Cl)cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700556	=	IC50	nM	289.0	CHEMBL3629	Homo sapiens	IC50	nM	289.0
309110	17689746	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700557	=	IC50	nM	141.0	CHEMBL3629	Homo sapiens	IC50	nM	141.0
309111	17689747	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1cc(F)cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700558	=	IC50	nM	204.0	CHEMBL3629	Homo sapiens	IC50	nM	204.0
309112	17689748	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ncsc12		CHEMBL3700561	=	IC50	nM	169.0	CHEMBL3629	Homo sapiens	IC50	nM	169.0
309113	17689749	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3scnc23)c1		CHEMBL3700562	=	IC50	nM	37.0	CHEMBL3629	Homo sapiens	IC50	nM	37.0
309114	17689750	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ncsc12		CHEMBL3700563	=	IC50	nM	120.0	CHEMBL3629	Homo sapiens	IC50	nM	120.0
309115	17689751	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ncsc12		CHEMBL3700564	=	IC50	nM	146.0	CHEMBL3629	Homo sapiens	IC50	nM	146.0
309116	17689752	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3scnc23)c1		CHEMBL3700565	=	IC50	nM	44.0	CHEMBL3629	Homo sapiens	IC50	nM	44.0
309117	17689753	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL1652697	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
309118	17689754	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2cnccc12		CHEMBL1652698	=	IC50	nM	19.0	CHEMBL3629	Homo sapiens	IC50	nM	19.0
309119	17689755	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)cc1		CHEMBL3700407	=	IC50	nM	60.0	CHEMBL3629	Homo sapiens	IC50	nM	60.0
309120	17689756	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(-c3nnn[nH]3)ccc2c2cnccc12		CHEMBL3700408	=	IC50	nM	130.0	CHEMBL3629	Homo sapiens	IC50	nM	130.0
309121	17689757	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL3700409	=	IC50	nM	200.0	CHEMBL3629	Homo sapiens	IC50	nM	200.0
309122	17689758	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL1652706	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	nM	7.0
309123	17689759	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccncc12		CHEMBL1652707	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	nM	6.0
309124	17689760	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COC(=O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccncc12		CHEMBL3700410	=	IC50	nM	1661.0	CHEMBL3629	Homo sapiens	IC50	nM	1661.0
309125	17689761	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(OCCCO)c1ccsc12		CHEMBL1652715	=	IC50	nM	1200.0	CHEMBL3629	Homo sapiens	IC50	nM	1200.0
309126	17689762	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCCO)c1ccsc12		CHEMBL1652716	=	IC50	nM	670.0	CHEMBL3629	Homo sapiens	IC50	nM	670.0
309127	17689763	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCO)c1ccsc12		CHEMBL3700381	=	IC50	nM	1100.0	CHEMBL3629	Homo sapiens	IC50	nM	1100.0
309128	17689764	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700382	=	IC50	nM	277.0	CHEMBL3629	Homo sapiens	IC50	nM	277.0
309129	17689765	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccccn1)c1ccsc12		CHEMBL3700383	=	IC50	nM	872.0	CHEMBL3629	Homo sapiens	IC50	nM	872.0
309130	17689766	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccsc12		CHEMBL3700384	=	IC50	nM	310.0	CHEMBL3629	Homo sapiens	IC50	nM	310.0
309131	17689767	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1cccnc1)c1ccsc12		CHEMBL3700385	=	IC50	nM	900.0	CHEMBL3629	Homo sapiens	IC50	nM	900.0
309132	17689768	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCN1CCOCC1)c1ccsc12		CHEMBL3700386	=	IC50	nM	1220.0	CHEMBL3629	Homo sapiens	IC50	nM	1220.0
309133	17689769	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCc1ccncc1)c1ccsc12		CHEMBL3700387	=	IC50	nM	518.0	CHEMBL3629	Homo sapiens	IC50	nM	518.0
309134	17689770	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccccc1Nc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700388	=	IC50	nM	550.0	CHEMBL3629	Homo sapiens	IC50	nM	550.0
309135	17689771	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(O)c1)c1ccsc12		CHEMBL3700389	=	IC50	nM	369.0	CHEMBL3629	Homo sapiens	IC50	nM	369.0
309136	17689772	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c(OC)c1		CHEMBL3700390	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	nM	2000.0
309137	17689773	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCN1CCCC1)c1ccsc12		CHEMBL3700487	=	IC50	nM	280.0	CHEMBL3629	Homo sapiens	IC50	nM	280.0
309138	17689774	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NCCc1ccccc1)c1ccsc12		CHEMBL3700488	=	IC50	nM	1006.0	CHEMBL3629	Homo sapiens	IC50	nM	1006.0
309139	17689775	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700392	=	IC50	nM	189.0	CHEMBL3629	Homo sapiens	IC50	nM	189.0
309140	17689776	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(c1ccccc1)c1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700393	=	IC50	nM	1500.0	CHEMBL3629	Homo sapiens	IC50	nM	1500.0
309141	17689777	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)cc1)c1ccsc12		CHEMBL3700394	=	IC50	nM	310.0	CHEMBL3629	Homo sapiens	IC50	nM	310.0
309142	17689778	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccsc12		CHEMBL3700395	=	IC50	nM	150.0	CHEMBL3629	Homo sapiens	IC50	nM	150.0
309143	17689779	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1ccccc1Nc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700396	=	IC50	nM	1100.0	CHEMBL3629	Homo sapiens	IC50	nM	1100.0
309144	17689780	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3639992	=	IC50	nM	120.0	CHEMBL3629	Homo sapiens	IC50	nM	120.0
309145	17689781	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(Cl)cc1)c1ccsc12		CHEMBL3700397	=	IC50	nM	210.0	CHEMBL3629	Homo sapiens	IC50	nM	210.0
309146	17689782	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)cc1F)c1ccsc12		CHEMBL3700398	=	IC50	nM	670.0	CHEMBL3629	Homo sapiens	IC50	nM	670.0
309147	17689783	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(NC1CC1)c1ccsc12		CHEMBL3700399	=	IC50	nM	970.0	CHEMBL3629	Homo sapiens	IC50	nM	970.0
309148	17689784	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(N1CCc3ccccc31)c1ccsc12		CHEMBL3700400	=	IC50	nM	580.0	CHEMBL3629	Homo sapiens	IC50	nM	580.0
309149	17689785	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)cc1Cl		CHEMBL3700401	=	IC50	nM	430.0	CHEMBL3629	Homo sapiens	IC50	nM	430.0
309150	17689786	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1O)c1ccsc12		CHEMBL3700402	=	IC50	nM	820.0	CHEMBL3629	Homo sapiens	IC50	nM	820.0
309151	17689787	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(N3CCOCC3)cc1)c1ccsc12		CHEMBL3700403	=	IC50	nM	1170.0	CHEMBL3629	Homo sapiens	IC50	nM	1170.0
309152	17689788	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(OC)c(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700404	=	IC50	nM	431.0	CHEMBL3629	Homo sapiens	IC50	nM	431.0
309153	17689789	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CN(C)CCNc1nc2cc(-c3nnn[nH]3)ccc2c2sccc12		CHEMBL3700489	=	IC50	nM	310.0	CHEMBL3629	Homo sapiens	IC50	nM	310.0
309154	17689790	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700490	=	IC50	nM	372.0	CHEMBL3629	Homo sapiens	IC50	nM	372.0
309155	17689791	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1Cl		CHEMBL3700491	=	IC50	nM	382.0	CHEMBL3629	Homo sapiens	IC50	nM	382.0
309156	17689792	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700492	=	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
309157	17689793	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Clc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1		CHEMBL3700493	=	IC50	nM	407.0	CHEMBL3629	Homo sapiens	IC50	nM	407.0
309158	17689794	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc1Cl		CHEMBL3700494	=	IC50	nM	462.0	CHEMBL3629	Homo sapiens	IC50	nM	462.0
309159	17689795	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1ccc(OC)c(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700495	=	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
309160	17689796	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	FC(F)(F)Oc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3639993	=	IC50	nM	392.0	CHEMBL3629	Homo sapiens	IC50	nM	392.0
309161	17689797	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(C)Oc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700496	=	IC50	nM	270.0	CHEMBL3629	Homo sapiens	IC50	nM	270.0
309162	17689798	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)cc(OC)c1		CHEMBL3700497	=	IC50	nM	350.0	CHEMBL3629	Homo sapiens	IC50	nM	350.0
309163	17689799	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	COc1cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)ccc1F		CHEMBL3700498	=	IC50	nM	890.0	CHEMBL3629	Homo sapiens	IC50	nM	890.0
309164	17689800	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	FC(F)(F)c1cccc(Nc2nc3cc(C4=NNNN4)ccc3c3sccc23)c1		CHEMBL3700499	=	IC50	nM	406.0	CHEMBL3629	Homo sapiens	IC50	nM	406.0
309165	17689801	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	OCc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700500	=	IC50	nM	216.0	CHEMBL3629	Homo sapiens	IC50	nM	216.0
309166	17689802	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Clc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700501	=	IC50	nM	181.0	CHEMBL3629	Homo sapiens	IC50	nM	181.0
309167	17689803	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700502	=	IC50	nM	283.0	CHEMBL3629	Homo sapiens	IC50	nM	283.0
309168	17689804	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	NS(=O)(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700503	=	IC50	nM	268.0	CHEMBL3629	Homo sapiens	IC50	nM	268.0
309169	17689805	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CC(=O)Nc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700504	=	IC50	nM	524.0	CHEMBL3629	Homo sapiens	IC50	nM	524.0
309170	17689806	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Brc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700505	=	IC50	nM	140.0	CHEMBL3629	Homo sapiens	IC50	nM	140.0
309171	17689807	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Fc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700506	=	IC50	nM	96.0	CHEMBL3629	Homo sapiens	IC50	nM	96.0
309172	17689808	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Cc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700507	=	IC50	nM	375.0	CHEMBL3629	Homo sapiens	IC50	nM	375.0
309173	17689809	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCOc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700508	=	IC50	nM	423.0	CHEMBL3629	Homo sapiens	IC50	nM	423.0
309174	17689810	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	CCc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700509	=	IC50	nM	509.0	CHEMBL3629	Homo sapiens	IC50	nM	509.0
309175	17689811	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	c1cc2c(Nc3ccc4c(c3)OCCO4)nc3cc(-c4nnn[nH]4)ccc3c2s1		CHEMBL3700510	=	IC50	nM	630.0	CHEMBL3629	Homo sapiens	IC50	nM	630.0
309176	17689812	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)[nH]c(=O)c1ncsc12		CHEMBL3700559	=	IC50	nM	4700.0	CHEMBL3629	Homo sapiens	IC50	nM	4700.0
309177	17689813	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	Nc1nc2c(=O)[nH]c3cc(C(=O)O)ccc3c2s1		CHEMBL3700560	=	IC50	nM	3400.0	CHEMBL3629	Homo sapiens	IC50	nM	3400.0
309178	17689814	CHEMBL3706356	In Vitro Cell-Free Assay: Test compounds in aqueous solution were added at a volume of 10 microliters, to a reaction mixture comprising 10 microliters Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM beta-glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol), 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM), 10 microliters of recombinant human CK2 (25 ng dissolved in ADB; Upstate). Reactions were initiated by the addition of 10 microliters of ATP Solution (90% 75 mM MgCl2, 75 micromolar ATP dissolved in ADB; 10% [gamma-33P]ATP (stock 1 mCi/100 ul; 3000 Ci/mmol (Perkin Elmer) and maintained for 10 minutes at 30 degrees C. The reactions were quenched with 100 microliters of 0.75% phosphoric acid, then transferred to and filtered through a phosphocellulose filter plate (Millipore). After washing each well 5 times with 0.75% phosphoric acid, the plate was dried under vacuum for 5 min.	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ncsc12		CHEMBL3700561	=	IC50	nM	219.0	CHEMBL3629	Homo sapiens	IC50	nM	219.0
309179	17689815	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ncsc12		CHEMBL3700564	=	IC50	nM	25800.0	CHEMBL3629	Homo sapiens	IC50	nM	25800.0
309180	17689816	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1ccsc12		CHEMBL3700512	=	IC50	nM	4338.0	CHEMBL3629	Homo sapiens	IC50	nM	4338.0
309181	17689817	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ccsc12		CHEMBL3700513	=	IC50	nM	3564.0	CHEMBL3629	Homo sapiens	IC50	nM	3564.0
309182	17689818	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	N#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700520	=	IC50	nM	10660.0	CHEMBL3629	Homo sapiens	IC50	nM	10660.0
309183	17689819	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3sccc23)c1		CHEMBL3700521	=	IC50	nM	8360.0	CHEMBL3629	Homo sapiens	IC50	nM	8360.0
309184	17689820	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2sccc12		CHEMBL3700382	=	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	nM	50000.0
309185	17689821	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccsc12		CHEMBL3700384	=	IC50	nM	15700.0	CHEMBL3629	Homo sapiens	IC50	nM	15700.0
309186	17689822	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	c1ccc(Nc2nc3cc(-c4nnc[nH]4)ccc3c3sccc23)cc1		CHEMBL3700566	=	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	nM	50000.0
309187	17689823	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Clc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700501	=	IC50	nM	9590.0	CHEMBL3629	Homo sapiens	IC50	nM	9590.0
309188	17689824	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	CNC(=O)c1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700502	=	IC50	nM	37890.0	CHEMBL3629	Homo sapiens	IC50	nM	37890.0
309189	17689825	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Fc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3sccc23)c1		CHEMBL3700506	=	IC50	nM	4426.0	CHEMBL3629	Homo sapiens	IC50	nM	4426.0
309190	17689826	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(Cl)cc(Cl)c1)c1ccsc12		CHEMBL3700552	=	IC50	nM	580.0	CHEMBL3629	Homo sapiens	IC50	nM	580.0
309191	17689827	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL1652697	=	IC50	nM	7400.0	CHEMBL3629	Homo sapiens	IC50	nM	7400.0
309192	17689828	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	CN(C)CCNc1nc2cc(C(=O)O)ccc2c2cnccc12		CHEMBL1652698	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	nM	50000.0
309193	17689829	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	COC(=O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL3700409	=	IC50	nM	19870.0	CHEMBL3629	Homo sapiens	IC50	nM	19870.0
309194	17689830	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	COc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL1652706	=	IC50	nM	2325.0	CHEMBL3629	Homo sapiens	IC50	nM	2325.0
309195	17689831	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccncc12		CHEMBL1652707	=	IC50	nM	464.0	CHEMBL3629	Homo sapiens	IC50	nM	464.0
309196	17689832	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	COC(=O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ccncc12		CHEMBL3700410	=	IC50	nM	7066.0	CHEMBL3629	Homo sapiens	IC50	nM	7066.0
309197	17689833	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	COC(=O)c1ccc2c(c1)nc(Nc1cccc(OC)c1)c1ccncc12		CHEMBL3700411	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	nM	50000.0
309198	17689834	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	COC(=O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ncncc12		CHEMBL3700567	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	nM	50000.0
309199	17689835	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1ncncc12		CHEMBL1682280	=	IC50	nM	1056.0	CHEMBL3629	Homo sapiens	IC50	nM	1056.0
309200	17689836	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ccncc12		CHEMBL1652708	=	IC50	nM	2933.0	CHEMBL3629	Homo sapiens	IC50	nM	2933.0
309201	17689837	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(NCCc1ccccc1)c1ccncc12		CHEMBL1652704	=	IC50	nM	688.0	CHEMBL3629	Homo sapiens	IC50	nM	688.0
309202	17689838	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	100.0	CHEMBL3629	Homo sapiens	IC50	nM	100.0
309203	17689839	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1ncncc12		CHEMBL1682281	=	IC50	nM	269.0	CHEMBL3629	Homo sapiens	IC50	nM	269.0
309204	17689840	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(F)c1)c1ncncc12		CHEMBL1682282	=	IC50	nM	26.0	CHEMBL3629	Homo sapiens	IC50	nM	26.0
309205	17689841	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cncnc23)c1		CHEMBL1682283	=	IC50	nM	98.0	CHEMBL3629	Homo sapiens	IC50	nM	98.0
309206	17689842	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Fc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)c1		CHEMBL3700413	=	IC50	nM	630.0	CHEMBL3629	Homo sapiens	IC50	nM	630.0
309207	17689843	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Fc1cc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)ccc1Cl		CHEMBL3700414	=	IC50	nM	220.0	CHEMBL3629	Homo sapiens	IC50	nM	220.0
309208	17689844	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(Cl)cc1)c1ccncc12		CHEMBL1652710	=	IC50	nM	17.0	CHEMBL3629	Homo sapiens	IC50	nM	17.0
309209	17689845	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnccc23)c1		CHEMBL1652737	=	IC50	nM	70.0	CHEMBL3629	Homo sapiens	IC50	nM	70.0
309210	17689846	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Clc1cccc(Nc2nc3cc(-c4nnn[nH]4)ccc3c3cnccc23)c1		CHEMBL1652742	=	IC50	nM	1016.0	CHEMBL3629	Homo sapiens	IC50	nM	1016.0
309211	17689847	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(NCCc1cccc(Cl)c1)c1ccncc12		CHEMBL3700416	=	IC50	nM	640.0	CHEMBL3629	Homo sapiens	IC50	nM	640.0
309212	17689848	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(NCCc1cccc(F)c1)c1ccncc12		CHEMBL3700417	=	IC50	nM	3600.0	CHEMBL3629	Homo sapiens	IC50	nM	3600.0
309213	17689849	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(NCCCc1ccccc1)c1ccncc12		CHEMBL1652705	=	IC50	nM	2500.0	CHEMBL3629	Homo sapiens	IC50	nM	2500.0
309214	17689850	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cc(F)cc(F)c1)c1ccncc12		CHEMBL3700418	=	IC50	nM	1351.0	CHEMBL3629	Homo sapiens	IC50	nM	1351.0
309215	17689851	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCOC)nc23)c1		CHEMBL3700431	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
309216	17689852	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1nc(NC3CC3)ncc12		CHEMBL1682292	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
309217	17689853	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1ncncc12		CHEMBL1682285	=	IC50	nM	98.0	CHEMBL3629	Homo sapiens	IC50	nM	98.0
309218	17689854	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Nc1cc2c(Nc3cccc(Cl)c3)nc3cc(C(=O)O)ccc3c2cn1		CHEMBL3703937	=	IC50	nM	44.0	CHEMBL3629	Homo sapiens	IC50	nM	44.0
309219	17689855	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(C(F)(F)F)c1)c1nc(NC3CC3)ncc12		CHEMBL1682297	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
309220	17689856	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	CCNc1ncc2c(n1)c(Nc1cccc(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL1682290	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
309221	17689857	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	Nc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700437	=	IC50	nM	44.0	CHEMBL3629	Homo sapiens	IC50	nM	44.0
309222	17689858	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	O=C(O)c1ccc2c(c1)nc(Nc1ccc(F)c(Cl)c1)c1nc(NC3CC3)ncc12		CHEMBL3700438	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	nM	30.0
309223	17689859	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	COCCNc1ncc2c(n1)c(Nc1ccc(F)c(Cl)c1)nc1cc(C(=O)O)ccc12		CHEMBL3700439	=	IC50	nM	47.0	CHEMBL3629	Homo sapiens	IC50	nM	47.0
309224	17689860	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCCOCC)nc23)c1		CHEMBL3700440	=	IC50	nM	172.0	CHEMBL3629	Homo sapiens	IC50	nM	172.0
309225	17689861	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCC4CCCO4)nc23)c1		CHEMBL3700443	=	IC50	nM	11.0	CHEMBL3629	Homo sapiens	IC50	nM	11.0
309226	17689862	CHEMBL3706357	Modulation of Endogenous Assay: The human leukemia Jurkat T-cell line was maintained in RPMI 1640 (Cambrex) supplemented with 10% fetal calf serum and 50 ng/ml Geutamycin. Before treatment cells were washed, resuspended at a density of about 106 cells/milliliter in medium containing 1% fetal calf serum and incubated in the presence of indicated mounts of drug for two hours. Cells were recovered by centrifugation, lysed using a hypotonic buffer (20 mM Tris/HCl pH 7.4; 2 mM EDTA; 5 mM EGTA; 10 mM mercaptoethanol; 10 mM NaF; 1 uM Okadaic acid; 10% v/v glycerol; 0.05% NP-40; 1% Protease Inhibitor Cocktail) and protein from the cleared lysate was diluted to 1 microgram per microliter in Assay Dilution Buffer (ADB; 20 mM MOPS, pH 7.2, 25 mM -glycerolphosphate, 5 mM EGTA, 1 mM sodium orthovanadate and 1 mM dithiothreitol). To 20 microliters of diluted protein was added 10 microliters of substrate peptide (RRRDDDSDDD, dissolved in ADB at a concentration of 1 mM) and 10 microliters of PKA Inhibitor cocktail (Upstate).	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cnc(NCC4CC4)nc23)c1		CHEMBL3700444	=	IC50	nM	27.0	CHEMBL3629	Homo sapiens	IC50	nM	27.0
379181	17752807	CHEMBL3888187	Capillary Electrophoresis: IC50 values were obtained from capillary electrophoretic inhibition test.	B	Cc1ccc(N/C=C2\C(=O)CCc3c2oc2c(Cl)c(Cl)c(O)cc32)cc1		CHEMBL3920024	=	IC50	nM	30.0	CHEMBL3629	Homo sapiens	IC50	nM	30.0
379182	17752808	CHEMBL3888187	Capillary Electrophoresis: IC50 values were obtained from capillary electrophoretic inhibition test.	B	CC(C)=CC(=O)c1oc2c(Cl)c(Cl)c(O)c(C#N)c2c1N		CHEMBL1765541	=	IC50	nM	200.0	CHEMBL3629	Homo sapiens	IC50	nM	200.0
379183	17752809	CHEMBL3888187	Capillary Electrophoresis: IC50 values were obtained from capillary electrophoretic inhibition test.	B	CC(=O)Oc1c(Cl)c(Cl)c2oc(C(=O)C=C(C)C)c(N)c2c1C#N		CHEMBL1765542	=	IC50	nM	200.0	CHEMBL3629	Homo sapiens	IC50	nM	200.0
379184	17752810	CHEMBL3888187	Capillary Electrophoresis: IC50 values were obtained from capillary electrophoretic inhibition test.	B	CCOC(=O)c1oc2c(Cl)c(Cl)c(OC(C)=O)c(C#N)c2c1N		CHEMBL1765543	=	IC50	nM	2400.0	CHEMBL3629	Homo sapiens	IC50	nM	2400.0
	17979243	CHEMBL3998048	Inhibition of full length recombinant human His-tagged CK2alpha1 expressed in baculovirus expression system at 10 uM by Z'-LYTE assay relative to control	B	CC1=Nc2c(Sc3ccccc3)ncnc2Sc2ccccc21		CHEMBL4061152	=	Inhibition	%	3.0	CHEMBL3629	Homo sapiens	INH	%	3.0
	18114413	CHEMBL4025081	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual activity at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2cc(-c3cccc(NC(=O)c4ccc(C(C)(C)C)cc4)c3C)cn(C)c2=O)ccc1C(=O)N1CCOCC1		CHEMBL4077123	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	18153327	CHEMBL4034305	Inhibition of CK2a1 protein kinase domain (unknown origin) at 10 uM	B	c1cc(-c2c[nH]c3cnccc23)ccn1		CHEMBL4084955	=	Inhibition	%	9.4	CHEMBL3629	Homo sapiens	INH	%	9.4
	18158923	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	CC(C)Oc1ccc(CN)cc1Cl.Cl		CHEMBL4105345	=	Kd	nM	300000.0	CHEMBL3629	Homo sapiens	Kd	uM	300.0
	18158924	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	CCCOc1ccc(CN)cc1Cl.Cl		CHEMBL4100054	=	Kd	nM	629000.0	CHEMBL3629	Homo sapiens	Kd	uM	629.0
	18158925	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	Cl.NCc1ccc(OC2CCCC2)c(Cl)c1		CHEMBL4082041	=	Kd	nM	500000.0	CHEMBL3629	Homo sapiens	Kd	uM	500.0
	18158926	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	Cl.NCc1ccc(-c2ccoc2)c(Cl)c1		CHEMBL4061844	=	Kd	nM	520000.0	CHEMBL3629	Homo sapiens	Kd	uM	520.0
	18158927	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	Cl.NCc1ccc(-c2ccccc2)c(Cl)c1		CHEMBL4089903	=	Kd	nM	270000.0	CHEMBL3629	Homo sapiens	Kd	uM	270.0
	18158928	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	Nc1cccc(C(=O)O)c1		CHEMBL307782	>	Kd	nM	500000.0	CHEMBL3629	Homo sapiens	Kd	uM	500.0
	18158929	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	Cc1ccc(O)c(C(=O)O)c1		CHEMBL1161012	=	Kd	nM	58000.0	CHEMBL3629	Homo sapiens	Kd	uM	58.0
	18158930	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	COC(=O)CC(=O)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl	Outside typical range	CHEMBL4088836	=	Kd	nM	250000.0	CHEMBL3629	Homo sapiens	Kd	uM	250.0
	18158931	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	O=C(O)CC(=O)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1	Outside typical range	CHEMBL4104331	=	Kd	nM	250000.0	CHEMBL3629	Homo sapiens	Kd	uM	250.0
	18158932	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	O=C(CC(=O)Nc1cccc(C(=O)O)c1)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1.O=C(O)C(F)(F)F		CHEMBL4086439	=	Kd	nM	1640.0	CHEMBL3629	Homo sapiens	Kd	uM	1.64
	18158933	CHEMBL4035520	Binding affinity to CK2alpha (unknown origin) by ITC	B	O=C(CCNCc1ccc(-c2ccccc2)c(Cl)c1)NCCC(=O)Nc1cccc(C(=O)O)c1		CHEMBL4070389	=	Kd	nM	320.0	CHEMBL3629	Homo sapiens	Kd	uM	0.32
Not Active	18158934	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	Nc1cc(Br)cnc1N		CHEMBL4060760		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
Not Active	18158935	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	NC(=O)c1ccc(O)cc1		CHEMBL123617		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
	18158936	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=c1cc(O)c2ccccc2o1		CHEMBL301141	=	Delta Tm	degrees C	3.8	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.8
	18158937	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1ccc[nH]c1=O		CHEMBL53297	=	Delta Tm	degrees C	-1.8	CHEMBL3629	Homo sapiens	deltaTm	degrees C	-1.8
	18158938	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	NNc1ccc(C(=O)O)cc1		CHEMBL3189010	=	Delta Tm	degrees C	3.8	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.8
	18158939	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	Cc1cc(C(=O)O)ccc1N		CHEMBL3278361	=	Delta Tm	degrees C	0.5	CHEMBL3629	Homo sapiens	deltaTm	degrees C	0.5
	18158940	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)Cc1ccc(Cl)c(Cl)c1		CHEMBL3116309	=	Delta Tm	degrees C	0.7	CHEMBL3629	Homo sapiens	deltaTm	degrees C	0.7
	18158941	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1ccc2cc[nH]c2c1		CHEMBL1229732	=	Delta Tm	degrees C	3.0	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.0
	18158942	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1cccc(C(=O)O)n1		CHEMBL284104	=	Delta Tm	degrees C	-0.5	CHEMBL3629	Homo sapiens	deltaTm	degrees C	-0.5
	18158943	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	Cc1ccc(O)c(C(=O)O)c1		CHEMBL1161012	=	Delta Tm	degrees C	4.1	CHEMBL3629	Homo sapiens	deltaTm	degrees C	4.1
	18158944	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1ccc(O)cc1O		CHEMBL328910	=	Delta Tm	degrees C	3.2	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.2
	18158945	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1ccc(O)c(O)c1		CHEMBL37537	=	Delta Tm	degrees C	2.4	CHEMBL3629	Homo sapiens	deltaTm	degrees C	2.4
	18158946	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	Nc1cccc(C(=O)O)c1		CHEMBL307782	=	Delta Tm	degrees C	0.0	CHEMBL3629	Homo sapiens	deltaTm	degrees C	0.0
Not Active	18158947	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1cc2cc(O)ccc2[nH]1		CHEMBL1368373		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
	18158948	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)C(=O)Cc1ccccc1		CHEMBL1162488	=	Delta Tm	degrees C	-0.6	CHEMBL3629	Homo sapiens	deltaTm	degrees C	-0.6
	18158949	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	CCCCOC(=O)N1CCC(N)CC1		CHEMBL4091586	=	Delta Tm	degrees C	0.3	CHEMBL3629	Homo sapiens	deltaTm	degrees C	0.3
	18158950	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1cc2cc(F)ccc2[nH]1		CHEMBL23507	=	Delta Tm	degrees C	4.1	CHEMBL3629	Homo sapiens	deltaTm	degrees C	4.1
Not Active	18158951	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	COc1cc(CC(=O)O)ccc1O		CHEMBL1562		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
	18158952	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)CCc1ccc(O)cc1		CHEMBL1172560	=	Delta Tm	degrees C	3.1	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.1
	18158953	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	OC1CCC(N2CCNCC2)CC1		CHEMBL4092674	=	Delta Tm	degrees C	0.8	CHEMBL3629	Homo sapiens	deltaTm	degrees C	0.8
Not Active	18158954	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)Cc1cc(=O)oc2ccccc12		CHEMBL274190		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
Not Active	18158955	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1cc(=O)c2ccccc2o1		CHEMBL83628		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
Not Active	18158956	CHEMBL4035521	Binding affinity to CK2alpha (unknown origin) assessed as change in melting temperature by thermal shift assay	B	O=C(O)c1ccc2ccccc2n1		CHEMBL1160559		deltaTm			CHEMBL3629	Homo sapiens	deltaTm		
	18158957	CHEMBL4035522	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay	B	Cc1ccc(O)c(C(=O)O)c1	Non standard unit for type	CHEMBL1161012	=	INH	uM	100.0	CHEMBL3629	Homo sapiens	INH	uM	100.0
	18158958	CHEMBL4035522	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay	B	O=C(CCNCc1ccc(-c2ccccc2)c(Cl)c1)NCCC(=O)Nc1cccc(C(=O)O)c1		CHEMBL4070389	=	IC50	nM	370.0	CHEMBL3629	Homo sapiens	IC50	uM	0.37
	18158959	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	CNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4081901	=	Inhibition	%	44.0	CHEMBL3629	Homo sapiens	INH	%	44.0
	18158960	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	CCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4099900	=	Inhibition	%	23.0	CHEMBL3629	Homo sapiens	INH	%	23.0
	18158961	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	CCCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4071366	=	Inhibition	%	33.0	CHEMBL3629	Homo sapiens	INH	%	33.0
	18158962	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	Cl.OCCCNCc1ccc(-c2ccccc2)c(Cl)c1		CHEMBL4092160	=	Inhibition	%	47.0	CHEMBL3629	Homo sapiens	INH	%	47.0
	18158963	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	Cl.Cl.NCCCCNCc1ccc(-c2ccccc2)c(Cl)c1		CHEMBL4062720	=	Inhibition	%	18.0	CHEMBL3629	Homo sapiens	INH	%	18.0
	18158964	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	CC(=O)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4084406	=	Inhibition	%	39.0	CHEMBL3629	Homo sapiens	INH	%	39.0
	18158965	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	Cl.NC(=O)CCNCc1ccc(-c2ccccc2)c(Cl)c1		CHEMBL4100858	=	Inhibition	%	16.0	CHEMBL3629	Homo sapiens	INH	%	16.0
	18158966	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	CC(=O)NCCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4074095	=	Inhibition	%	12.0	CHEMBL3629	Homo sapiens	INH	%	12.0
	18158967	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	CS(=O)(=O)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4067611	=	Inhibition	%	51.0	CHEMBL3629	Homo sapiens	INH	%	51.0
	18158968	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	COC(=O)CC(=O)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1.Cl		CHEMBL4088836	=	Inhibition	%	46.0	CHEMBL3629	Homo sapiens	INH	%	46.0
	18158969	CHEMBL4035523	Inhibition of CK2alpha (unknown origin) at 500 uM using RRRADDSDDDD as substrate after 40 mins by ADP-Glo assay relative to control	B	O=C(O)CC(=O)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1		CHEMBL4104331	=	Inhibition	%	20.0	CHEMBL3629	Homo sapiens	INH	%	20.0
	18168912	CHEMBL4037129	Binding affinity to human CK2alpha expressed in Escherichia coli BL21(DE3)	B	O=C(CCNCc1ccc(-c2ccccc2)c(Cl)c1)NCCC(=O)Nc1cccc(C(=O)O)c1		CHEMBL4070389	=	Kd	nM	320.0	CHEMBL3629	Homo sapiens	Kd	uM	0.32
	18203605	CHEMBL4043892	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in HEK293 cells assessed as residual activity at 1000 nM after 30 mins by Kinomescan method relative to control	B	COc1cc(OC)c(Cl)c(N2Cc3cnc(Nc4ccc(F)cc4)nc3N(C3CCN(C(=O)/C=C/CN(C)C)CC3)C2=O)c1Cl		CHEMBL4092508	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	18232220	CHEMBL4050287	Binding affinity to CK2alpha (unknown origin) (1 to 335 residues) assessed as dissociation half life preincubated for 15 mins followed by ARC-1424-5O addition by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4089961	=	T1/2	hr	0.0825	CHEMBL3629	Homo sapiens	t1/2	s	297.0
	18232221	CHEMBL4050282	Inhibition of CK2alpha (unknown origin) (1 to 335 residues) using 5-TAMRA-RADDSDDDDD as substrate after 30 mins by fluorescence imaging method	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	IC50	nM	4.0	CHEMBL3629	Homo sapiens	IC50	nM	4.0
	18232222	CHEMBL4050282	Inhibition of CK2alpha (unknown origin) (1 to 335 residues) using 5-TAMRA-RADDSDDDDD as substrate after 30 mins by fluorescence imaging method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)O		CHEMBL4067866	=	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	18232223	CHEMBL4050282	Inhibition of CK2alpha (unknown origin) (1 to 335 residues) using 5-TAMRA-RADDSDDDDD as substrate after 30 mins by fluorescence imaging method	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	20.0	CHEMBL3629	Homo sapiens	IC50	nM	20.0
	18232226	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4089961	=	Kd	nM	0.016	CHEMBL3629	Homo sapiens	Kd	nM	0.016
	18232227	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Kd	nM	0.037	CHEMBL3629	Homo sapiens	Kd	nM	0.037
	18232228	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)CCCCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4072540	=	Kd	nM	2.403	CHEMBL3629	Homo sapiens	Kd	nM	2.403
	18232229	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4076226	=	Kd	nM	0.55	CHEMBL3629	Homo sapiens	Kd	nM	0.55
	18232230	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)CCCCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4077233	=	Kd	nM	0.71	CHEMBL3629	Homo sapiens	Kd	nM	0.71
	18232231	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4099729	=	Kd	nM	0.094	CHEMBL3629	Homo sapiens	Kd	nM	0.094
	18232232	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCNc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4075338	=	Kd	nM	0.17	CHEMBL3629	Homo sapiens	Kd	nM	0.17
	18232233	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)O		CHEMBL4067866	=	Kd	nM	5.89	CHEMBL3629	Homo sapiens	Kd	nM	5.89
	18232234	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4091080	=	Kd	nM	1.57	CHEMBL3629	Homo sapiens	Kd	nM	1.57
	18232235	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)O		CHEMBL4070115	=	Kd	nM	2.38	CHEMBL3629	Homo sapiens	Kd	nM	2.38
	18232236	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4069112	=	Kd	nM	0.42	CHEMBL3629	Homo sapiens	Kd	nM	0.42
	18232237	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)c1ccc2c(c1)[nH]c(=O)c1ccncc12		CHEMBL3696944	=	Kd	nM	8.9	CHEMBL3629	Homo sapiens	Kd	nM	8.9
	18232238	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Kd	nM	0.56	CHEMBL3629	Homo sapiens	Kd	nM	0.56
	18232240	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Kd	nM	0.5623	CHEMBL3629	Homo sapiens	pKd		9.25
	18232241	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)c1ccc2c(c1)[nH]c(=O)c1ccncc12		CHEMBL3696944	=	Kd	nM	8.913	CHEMBL3629	Homo sapiens	pKd		8.05
	18232242	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4069112	=	Kd	nM	0.4169	CHEMBL3629	Homo sapiens	pKd		9.38
	18232243	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)O		CHEMBL4070115	=	Kd	nM	2.399	CHEMBL3629	Homo sapiens	pKd		8.62
	18232244	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4091080	=	Kd	nM	1.585	CHEMBL3629	Homo sapiens	pKd		8.8
	18232245	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)O		CHEMBL4067866	=	Kd	nM	5.888	CHEMBL3629	Homo sapiens	pKd		8.23
	18232246	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	O=C(O)C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCNc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4075338	=	Kd	nM	0.1622	CHEMBL3629	Homo sapiens	pKd		9.79
	18232247	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4099729	=	Kd	nM	0.09333	CHEMBL3629	Homo sapiens	pKd		10.03
	18232248	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)CCCCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4077233	=	Kd	nM	0.7079	CHEMBL3629	Homo sapiens	pKd		9.15
	18232249	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4076226	=	Kd	nM	0.5495	CHEMBL3629	Homo sapiens	pKd		9.26
	18232250	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)CCCCCCCCn1c(=O)c2ccncc2c2ccc(C(=O)O)cc21)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O		CHEMBL4072540	=	Kd	nM	2.399	CHEMBL3629	Homo sapiens	pKd		8.62
	18232251	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4077554	=	Kd	nM	0.03162	CHEMBL3629	Homo sapiens	pKd		10.5
	18232252	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCCOc1nc2cc(C(=O)O)ccc2c2cnccc12)C(=O)O		CHEMBL4089961	=	Kd	nM	0.01288	CHEMBL3629	Homo sapiens	pKd		10.89
	18232253	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21)C(=O)O		CHEMBL4061407	=	Kd	nM	0.5	CHEMBL3629	Homo sapiens	Kd	nM	0.5
	18232254	CHEMBL4050279	Inhibition of ARC-1504 binding to CK2alpha (unknown origin) (1 to 335 residues) measured after 15 mins by fluorescence anisotropic method	B	CCN1c2cc(S(=O)(=O)O)ccc2/C(=C\C=C\C=C\C2=[N+](CC)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C1(C)CCCC(=O)NCCCC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)CCCCCCCn1cnc2c(Br)c(Br)c(Br)c(Br)c21)C(=O)O		CHEMBL4075701	=	Kd	nM	0.4	CHEMBL3629	Homo sapiens	Kd	nM	0.4
	18253323	CHEMBL4054945	Inhibition of wild-type human full length CK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	CC1(C)[C@H](Nc2c(C(N)=O)cnn3cc(-c4ccccc4)cc23)CC[C@]1(C)N		CHEMBL4096145	=	Activity	%	56.0	CHEMBL3629	Homo sapiens	Activity	%	56.0
	18253324	CHEMBL4054945	Inhibition of wild-type human full length CK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual activity at 50 nM by Kinomescan method relative to control	B	COc1ccc(-c2cc3c(N[C@@H]4CC[C@](C)(N)C4(C)C)c(C(N)=O)cnn3c2)cn1		CHEMBL4080797	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	18282018	CHEMBL4119973	Inhibition of CK2alpha1 (unknown origin) at 1 uM by FRET assay relative to control	B	CC(C)n1nc(-c2cnc(N)c(OC(F)(F)F)c2)cc1[C@@H]1[C@H]2CN(C3COC3)C[C@H]21		CHEMBL3719135	=	Inhibition	%	1.5	CHEMBL3629	Homo sapiens	INH	%	1.5
	18282337	CHEMBL4119973	Inhibition of CK2alpha1 (unknown origin) at 1 uM by FRET assay relative to control	B	Nc1ncc(-c2cc([C@@H]3[C@H]4CN(C5COC5)C[C@H]43)n(CC3CC3)n2)cc1C(F)(F)F		CHEMBL3715238	=	Inhibition	%	3.5	CHEMBL3629	Homo sapiens	INH	%	3.5
	18286296	CHEMBL4121531	Inhibition of CK2alpha1 (unknown origin) at 10 uM in presence of ATP relative to control	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12		CHEMBL4128926	=	Inhibition	%	0.0	CHEMBL3629	Homo sapiens	INH	%	0.0
	18286297	CHEMBL4121532	Inhibition of CK2alpha2 (unknown origin) at 10 uM in presence of ATP relative to control	B	CC(C)(C)NS(=O)(=O)c1ccc(-c2sc(C(=O)N[C@H]3C[C@H](C(=O)O)C3)nc2CC2CCCCC2)c2ccccc12		CHEMBL4128926	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	INH	%	2.0
	18407899	CHEMBL4151455	Inhibition of human CSNK2A1 expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	B	COc1ccc2c(c1)[nH]c1c(CO)nccc12		CHEMBL4066450	=	Activity	%	34.0	CHEMBL3629	Homo sapiens	Activity	%	34.0
	18407940	CHEMBL4151455	Inhibition of human CSNK2A1 expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	B	COc1ccc2c(c1)[nH]c1c(C)nc(CO)cc12		CHEMBL4173266	=	Activity	%	8.3	CHEMBL3629	Homo sapiens	Activity	%	8.3
	18407985	CHEMBL4151455	Inhibition of human CSNK2A1 expressed in mammalian expression system assessed as remaining enzyme activity at 10 uM by kinome scan assay	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	11.0	CHEMBL3629	Homo sapiens	Activity	%	11.0
	18440147	CHEMBL4156971	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding at 1 uM by Kinomescan method relative to control	B	Cc1cccc(S(=O)(=O)Nc2cc(-c3sc(NC(=O)[C@@H](N)C(C)C)nc3C)cnc2Cl)c1		CHEMBL4174988	=	Activity	%	87.0	CHEMBL3629	Homo sapiens	Activity	%	87.0
	18443255	CHEMBL4157906	Inhibition of human CK2alpha assessed as enzyme residual activity at 100 nM by radiometric filter binding assay relative to control	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O		CHEMBL4177303	=	Activity	%	1.9	CHEMBL3629	Homo sapiens	Activity	%	1.9
	18443256	CHEMBL4157899	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)[se]1)C(=O)O		CHEMBL4162173	=	Kd	nM	0.34	CHEMBL3629	Homo sapiens	Kd	nM	0.34
	18443257	CHEMBL4157899	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)[se]4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1		CHEMBL4172847	=	Kd	nM	0.85	CHEMBL3629	Homo sapiens	Kd	nM	0.85
Not Determined	18443258	CHEMBL4157900	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	Nc1ncc(-c2ccc(C(=O)O)cc2)s1		CHEMBL4166028		Time			CHEMBL3629	Homo sapiens	Time		
	18443259	CHEMBL4157900	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O	Non standard unit for type	CHEMBL4177303	=	Time	microsec	82.0	CHEMBL3629	Homo sapiens	Time	microsec	82.0
	18443260	CHEMBL4157900	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)s4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1	Non standard unit for type	CHEMBL4169451	=	Time	microsec	62.0	CHEMBL3629	Homo sapiens	Time	microsec	62.0
	18443261	CHEMBL4157900	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)[se]1)C(=O)O	Non standard unit for type	CHEMBL4162173	=	Time	microsec	55.0	CHEMBL3629	Homo sapiens	Time	microsec	55.0
	18443262	CHEMBL4157900	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using non-deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)[se]4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1	Non standard unit for type	CHEMBL4172847	=	Time	microsec	39.0	CHEMBL3629	Homo sapiens	Time	microsec	39.0
Not Determined	18443263	CHEMBL4157901	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as maximal luminescence intensity of the complex after 15 to 60 mins by luminescence assay relative to ARC-1527	B	Nc1ncc(-c2ccc(C(=O)O)cc2)s1		CHEMBL4166028		FC			CHEMBL3629	Homo sapiens	FC		
	18443264	CHEMBL4157901	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as maximal luminescence intensity of the complex after 15 to 60 mins by luminescence assay relative to ARC-1527	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)s4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1		CHEMBL4169451	=	FC		76.0	CHEMBL3629	Homo sapiens	FC		76.0
	18443265	CHEMBL4157901	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as maximal luminescence intensity of the complex after 15 to 60 mins by luminescence assay relative to ARC-1527	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)[se]1)C(=O)O		CHEMBL4162173	=	FC		46.0	CHEMBL3629	Homo sapiens	FC		46.0
	18443266	CHEMBL4157901	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as maximal luminescence intensity of the complex after 15 to 60 mins by luminescence assay relative to ARC-1527	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)[se]4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1		CHEMBL4172847	=	FC		5300.0	CHEMBL3629	Homo sapiens	FC		5300.0
Active	18443275	CHEMBL4157905	Displacement of 5-TAMRA-labeled ARC-1530 from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O		CHEMBL4177303		Activity			CHEMBL3629	Homo sapiens	Activity		
	18443276	CHEMBL4157899	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	Nc1ncc(-c2ccc(C(=O)O)cc2)s1		CHEMBL4166028	=	Kd	nM	48.0	CHEMBL3629	Homo sapiens	Kd	nM	48.0
	18443295	CHEMBL4157903	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)[se]4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1	Non standard unit for type	CHEMBL4172847	=	Time	microsec	58.0	CHEMBL3629	Homo sapiens	Time	microsec	58.0
Active	18443310	CHEMBL4157905	Displacement of 5-TAMRA-labeled ARC-1530 from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)[se]1)C(=O)O		CHEMBL4162173		Activity			CHEMBL3629	Homo sapiens	Activity		
	18443311	CHEMBL4157899	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc1ncc(-c2ccc(C(=O)O)cc2)s1)C(=O)O		CHEMBL4177303	=	Kd	nM	0.58	CHEMBL3629	Homo sapiens	Kd	nM	0.58
	18443312	CHEMBL4157899	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)s4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1		CHEMBL4169451	=	Kd	nM	0.4	CHEMBL3629	Homo sapiens	Kd	nM	0.4
	18443316	CHEMBL4157905	Displacement of 5-TAMRA-labeled ARC-1530 from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	IC50	nM	170.0	CHEMBL3629	Homo sapiens	IC50	nM	170.0
	18443317	CHEMBL4157903	Displacement of ARC-1504/ARC-1513-5O from CK2alpha (unknown origin) (1 to 335 residues) assessed as photoluminescence lifetime using deoxygenated solution after 15 to 60 mins by luminescence assay	B	CN(C)c1ccc2c(-c3ccc(C(=O)NCCCC[C@@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CCCCCNC(=O)CCC(=O)Nc4ncc(-c5ccc(C(=O)O)cc5)s4)C(=O)O)cc3C(=O)[O-])c3ccc(=[N+](C)C)cc-3oc2c1	Non standard unit for type	CHEMBL4169451	=	Time	microsec	165.0	CHEMBL3629	Homo sapiens	Time	microsec	165.0
	18443324	CHEMBL4157905	Displacement of 5-TAMRA-labeled ARC-1530 from CK2alpha (unknown origin) (1 to 335 residues) after 15 to 60 mins by luminescence assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	0.5	CHEMBL3629	Homo sapiens	IC50	nM	0.5
	18449824	CHEMBL4178061	Inhibition of human CK2alpha (2 to 391 residues) assessed as residual activity at 500 nM in presence of 33P-ATP by filter binding assay relative to control	B	Cc1cccc(-c2nc(N)sc2-c2ccc3ncccc3n2)c1		CHEMBL4209540	=	Activity	%	119.0	CHEMBL3629	Homo sapiens	Activity	%	119.0
	18470578	CHEMBL4182572	Inhibition of human CK2a1 at 10 uM by ADP-Glo kinase assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978	=	Inhibition	%	64.0	CHEMBL3629	Homo sapiens	INH	%	64.0
	18470747	CHEMBL4182572	Inhibition of human CK2a1 at 10 uM by ADP-Glo kinase assay	B	Cc1nc(N)c2ccn(C3CCN(C(=O)c4ccc(S(=O)(=O)F)cc4)CC3)c2n1		CHEMBL4206295	=	Inhibition	%	16.0	CHEMBL3629	Homo sapiens	INH	%	16.0
	18470748	CHEMBL4182572	Inhibition of human CK2a1 at 10 uM by ADP-Glo kinase assay	B	Nc1ncnc2c1ccn2C1CCN(C(=O)c2ccc(S(=O)(=O)F)cc2)CC1		CHEMBL4218073	=	Inhibition	%	9.0	CHEMBL3629	Homo sapiens	INH	%	9.0
	18484587	CHEMBL4185750	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	CCC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL4206831	=	Activity	%	47.0	CHEMBL3629	Homo sapiens	Activity	%	47.0
	18485034	CHEMBL4185750	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in HEK293 cells at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccc(C(=O)Nc2ccc(Nc3ncc4c(n3)N(C)c3ccc(C)cc3C(=O)N4C)cc2)cc1		CHEMBL3969370	=	Activity	%	95.0	CHEMBL3629	Homo sapiens	Activity	%	95.0
	18507842	CHEMBL4190920	Inhibition of recombinant full-length human CK2alpha2 at 1 uM using RRRDDDSDDD as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	3.0	CHEMBL3629	Homo sapiens	INH	%	3.0
	18507843	CHEMBL4190919	Inhibition of recombinant full-length human CK2alpha1 at 1 uM using RRRDDDSDDD as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	19.0	CHEMBL3629	Homo sapiens	INH	%	19.0
	18507844	CHEMBL4190918	Inhibition of recombinant full-length human CK2 at 1 uM using RRRDDDSDDD as substrate after 40 mins in presence of [gamma-33P]ATP by scintillation counting method	B	CS(=O)(=O)c1ccc(-n2nc(-c3cnc4[nH]ccc4c3)c3c(N)ncnc32)cc1		CHEMBL4207014	=	Inhibition	%	2.0	CHEMBL3629	Homo sapiens	INH	%	2.0
	18580177	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(NCCCN)n3)c2c1		CHEMBL4229130	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	18580178	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)NCCCNc1cncc(-n2ncc3ccc(NC(C)C)cc32)n1		CHEMBL4225378	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	18580179	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)NCC(=O)Nc1ccc2cnn(-c3cncc(C#N)n3)c2c1		CHEMBL4224786	=	IC50	nM	2700.0	CHEMBL3629	Homo sapiens	IC50	uM	2.7
	18580180	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)NCCCC(=O)Nc1ccc2cnn(-c3cncc(C#N)n3)c2c1		CHEMBL4225633	=	IC50	nM	13000.0	CHEMBL3629	Homo sapiens	IC50	uM	13.0
	18580181	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)NCCC(=O)Nc1ccc2cnn(-c3cncc(C#N)n3)c2c1		CHEMBL4225046	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	18580182	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)Nc1cccc(-c2ccc3cnn(-c4cncc(C#N)n4)c3c2)c1		CHEMBL4225896	=	IC50	nM	13000.0	CHEMBL3629	Homo sapiens	IC50	uM	13.0
	18580183	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2ccn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1		CHEMBL4225287	=	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	uM	0.003
	18580184	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(CN)cc4)n3)c2c1		CHEMBL4227791	=	IC50	nM	310.0	CHEMBL3629	Homo sapiens	IC50	uM	0.31
	18580185	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)NCc1ccc(-c2cncc(-n3ncc4ccc(NC(C)C)cc43)n2)cc1		CHEMBL4225206	=	IC50	nM	20000.0	CHEMBL3629	Homo sapiens	IC50	uM	20.0
	18580186	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)NS(C)(=O)=O)cc4)n3)c2c1		CHEMBL4224693	=	IC50	nM	360.0	CHEMBL3629	Homo sapiens	IC50	uM	0.36
	18580187	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(O)C(F)(F)F)cc4)n3)c2c1		CHEMBL4228564	>	IC50	nM	30000.0	CHEMBL3629	Homo sapiens	IC50	uM	30.0
	18580188	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(-c5nnn[nH]5)cc4)n3)c2c1		CHEMBL4224959	=	IC50	nM	130.0	CHEMBL3629	Homo sapiens	IC50	uM	0.13
	18580189	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cn4)n3)c2c1		CHEMBL4228363	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	uM	0.007
	18580190	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)nc4)n3)c2c1		CHEMBL4225224	=	IC50	nM	297.0	CHEMBL3629	Homo sapiens	IC50	uM	0.297
	18580191	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	Cc1cc(-c2cncc(-n3ncc4ccc(NC(C)C)cc43)n2)ccc1C(=O)O		CHEMBL4225330	=	IC50	nM	460.0	CHEMBL3629	Homo sapiens	IC50	uM	0.46
	18580192	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)c(F)c4)n3)c2c1		CHEMBL4224859	=	IC50	nM	7.0	CHEMBL3629	Homo sapiens	IC50	uM	0.007
	18580193	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	COc1cc(C(=O)O)ccc1-c1cncc(-n2ncc3ccc(NC(C)C)cc32)n1		CHEMBL4227028	=	IC50	nM	112.0	CHEMBL3629	Homo sapiens	IC50	uM	0.112
	18580194	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4Cl)n3)c2c1		CHEMBL4227886	=	IC50	nM	15.0	CHEMBL3629	Homo sapiens	IC50	uM	0.015
	18580195	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4F)n3)c2c1		CHEMBL4227817	=	IC50	nM	5.0	CHEMBL3629	Homo sapiens	IC50	uM	0.005
	18580196	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1		CHEMBL4228654	=	IC50	nM	5.0	CHEMBL3629	Homo sapiens	IC50	uM	0.005
	18580197	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4cccc(C(=O)O)c4)n3)c2c1		CHEMBL4227556	=	IC50	nM	4800.0	CHEMBL3629	Homo sapiens	IC50	uM	4.8
	18580204	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4csc(C(=O)O)c4)n3)c2c1		CHEMBL4228394	=	IC50	nM	26.0	CHEMBL3629	Homo sapiens	IC50	uM	0.026
	18580205	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CN(C)C(=O)c1ccc(Nc2ncc(-c3ccc(C(=O)O)cc3)cn2)cc1		CHEMBL4229169	=	IC50	nM	560.0	CHEMBL3629	Homo sapiens	IC50	uM	0.56
	18580206	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	COc1nc(Nc2ccc(C(=O)N(C)C)cc2)ncc1-c1ccc(C(N)=O)s1		CHEMBL4228074	=	IC50	nM	4600.0	CHEMBL3629	Homo sapiens	IC50	uM	4.6
	18580207	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	COc1nc(Nc2ccc(C(=O)N(C)C)cc2)ncc1-c1csc(C(=O)O)c1		CHEMBL4226991	=	IC50	nM	360.0	CHEMBL3629	Homo sapiens	IC50	uM	0.36
	18580208	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	COc1nc(Nc2ccc(C(=O)N(C)C)cc2)ncc1-c1ccc(C(=O)O)s1		CHEMBL4224729	=	IC50	nM	70.0	CHEMBL3629	Homo sapiens	IC50	uM	0.07
	18580209	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	COc1nc(Nc2ccc(C(=O)N(C)C)cc2)ncc1-c1cc(C(=O)O)cs1		CHEMBL4228242	=	IC50	nM	100.0	CHEMBL3629	Homo sapiens	IC50	uM	0.1
	18580210	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)Nc1ccc2c(c1)c(-c1cc(NC3CC3)n3ncc(C#N)c3n1)cn2CCC(=O)O		CHEMBL2062585	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	18580211	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)Nc1cc(Nc2cc(NC3CC3)n3ncc(C#N)c3n2)ccc1C		CHEMBL2409175	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	18580212	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	CC(=O)Nc1ccc2ccn(-c3cc(NC4CC4)n4ncc(C#N)c4n3)c2c1		CHEMBL2062563	=	IC50	nM	10.0	CHEMBL3629	Homo sapiens	IC50	nM	10.0
	18580213	CHEMBL4222671	Inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells using CK2tide as substrate treated for 20 mins measured after 90 mins in presence of MgCl2 by caliper mobility shift assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	<	IC50	nM	3.0	CHEMBL3629	Homo sapiens	IC50	nM	3.0
	18580250	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-n4ccc(CC(=O)O)c4)n3)c2c1		CHEMBL1231683	=	IC50	nM	2700.0	CHEMBL3629	Homo sapiens	IC50	uM	2.7
	18580251	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4csc(C(=O)O)c4)n3)c2c1		CHEMBL4228394	>	IC50	nM	3300.0	CHEMBL3629	Homo sapiens	IC50	uM	3.3
	18580252	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1		CHEMBL4228654	=	IC50	nM	110.0	CHEMBL3629	Homo sapiens	IC50	uM	0.11
	18580253	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4F)n3)c2c1		CHEMBL4227817	=	IC50	nM	340.0	CHEMBL3629	Homo sapiens	IC50	uM	0.34
	18580254	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4Cl)n3)c2c1		CHEMBL4227886	=	IC50	nM	3400.0	CHEMBL3629	Homo sapiens	IC50	uM	3.4
	18580255	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)c(F)c4)n3)c2c1		CHEMBL4224859	=	IC50	nM	180.0	CHEMBL3629	Homo sapiens	IC50	uM	0.18
	18580256	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)nc4)n3)c2c1		CHEMBL4225224	=	IC50	nM	4300.0	CHEMBL3629	Homo sapiens	IC50	uM	4.3
	18580257	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cn4)n3)c2c1		CHEMBL4228363	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	uM	1.0
	18580258	CHEMBL4222674	Inhibition of CK2alpha in human HCT116 or human DLD1 cells assessed as decrease in AKT phosphorylation at S129 residue after 3 to 24 hrs by Western blot method	B	CC(C)Nc1ccc2ccn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1		CHEMBL4225287	=	IC50	nM	96.0	CHEMBL3629	Homo sapiens	IC50	uM	0.096
	18580334	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-n4ccc(CC(=O)O)c4)n3)c2c1		CHEMBL1231683	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580335	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4csc(C(=O)O)c4)n3)c2c1		CHEMBL4228394	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580336	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1		CHEMBL4228654	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580337	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4F)n3)c2c1		CHEMBL4227817	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580338	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cc4Cl)n3)c2c1		CHEMBL4227886	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580339	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)c(F)c4)n3)c2c1		CHEMBL4224859	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580340	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)nc4)n3)c2c1		CHEMBL4225224	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580341	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2cnn(-c3cncc(-c4ccc(C(=O)O)cn4)n3)c2c1		CHEMBL4228363	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18580342	CHEMBL4222696	Ratio of IC50 for inhibition of CK2alpha in human HCT116 cells assessed as decrease in AKT phosphorylation at S129 residue to IC50 for inhibition of recombinant human full length N-terminal His6-tagged CK2alpha expressed in Sf21 insect cells	B	CC(C)Nc1ccc2ccn(-c3cncc(-c4ccc(C(=O)O)cc4)n3)c2c1		CHEMBL4225287	=	Ratio IC50		10.0	CHEMBL3629	Homo sapiens	Ratio IC50		10.0
	18590829	CHEMBL4224406	Inhibition of CK2alpha (unknown origin) (2 to 329 residues) expressed in Escherichia coli BL21 (DE3) using RRRADDSDDDD substrate incubated for 40 mins by ADP-Glo kinase assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	14.7	CHEMBL3629	Homo sapiens	IC50	nM	14.7
	18590900	CHEMBL4224409	Inhibition of CK2alpha (unknown origin) (2 to 329 residues) expressed in Escherichia coli BL21 (DE3) assessed as reduction in phosphorylation activity at 100 uM using using fluorescein tagged RLYGFKIHPMAYQLQ probe incubated for 10 mins by fluorescence assay	B	NCc1cc(Cl)cc(-c2cccc3[nH]ccc23)c1		CHEMBL4227516	=	Inhibition	%	18.0	CHEMBL3629	Homo sapiens	INH	%	18.0
	18590902	CHEMBL4224411	Inhibition of GST-tagged human recombinant CK2alpha (1 to 335 residues) expressed in Escherichia coli BL21 by radiometric kinase assay	B	O=[N+]([O-])c1ccc2c(/N=N/c3ccc4ccccc4c3O)c(O)cc(S(=O)(=O)O)c2c1		CHEMBL459510	=	IC50	nM	400.0	CHEMBL3629	Homo sapiens	IC50	uM	0.4
	18655585	CHEMBL4230650	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	Cc1ccc(NC(=O)c2ccc(CN(CCN(C)C)C(=O)c3cccnc3)cc2)cc1Nc1nccc(-c2cccnc2)n1		CHEMBL4247298	=	Activity	%	81.0	CHEMBL3629	Homo sapiens	Activity	%	81.0
	18693974	CHEMBL4253427	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 0.1 uM by Z'-Lyte assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	5.0	CHEMBL3629	Homo sapiens	INH	%	5.0
	18694056	CHEMBL4253509	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 1 uM by Z'-Lyte assay relative to control	B	CC1=Nc2c(F)cc(-c3nc(Nc4ccc(C5CCN(C)CC5)cn4)ncc3F)cc2C12CCCC2		CHEMBL4277900	=	Inhibition	%	23.0	CHEMBL3629	Homo sapiens	INH	%	23.0
	18725376	CHEMBL4259073	Inhibition of CK2-alpha1 (unknown origin)	B	CC(=O)n1nc(C)c(-c2ccc(Cl)c(Cl)c2)c1N		CHEMBL4276946	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	uM	100.0
	18731295	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2)Nc1ccccc1F		CHEMBL4279395	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731296	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1cccc(F)c1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2		CHEMBL4290076	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731297	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1ccc(F)cc1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2		CHEMBL4294548	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731298	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCOC(=O)c1cccc(NC(=O)Nc2nc3c(s2)CC(N2C(=O)c4ccccc4C2=O)CC3)c1		CHEMBL4286639	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731299	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCOC(=O)c1ccc(NC(=O)Nc2nc3c(s2)CC(N2C(=O)c4ccccc4C2=O)CC3)cc1		CHEMBL4291140	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731300	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	COc1ccc(NC(=O)Nc2nc3c(s2)CC(N2C(=O)c4ccccc4C2=O)CC3)cc1		CHEMBL4283288	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731301	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCOC(O)(Nc1cccc(C(=O)O)c1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2		CHEMBL4277917	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731302	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCOC(O)(Nc1ccc(C(=O)O)cc1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2		CHEMBL4288568	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731303	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccccc1F)C1CCc2nc(NC(=O)Nc3ccccc3F)sc2C1		CHEMBL4291923	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731304	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(F)c1)C1CCc2nc(NC(=O)Nc3cccc(F)c3)sc2C1		CHEMBL4287424	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731305	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(F)cc1)C1CCc2nc(NC(=O)Nc3ccc(F)cc3)sc2C1		CHEMBL4276769	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731306	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(C(=O)OCC)c1)C1CCc2nc(NC(=O)Nc3cccc(C(=O)OCC)c3)sc2C1		CHEMBL4290835	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731307	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(C(=O)OCC)cc1)C1CCc2nc(NC(=O)Nc3ccc(C(=O)OCC)cc3)sc2C1		CHEMBL4280201	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731308	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(OC)cc1)C1CCc2nc(NC(=O)Nc3ccc(OC)cc3)sc2C1		CHEMBL4294233	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731309	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(C(=O)O)c1)C1CCc2nc(NC(=O)Nc3cccc(C(=O)O)c3)sc2C1		CHEMBL4283652	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731310	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(C(=O)O)cc1)C1CCc2nc(NC(=O)Nc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4288927	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731311	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1nc2c(s1)CC(NC(=O)Nc1ccccc1F)CC2)Nc1ccccc1F		CHEMBL4281341	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731312	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1cccc(F)c1)Nc1nc2c(s1)CC(NC(=O)Nc1cccc(F)c1)CC2		CHEMBL4278794	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731313	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1ccc(F)cc1)Nc1nc2c(s1)CC(NC(=O)Nc1ccc(F)cc1)CC2		CHEMBL4282748	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731314	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCOC(=O)c1cccc(NC(=O)Nc2nc3c(s2)CC(NC(=O)Nc2cccc(C(=O)OCC)c2)CC3)c1		CHEMBL4291453	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731315	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCOC(=O)c1ccc(NC(=O)Nc2nc3c(s2)CC(NC(=O)Nc2ccc(C(=O)OCC)cc2)CC3)cc1		CHEMBL4279892	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731316	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	COc1ccc(NC(=O)Nc2nc3c(s2)CC(NC(=O)Nc2ccc(OC)cc2)CC3)cc1		CHEMBL4290542	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731317	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1cccc(C(=O)O)c1)Nc1nc2c(s1)CC(NC(=O)Nc1cccc(C(=O)O)c1)CC2		CHEMBL4279366	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731318	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	O=C(Nc1ccc(C(=O)O)cc1)Nc1nc2c(s1)CC(NC(=O)Nc1ccc(C(=O)O)cc1)CC2		CHEMBL4293946	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731319	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccccc1F)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4283767	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731320	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(F)c1)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4282680	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731321	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(F)cc1)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4282490	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731322	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(C(=O)OCC)c1)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4289709	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731323	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(C(=O)OCC)cc1)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4290122	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731324	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(OC)cc1)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4286291	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731325	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccccc1F)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4294175	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731326	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(F)c1)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4282908	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731327	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(F)cc1)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4287186	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731328	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1cccc(C(=O)O)c1)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4279439	>	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731329	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(C(=O)O)cc1)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4287360	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731330	CHEMBL4260237	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system at 11 uM using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay relative to control	B	CCCN(C(=O)Nc1ccc(OC)cc1)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4292130	<	Inhibition	%	30.0	CHEMBL3629	Homo sapiens	INH	%	30.0
	18731331	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCOC(=O)c1cccc(NC(=O)Nc2nc3c(s2)CC(N2C(=O)c4ccccc4C2=O)CC3)c1		CHEMBL4286639	=	IC50	nM	7900.0	CHEMBL3629	Homo sapiens	IC50	uM	7.9
	18731332	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCOC(O)(Nc1cccc(C(=O)O)c1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2		CHEMBL4277917	=	IC50	nM	1900.0	CHEMBL3629	Homo sapiens	IC50	uM	1.9
	18731333	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCOC(O)(Nc1ccc(C(=O)O)cc1)Nc1nc2c(s1)CC(N1C(=O)c3ccccc3C1=O)CC2		CHEMBL4288568	=	IC50	nM	4900.0	CHEMBL3629	Homo sapiens	IC50	uM	4.9
	18731334	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCCN(C(=O)Nc1cccc(C(=O)O)c1)C1CCc2nc(NC(=O)Nc3cccc(C(=O)O)c3)sc2C1		CHEMBL4283652	=	IC50	nM	2800.0	CHEMBL3629	Homo sapiens	IC50	uM	2.8
	18731335	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCOC(=O)c1cccc(NC(=O)Nc2nc3c(s2)CC(NC(=O)Nc2cccc(C(=O)OCC)c2)CC3)c1		CHEMBL4291453	=	IC50	nM	20400.0	CHEMBL3629	Homo sapiens	IC50	uM	20.4
	18731336	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	O=C(Nc1cccc(C(=O)O)c1)Nc1nc2c(s1)CC(NC(=O)Nc1cccc(C(=O)O)c1)CC2		CHEMBL4279366	=	IC50	nM	12400.0	CHEMBL3629	Homo sapiens	IC50	uM	12.4
	18731337	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCCN(C(=O)Nc1cccc(C(=O)OCC)c1)C1CCc2nc(NCc3ccc(C(=O)OC)cc3)sc2C1		CHEMBL4289709	=	IC50	nM	4600.0	CHEMBL3629	Homo sapiens	IC50	uM	4.6
	18731365	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	IC50	nM	1480.0	CHEMBL3629	Homo sapiens	IC50	nM	1480.0
	18731366	CHEMBL4260238	Inhibition of recombinant full length human His-tagged CK2alpha1 expressed in baculovirus expression system using ser/thr-11 peptide as substrate measured after 1 hr by Z'-Lyte assay	B	CCCN(C(=O)Nc1cccc(C(=O)O)c1)C1CCc2nc(NCc3ccc(C(=O)O)cc3)sc2C1		CHEMBL4279439	=	IC50	nM	4000.0	CHEMBL3629	Homo sapiens	IC50	uM	4.0
	18751664	CHEMBL4264239	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as remaining unbound target protein level at 1000 nM by Kinomescan method relative to control	B	COCCN[C@H]1CC[C@H](Nc2cc(-c3csc(NCC4(C#N)CCOCC4)n3)c(Cl)cn2)CC1		CHEMBL4281048	=	Activity	%	81.0	CHEMBL3629	Homo sapiens	Activity	%	81.0
	18857908	CHEMBL4307754	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	CC(C)N1C(=O)C(NCCCN(C)C)=C(c2cn(C)c3ccccc23)C1=O.Cl		CHEMBL4533018	=	Activity	%	98.0	CHEMBL3629	Homo sapiens	Activity	%	98.0
	18892584	CHEMBL4314759	Inhibition of recombinant full length human CK2alpha1 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	88.0	CHEMBL3629	Homo sapiens	Activity	%	88.0
	18892585	CHEMBL4314760	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	Cc1cc(C)c(CNc2nc(Cl)nc3c2ncn3C2CCCC2)c(=O)[nH]1		CHEMBL4557538	=	Activity	%	89.5	CHEMBL3629	Homo sapiens	Activity	%	89.5
	18937833	CHEMBL4327647	Inhibition of human CK2A assessed as residual activity at 1 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	B	ClC/C=C/C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4438024	=	Activity	%	124.08	CHEMBL3629	Homo sapiens	Activity	%	124.08
	18937834	CHEMBL4327647	Inhibition of human CK2A assessed as residual activity at 1 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	B	C(=C/c1ccccc1)\C[N+]12CN3CN(CN(C3)C1)C2.[Cl-]		CHEMBL4446405	=	Activity	%	124.03	CHEMBL3629	Homo sapiens	Activity	%	124.03
	18938487	CHEMBL4328007	Inhibition of human CK2A assessed as residual activity at 100 uM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay relative to control	B	O=C1Nc2ccc(I)cc2/C1=C/c1cc(Br)c(O)c(Br)c1		CHEMBL72365	<	Activity	%	65.0	CHEMBL3629	Homo sapiens	Activity	%	65.0
Not Determined	18938862	CHEMBL4328371	Inhibition of human CK2A using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	B	CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4		CHEMBL388978		IC50			CHEMBL3629	Homo sapiens	IC50		
	18938863	CHEMBL4328371	Inhibition of human CK2A using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	B	O=C1Nc2ccc(I)cc2/C1=C/c1cc(Br)c(O)c(Br)c1		CHEMBL72365	=	IC50	nM	279.0	CHEMBL3629	Homo sapiens	IC50	10'-7M	2.79
	18958825	CHEMBL4333344	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)Nc1sc(C(=O)c2ccc(Cl)s2)c(N)c1C#N		CHEMBL4563315	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	18964187	CHEMBL4335030	Inhibition of recombinant full length human CK2alpha1 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	57.0	CHEMBL3629	Homo sapiens	Activity	%	57.0
	18964188	CHEMBL4335030	Inhibition of recombinant full length human CK2alpha1 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	59.0	CHEMBL3629	Homo sapiens	Activity	%	59.0
	18964189	CHEMBL4335031	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	N=C1NC(=O)/C(=C\c2ccc(-c3cccc([N+](=O)[O-])c3)o2)S1		CHEMBL4455512	=	Activity	%	52.0	CHEMBL3629	Homo sapiens	Activity	%	52.0
	18964190	CHEMBL4335031	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C=CCOC(=O)c1cc(-c2ccc(/C=C3/NC(=S)NC3=O)o2)ccc1Cl		CHEMBL4568120	=	Activity	%	73.0	CHEMBL3629	Homo sapiens	Activity	%	73.0
	18971702	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	CCCCCCCCCCCC1=C(O)C(=O)C2=C(OC(N)=C(C#N)C2[N+](=O)[O-])C1=O		CHEMBL4443718	=	Ki	nM	220.0	CHEMBL3629	Homo sapiens	Ki	uM	0.22
	18971703	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1oc2c(Br)c(O)ccc2c2ccc(O)cc12		CHEMBL4465651	=	Ki	nM	7.0	CHEMBL3629	Homo sapiens	Ki	uM	0.007
	18971704	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28	=	Ki	nM	740.0	CHEMBL3629	Homo sapiens	Ki	uM	0.74
	18971706	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1oc2cc(O)ccc2c2oc3cc(O)ccc3c12		CHEMBL30707	=	Ki	nM	7670.0	CHEMBL3629	Homo sapiens	Ki	uM	7.67
	18971708	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	Cc1c(Br)c(=O)oc2c(Br)c(O)ccc12		CHEMBL273101	=	Ki	nM	60.0	CHEMBL3629	Homo sapiens	Ki	uM	0.06
	18971709	CHEMBL4336764	Inhibition of CK2alpha in human PLC1 cells using (Arg)3(Glu)3Thr(Glu)3 as substrate after 24 hrs in presence of [32P]gammaGTP	B	CN(C)c1nc2c(Br)c(Br)c(Br)c(Br)c2[nH]1		CHEMBL376505	=	Ki	nM	4500.0	CHEMBL3629	Homo sapiens	Ki	uM	4.5
	18971710	CHEMBL4336764	Inhibition of CK2alpha in human PLC1 cells using (Arg)3(Glu)3Thr(Glu)3 as substrate after 24 hrs in presence of [32P]gammaGTP	B	OC[C@H]1O[C@H](n2cnc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O		CHEMBL3706697	=	Ki	nM	400.0	CHEMBL3629	Homo sapiens	Ki	uM	0.4
	18971711	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1oc2c(O)c(O)cc3c(=O)oc4c(O)c(O)cc1c4c23		CHEMBL6246	=	Ki	nM	20.0	CHEMBL3629	Homo sapiens	Ki	uM	0.02
	18971712	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	Cc1cc(O)c2c(c1)C(=O)c1cc(O)cc(O)c1C2=O		CHEMBL289277	=	Ki	nM	1500.0	CHEMBL3629	Homo sapiens	Ki	uM	1.5
	18971713	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)ccc12		CHEMBL31574	=	Ki	nM	350.0	CHEMBL3629	Homo sapiens	Ki	uM	0.35
	18971716	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=C1c2c(O)cccc2C(=O)c2c([N+](=O)[O-])ccc(O)c21		CHEMBL574060	=	Ki	nM	800.0	CHEMBL3629	Homo sapiens	Ki	uM	0.8
	18971717	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1c2c(O)cccc2oc2c([N+](=O)[O-])ccc(O)c12		CHEMBL270512	=	Ki	nM	780.0	CHEMBL3629	Homo sapiens	Ki	uM	0.78
	18971723	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=c1c(O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12		CHEMBL50	=	Ki	nM	1180.0	CHEMBL3629	Homo sapiens	Ki	uM	1.18
	18971724	CHEMBL4336765	Inhibition of CK2alpha (unknown origin)	B	O=C1c2ccc(O)c(O)c2C(=O)c2c(O)ccc(O)c21		CHEMBL29898	=	Ki	nM	60.0	CHEMBL3629	Homo sapiens	Ki	uM	0.06
	18971725	CHEMBL4336764	Inhibition of CK2alpha in human PLC1 cells using (Arg)3(Glu)3Thr(Glu)3 as substrate after 24 hrs in presence of [32P]gammaGTP	B	Brc1c(Br)c(Br)c2[nH]nnc2c1Br		CHEMBL177820	=	Ki	nM	300.0	CHEMBL3629	Homo sapiens	Ki	uM	0.3
	18971726	CHEMBL4336764	Inhibition of CK2alpha in human PLC1 cells using (Arg)3(Glu)3Thr(Glu)3 as substrate after 24 hrs in presence of [32P]gammaGTP	B	Brc1c(Br)c(Br)c2[nH]cnc2c1Br		CHEMBL373937	=	Ki	nM	40.0	CHEMBL3629	Homo sapiens	Ki	uM	0.04
	18971727	CHEMBL4336763	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDDD as substrate in presence of [gamma33P]-ATP by autoradiography	B	O=C(O)/C=C/c1cc(Br)c(Br)c(Br)c1Br		CHEMBL270724	=	Ki	nM	77.0	CHEMBL3629	Homo sapiens	Ki	uM	0.077
	18971728	CHEMBL4336763	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDDD as substrate in presence of [gamma33P]-ATP by autoradiography	B	COc1ccc(C(=O)Nc2nnc(-c3ccc(C(=O)O)cc3)s2)cc1		CHEMBL2087008	=	Ki	nM	32.0	CHEMBL3629	Homo sapiens	Ki	uM	0.032
	18971729	CHEMBL4336763	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDDD as substrate in presence of [gamma33P]-ATP by autoradiography	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Ki	nM	0.38	CHEMBL3629	Homo sapiens	Ki	nM	0.38
	18971730	CHEMBL4336763	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDDD as substrate in presence of [gamma33P]-ATP by autoradiography	B	C#Cc1cccc(Nc2nc3cc(C(=O)O)ccc3c3cncnc23)c1		CHEMBL1682283	=	Ki	nM	420.0	CHEMBL3629	Homo sapiens	Ki	uM	0.42
	18971848	CHEMBL4336858	Inhibition of recombinant full length human CK2alpha1 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	68.0	CHEMBL3629	Homo sapiens	Activity	%	68.0
	18971849	CHEMBL4336859	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	C[C@@H](c1ccccc1)n1nnc2cnc3ccc(-c4cnc5[nH]ccc5c4)cc3c21		CHEMBL4472294	=	Activity	%	83.0	CHEMBL3629	Homo sapiens	Activity	%	83.0
	18989215	CHEMBL4340757	Inhibition of recombinant human full-length N-terminal GST-fused CK2-alpha1 (M1 to Q391 residues) expressed in Sf9 insect cells using casein as substrate measured after 60 mins in presence of [gamma-33P]-ATP by scintillation counting method	B	CN(CCc1ccc(-c2ccccc2)cc1)Cc1cn(C)c2ccc(C(=O)Nc3ccc(F)cc3)cc12		CHEMBL4446681	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	uM	100.0
	18989949	CHEMBL4340974	Inhibition of N-terminal GST tagged full length human CK2-alpha1 (M1-Q391) expressed in Sf9 insect cells using casein as substrate at 1 uM by Filter binding assay relative to control	B	COCCN1CCOc2c1cnn1c(-c3ccc4cccc(NCC5CCNCC5)c4n3)nnc21		CHEMBL4556293	<	Inhibition	%	25.0	CHEMBL3629	Homo sapiens	INH	%	25.0
	19005804	CHEMBL4344399	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual bound protein level at 10 uM by Kinomescan method relative to control	B	COc1ccc2c3ccnc(C)c3n(CCCC(N)=O)c2c1		CHEMBL4474836	=	Activity	%	31.0	CHEMBL3629	Homo sapiens	Activity	%	31.0
	19005805	CHEMBL4344399	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual bound protein level at 10 uM by Kinomescan method relative to control	B	COc1ccc2c(c1)[nH]c1c(C)nccc12		CHEMBL269538	=	Activity	%	11.0	CHEMBL3629	Homo sapiens	Activity	%	11.0
	19005806	CHEMBL4344399	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual bound protein level at 10 uM by Kinomescan method relative to control	B	COc1ccc2c(c1)[nH]c1c(CO)nccc12		CHEMBL4066450	=	Activity	%	34.0	CHEMBL3629	Homo sapiens	Activity	%	34.0
	19032220	CHEMBL4349813	Inhibition of recombinant human full length N-terminal GST and C-terminal His6-tagged CK2-alpha (M1 to Q391) expressed in Sf9 insect cells at 20 nM using phosphatidylserine as substrate incubated for 60 mins in presence of [33P]-ATP by scintillation counting method	B	Cn1cc(-c2n[nH]c3ccc(NCc4cc(F)ccc4S(C)(=O)=O)cc23)cn1		CHEMBL4555442	=	Inhibition	%	7.0	CHEMBL3629	Homo sapiens	INH	%	7.0
Not Active	19039832	CHEMBL4351810	Inhibition of recombinant full length human CK2alpha2 at 10 uM using RRRDDDSDDD as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	19039833	CHEMBL4351809	Inhibition of recombinant full length human CK2alpha1 at 10 uM using RRRDDDSDDD as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method	B	CN1C[C@H](Nc2nc3cc[nH]c3c(=O)n2C)C[C@H](c2ccc3c(c2)OCCO3)C1		CHEMBL4574669		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	19041065	CHEMBL4352326	Inhibition of human CK2A at 10 uM using RRRDDDSDDD as substrate in presence of [gamma-33P]-ATP	B	CC(C)(C)C(=O)N1N=CC[C@H]1c1ccccc1		CHEMBL4521353		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	19059527	CHEMBL4357828	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1ccccc1Nc1nc(Nc2ccc(N3CCN(C)CC3)cc2)ncc1C(=O)Nc1c(C)cccc1Cl		CHEMBL4515441	=	Activity	%	68.0	CHEMBL3629	Homo sapiens	Activity	%	68.0
	19090098	CHEMBL4365672	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual activity at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccnc1)c1cc(C(=O)c2c(F)cccc2Br)c[nH]1		CHEMBL4436895	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	19091880	CHEMBL4366354	Inhibition of human CK2A at 100 nM using RRRDDDSDDD as substrate by [gamma-33P]-ATP assay	B	COc1ccc(N2C(=O)COc3ccc(-c4cnc(OC)c(NS(=O)(=O)c5ccc(F)cc5)c4)cc32)cc1		CHEMBL4528675	=	Inhibition	%	12.7	CHEMBL3629	Homo sapiens	INH	%	12.7
	19144709	CHEMBL4377725	Inhibition of full length recombinant human CK2alpha1 at 1 uM using RRRDDDSDDD as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	-5.0	CHEMBL3629	Homo sapiens	INH	%	-5.0
	19144710	CHEMBL4377726	Inhibition of full length recombinant human CK2alpha2 at 1 uM using RRRDDDSDDD as substrate measured after 40 mins in presence of [gamma33P]ATP by scintillation counting method relative to control	B	CN(C)C(=O)c1cc2cnc(Nc3ccc(NC(=O)CCCCCCCN=C=S)cc3)nc2n1C1CCCC1		CHEMBL4548580	=	Inhibition	%	-4.0	CHEMBL3629	Homo sapiens	INH	%	-4.0
	19147800	CHEMBL4379196	Inhibition of recombinant full length human CK2alpha1 using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	uM	10.0
	19147801	CHEMBL4379197	Inhibition of recombinant full length human CK2alpha2 using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by radiometric scintillation counting analysis	B	CN(C)c1ccc(C(=O)Nc2cccc(NC(=O)COc3ccc4c(=O)ccoc4c3)c2)cc1		CHEMBL4438748	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	uM	10.0
	19159355	CHEMBL4382459	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	C=CC(=O)Nc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC)cc1N(C)CCN(C)C		CHEMBL4473365	=	Activity	%	89.0	CHEMBL3629	Homo sapiens	Activity	%	89.0
	19180997	CHEMBL4387208	Inhibition of recombinant full length human His-tagged CK2 alpha 1 expressed in baculovirus expression system at 0.1 uM using serine/threonine-11 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1		CHEMBL3301610	=	Inhibition	%	31.5	CHEMBL3629	Homo sapiens	INH	%	31.5
	19181223	CHEMBL4387208	Inhibition of recombinant full length human His-tagged CK2 alpha 1 expressed in baculovirus expression system at 0.1 uM using serine/threonine-11 peptide as substrate incubated for 60 mins by Z'-LYTE assay relative to control	B	CCN1CC2(C1)CN(c1ccc(Nc3ncc(F)c(-c4cnn5c4[C@H](C)CCCC5)n3)nc1)C2		CHEMBL4545456	=	Inhibition	%	0.5	CHEMBL3629	Homo sapiens	INH	%	0.5
	19191652	CHEMBL4389178	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@H]2CCCN(c3ncnc4[nH]ccc34)C2)c1)Nc1ccccc1N1CCCC1		CHEMBL4555459	=	Inhibition	%	67.0	CHEMBL3629	Homo sapiens	INH	%	67.0
	19191841	CHEMBL4389655	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system at 1 uM by Kinomescan method relative to control	B	O=C(Nc1cccc([C@@H]2CN(c3ncnc4[nH]ccc34)CCN2CCO)c1)Nc1c(F)cccc1N1CCCC1		CHEMBL4564973	=	Inhibition	%	93.0	CHEMBL3629	Homo sapiens	INH	%	93.0
	19199941	CHEMBL4391281	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 10 uM by Kinomescan method relative to control	B	O=C(Nc1cc(-c2cn(CCNc3c4c(nc5ccccc35)CCCC4)nn2)ccn1)Nc1cccc2c1C1CCCCN1C2=O		CHEMBL4559936	=	Activity	%	33.0	CHEMBL3629	Homo sapiens	Activity	%	33.0
	19266376	CHEMBL4405326	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	CC[C@H](Nc1nc(N)nc(C)c1C#N)c1nc2cccc(NCc3ccc(C(=O)NO)cc3)c2c(=O)n1-c1ccccc1		CHEMBL4455923	<	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
	19274925	CHEMBL4407590	Inhibition of recombinant human full-length His-tagged CSNK2A1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Br)cccc3Br)c(N)nc2n1		CHEMBL57531	=	Inhibition	%	4.0	CHEMBL3629	Homo sapiens	INH	%	4.0
	19274926	CHEMBL4407590	Inhibition of recombinant human full-length His-tagged CSNK2A1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	Nc1ncc2cc(-c3c(Cl)cccc3-c3cccnc3)c(N3C[C@H]4[C@H](N)[C@H]4C3)nc2n1		CHEMBL4453148	=	Inhibition	%	0.0	CHEMBL3629	Homo sapiens	INH	%	0.0
	19274927	CHEMBL4407590	Inhibition of recombinant human full-length His-tagged CSNK2A1 expressed in baculovirus expression system at 25 uM using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr by Z'-lyte assay relative to control	A	CC(C)COc1cccc(Cl)c1-c1cc2cnc(N)nc2nc1N1C[C@H]2[C@H](N)[C@H]2C1		CHEMBL4546703	=	Inhibition	%	1.0	CHEMBL3629	Homo sapiens	INH	%	1.0
	19275963	CHEMBL4407966	Inhibition of recombinant full length human CK2alpha1 at 1 uM using RRRDDDSDDD as substrate incubated for 40 mins in presence of [gamma-33P]-ATP by scintillation counting method relative to control	B	Cc1ccc(NC(=O)C2(C(=O)Nc3ccc(Nc4ncc(F)c(-c5cc(F)c6nc(C)n(C(C)C)c6c5)n4)cc3)CC2)cc1		CHEMBL4445335	=	Inhibition	%	36.0	CHEMBL3629	Homo sapiens	INH	%	36.0
Active	19303618	CHEMBL4414191	Inhibition EGFP-CK2alpha (unknown origin) expressed in human HeLa cells induction of EGFP-CK2alpha translocation from nucleoli to nuclear matrix and cytoplasm at 15 uM after 12 hrs by Hoechst-33342-staining based microscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	19303619	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)Cc1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4576793	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	19303620	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccccc1Nc1nc(-c2cccc([N+](=O)[O-])c2)cs1		CHEMBL4534418	=	IC50	nM	8000.0	CHEMBL3629	Homo sapiens	IC50	uM	8.0
	19303621	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=[N+]([O-])c1cccc(-c2csc(Nc3ccccc3)n2)c1		CHEMBL1617004	>	IC50	nM	25000.0	CHEMBL3629	Homo sapiens	IC50	uM	25.0
	19303623	CHEMBL4414145	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	IC50	nM	600.0	CHEMBL3629	Homo sapiens	IC50	uM	0.6
	19303624	CHEMBL4414145	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4556528	=	IC50	nM	3000.0	CHEMBL3629	Homo sapiens	IC50	uM	3.0
	19303625	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	COC(=O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4469688	>	IC50	nM	25000.0	CHEMBL3629	Homo sapiens	IC50	uM	25.0
	19303626	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	COc1cccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)c1		CHEMBL4526405	=	IC50	nM	12000.0	CHEMBL3629	Homo sapiens	IC50	uM	12.0
	19303627	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	COc1ccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)cc1		CHEMBL4449524	=	IC50	nM	6000.0	CHEMBL3629	Homo sapiens	IC50	uM	6.0
	19303628	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	COc1ccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)c(OC)c1		CHEMBL4454829	=	IC50	nM	13000.0	CHEMBL3629	Homo sapiens	IC50	uM	13.0
	19303629	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc(O)cc3O)cs2)cc1		CHEMBL590969	=	IC50	nM	7000.0	CHEMBL3629	Homo sapiens	IC50	uM	7.0
	19303630	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cc(Br)ccc3O)cs2)cc1		CHEMBL4442613	=	IC50	nM	5000.0	CHEMBL3629	Homo sapiens	IC50	uM	5.0
	19303631	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	CC(C)(C)c1csc(Nc2ccc(C(=O)O)cc2)n1		CHEMBL4474287	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	19303632	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccccn3)cs2)cc1		CHEMBL4455046	=	IC50	nM	19000.0	CHEMBL3629	Homo sapiens	IC50	uM	19.0
	19303633	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccsc3)cs2)cc1		CHEMBL4476631	=	IC50	nM	5000.0	CHEMBL3629	Homo sapiens	IC50	uM	5.0
	19303634	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4556528	=	IC50	nM	3000.0	CHEMBL3629	Homo sapiens	IC50	uM	3.0
	19303635	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cc4ccccc4oc3=O)cs2)cc1		CHEMBL4443629	=	IC50	nM	8000.0	CHEMBL3629	Homo sapiens	IC50	uM	8.0
	19303636	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cc4ccccc4o3)cs2)cc1		CHEMBL4549952	=	IC50	nM	14000.0	CHEMBL3629	Homo sapiens	IC50	uM	14.0
	19303637	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4sccc4c3)cs2)cc1		CHEMBL4552669	=	IC50	nM	4000.0	CHEMBL3629	Homo sapiens	IC50	uM	4.0
	19303638	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4578037	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	19303639	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	N#Cc1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4461761	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	19303640	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1cccc(Nc2nc(-c3ccc4ccccc4c3)cs2)c1		CHEMBL4579088	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	uM	2.0
	19303641	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	COc1ccc(C(=O)O)cc1Nc1nc(-c2ccc3ccccc3c2)cs1		CHEMBL4559313	=	IC50	nM	8000.0	CHEMBL3629	Homo sapiens	IC50	uM	8.0
	19303642	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	IC50	nM	600.0	CHEMBL3629	Homo sapiens	IC50	uM	0.6
	19303643	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	14.7	CHEMBL3629	Homo sapiens	IC50	nM	14.7
	19303644	CHEMBL4414160	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	IC50	nM	17.0	CHEMBL3629	Homo sapiens	IC50	nM	17.0
Not Determined	19303645	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=[N+]([O-])c1cccc(-c2csc(Nc3ccccc3)n2)c1		CHEMBL1617004		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303646	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)Cc1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4576793		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303647	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccccc1Nc1nc(-c2cccc([N+](=O)[O-])c2)cs1		CHEMBL4534418		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303648	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	COC(=O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4469688		Kd			CHEMBL3629	Homo sapiens	Kd		
	19303649	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	COc1cccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)c1		CHEMBL4526405	=	Kd	nM	14000.0	CHEMBL3629	Homo sapiens	Kd	uM	14.0
	19303650	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	COc1ccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)cc1		CHEMBL4449524	=	Kd	nM	7000.0	CHEMBL3629	Homo sapiens	Kd	uM	7.0
Not Determined	19303651	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	COc1ccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)c(OC)c1		CHEMBL4454829		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303652	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc(O)cc3O)cs2)cc1		CHEMBL590969		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303653	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3cc(Br)ccc3O)cs2)cc1		CHEMBL4442613		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303654	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	CC(C)(C)c1csc(Nc2ccc(C(=O)O)cc2)n1		CHEMBL4474287		Kd			CHEMBL3629	Homo sapiens	Kd		
	19303655	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccccn3)cs2)cc1		CHEMBL4455046	=	Kd	nM	20000.0	CHEMBL3629	Homo sapiens	Kd	uM	20.0
	19303656	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccsc3)cs2)cc1		CHEMBL4476631	=	Kd	nM	6000.0	CHEMBL3629	Homo sapiens	Kd	uM	6.0
	19303657	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4556528	=	Kd	nM	600.0	CHEMBL3629	Homo sapiens	Kd	uM	0.6
Not Determined	19303658	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3cc4ccccc4oc3=O)cs2)cc1		CHEMBL4443629		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303659	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3cc4ccccc4o3)cs2)cc1		CHEMBL4549952		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303660	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4sccc4c3)cs2)cc1		CHEMBL4552669		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303661	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4578037		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303662	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	N#Cc1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4461761		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303663	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1cccc(Nc2nc(-c3ccc4ccccc4c3)cs2)c1		CHEMBL4579088		Kd			CHEMBL3629	Homo sapiens	Kd		
Not Determined	19303664	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	COc1ccc(C(=O)O)cc1Nc1nc(-c2ccc3ccccc3c2)cs1		CHEMBL4559313		Kd			CHEMBL3629	Homo sapiens	Kd		
	19303665	CHEMBL4414161	Binding affinity to recombinant human GST-tagged CK2alpha after 120 secs by surface plasmon resonance analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	Kd	nM	300.0	CHEMBL3629	Homo sapiens	Kd	uM	0.3
	19303666	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	CS(=O)(=O)NC(=O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4576430	=	Inhibition	%	41.0	CHEMBL3629	Homo sapiens	INH	%	41.0
	19303667	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	Cc1ccc(S(=O)(=O)NC(=O)c2ccc(Nc3nc(-c4ccc5ccccc5c4)cs3)cc2)cc1		CHEMBL4439777	=	Inhibition	%	54.0	CHEMBL3629	Homo sapiens	INH	%	54.0
	19303668	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	CC(=O)OCOC(=O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4449433	=	Inhibition	%	7.0	CHEMBL3629	Homo sapiens	INH	%	7.0
	19303669	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	CC(=O)OCOC(=O)c1ccc(Nc2nc(-c3ccsc3)cs2)cc1		CHEMBL4474528	=	Inhibition	%	37.0	CHEMBL3629	Homo sapiens	INH	%	37.0
	19303670	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	CC(=O)OCOC(=O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4535799	=	Inhibition	%	41.0	CHEMBL3629	Homo sapiens	INH	%	41.0
	19303676	CHEMBL4414164	Competitive inhibition of recombinant human GST-tagged CK2alpha by Lineweaver-Burk plot analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	Ki	nM	180.0	CHEMBL3629	Homo sapiens	Ki	uM	0.18
	19303678	CHEMBL4414166	Allosteric binding affinity to human CK2alpha (1 to 335 residues) at 300 uM secs by ITC assay	B	O=[N+]([O-])c1cccc(-c2csc(Nc3ccccc3)n2)c1		CHEMBL1617004	=	Kd	nM	14400.0	CHEMBL3629	Homo sapiens	Kd	uM	14.4
	19303679	CHEMBL4414166	Allosteric binding affinity to human CK2alpha (1 to 335 residues) at 300 uM secs by ITC assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	Kd	nM	110.0	CHEMBL3629	Homo sapiens	Kd	uM	0.11
	19303680	CHEMBL4414167	Inhibition of recombinant human GST-tagged CK2alpha V73A mutant in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	IC50	nM	1700.0	CHEMBL3629	Homo sapiens	IC50	uM	1.7
	19303682	CHEMBL4414151	Inhibition of recombinant human GST-tagged CK2alpha H160A mutant in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	uM	1.0
	19303686	CHEMBL4414157	Inhibition of CK2alpha (unknown origin) assessed as reduction in enzyme activity at 5 uM in presence of ATP relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	>	Activity	%	50.0	CHEMBL3629	Homo sapiens	Activity	%	50.0
	19303713	CHEMBL4414188	Inhibition of CK2alpha (unknown origin) assessed as reduction in GST-Six1 phosphorylation in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	uM	1.0
	19303714	CHEMBL4414188	Inhibition of CK2alpha (unknown origin) assessed as reduction in GST-Six1 phosphorylation in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	uM	2.0
	19303715	CHEMBL4414188	Inhibition of CK2alpha (unknown origin) assessed as reduction in GST-Six1 phosphorylation in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	7000.0	CHEMBL3629	Homo sapiens	IC50	uM	7.0
	19303716	CHEMBL4414189	Inhibition of CK2alpha (unknown origin) assessed as reduction in nucleolin phosphorylation in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	IC50	nM	3800.0	CHEMBL3629	Homo sapiens	IC50	uM	3.8
	19303717	CHEMBL4414189	Inhibition of CK2alpha (unknown origin) assessed as reduction in nucleolin phosphorylation in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	2000.0	CHEMBL3629	Homo sapiens	IC50	uM	2.0
	19303718	CHEMBL4414189	Inhibition of CK2alpha (unknown origin) assessed as reduction in nucleolin phosphorylation in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	42000.0	CHEMBL3629	Homo sapiens	IC50	uM	42.0
Active	19303720	CHEMBL4414192	Inhibition EGFP-CK2alpha (unknown origin) expressed in human HeLa cells induction of EGFP-CK2alpha translocation from nucleoli to nuclear matrix and cytoplasm at 8 uM after 12 hrs by Hoechst-33342-staining based microscopy	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	19303721	CHEMBL4414193	Inhibition EGFP-CK2alpha (unknown origin) expressed in human HeLa cells induction of EGFP-CK2alpha translocation from nucleoli to nuclear matrix and cytoplasm at 40 uM after 12 hrs by Hoechst-33342-staining based microscopy	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	19303722	CHEMBL4414194	Inhibition of recombinant human CK2alpha using RRRDDDSDDD substrate and [gamma-33P]ATP by scintillation counting method	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	nM	14.0
	19303727	CHEMBL4414199	Inhibition of CK2alpha (unknown origin) using RRRADDSDDDD substrate incubated for 40 mins by ADP-Glo kinase assay	B	CCc1ccccc1-c1c(Cl)cc(CNCCc2nc3ccccc3[nH]2)cc1Cl		CHEMBL4439686	=	IC50	nM	7000.0	CHEMBL3629	Homo sapiens	IC50	uM	7.0
	19303732	CHEMBL4414204	Ratio of I50 for inhibition of CK2alpha in human 786-0 cells assessed as decrease in Akt1 phosphorylation at Ser129 after 24 hrs by Western blot analysis to IC50 for inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	Ratio IC50		5.0	CHEMBL3629	Homo sapiens	Ratio IC50		5.0
	19303733	CHEMBL4414204	Ratio of I50 for inhibition of CK2alpha in human 786-0 cells assessed as decrease in Akt1 phosphorylation at Ser129 after 24 hrs by Western blot analysis to IC50 for inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl		CHEMBL105442	=	Ratio IC50		5.0	CHEMBL3629	Homo sapiens	Ratio IC50		5.0
	19303734	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1		CHEMBL4556528	=	Inhibition	%	67.0	CHEMBL3629	Homo sapiens	INH	%	67.0
	19303736	CHEMBL4414162	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	Inhibition	%	96.0	CHEMBL3629	Homo sapiens	INH	%	96.0
	19303750	CHEMBL4414205	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1cccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)c1		CHEMBL4557432	=	IC50	nM	27700.0	CHEMBL3629	Homo sapiens	IC50	uM	27.7
	19303754	CHEMBL4414205	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4462082	=	IC50	nM	7000.0	CHEMBL3629	Homo sapiens	IC50	uM	7.0
	19303756	CHEMBL4414208	Mixed-type inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by Lineweaver-Burk plot analysis	B	O=C(O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4462082	=	Ki	nM	1600.0	CHEMBL3629	Homo sapiens	Ki	uM	1.6
	19303757	CHEMBL4414209	Inhibition of CK2alpha (unknown origin) assessed as residual activity at 50 uM relative to control	B	O=C(O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4462082	=	Activity	%	0.0	CHEMBL3629	Homo sapiens	Activity	%	0.0
	19303802	CHEMBL4414277	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	O=[N+]([O-])c1cccc(-c2csc(Nc3ccccc3)n2)c1		CHEMBL1617004	=	Inhibition	%	27.0	CHEMBL3629	Homo sapiens	INH	%	27.0
	19303803	CHEMBL4414277	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	COC(=O)c1ccc(Nc2nc(-c3cccc([N+](=O)[O-])c3)cs2)cc1		CHEMBL4469688	=	Inhibition	%	9.0	CHEMBL3629	Homo sapiens	INH	%	9.0
	19303804	CHEMBL4414277	Inhibition of recombinant human GST-tagged CK2alpha at 10 uM in presence of ATP by radiometric kinase assay relative to control	B	O=C(O)c1ccc(Nc2nccs2)cc1		CHEMBL4466673	=	Inhibition	%	0.0	CHEMBL3629	Homo sapiens	INH	%	0.0
	19303805	CHEMBL4414205	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959	=	IC50	nM	9000.0	CHEMBL3629	Homo sapiens	IC50	uM	9.0
	19303806	CHEMBL4414208	Mixed-type inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by Lineweaver-Burk plot analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959	=	Ki	nM	1100.0	CHEMBL3629	Homo sapiens	Ki	uM	1.1
	19303807	CHEMBL4414253	Non-ATP competitive binding affinity to GST-tagged CK2alpha (unknown origin) assessed as melting temperature at 50 uM by temperature-dependent circular dichroism (Rvb = 53.2 degC)	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959	=	Tm	degrees C	50.3	CHEMBL3629	Homo sapiens	Tm	degrees C	50.3
Active	19303809	CHEMBL4414256	Binding affinity to CK2alpha (unknown origin) at 500 uM in presence of kinase inhibitor CX-4945 by STD-based NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	19303810	CHEMBL4414257	Binding affinity to CK2alpha ATP binding site (unknown origin) assessed as reduction in AMP-PNP binding at 500 uM by STD-based NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	19303811	CHEMBL4414271	Competitive binding affinity to CK2alpha (1 to 335 residues) (unknown origin) at 10 uM in presence of IP6 by nESI-MS analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	19303812	CHEMBL4414272	Competitive binding affinity to CK2alpha (1 to 335 residues) (unknown origin) at 10 uM in presence of IP6 and CX-4945 by nESI-MS analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	19303813	CHEMBL4414296	Binding affinity to CK2alpha (unknown origin) at 500 uM by STD-based NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	19303814	CHEMBL4414298	Competitive binding affinity to CK2alpha (1 to 335 residues) (unknown origin) at 10 uM by native mass spectrometry	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Active	19303815	CHEMBL4414299	Competitive binding affinity to CK2alpha (1 to 335 residues) (unknown origin) at 10 uM in presence of IP6 by native mass spectrometry	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
	19303816	CHEMBL4414205	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	3400.0	CHEMBL3629	Homo sapiens	IC50	uM	3.4
	19303817	CHEMBL4414208	Mixed-type inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by Lineweaver-Burk plot analysis	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	Ki	nM	700.0	CHEMBL3629	Homo sapiens	Ki	uM	0.7
Not Determined	19303835	CHEMBL4414258	Inhibition of recombinant human GST-tagged CK2alpha Y26A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	19303836	CHEMBL4414259	Inhibition of recombinant human GST-tagged CK2alpha K71A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300		IC50			CHEMBL3629	Homo sapiens	IC50		
	19303837	CHEMBL4414260	Inhibition of recombinant human GST-tagged CK2alpha V73A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	4000.0	CHEMBL3629	Homo sapiens	IC50	uM	4.0
	19303838	CHEMBL4414261	Inhibition of recombinant human GST-tagged CK2alpha K74A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	6000.0	CHEMBL3629	Homo sapiens	IC50	uM	6.0
Not Determined	19303839	CHEMBL4414262	Inhibition of recombinant human GST-tagged CK2alpha K76A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300		IC50			CHEMBL3629	Homo sapiens	IC50		
	19303840	CHEMBL4414263	Inhibition of recombinant human GST-tagged CK2alpha K77A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	10900.0	CHEMBL3629	Homo sapiens	IC50	uM	10.9
Not Determined	19303841	CHEMBL4414264	Inhibition of recombinant human GST-tagged CK2alpha I78A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300		IC50			CHEMBL3629	Homo sapiens	IC50		
	19303842	CHEMBL4414265	Inhibition of recombinant human GST-tagged CK2alpha H160A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	IC50	nM	7700.0	CHEMBL3629	Homo sapiens	IC50	uM	7.7
Not Determined	19303843	CHEMBL4414266	Inhibition of recombinant human GST-tagged CK2alpha E180A mutant in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300		IC50			CHEMBL3629	Homo sapiens	IC50		
	19303853	CHEMBL4414286	Inhibition of CK2alpha' (unknown origin) assessed as residual activity at 50 uM relative to control	B	O=C(O)c1ccc(Nc2nc(-c3cccc(Br)c3)cs2)cc1		CHEMBL4458300	=	Activity	%	48.0	CHEMBL3629	Homo sapiens	Activity	%	48.0
	19303863	CHEMBL4414205	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	COc1cccc(-c2csc(Nc3ccc(C(=O)O)cc3)n2)c1		CHEMBL4526405	=	IC50	nM	12000.0	CHEMBL3629	Homo sapiens	IC50	uM	12.0
	19303864	CHEMBL4414205	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric kinase assay	B	O=C(O)c1ccc(Nc2nc(-c3ccccn3)cs2)cc1		CHEMBL4455046	=	IC50	nM	14000.0	CHEMBL3629	Homo sapiens	IC50	uM	14.0
	19303865	CHEMBL4414254	Non-ATP competitive binding affinity to GST-tagged CK2alpha (unknown origin) assessed as melting temperature at 6.25 uM by temperature-dependent circular dichroism (Rvb = 53.2 degC)	B	O=C(O)c1ccc(Nc2nc(-c3ccccn3)cs2)cc1		CHEMBL4455046	=	Tm	degrees C	52.0	CHEMBL3629	Homo sapiens	Tm	degrees C	52.0
Active	19303867	CHEMBL4414257	Binding affinity to CK2alpha ATP binding site (unknown origin) assessed as reduction in AMP-PNP binding at 500 uM by STD-based NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccn3)cs2)cc1		CHEMBL4455046		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	19303868	CHEMBL4414296	Binding affinity to CK2alpha (unknown origin) at 500 uM by STD-based NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccn3)cs2)cc1		CHEMBL4455046		Activity			CHEMBL3629	Homo sapiens	Activity		
	19303869	CHEMBL4414278	Inhibition of CK2alpha (unknown origin) incubated for 40 mins by ADP-Glo kinase assay	B	CCc1ccccc1-c1c(Cl)cc(CNCCc2nc3ccccc3[nH]2)cc1Cl		CHEMBL4439686	=	IC50	nM	7000.0	CHEMBL3629	Homo sapiens	IC50	uM	7.0
	19303870	CHEMBL4414254	Non-ATP competitive binding affinity to GST-tagged CK2alpha (unknown origin) assessed as melting temperature at 6.25 uM by temperature-dependent circular dichroism (Rvb = 53.2 degC)	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	Tm	degrees C	55.4	CHEMBL3629	Homo sapiens	Tm	degrees C	55.4
Not Active	19303874	CHEMBL4414297	Binding affinity to CK2alpha (unknown origin) at 100 uM in presence of AMP-PNP by STD-based NMR spectroscopy	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165		Activity			CHEMBL3629	Homo sapiens	Activity		
	19303875	CHEMBL4414273	Inhibition of recombinant human GST-tagged CK2alpha in presence of ATP by radiometric filter-binding assay	B	O=C(O)c1ccc2c(c1)nc(Nc1ccccc1)c1ccncc12		CHEMBL1652697	=	IC50	nM	14.0	CHEMBL3629	Homo sapiens	IC50	nM	14.0
Active	19303876	CHEMBL4414296	Binding affinity to CK2alpha (unknown origin) at 500 uM by STD-based NMR spectroscopy	B	Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)NP(=O)(O)O)[C@@H](O)[C@H]1O		CHEMBL1230989		Activity			CHEMBL3629	Homo sapiens	Activity		
	19371119	CHEMBL4424876	Inhibition of human full length His6-tagged CK2alpha expressed in baculovirus infected Sf21 insect cells using Casein Kinase 2 substrate peptide	A	COc1cc(C2CN(C(=O)c3cc(COC[C@@H](O)CO)ccn3)C2)ccc1OCc1ccc(C2CC2)cc1		CHEMBL4474690	>	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
	19470457	CHEMBL4478506	Inhibition of full length human CSNK2A1 expressed in mammalian system assessed as remaining enzyme activity at 1 uM by KINOMEScan assay relative to control	B	C[C@H]1NC(=O)c2cc(-c3cccc4c(=O)n(C)c(NC(C)(C)C)nc34)[nH]c21		CHEMBL3979678	=	Activity	%	3.5	CHEMBL3629	Homo sapiens	Activity	%	3.5
	19476564	CHEMBL4479712	Inhibition of full-length recombinant human His-tagged CSNK2A1 expressed in baculovirus expression system by Z'-LYTE assay	B	O=C(NCC(F)(F)F)c1cc(-c2cnn3cc(-c4ccc(OCCN5CCCCC5)cc4)cnc23)cs1		CHEMBL4569508	=	IC50	nM	8300.0	CHEMBL3629	Homo sapiens	IC50	nM	8300.0
	19476664	CHEMBL4479712	Inhibition of full-length recombinant human His-tagged CSNK2A1 expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)NCC(F)(F)F)c4)cnn3c2)cn1		CHEMBL4550702	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	nM	100000.0
	19476764	CHEMBL4479712	Inhibition of full-length recombinant human His-tagged CSNK2A1 expressed in baculovirus expression system by Z'-LYTE assay	B	Cn1cc(-c2cnc3c(-c4csc(C(=O)N[C@@H]5CCCC[C@@H]5N)c4)cnn3c2)cn1		CHEMBL4568087	>	IC50	nM	10000.0	CHEMBL3629	Homo sapiens	IC50	nM	10000.0
	19476864	CHEMBL4479712	Inhibition of full-length recombinant human His-tagged CSNK2A1 expressed in baculovirus expression system by Z'-LYTE assay	B	Cc1sc(C(=O)N[C@@H]2[C@H](N)CCCC2(F)F)cc1-c1cnn2cc(Cl)cnc12		CHEMBL4552628	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	nM	100000.0
	20600500	CHEMBL4603452	Inhibition of recombinant human full-length His-tagged CSNK2A1 expressed in baculovirus expression system using FRET-labeled Ser/Thr 11 peptide as substrate measured after 1 hr in presence of ATP by Z'-lyte assay	B	C[C@@H]1C[C@H]1C(=O)N1CCN(c2cnc(C#N)c(-c3cnn(C)c3)n2)C[C@H]1C		CHEMBL4634634	>	IC50	nM	100000.0	CHEMBL3629	Homo sapiens	IC50	uM	100.0
Active	20604879	CHEMBL4604580	Inhibition of CK2alpha in human C33A cells at 2 to 4 uM after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604880	CHEMBL4604662	Inhibition of CK2alpha in human HeLa cells at 2 to 4 uM after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604881	CHEMBL4604663	Inhibition of CK2alpha in human SiHa cells at 2 to 4 uM after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604882	CHEMBL4604664	Inhibition of CK2alpha in human CaSki cells at 2 to 4 uM after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604887	CHEMBL4604669	Inhibition of CK2alpha in human C33A cells at 40 uM after 48 hrs by Western blot analysis	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604888	CHEMBL4604670	Inhibition of CK2alpha in human HeLa cells at 40 uM after 48 hrs by Western blot analysis	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604889	CHEMBL4604671	Inhibition of CK2alpha in human SiHa cells at 40 uM after 48 hrs by Western blot analysis	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	20604890	CHEMBL4604672	Inhibition of CK2alpha in human CaSki cells at 40 uM after 48 hrs by Western blot analysis	B	O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12		CHEMBL28		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	20604891	CHEMBL4604673	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human HeLa cells after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233	=	Ratio		10.0	CHEMBL3629	Homo sapiens	Ratio		10.0
	20604892	CHEMBL4604674	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human C33A cells after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233	=	Ratio		10.0	CHEMBL3629	Homo sapiens	Ratio		10.0
	20604893	CHEMBL4604675	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human SiHa cells after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233	=	Ratio		10.0	CHEMBL3629	Homo sapiens	Ratio		10.0
	20604894	CHEMBL4604676	Potency index, ratio for inhibition activity of apigenin to test compound for inhibition of CK2alpha in human CaSki cells after 48 hrs by Western blot analysis	B	O[C@]12C=C(c3nccc4c3[nH]c3ccccc34)[C@@H]3CCN(CCCC/C=C\CC1)C[C@@]31C[C@@H]3/C=C\CCCCN3[C@@H]21		CHEMBL403233	=	Ratio		10.0	CHEMBL3629	Homo sapiens	Ratio		10.0
	20714343	CHEMBL4629868	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cccc(C(F)(F)F)c1		CHEMBL1835063	=	Activity	%	6.5	CHEMBL3629	Homo sapiens	Activity	%	6.5
	20714344	CHEMBL4629868	Binding affinity to wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	CC(C)(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C)c1		CHEMBL4648967	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	20714370	CHEMBL4629879	Inhibition of human CK2a using RRRDDDSDDD as substrate in presence of [gamma-33P]-ATP by hotspot kinase assay	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cccc(C(F)(F)F)c1		CHEMBL1835063	=	IC50	nM	9131.0	CHEMBL3629	Homo sapiens	IC50	uM	9.131
	20714412	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cccc(C(F)(F)F)c1		CHEMBL1835063	=	Delta Tm	degrees C	3.77	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.77
	20714413	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1		CHEMBL4639597	=	Delta Tm	degrees C	5.89	CHEMBL3629	Homo sapiens	deltaTm	degrees C	5.89
	20714414	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)(C)c1cccc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)c1		CHEMBL4632574	=	Delta Tm	degrees C	3.02	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.02
	20714415	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CS(=O)(=O)c1cccc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)c1		CHEMBL4640445	=	Delta Tm	degrees C	5.11	CHEMBL3629	Homo sapiens	deltaTm	degrees C	5.11
	20714416	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	NC(=O)c1cnc(N2CCC[C@H](N)C2)nc1Nc1cccc(-c2ccccc2)c1		CHEMBL4644948	=	Delta Tm	degrees C	3.79	CHEMBL3629	Homo sapiens	deltaTm	degrees C	3.79
	20714417	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)(C#N)c1cccc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)c1		CHEMBL4640492	=	Delta Tm	degrees C	9.51	CHEMBL3629	Homo sapiens	deltaTm	degrees C	9.51
	20714418	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C)c1		CHEMBL4648967	=	Delta Tm	degrees C	-0.03	CHEMBL3629	Homo sapiens	deltaTm	degrees C	-0.03
	20714419	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)c1		CHEMBL4634851	=	Delta Tm	degrees C	4.05	CHEMBL3629	Homo sapiens	deltaTm	degrees C	4.05
	20714420	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(S(C)(=O)=O)c1		CHEMBL4632457	=	Delta Tm	degrees C	1.85	CHEMBL3629	Homo sapiens	deltaTm	degrees C	1.85
	20714421	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)(C#N)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(-c2ccccc2)c1		CHEMBL4633229	=	Delta Tm	degrees C	-0.21	CHEMBL3629	Homo sapiens	deltaTm	degrees C	-0.21
	20714422	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)(C#N)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)(C)C#N)c1		CHEMBL4640712	=	Delta Tm	degrees C	0.56	CHEMBL3629	Homo sapiens	deltaTm	degrees C	0.56
	20714423	CHEMBL4629888	Binding affinity to CK2a (unknown origin) assessed as change in melting temperature at 10 uM by SYPRO Orange dye based fluorescence assay	B	CC(C)c1cc(Nc2nc(N3CCC[C@H](N)C3)ncc2C(N)=O)cc(C(C)C)n1		CHEMBL4635883	=	Delta Tm	degrees C	1.54	CHEMBL3629	Homo sapiens	deltaTm	degrees C	1.54
	22392022	CHEMBL4667117	Inhibition of recombinant human His-tagged full length CK2alpha1 expressed in baculovirus expression system using Ser/Thr 1 as substrate at 10 uM incubated for 60 mins by Z'-Lyte assay relative to control	B	CN1C(=O)[C@@H](NC(=O)c2n[nH]c3ncc(C(F)(F)C(F)(F)F)cc23)COc2ccccc21		CHEMBL4785812	=	Inhibition	%	4.5	CHEMBL3629	Homo sapiens	INH	%	4.5
	22415126	CHEMBL4672234	Inhibition of CK2 alpha (unknown origin) at 10 uM relative to control	B	O=C1c2ccc(O)c(O)c2C(=O)c2c(O)ccc(O)c21		CHEMBL29898	=	Inhibition	%	83.69	CHEMBL3629	Homo sapiens	INH	%	83.69
	22415127	CHEMBL4672234	Inhibition of CK2 alpha (unknown origin) at 10 uM relative to control	B	Cc1cc(NC2=NC(=O)/C(=C\c3c4ccccc4cc4ccccc34)S2)no1		CHEMBL4751362	=	Inhibition	%	76.34	CHEMBL3629	Homo sapiens	INH	%	76.34
	22415173	CHEMBL4672267	Inhibition of CK2 alpha (unknown origin) relative to control	B	Cc1cc(NC2=NC(=O)/C(=C\c3c4ccccc4cc4ccccc34)S2)no1		CHEMBL4751362	=	IC50	nM	171.0	CHEMBL3629	Homo sapiens	IC50	uM	0.171
	22415174	CHEMBL4672267	Inhibition of CK2 alpha (unknown origin) relative to control	B	O=C1c2ccc(O)c(O)c2C(=O)c2c(O)ccc(O)c21		CHEMBL29898	=	IC50	nM	110.0	CHEMBL3629	Homo sapiens	IC50	uM	0.11
Active	22418281	CHEMBL4672725	Binding affinity to CK2alpha (unknown origin) incubated for 10 mins by hydrogen-deuterium exchange mass spectrometry	B	O=C(CC(=O)Nc1cccc(C(=O)O)c1)NCCCNCc1ccc(-c2ccccc2)c(Cl)c1		CHEMBL4115984		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	22418282	CHEMBL4672725	Binding affinity to CK2alpha (unknown origin) incubated for 10 mins by hydrogen-deuterium exchange mass spectrometry	B	CCc1ccccc1-c1ccc(CN)cc1Cl		CHEMBL4224990		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	22418283	CHEMBL4672725	Binding affinity to CK2alpha (unknown origin) incubated for 10 mins by hydrogen-deuterium exchange mass spectrometry	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
	22418284	CHEMBL4672726	Binding affinity to CK2alpha (unknown origin) assessed as dissociation rate constant at 500 uM by STD NMR spectroscopy	B	O=C(O)c1ccc2c(c1)cc(Nc1cccc(Cl)c1)c1ccncc12	Non standard unit for type	CHEMBL4749859	=	K	/s	0.0039	CHEMBL3629	Homo sapiens	K	/s	0.0039
Active	22418285	CHEMBL4672727	Binding affinity to CK2alpha (unknown origin) at 500 uM by Water-LOGSY NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Active	22418286	CHEMBL4672728	Binding affinity to CK2alpha (unknown origin) at 500 uM by CPMG NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Active	22418287	CHEMBL4672729	Binding affinity to CK2alpha (unknown origin) at 500 uM in presence of CX4945 by Water-LOGSY NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Active	22418288	CHEMBL4672730	Binding affinity to CK2alpha (unknown origin) at 500 uM in presence of CX4945 by CPMG NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Active	22418289	CHEMBL4672731	Binding affinity to CK2alpha (unknown origin) at 500 uM in presence of CAM4066 by NMR spectroscopy	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
	22418290	CHEMBL4672732	Binding affinity to CK2alpha (unknown origin) by ITC analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531	=	Kd	nM	2200.0	CHEMBL3629	Homo sapiens	Kd	uM	2.2
	22418291	CHEMBL4672732	Binding affinity to CK2alpha (unknown origin) by ITC analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959	=	Kd	nM	22000.0	CHEMBL3629	Homo sapiens	Kd	uM	22.0
Not Active	22418292	CHEMBL4672733	Binding affinity to CK2alpha (unknown origin) in presence of CX4945 by ITC analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Active	22418293	CHEMBL4672733	Binding affinity to CK2alpha (unknown origin) in presence of CX4945 by ITC analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccccc3)cs2)cc1		CHEMBL1621959		Activity			CHEMBL3629	Homo sapiens	Activity		
Not Active	22418294	CHEMBL4672734	Binding affinity to CK2alpha (unknown origin) in presence of CAM4066 by ITC analysis	B	O=C(O)c1ccc(Nc2nc(-c3ccc4ccccc4c3)cs2)cc1O		CHEMBL4520531		Activity			CHEMBL3629	Homo sapiens	Activity		
	22423711	CHEMBL4674431	Inhibition of human CK2A using RRRDDDSDDD as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OC1CCCCC1		CHEMBL4785602	=	Activity	%	92.47	CHEMBL3629	Homo sapiens	Activity	%	92.47
	22423712	CHEMBL4674431	Inhibition of human CK2A using RRRDDDSDDD as substrate assessed as residual activity at 1 uM by [gamma-33P]-ATP assay relative to control	B	Nc1ncc(-c2cnc(C3CCNCC3)s2)cc1OCc1ccncc1		CHEMBL4749141	=	Activity	%	96.67	CHEMBL3629	Homo sapiens	Activity	%	96.67
Active	22793104	CHEMBL4710103	Inhibition of N-terminal His6-tagged CK2alpha (1 to 337 residues) (unknown origin) expressed in BL21(DE3) cells assessed as change in melting temperature at 10 uM by SYPRO Orange dye based DSF assay	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	22793105	CHEMBL4710103	Inhibition of N-terminal His6-tagged CK2alpha (1 to 337 residues) (unknown origin) expressed in BL21(DE3) cells assessed as change in melting temperature at 10 uM by SYPRO Orange dye based DSF assay	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	22793108	CHEMBL4710105	Binding affinity to N-terminal His6-tagged CK2alpha (1 to 337 residues) (unknown origin) expressed in BL21(DE3) cells by isothermal titration calorimetry	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819	=	Kd	nM	12.0	CHEMBL3629	Homo sapiens	Kd	nM	12.0
	22793109	CHEMBL4710105	Binding affinity to N-terminal His6-tagged CK2alpha (1 to 337 residues) (unknown origin) expressed in BL21(DE3) cells by isothermal titration calorimetry	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618	=	Kd	nM	82.0	CHEMBL3629	Homo sapiens	Kd	nM	82.0
Active	22793110	CHEMBL4710106	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system at 1 uM by Kinomescan method	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	22793114	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc(-c2cnn3ccc(N(CCOCCO)C(=O)OC(C)(C)C)nc23)cc1O		CHEMBL4744728	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	22793115	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819	=	IC50	nM	1510.0	CHEMBL3629	Homo sapiens	IC50	uM	1.51
	22793116	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCN(C(=O)OC(C)(C)C)c1ccn3ncc-2c3n1		CHEMBL4779625	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	22793117	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	22793118	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4778998	>	IC50	nM	50000.0	CHEMBL3629	Homo sapiens	IC50	uM	50.0
	22793119	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4795226	=	IC50	nM	5730.0	CHEMBL3629	Homo sapiens	IC50	uM	5.73
	22793120	CHEMBL4710110	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	96.0	CHEMBL3629	Homo sapiens	IC50	uM	0.096
	22793128	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc(-c2cnn3ccc(N(CCOCCO)C(=O)OC(C)(C)C)nc23)cc1O		CHEMBL4744728	=	IC50	nM	7520.0	CHEMBL3629	Homo sapiens	IC50	uM	7.52
	22793129	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N(CCOCCO)c1ccn2ncc(-c3ccc(C(=O)O)c(O)c3)c2n1		CHEMBL4793819	=	IC50	nM	8.0	CHEMBL3629	Homo sapiens	IC50	uM	0.008
	22793130	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCN(C(=O)OC(C)(C)C)c1ccn3ncc-2c3n1		CHEMBL4779625	=	IC50	nM	70900.0	CHEMBL3629	Homo sapiens	IC50	uM	70.9
	22793131	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	CC(C)(C)OC(=O)N1CCOCCOc2cc(ccc2C(=O)O)-c2cnn3ccc1nc23		CHEMBL4757618	=	IC50	nM	40.0	CHEMBL3629	Homo sapiens	IC50	uM	0.04
	22793132	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	COC(=O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4778998	=	IC50	nM	13200.0	CHEMBL3629	Homo sapiens	IC50	uM	13.2
	22793133	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2cc1OCCOCCNc1ccn3ncc-2c3n1		CHEMBL4795226	=	IC50	nM	75.0	CHEMBL3629	Homo sapiens	IC50	uM	0.075
	22793134	CHEMBL4710112	Displacement of fluorescent tracer from full-length human C-terminal NanoLuc-tagged CK2alpha expressed in HEK293T permeabilized cells measured after 2 hrs by NanoBRET assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	6.0	CHEMBL3629	Homo sapiens	IC50	uM	0.006
	22793202	CHEMBL4710174	Inhibition of recombinant human CK2alpha in presence of ATP at Km concentration by radiometric filter-binding assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	1.0	CHEMBL3629	Homo sapiens	IC50	nM	1.0
	22809775	CHEMBL4713310	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 1 uM using RRRDDDSDDD as substrate incubated for 40 mins in presence of Km ATP by radiometric scintillation counting analysis relative to control	B	CNC(=O)c1cnc2[nH]ccc2c1N[C@@H]1CCN(Cc2ccc(Cl)cc2)[C@H](C)C1		CHEMBL4761365	=	Activity	%	91.0	CHEMBL3629	Homo sapiens	Activity	%	91.0
	22815899	CHEMBL4714745	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system at 10 uM by Kinomescan method relative to control	B	CNC(=O)CN(Cc1ccccc1OC(F)F)C(=O)c1c[nH]c(C(=O)N2Cc3ccc(C(N)=O)cc3C2)n1		CHEMBL4752978	>	Inhibition	%	65.0	CHEMBL3629	Homo sapiens	INH	%	65.0
	22843439	CHEMBL4720436	Inhibition of human CK2A assessed as residual activity using RRRDDDSDDD as substrate at 1 uM by [gamma-33P]-ATP assay relative to control	B	O=C(Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1OCCCN1CCOCC1)c1cc([N+](=O)[O-])ccc1F		CHEMBL4750196	=	Activity	%	89.35	CHEMBL3629	Homo sapiens	Activity	%	89.35
	22844670	CHEMBL4721345	Inhibition of CK2alpha (unknown origin) assessed as residual activity at 1 uM by Kinomescan method relative to control	B	CCOc1nc(Nc2ccc(C(=O)N3CCOCC3)cc2OC)nc2[nH]ccc12		CHEMBL4794578	=	Activity	%	79.9	CHEMBL3629	Homo sapiens	Activity	%	79.9
Not Active	22909889	CHEMBL4734057	Inhibition of recombinant human full length His-tagged CSNK2A1 expressed in baculovirus expression system using serine/threonine-11 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	c1ccc(CSc2ncnc3[nH]cnc23)cc1		CHEMBL397434		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	22909890	CHEMBL4734057	Inhibition of recombinant human full length His-tagged CSNK2A1 expressed in baculovirus expression system using serine/threonine-11 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Clc1cccc(CSc2ncnc3[nH]cnc23)c1		CHEMBL4754930		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Not Active	22909891	CHEMBL4734057	Inhibition of recombinant human full length His-tagged CSNK2A1 expressed in baculovirus expression system using serine/threonine-11 peptide as substrate at 10 uM incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Brc1ccccc1CSc1ncnc2[nH]cnc12		CHEMBL4776788		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	22949084	CHEMBL4765741	Inhibition of human CK2alpha1 assessed as residual activity at 0.1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	105.0	CHEMBL3629	Homo sapiens	Activity	%	105.0
	22949085	CHEMBL4765741	Inhibition of human CK2alpha1 assessed as residual activity at 0.1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	97.0	CHEMBL3629	Homo sapiens	Activity	%	97.0
	22949086	CHEMBL4765741	Inhibition of human CK2alpha1 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	98.0	CHEMBL3629	Homo sapiens	Activity	%	98.0
	22949087	CHEMBL4765741	Inhibition of human CK2alpha1 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	90.0	CHEMBL3629	Homo sapiens	Activity	%	90.0
	22949088	CHEMBL4765741	Inhibition of human CK2alpha1 assessed as residual activity at 0.1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	101.0	CHEMBL3629	Homo sapiens	Activity	%	101.0
	22949089	CHEMBL4765741	Inhibition of human CK2alpha1 assessed as residual activity at 0.1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	102.0	CHEMBL3629	Homo sapiens	Activity	%	102.0
	22949090	CHEMBL4765742	Inhibition of human CK2alpha1 assessed as residual activity at 1 uM relative to control	B	CNS(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(OC)cc13)C(=O)N2		CHEMBL104519	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	22949091	CHEMBL4765742	Inhibition of human CK2alpha1 assessed as residual activity at 1 uM relative to control	B	CN(C)S(=O)(=O)c1ccc2c(c1)/C(=C/c1cn(C)c3ccc(O)cc13)C(=O)N2		CHEMBL4798255	=	Activity	%	89.0	CHEMBL3629	Homo sapiens	Activity	%	89.0
	22949092	CHEMBL4765742	Inhibition of human CK2alpha1 assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(=O)(=O)N(C)C)cc31)cn2C		CHEMBL322153	=	Activity	%	90.0	CHEMBL3629	Homo sapiens	Activity	%	90.0
	22949093	CHEMBL4765742	Inhibition of human CK2alpha1 assessed as residual activity at 1 uM relative to control	B	COc1ccc2[nH]cc(/C=C3\C(=O)Nc4ccc(S(N)(=O)=O)cc43)c2c1		CHEMBL106226	=	Activity	%	84.0	CHEMBL3629	Homo sapiens	Activity	%	84.0
	22949094	CHEMBL4765742	Inhibition of human CK2alpha1 assessed as residual activity at 1 uM relative to control	B	COc1ccc2c(c1)c(/C=C1\C(=O)Nc3ccc(S(N)(=O)=O)cc31)cn2C		CHEMBL104333	=	Activity	%	94.0	CHEMBL3629	Homo sapiens	Activity	%	94.0
	22949095	CHEMBL4765742	Inhibition of human CK2alpha1 assessed as residual activity at 1 uM relative to control	B	Cn1cc(/C=C2\C(=O)Nc3ccc(S(N)(=O)=O)cc32)c2ccccc21		CHEMBL104279	=	Activity	%	96.0	CHEMBL3629	Homo sapiens	Activity	%	96.0
	22952797	CHEMBL4766734	Inhibition of recombinant full length human CK2alpha1 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	99.0	CHEMBL3629	Homo sapiens	Activity	%	99.0
	22952798	CHEMBL4766735	Inhibition of recombinant full length human CK2alpha2 assessed as residual activity at 10 uM using RRRDDDSDDD as substrate incubated 40 mins in presence of [gamma-33ATP] by scintillation counting based radiometry assay relative to control	B	CC(C)(C)c1cc(NC(=O)Nc2ccc(Nc3ncnc4c3OCCCN4)cc2)no1		CHEMBL4793380	=	Activity	%	98.0	CHEMBL3629	Homo sapiens	Activity	%	98.0
	22961266	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(C(F)(F)F)s2)ccc1O		CHEMBL4792639	=	IC50	nM	1370.0	CHEMBL3629	Homo sapiens	IC50	uM	1.37
	22961267	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(C)s2)ccc1O		CHEMBL4799521	=	IC50	nM	880.0	CHEMBL3629	Homo sapiens	IC50	uM	0.88
	22961268	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(C(C)(C)C)s2)ccc1O		CHEMBL4778120	=	IC50	nM	360.0	CHEMBL3629	Homo sapiens	IC50	uM	0.36
	22961269	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(Br)s2)ccc1O		CHEMBL4795023	=	IC50	nM	280.0	CHEMBL3629	Homo sapiens	IC50	uM	0.28
	22961270	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	N#C/C(=C\c1ccc(O)c([N+](=O)[O-])c1)C(=O)Nc1nnc(C(F)(F)F)s1		CHEMBL4783065	=	IC50	nM	710.0	CHEMBL3629	Homo sapiens	IC50	uM	0.71
	22961271	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	Cc1nnc(NC(=O)/C(C#N)=C/c2ccc(O)c([N+](=O)[O-])c2)s1		CHEMBL4784643	=	IC50	nM	320.0	CHEMBL3629	Homo sapiens	IC50	uM	0.32
	22961272	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	N#C/C(=C\c1ccc(O)c([N+](=O)[O-])c1)C(=O)Nc1nnc(Br)s1		CHEMBL4798710	=	IC50	nM	370.0	CHEMBL3629	Homo sapiens	IC50	uM	0.37
	22961273	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	N#C/C(=C\c1ccc(O)c(Br)c1)C(=O)Nc1nnc(Br)s1		CHEMBL4796675	=	IC50	nM	1300.0	CHEMBL3629	Homo sapiens	IC50	uM	1.3
Not Determined	22961274	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	N#C/C(=C\c1ccc(N)cc1)C(=O)Nc1nnc(C(F)(F)F)s1		CHEMBL4785453		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	22961275	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	Cc1nnc(NC(=O)/C(C#N)=C/c2ccc(N)cc2)s1		CHEMBL4781256		IC50			CHEMBL3629	Homo sapiens	IC50		
Not Determined	22961276	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	CC(C)(C)c1nnc(NC(=O)/C(C#N)=C/c2ccc(N)cc2)s1		CHEMBL4788189		IC50			CHEMBL3629	Homo sapiens	IC50		
	22961277	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2cc(C(F)(F)F)ccc2Cl)ccc1O		CHEMBL4789806	=	IC50	nM	370.0	CHEMBL3629	Homo sapiens	IC50	uM	0.37
Not Determined	22961278	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2ccc([N+](=O)[O-])cc2)ccc1O		CHEMBL4795570		IC50			CHEMBL3629	Homo sapiens	IC50		
	22961279	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2ccccc2O)ccc1O		CHEMBL4776391	=	IC50	nM	330.0	CHEMBL3629	Homo sapiens	IC50	uM	0.33
	22961280	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	O=C(CCNCc1ccc(-c2ccccc2)c(Cl)c1)NCCC(=O)Nc1cccc(C(=O)O)c1		CHEMBL4070389	=	IC50	nM	370.0	CHEMBL3629	Homo sapiens	IC50	nM	370.0
	22961281	CHEMBL4768882	Inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	O=C(O)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL1230165	=	IC50	nM	1.0	CHEMBL3629	Homo sapiens	IC50	nM	1.0
	22961282	CHEMBL4768883	Potency index, ratio of IC50 of SRPIN803-rev to IC50 of compound for inhibition of recombinant human CK2alpha (1 to 336 residues) expressed in Escherichia coli BL21 (DE3) using RRADDSDDDD as substrate incubated for 10 mins in presence of [gamma-33P]-ATP by scintillation counting assay	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(C(C)(C)C)s2)ccc1O		CHEMBL4778120	=	Ratio IC50		4.0	CHEMBL3629	Homo sapiens	Ratio IC50		4.0
	22961286	CHEMBL4768885	Inhibition of CK2alpha (unknown origin) at 1 uM by PanQuinase assay relative to control	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(Br)s2)ccc1O		CHEMBL4795023	>	Inhibition	%	50.0	CHEMBL3629	Homo sapiens	INH	%	50.0
Active	22961288	CHEMBL4768887	Inhibition of CK2alpha in human Jurkat cells assessed as reduction in Akt Ser129 phosphorylation at 5 to 20 uM incubated for 16 hrs by Western blot analysis	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(C(F)(F)F)s2)ccc1O		CHEMBL4792639		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
Active	22961289	CHEMBL4768887	Inhibition of CK2alpha in human Jurkat cells assessed as reduction in Akt Ser129 phosphorylation at 5 to 20 uM incubated for 16 hrs by Western blot analysis	B	COc1cc(/C=C(\C#N)C(=O)Nc2nnc(Br)s2)ccc1O		CHEMBL4795023		Inhibition	%		CHEMBL3629	Homo sapiens	INH		
	23122513	CHEMBL4804864	Inhibition of human CSNK2A1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN1CCN(C(=O)c2ccc3cc(CCNc4ccnc5ccc(C#N)cc45)ccc3c2)CC1		CHEMBL4878072	=	Activity	%	56.0	CHEMBL3629	Homo sapiens	Activity	%	56.0
	23123208	CHEMBL4805452	Inhibition of human CSNK2A1 assessed as percent of control at 1000 nM by KINOMEscan assay relative to control	B	COc1cc2nc(NC3CC3)nc(NC3CCN(C(C)C)CC3)c2cc1OC.O=C(O)C(F)(F)F		CHEMBL4870304	=	Activity	%	61.0	CHEMBL3629	Homo sapiens	Activity	%	61.0
	23123683	CHEMBL4805927	Inhibition of DNA-tagged human CSNK2A1 assessed as percent of control at 50000 nM by qPCR analysis relative to control	B	CN1C(=O)/C(=C2/C(=O)Nc3ccccc32)c2ccccc21		CHEMBL607535	=	Activity	%	79.0	CHEMBL3629	Homo sapiens	Activity	%	79.0
	23124506	CHEMBL4806469	Inhibition of human CSNK2A1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	100.0	CHEMBL3629	Homo sapiens	Activity	%	100.0
	23124507	CHEMBL4806469	Inhibition of human CSNK2A1 assessed as percent of control at 2000 nM by KINOMEscan assay relative to control	B	CN(C)C(=O)c1ccc(N2CCCN(c3ccnc4sc(C(N)=O)c(N)c34)CC2)cc1		CHEMBL2348350	=	Activity	%	59.0	CHEMBL3629	Homo sapiens	Activity	%	59.0
	23125759	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Br)c1ccncc12.[Na+]		CHEMBL4871728	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125760	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(ccc3ccncc32)c1.[Na+]		CHEMBL4852889	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125761	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Cl)c1ccncc12.[Na+]		CHEMBL4874005	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125762	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Nc1cccc(Cl)c1)c1ccncc12.[Na+]		CHEMBL4864298	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125763	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Nc1ccc(Cl)cc1)c1ccncc12.[Na+]		CHEMBL4869607	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125764	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(-c1ccc(Cl)cc1)c1ccncc12.[Na+]		CHEMBL4878788	=	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125765	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(-c1cccnc1)c1ccncc12.[Na+]		CHEMBL4855640	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125766	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(-c1ccncc1)c1ccncc12.[Na+]		CHEMBL4858891	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125767	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Cc1cc2cc(C(=O)[O-])ccc2c2cnccc12.[Na+]		CHEMBL4855827	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125768	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Nc1ccc(-c2cc3cc(C(=O)[O-])ccc3c3cnccc23)cn1.[Na+]		CHEMBL4849181	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125769	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(-c1cc[nH]n1)c1ccncc12.[Na+]		CHEMBL4856281	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125770	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(NC1CCCCC1)c1ccncc12.[Na+]		CHEMBL4871526	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125771	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C(O)c1ccc2c(c1)cc(N[C@@H]1CCCNC1)c1ccncc12		CHEMBL4855950	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
	23125772	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	N[C@@H]1CCCN(c2cc3cc(C(=O)O)ccc3c3cnccc23)C1		CHEMBL4877279	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125773	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(NC1CCCC1)c1ccncc12.[Na+]		CHEMBL4855218	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125774	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	CCC(C)Nc1cc2cc(C(=O)[O-])ccc2c2cnccc12.[Na+]		CHEMBL4856136	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125775	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(NC1CC1)c1ccncc12.[Na+]		CHEMBL4877989	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125776	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(NC1CCC1)c1ccncc12.[Na+]		CHEMBL4856667	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125777	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	CC[C@H](C)Nc1cc2cc(C(=O)O)ccc2c2cnccc12		CHEMBL4867159	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125778	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(N1CCCCC1)c1ccncc12.[Na+]		CHEMBL4862671	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125779	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	CC(C)Nc1cc2cc(C(=O)[O-])ccc2c2cnccc12.[Na+]		CHEMBL4871816	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125780	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	CC[C@@H](C)Nc1cc2cc(C(=O)[O-])ccc2c2cnccc12.[Na+]		CHEMBL4867675	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125781	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Br)c1ccnc(Cl)c12.[Na+]		CHEMBL4870585	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125782	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Br)c1cc(Cl)ncc12.[Na+]		CHEMBL4874370	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
	23125783	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(ccc3ccnc(Cl)c32)c1.[Na+]		CHEMBL4848434	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125784	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc([N+](=O)[O-])c1ccncc12.[Na+]		CHEMBL4867336	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125785	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	N#Cc1cc2cc(C(=O)[O-])ccc2c2cnccc12.[Na+]		CHEMBL4850936	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125786	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(C1CC1)c1ccncc12.[Na+]		CHEMBL4862119	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125787	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Nc1nccc2c(Br)cc3cc(C(=O)[O-])ccc3c12.[Na+]		CHEMBL4853293	<	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125788	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	CN(C)c1nccc2c(Br)cc3cc(C(=O)[O-])ccc3c12.[Na+]		CHEMBL4879266	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
	23125789	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	O=C([O-])c1ccc2c(c1)cc(Br)c1ccnc(NC3CC3)c12.[Na+]		CHEMBL4846302	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
	23125790	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	CNc1nccc2c(Br)cc3cc(C(=O)[O-])ccc3c12.[Na+]		CHEMBL4856868	=	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125791	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	NC(=O)c1ccc2c(c1)cc(Br)c1ccnc(N)c12		CHEMBL4876205	=	IC50	nM	1000.0	CHEMBL3629	Homo sapiens	IC50	nM	1000.0
	23125792	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	COc1nccc2c(Br)cc3cc(C(=O)[O-])ccc3c12.[Na+]		CHEMBL4870359	=	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23125793	CHEMBL4807033	Inhibition of CSNK2A1(unknown origin) using Ser/Thr 11 as substrate incubated for 60 mins in presence of ATP by Z'-LYTE assay	B	Nc1nccc2cc(Br)c3cc(C(=O)[O-])ccc3c12.[Na+]		CHEMBL4852867	=	IC50	nM	300.0	CHEMBL3629	Homo sapiens	IC50	nM	300.0
	23127969	CHEMBL4807798	Inhibition of CK2alpha1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL3629	Homo sapiens	Activity	%	75.0
	23127970	CHEMBL4807798	Inhibition of CK2alpha1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3629	Homo sapiens	Activity	%	75.0
	23127971	CHEMBL4807798	Inhibition of CK2alpha1 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3629	Homo sapiens	Activity	%	75.0
	23127972	CHEMBL4807799	Inhibition of CK2alpha2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)csc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL4867844	>	Activity	%	75.0	CHEMBL3629	Homo sapiens	Activity	%	75.0
	23127973	CHEMBL4807799	Inhibition of CK2alpha2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(Cl)ccnc3C)s2)cc(NN2CCN(CCO)CC2)n1		CHEMBL4855726	>	Activity	%	75.0	CHEMBL3629	Homo sapiens	Activity	%	75.0
	23127974	CHEMBL4807799	Inhibition of CK2alpha2 (unknown origin) assessed as residual activity measured at 1 uM	B	Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1		CHEMBL1421	>	Activity	%	75.0	CHEMBL3629	Homo sapiens	Activity	%	75.0
	23144149	CHEMBL4808937	Inhibition of CK2alpha (unknown origin) assessed as residual activity at 1 uM relative to control	B	O=C(NCCO)c1ccc2c(c1)nc(Nc1cccc(Cl)c1)c1ccncc12		CHEMBL4860630	=	Activity	%	0.0	CHEMBL3629	Homo sapiens	Activity	%	0.0
	23195918	CHEMBL4819733	Inhibition of human recombinant full length CSNK2A1 using RRRDDDSDDD peptide as substrate at 100 nM direct filter-binding radiometric kinase activity assay relative to control	B	COc1cc(N2CCN(C)CC2)ccc1Nc1ncc2c(C)cc(=O)n([C@H]3CC[C@@H](NC(=O)C4CCCCC4)CC3)c2n1		CHEMBL4875028	=	Inhibition	%	69.0	CHEMBL3629	Homo sapiens	INH	%	69.0
	23234005	CHEMBL4827585	Inhibition of wild-type human full length CSNK2A1 (M1 to Q391 residues) expressed in mammalian expression system assessed as residual binding level at 1 uM by Kinomescan method relative to control	B	O=C(O)c1ccc(-c2cnn3ccc(-c4ccccc4)nc23)cc1C1CCCC1		CHEMBL4877552	<	Activity	%	10.0	CHEMBL3629	Homo sapiens	Activity	%	10.0
	23248245	CHEMBL4830422	Inhibition of human CK2A using RRRDDDSDDD as substrate assessed as enzyme activity incubated for 2 hrs by [gamma-33P]-ATP assay relative to control	B	CC(C)c1c2cc(-c3ccnc(Nc4ccc5c(N6CCN(C)CC6)ccnc5c4)n3)ccc2nn1C		CHEMBL4856177	<	Activity	%	20.0	CHEMBL3629	Homo sapiens	Activity	%	20.0
	23289190	CHEMBL4839028	Inhibition of CK2alpha1 (unknown origin)	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921	=	IC50	nM	13.9	CHEMBL3629	Homo sapiens	IC50	nM	13.9
	23289205	CHEMBL4839043	Inhibition of CK2alpha1 (unknown origin) at 0.1 uM	B	CCN1CCN(c2ccc(Nc3ncc4scc(-c5cccc(NS(C)(=O)=O)c5)c4n3)cc2)CC1		CHEMBL4846921	=	Inhibition	%	95.5	CHEMBL3629	Homo sapiens	INH	%	95.5
Not Active	23317348	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCC(=N\O)/C(C)=C/c1ccc(F)cc1		CHEMBL3697701		% Control	%	74.0	CHEMBL3629	Homo sapiens	% Control	%	74.0
Not Active	23317816	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCC(=N\O)/C(C)=C/c1ccc(F)c(C)c1		CHEMBL3701197		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23318486	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cn1cncc1[C@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4586794		% Control	%	63.0	CHEMBL3629	Homo sapiens	% Control	%	63.0
Not Active	23318966	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cn1cncc1[C@@](O)(COc1ccc(C#N)cc1-c1ccc(OC(F)(F)F)cc1)c1ccc(C#N)cc1		CHEMBL4526341		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23319605	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCCCN(CCCC)C(=O)CN1C[C@H](c2cc(OC)c3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1CC(C)(C)CCC		CHEMBL111612		% Control	%	68.5	CHEMBL3629	Homo sapiens	% Control	%	68.5
Not Active	23320078	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCCCN(CCCC)C(=O)CN1C[C@@H](c2cc(OC)c3c(c2)OCO3)[C@H](C(=O)O)[C@H]1CC(C)(C)CCC		CHEMBL4513786		% Control	%	88.6	CHEMBL3629	Homo sapiens	% Control	%	88.6
Not Active	23320756	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	c1ccc(N2CCN(Cc3nc4ccccc4[nH]3)CC2)nc1		CHEMBL440687		% Control	%	97.0	CHEMBL3629	Homo sapiens	% Control	%	97.0
Not Active	23321224	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CSc1cccnc1N1CCN(Cc2nc3ccccc3[nH]2)CC1		CHEMBL4630641		% Control	%	81.0	CHEMBL3629	Homo sapiens	% Control	%	81.0
Not Active	23321854	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCCOc1ccc([C@H]2[C@H](C(=O)O)[C@@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL332794		% Control	%	69.0	CHEMBL3629	Homo sapiens	% Control	%	69.0
Not Active	23322322	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCCOc1ccc([C@@H]2[C@@H](C(=O)O)[C@H](c3ccc4c(c3)OCO4)CN2CC(=O)Nc2c(CC)cccc2CC)cc1		CHEMBL4533479		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23323011	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1ccc2c(c1)O[C@@H](c1ccc(OC)c(OC)c1)C[C@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4093612		% Control	%	94.0	CHEMBL3629	Homo sapiens	% Control	%	94.0
Not Active	23323479	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1ccc2c(c1)O[C@H](c1ccc(OC)c(OC)c1)C[C@@H]2NC(=O)C1(c2ccc3c(c2)OC(F)(F)O3)CC1		CHEMBL4066040		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23323978	CHEMBL4880597	CK2 (h) Millipore kinase activity assay	B	CC1=C(C#N)C(c2ccc3[nH]nc(C)c3c2)C(C#N)=C(C)N1		CHEMBL4593677		Inhibition	%	-8.0	CHEMBL3629	Homo sapiens	% inhibition	%	-8.0
Not Active	23324333	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC1=C(C#N)[C@@H](c2ccc3[nH]nc(C)c3c2)C(C#N)=C(c2ccc(Cl)cc2)N1		CHEMBL4522773		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23324968	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@H]1CC[C@@H](Cn2nnc3ccccc3c2=O)[C@@H]1C(=O)O		CHEMBL4585243		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23325436	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(c1ccc(OCCC2CCOCC2)cc1)[C@@H]1CC[C@H](Cn2nnc3ccccc3c2=O)[C@H]1C(=O)O		CHEMBL4539943		% Control	%	87.0	CHEMBL3629	Homo sapiens	% Control	%	87.0
Not Active	23326083	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	NS(=O)(=O)c1cc(NC(=O)Cc2ccccc2)ccc1Oc1cccc(Cl)c1		CHEMBL4521594		% Control	%	96.0	CHEMBL3629	Homo sapiens	% Control	%	96.0
Not Active	23326551	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	NS(=O)(=O)c1cc(NC(=O)C2(c3ccccc3Cl)CC2)ccc1Oc1cccc(Cl)c1		CHEMBL4516843		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23327251	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4537788		% Control	%	66.0	CHEMBL3629	Homo sapiens	% Control	%	66.0
Not Active	23327719	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(NCc1ncc(C(F)(F)F)cc1Cl)c1ccc2c(c1)C1(CCS(=O)(=O)CC1)[C@@H](C1CC1)N2S(=O)(=O)c1ccc(F)cc1		CHEMBL4564312		% Control	%	67.0	CHEMBL3629	Homo sapiens	% Control	%	67.0
Not Active	23328306	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C#N)cc1		CHEMBL4448899		% Control	%	78.0	CHEMBL3629	Homo sapiens	% Control	%	78.0
Not Active	23328774	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1c(NC(=O)c2cc(C(N)=O)nc3cc(F)ccc23)c(C(F)(F)F)nn1Cc1ccc(C(C)(C)C)cc1		CHEMBL4552180		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23329301	CHEMBL4881008	CK21(h) Eurofins Kinase panel	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% residual kinase activity	%	92.0	CHEMBL3629	Homo sapiens	% residual kinase activity	%	92.0
Not Active	23329720	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN1CCN(c2cnc3c(C4CCN(C(=O)c5ccc(OC(F)(F)F)cc5N)CC4)ncnc3c2)CC1		CHEMBL4445670		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23330188	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1nc(C2CCN(C(=O)c3ccc(OC(F)(F)F)cc3N)CC2)c2ncc(N3CCN(C)CC3)cc2n1		CHEMBL4455582		% Control	%	99.0	CHEMBL3629	Homo sapiens	% Control	%	99.0
Not Active	23330944	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(N1CCS(=O)(=O)CC1)N1C[C@H](c2ccc(OC(F)(F)F)cc2)C[C@H](c2nc(C3CC3)no2)C1		CHEMBL4630644		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23331412	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1noc([C@H]2C[C@@H](c3ccc(C(F)(F)F)cc3)CN(C(=O)N3CCS(=O)(=O)C3)C2)n1		CHEMBL4630643		% Control	%	86.0	CHEMBL3629	Homo sapiens	% Control	%	86.0
Not Active	23331999	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1cc(C)c(-n2ccn3nc(-c4cccnc4)cc23)cc1NC(=O)c1cc(C#N)cc(S(F)(F)(F)(F)F)c1		CHEMBL3907057		% Control	%	74.2	CHEMBL3629	Homo sapiens	% Control	%	74.2
Not Active	23332467	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1cc(NC(=O)c2cccc(S(F)(F)(F)(F)F)c2)cc(-n2ccn3nc(-c4cccnc4)cc23)c1		CHEMBL4526351		% Control	%	66.7	CHEMBL3629	Homo sapiens	% Control	%	66.7
Not Active	23333183	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(=O)C1=C(C)N(c2cccc(C(F)(F)F)c2)C(=O)N[C@@H]1c1ccc(C#N)nc1		CHEMBL3617968		% Control	%	94.8	CHEMBL3629	Homo sapiens	% Control	%	94.8
Not Active	23333822	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CNCc1ccccc1-c1csc([C@@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4535474		% Control	%	83.0	CHEMBL3629	Homo sapiens	% Control	%	83.0
Not Active	23334290	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CNCc1ccccc1-c1csc([C@H](C)Nc2nc(C)nc3cc(OC)c(OC)cc23)c1		CHEMBL4520788		% Control	%	91.0	CHEMBL3629	Homo sapiens	% Control	%	91.0
Not Active	23334884	CHEMBL4881508	CK2 (h) Upstate kinase activity assay	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		Inhibition	%	6.0	CHEMBL3629	Homo sapiens	% inhibition	%	6.0
Not Active	23335269	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1c[nH]c2nccc(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)c12		CHEMBL1971943		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23335737	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cn1cc(Cl)c2c(Oc3c(F)cc(Nc4cc(Cl)nc(N)n4)cc3F)ccnc21		CHEMBL4546802		% Control	%	98.0	CHEMBL3629	Homo sapiens	% Control	%	98.0
Not Active	23336364	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(NC[C@H]1[C@@H]2CN(C(=O)OCc3cc(C(F)(F)F)cc(C(F)(F)F)c3)C[C@H]12)c1ccc2[nH]nnc2c1		CHEMBL4165749		% Control	%	84.0	CHEMBL3629	Homo sapiens	% Control	%	84.0
Not Active	23336832	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1nccc(COC(=O)N2C[C@H]3[C@H](CNC(=O)c4ccc5[nH]nnc5c4)[C@H]3C2)n1		CHEMBL4552354		% Control	%	81.0	CHEMBL3629	Homo sapiens	% Control	%	81.0
Not Active	23337560	CHEMBL4881931	CSNK2A1 Invitrogen selectivity data (BI)	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Ctrl	%	97.0	CHEMBL3629	Homo sapiens	% Ctrl	%	97.0
Not Active	23337913	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN(C)C(=O)Cn1cc(-c2nc([C@@](C)(c3ccc(-c4cnc(N)nc4)cc3)C3CC3)no2)cn1		CHEMBL3417525		% Control	%	88.0	CHEMBL3629	Homo sapiens	% Control	%	88.0
Not Active	23338381	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN(C)C(=O)Cn1cc(-c2nc(C3(c4ccc(-c5cnc(N)nc5)cc4)CC3)no2)cn1		CHEMBL4560241		% Control	%	73.0	CHEMBL3629	Homo sapiens	% Control	%	73.0
Not Active	23338993	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCS(=O)(=O)c1cc2cc(C[C@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL3358954		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23339461	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCS(=O)(=O)c1cc2cc(C[C@@](O)(CC(C)(C)c3ccc(F)cc3C(N)=O)C(F)(F)F)[nH]c2cn1		CHEMBL4531220		% Control	%	75.0	CHEMBL3629	Homo sapiens	% Control	%	75.0
Not Active	23340098	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CS(=O)(=O)c1cc(C2(NC(=O)c3cncc4c3cnn4-c3ccc(F)cc3)CC2)ccn1		CHEMBL4456123		% Control	%	64.0	CHEMBL3629	Homo sapiens	% Control	%	64.0
Not Active	23340566	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CS(=O)(=O)NCC[C@H](NC(=O)c1cncc2c1cnn2-c1ccc(F)cc1)c1ccnc(S(C)(=O)=O)c1		CHEMBL4539555		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23341223	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(=O)N1CCC(c2ccc(C(=O)NC(=N)N)cc2C(F)(F)F)CC1		CHEMBL2170610		% Control	%	95.0	CHEMBL3629	Homo sapiens	% Control	%	95.0
Not Active	23341691	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(=O)N1CCC(c2ccc(C(=O)NC3=NCCN3)cc2C(F)(F)F)CC1		CHEMBL4540759		% Control	%	86.0	CHEMBL3629	Homo sapiens	% Control	%	86.0
Not Active	23342307	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCC(=O)N[C@H]1CC[C@@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834184		% Control	%	74.0	CHEMBL3629	Homo sapiens	% Control	%	74.0
Not Active	23342775	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCC(=O)N[C@@H]1CC[C@H](C(=O)N(C)c2ccc(-c3nc4ccccc4o3)cc2)C1		CHEMBL1834199		% Control	%	98.0	CHEMBL3629	Homo sapiens	% Control	%	98.0
Not Active	23343247	CHEMBL4882432	CSNK2A1 Invitrogen selectivity data (BI)	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Ctrl	%	89.0	CHEMBL3629	Homo sapiens	% Ctrl	%	89.0
Not Active	23343405	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCOC(=O)c1cc2cc(-c3cc(C(=O)NCc4ccc(C(=O)O)cc4)nn3C)ccc2[nH]1		CHEMBL1939876		% Control	%	81.0	CHEMBL3629	Homo sapiens	% Control	%	81.0
Not Active	23343873	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cn1nc(C(=O)NCc2ccc(C(=O)O)cc2)cc1-c1ccc2[nH]ccc2c1		CHEMBL1939880		% Control	%	68.0	CHEMBL3629	Homo sapiens	% Control	%	68.0
Not Active	23344511	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCOCCn1cc(C(=O)Nc2ccc(-n3nc(-c4cccnc4)cc3C(F)(F)F)cn2)ccc1=O		CHEMBL4516982		% Control	%	70.0	CHEMBL3629	Homo sapiens	% Control	%	70.0
Not Active	23345084	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)O)CC5/C=C\CCCCC[C@H](NC(=O)OC5CCCC5)C(=O)N4C3)cc(-c3csc(NC(=O)C(C)C)n3)nc2c1C		CHEMBL4588900		% Control	%	81.0	CHEMBL3629	Homo sapiens	% Control	%	81.0
Not Active	23345552	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(N[C@H]1CCCCC/C=C\C2C[C@@]2(C(=O)O)NC(=O)[C@@H]2C[C@@H](Oc3ccncc3)CN2C1=O)OC1CCCC1		CHEMBL4516471		% Control	%	83.0	CHEMBL3629	Homo sapiens	% Control	%	83.0
Not Active	23346129	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1cc(Nc2nccc(C)n2)cc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)c1		CHEMBL3685796		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23346598	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1ccc(-c2cnc([C@@]3(O)CC[C@H](C(=O)O)C(C)(C)C3)s2)cc1Nc1cccc(C(F)(F)F)n1		CHEMBL4530401		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23347206	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1		CHEMBL4538174		% Control	%	94.0	CHEMBL3629	Homo sapiens	% Control	%	94.0
Not Active	23347689	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccn1		CHEMBL4557026		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23348268	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12		CHEMBL204232		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23348736	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(=O)c1c(NS(C)(=O)=O)c2cc(-c3ccc(Cl)cc3)c(-c3ccc(Cl)cc3Cl)nc2n(C)c1=O		CHEMBL4578164		% Control	%	92.0	CHEMBL3629	Homo sapiens	% Control	%	92.0
Not Active	23349323	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=S(=O)(NC1CCC(c2cc(F)ccc2F)(S(=O)(=O)c2ccc(Cl)cc2)CC1)C(F)(F)F		CHEMBL1091513		% Control	%	85.0	CHEMBL3629	Homo sapiens	% Control	%	85.0
Not Active	23349941	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1cc(-c2cn(C3CCc4c(F)cccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1cnc(C)c1		CHEMBL3609637		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23350409	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1cc(-c2cn(C3CCc4ccccc4N(CC(F)(F)F)C3=O)nn2)ccc1-n1ccc(C)n1		CHEMBL4534005		% Control	%	81.0	CHEMBL3629	Homo sapiens	% Control	%	81.0
Not Active	23351014	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN([C@@H]1CCc2c(CC(=O)O)c3ccccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL561132		% Control	%	82.0	CHEMBL3629	Homo sapiens	% Control	%	82.0
Not Active	23351482	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN([C@@H]1CCc2c(CC(=O)O)c3cc(S(C)(=O)=O)ccc3n2C1)S(=O)(=O)c1ccc(F)cc1		CHEMBL1643772		% Control	%	91.0	CHEMBL3629	Homo sapiens	% Control	%	91.0
Not Active	23352011	CHEMBL4882702	CSNK2A1 (CK2 alpha 1) Kinase screen	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		Inhibition	%	3.5	CHEMBL3629	Homo sapiens	% Inhibition	%	3.5002
Not Active	23352506	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H]1CN(c2cc(-c3n[nH]c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4098877		% Control	%	66.0	CHEMBL3629	Homo sapiens	% Control	%	66.0
Not Active	23352974	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H]1CN(c2cc(-c3nn(C)c4ccc(OC5(C)CC5)cc34)ncn2)C[C@@H](C)O1		CHEMBL4560589		% Control	%	76.0	CHEMBL3629	Homo sapiens	% Control	%	76.0
Not Active	23353856	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(O)c1cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc2c1		CHEMBL1800685		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23354324	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1c(C(=O)O)cc(-c2ccc(C3CCNCC3)cc2)c2ccc(-c3ccc(C(F)(F)F)cc3)cc12		CHEMBL4566600		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23355056	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COCCOc1nc(-c2ccc(Cl)nc2)nc2c1CN(C(=O)c1ncn3ccccc13)CC2		CHEMBL2204538		% Control	%	99.0	CHEMBL3629	Homo sapiens	% Control	%	99.0
Not Active	23355524	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(C)CC(=O)N1CCc2nc(-c3ccc(Br)cc3)nc(N(C)Cc3ccccc3)c2C1		CHEMBL4518342		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23356160	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC(C)(O)c1cncc(-c2nc3ccc(F)cc3n2C2CC2)c1		CHEMBL3582478		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23356628	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	FC(F)(F)c1ccc2c(c1)nc(-c1cccnc1)n2C1CC1		CHEMBL3582461		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23357237	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H](c1ccc(F)cc1)N(Cc1cccc(C(=O)O)c1)C(=O)c1cnc2ccccc2c1		CHEMBL3577885		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23357884	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(Nc1cccnn1)N1CCC(=Cc2cccc(Oc3ccc(C(F)(F)F)cn3)c2)CC1		CHEMBL1651534		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23358352	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(Nc1cccnn1)N1CC(C/C=C/c2cncc(Oc3ccc(C(F)(F)F)cn3)n2)C1		CHEMBL4780458		% Control	%	72.0	CHEMBL3629	Homo sapiens	% Control	%	72.0
Not Active	23358938	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1cccc(CNC(=O)c2nc3scc(COCc4ccc(C(=O)O)cc4)c3c(=O)[nH]2)c1		CHEMBL3337894		% Control	%	90.7	CHEMBL3629	Homo sapiens	% Control	%	90.7
Not Active	23359536	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3799292		% Control	%	67.0	CHEMBL3629	Homo sapiens	% Control	%	67.0
Not Active	23360004	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@@H](c1cccc(C#N)c1)n1cc(Cl)cc(C(N)=O)c1=N		CHEMBL3797887		% Control	%	72.0	CHEMBL3629	Homo sapiens	% Control	%	72.0
Not Active	23360589	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cn1nc(C(F)(F)F)cc1-c1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4455357		% Control	%	65.0	CHEMBL3629	Homo sapiens	% Control	%	65.0
Not Active	23361057	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Nc1cnc(N2CCc3cc(S(=O)(=O)Nc4c(F)cc(Cl)cc4F)cc(N4CCCC4=O)c32)nc1		CHEMBL4585920		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23361630	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1nc(N2CC[C@@H](O)C2)ncc1-c1cc(C(F)(F)F)cc2[nH]ncc12		CHEMBL3799512		% Control	%	85.0	CHEMBL3629	Homo sapiens	% Control	%	85.0
Not Active	23362166	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1cc(-n2nc(Cc3cc(F)cc(C(F)(F)F)c3)nc2C)ccc1C(N)=O		CHEMBL4082756		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23362634	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1nc(Cc2cccc(C(F)(F)F)c2)sc1-c1ccc(C(N)=O)nc1		CHEMBL4100408		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23364276	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1		CHEMBL4228713		% Control	%	89.0	CHEMBL3629	Homo sapiens	% Control	%	89.0
Not Active	23364744	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1		CHEMBL4551344		% Control	%	83.0	CHEMBL3629	Homo sapiens	% Control	%	83.0
Not Active	23365483	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1		CHEMBL3342332		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23366026	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Cc1c(Oc2c(F)cccc2F)c(OC(C)C)nn1-c1ncc(C2CC2)cc1F		CHEMBL3589752		% Control	%	82.0	CHEMBL3629	Homo sapiens	% Control	%	82.0
Not Active	23366616	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	Nc1c(C(=O)NCc2ccc(C(=O)NCCCC3CCCCC3)cc2)cnn1-c1ccccc1		CHEMBL4436748		% Control	%	70.0	CHEMBL3629	Homo sapiens	% Control	%	70.0
Not Active	23367084	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(NCCCC1CCCCC1)c1ccc(CNC(=O)c2cnn(-c3ccccc3)c2C(F)(F)F)cc1		CHEMBL4531775		% Control	%	94.0	CHEMBL3629	Homo sapiens	% Control	%	94.0
Not Active	23367518	CHEMBL4883871	CK2-alpha1 ProQinase selectivity panel	B	O=C1c2ccc(Nc3ccc(F)cc3F)cc2CCc2ccc(OC[C@H](O)CO)cc21		CHEMBL2152944		% Residual activity with Skepinone-L	%	95.0	CHEMBL3629	Homo sapiens	% Residual activity with Skepinone-L	%	95.0
Not Active	23367962	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(Nc1cnc(Oc2ccc(F)cc2)nc1)N1CCc2ncccc2[C@@H]1c1ccc(F)cc1		CHEMBL4458424		% Control	%	93.0	CHEMBL3629	Homo sapiens	% Control	%	93.0
Not Active	23368430	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C(Nc1ccc(Oc2ccc(F)cc2)cc1)N1CCc2ncccc2[C@H]1c1ccc(F)cc1		CHEMBL4592872		% Control	%	99.0	CHEMBL3629	Homo sapiens	% Control	%	99.0
Not Active	23369029	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H](c1ccnc(Nc2nc3ccc(-c4cc(N(C)C)ncn4)cc3[nH]2)c1)N1CCN(C(=O)CC(F)(F)F)CC1		CHEMBL4537673		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23369497	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN(C)c1ncnc(-c2ccc3nc(Nc4cc(CN5CCN(C(=O)CC(F)(F)F)CC5)ccn4)[nH]c3c2)c1Cl		CHEMBL4538591		% Control	%	80.0	CHEMBL3629	Homo sapiens	% Control	%	80.0
Not Active	23370023	CHEMBL4884267	CK2alpha1(h) Eurofins kinase panel	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% residual kinase activity	%	93.0	CHEMBL3629	Homo sapiens	% residual kinase activity	%	93.0
Not Active	23370465	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CCc1ccccc1C(=O)Nc1n[nH]c2c(C)c(F)c(C3C(C#N)=C(C)N(C)C(C)=C3C#N)cc12		CHEMBL4580220		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23370933	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CC1=C(C#N)C(c2ccc3c(c2)c(NC(=O)c2ccccc2C)nn3C)C(C#N)=C(C)N1		CHEMBL4630642		% Control	%	63.0	CHEMBL3629	Homo sapiens	% Control	%	63.0
Not Active	23371742	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNC(=O)c3cnc4ccccn34)cc2)C1		CHEMBL4591082		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23372210	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CS(=O)(=O)N1CCCC(NC(=O)[C@H](CCC2CCCCC2)NC(=O)c2ccc(CNc3ncnc4c3nnn4-c3ccccc3)cc2)C1		CHEMBL4568183		% Control	%	94.0	CHEMBL3629	Homo sapiens	% Control	%	94.0
	23372714	CHEMBL4884679	CK2alpha1(C2A1LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(Cc4ccccc4)nc3C2=O)COc2ccccc21		CHEMBL4088216		IC50	nM	1000.0	CHEMBL3629	Homo sapiens	pIC50		6.0
	23373123	CHEMBL4884970	CK2alpha1(C2A1LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3c(nn(Cc4ccccc4)c3Br)C2=O)COc2ccccc21		CHEMBL4549667		IC50	nM	1000.0	CHEMBL3629	Homo sapiens	pIC50		6.0
	23373484	CHEMBL4885261	CK2alpha1(C2A1LGF1) Takeda global kinase panel	B	CN1C(=O)[C@@H](N2CCc3cn(CC4CCS(=O)(=O)CC4)nc3C2=O)COc2ccccc21		CHEMBL4097778		IC50	nM	1000.0	CHEMBL3629	Homo sapiens	pIC50		6.0
Not Active	23374943	CHEMBL4885937	CK2_alpha1 Kinase panel	B	CC(C)(O)[C@H](F)CN1Cc2cc(NC(=O)c3cnn4cccnc34)c(N3CCOCC3)cc2C1=O		CHEMBL4475494		Inhibition	%	3.5	CHEMBL3629	Homo sapiens	% Inhibition	%	3.5
Not Active	23375637	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C1CCc2cc(Nc3cc(OC4CCOCC4)c([N+](=O)[O-])cc3Cl)ccc2N1		CHEMBL4075278		% Control	%	84.0	CHEMBL3629	Homo sapiens	% Control	%	84.0
Not Active	23376105	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	N#Cc1ccc(Nc2ccc3[nH]c(=O)[nH]c3c2)c(Cl)c1		CHEMBL4063249		% Control	%	80.0	CHEMBL3629	Homo sapiens	% Control	%	80.0
Not Active	23376682	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=c1nc(-c2ccccn2)sc2ccccc12		CHEMBL4516611		% Control	%	68.0	CHEMBL3629	Homo sapiens	% Control	%	68.0
Not Active	23377152	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	O=C1NC(c2ccccn2)Sc2ccccc21		CHEMBL4561806		% Control	%	61.0	CHEMBL3629	Homo sapiens	% Control	%	61.0
Not Active	23378010	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CNC(=O)Nc1ccc2c(c1)CC[C@@]21OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4282264		% Control	%	63.0	CHEMBL3629	Homo sapiens	% Control	%	63.0
Not Active	23378478	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CNC(=O)Nc1ccc2c(c1)[C@@]1(CC2)OC(=O)N(CC(=O)N(Cc2ccc(F)cc2)[C@@H](C)C(F)(F)F)C1=O		CHEMBL4536197		% Control	%	60.0	CHEMBL3629	Homo sapiens	% Control	%	60.0
Not Active	23379645	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)O)c(=O)n3ccccc23)CC1		CHEMBL1800285		% Control	%	86.0	CHEMBL3629	Homo sapiens	% Control	%	86.0
Not Active	23380113	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	N#CC1(c2ccccn2)CCN(Cc2cc(C(=O)N3CCCC3)c(=O)n3ccccc23)CC1		CHEMBL2204283		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23380807	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	COc1ccc2cc(OCC3(C(=O)O)CN(C(=O)c4ccc(F)cc4)C3)ccc2c1		CHEMBL3286797		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23381455	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@H](NC(=O)c1cnc2n1[C@](C)(Cc1ccc(C#N)cc1)C(=O)N2c1cc(Cl)c(F)c(Cl)c1)C(=O)NC1(c2ccccn2)CC1		CHEMBL4530740		% Control	%	81.0	CHEMBL3629	Homo sapiens	% Control	%	81.0
Not Active	23381923	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	C[C@@]1(Cc2ccc(C#N)cc2)C(=O)N(c2cc(Cl)cc(Cl)c2)c2ncc(C(=O)NC3(c4nc(C5CCC5)no4)CC3)n21		CHEMBL4577237		% Control	%	91.0	CHEMBL3629	Homo sapiens	% Control	%	91.0
Not Active	23382396	CHEMBL4887116	CK2 Invitrogen kinase activity assay	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		Inhibition	%	43.0	CHEMBL3629	Homo sapiens	% inhibition	%	43.0
Not Active	23382547	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1		CHEMBL3137331		% Control	%	61.0	CHEMBL3629	Homo sapiens	% Control	%	61.0
Slightly Active	23383015	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CN(c1ccnc(CNc2nc(Nc3ccc4c(c3)CC(=O)N4)ncc2C(F)(F)F)n1)S(C)(=O)=O		CHEMBL4518706		% Control	%	26.0	CHEMBL3629	Homo sapiens	% Control	%	26.0
Not Active	23383754	CHEMBL4887397	CSNK2A1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	92.0	CHEMBL3629	Homo sapiens	% Ctrl	%	92.0
Not Active	23383755	CHEMBL4887397	CSNK2A1 Invitrogen Lab (UK) kinase screen (BI)	B	CCC(F)(F)c1cc(N2CCC(S(C)(=O)=O)CC2)nc2sc(C(N)=O)c(N)c12		CHEMBL4522930		% Ctrl	%	107.0	CHEMBL3629	Homo sapiens	% Ctrl	%	107.0
Not Active	23384228	CHEMBL4887823	CK2(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	4.66	CHEMBL3629	Homo sapiens	% inhibition	%	4.66
Not Active	23384229	CHEMBL4887824	CK2alpha1(h) Millipore kinase panel	B	CC[C@@H](Nc1c(C#N)c(-c2ccc(-c3cccc(C)c3F)cc2)nc2cnccc12)C(=O)O		CHEMBL4802045		Inhibition	%	3.34	CHEMBL3629	Homo sapiens	% inhibition	%	3.34
Not Active	23384930	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CO[C@@H](C)c1c(Nc2ccc([C@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4568735		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23385397	CHEMBL4879654	KinomeScan assay: inhibition of CSNK2A1	B	CO[C@@H](C)c1c(Nc2ccc([C@@H](N(C)C(=O)C3CCS(=O)(=O)CC3)C(F)(F)F)cc2)cnc2cc(Cl)nn12		CHEMBL4584981		% Control	%	100.0	CHEMBL3629	Homo sapiens	% Control	%	100.0
Not Active	23385874	CHEMBL4888347	CK2alpha1 Invitrogen kinase panel	B	COc1nc2ccc([C@@](O)(c3ccccc3)C3CCN(C(C)=O)CC3)cc2c(Cl)c1Cc1ccc(-n2cccn2)cc1		CHEMBL4802042		Inhibition	%	2.0	CHEMBL3629	Homo sapiens	% inhibition	%	2.0
